

Vorwort

- [1] Bayer O, Loogen F, Wolter HH (Hrsg) (1967) Die Herzkatheterisierung bei angeborenen und erworbenen Herzfehlern, 2. Aufl., Thieme, Stuttgart (Erstauflage 1954)
- [2] Just H, Mengden HJv (1976) Kardiologische Diagnostik: Methodik, Messungen, Formeln, Nomogramme. Studienreihe Boehringer Mannheim. Mannheimer Morgenverlag, Mannheim
- [3] Schumacher G, Bühlmeyer K, Brodherr S (1978) Diagnostik angeborener Herzfehler, Band 1. Perimed, Erlangen
- [4] Schumacher G, Bühlmeyer K (1980) Diagnostik angeborener Herzfehler, Band 2. Perimed, Erlangen
- [5] Lichtlen PR (1990) Koronarangiographie, 2. Aufl. Perimed, Erlangen (Erstauflage 1978)
- [6] Grossman W (1986) Cardiac Catheterization and Angiography, 3rd ed. Lea & Febiger, Philadelphia
- [7] Baim DS (2006) Grossman's Cardiac Catheterization, Angiography and Intervention, 7th ed. Lippincott Williams & Wilkins, Philadelphia
- [8] Krakau I, Lapp H (1999) Das Herzkatheterbuch. Thieme, Stuttgart
- [9] Bonzel T, Hamm C (2009) Leitfaden Herzkatheter. Springer, Heidelberg
- [10] Erbel R, Sommerfeld U, Ashry M et al. Quality management in the heart catheterization laboratory. Z Kardiol (1994), 83 (Suppl 6), 43–55

1 Historischer Überblick

- [1] Mueller RL, Sanborn TA. The history of interventional cardiology: cardiac catheterization, angioplasty, and related interventions. *Am Heart J* 129:146–72, 1995
- [2] Morat JP, Doyon M. Function et nutrition. In: *Traite de Physiologie*. Libraires de l'Académie de médecine, Paris, 1899
- [3] Grossman's W, Baim S. Cardiac catheterization. In: *Cardiac catheterization, angiography and intervention*. 4th ed: pp 3–14, 2005, Lippincott, Williams & Wilkins, Philadelphia
- [4] Forßmann W. Sondierung des rechten Herzens. *Klin Wochenschr* 2085, 1929/II
- [5] Forßmann W. Über die Kontrastdarstellung der Höhlen des lebenden rechten Herzens und der Lungenschlagader. *Münchener Wochenschr* 78:489, 1931
- [6] Heuser C. Arteriografia directa, aortografia por impregnacion del reticulo endotelium, vasos grafias del pulmon por medio del sondeo de la auricula derecha. *Rev Asoc méd arge* 46:1119, 1932
- [7] Ravina A. L'exploration radiologique des vaisseaux pulmonaires par l'injection de substances de contrast. *Progr méd (Paris)* 1701, 1934
- [8] Loeffler L. Die Methode der Kontrastdarstellung der A. pulmonalis und des rechten Herzens am lebenden Menschen und ihr voraussichtliches klinisches Anwendungsbild. *Dtsch Z Chir* 259:342, 1944
- [9] Brannon ES, Ween HS, Warren JV. Atrial septal defect. Study of hemodynamics by the technique of right heart catheterization. *Am J Med Sci* 210:480, 1945
- [10] Cournand A, Baldwin JS, Hummelstein A. Cardiac catheterization in the diagnosis of congenital heart disease. *The Commonwealth Fund*, NY, 1947
- [11] Hellems HK, Haynes FW, Dexter L et al. Pulmonary „capillary“ pressure in man. *J Appl Physiol* 2:24, 1949
- [12] Lagerlöf H, Werkö L. Studies on circulation of blood in man. *Scand Clin Lab Invest* 7:147, 1949
- [13] Heller S, Kaiser K, Lochner W et al. Zur Bestimmung des Herzzeitvolumens mittels der Injektionsmethode bei fortlaufender Registrierung der Farbstoffkonzentration. *Z Kreisl-Forsch* 42:727, 1953
- [14] Gorlin R, Gorlin SG. Hydraulic formula for calculation of the area of the stenotic mitral valve, other cardiac valves and central circulatory shunts. *Am Heart J* 41:1, 1951
- [15] Seldinger SI. Catheter replacement of the needle in percutaneous arteriography; a new technique. *Acta Radiol* 39:358–76, 1953
- [16] Edholm P, Seldinger SI. Percutaneous catheterization of the renal artery. *Acta Radiol* 45:15–20, 1956
- [17] Gleichmann O, Vlacaakis N, Tsilos TH. Zur Entstehung des Herzspitzenstroms und Deutung systolischer Formveränderungen des Appexkardiogramms. *Z Kreislaufforsch* 60:789–807, 1971
- [18] Erbel R, Schweizer P, Lambertz H et al. Echoventriculography – a simultaneous analysis of two-dimensional echocardiography and cineventriculography. *Circulation* 67:205–15, 1983
- [19] Cobe C. Technique for transseptal catheterization of the left atrium. Preliminary report. *J Thorac Surg* 37:482, 1959
- [20] Ross J. Transseptal left heart catheterization. A new method of left atrial puncture. *Ann Surg* 149:395, 1959
- [21] Brockenbrough EC, Braunwald E, Ross J Jr. Transseptal left heart catheterization. A review of 450 studies and description of an improved technic. *Circulation* 25:15–21, 1962
- [22] Amplatz K, Ernst R, Lester RG et al. Retrograde left cardioangiography as a test of valvular competence. *Radiology* 72:268–9, 1959

- [23] Sones FM, Shirey EK. Cine coronary arteriography. *Mod Concepts Cardiovasc Dis* 31:735–8, 1962
- [24] Proudfit WL, Shirey EK, Sones FM. Selective cine coronary arteriography. Correlation with clinical findings in 1,000 patients. *Circulation* 33:901–10, 1966
- [25] Judkins MP. Selective coronary arteriography. I. A percutaneous transfemoral technique. *Radiology* 89:815–24, 1967
- [26] Bousen E, Judkins MP. A hook-tail „closed-end“ catheter for percutaneous selective cardioangiography. *Radiology* 87:872–7, 1966
- [27] Judkins MP. Percutaneous transfemoral selective coronary arteriography. *Radiol Clin North Am* 6:467–92, 1968
- [28] Judkins MP, Kidd HJ, Frische LH et al. Lumen-following safety J-guide for catheterization of tortuous vessels. *Radiology* 88:1127–30, 1967
- [29] Kiemeneij F, Laarman GJ. Percutaneous transradial artery approach for coronary stent implantation. *Cathet Cardiovasc Diagn* 30:173–8, 1993
- [30] Wilson WJ, Lee GB, Amplatz K. Biplane selective coronary arteriography via percutaneous transfemoral approach. *Am J Roentgenol Radium Ther Nucl Med* 100:332–40, 1967
- [31] Lee GB, Amplatz K. Selective coronary arteriography. *JAMA* 204:444–8, 1968
- [32] Schlesinger MJ, Zoll PM, Wessler S. The conus artery: a third coronary artery. *Am Heart J* 38:823, 1949
- [33] Freudenberg H, Bode W, Rafflenbeul W et al. Intravital and postmortem measurements of coronary stenosis. *Verh Dtsch Ges Kreislaufforsch* 43:301, 1977
- [34] Isner JM, Kishel J, Kent KM et al. Accuracy of angiographic determination of left main coronary arterial narrowing. Angiographic-histologic correlative analysis in 28 patients. *Circulation* 63:1056–65, 1981
- [35] Glagov S, Weisenberg E, Zarins CK et al. Compensatory enlargement of human atherosclerotic coronary arteries. *N Engl J Med* 316:1371–5, 1987
- [36] Ge J, Erbel R, Zamorano J et al. Coronary artery remodelling in atherosclerotic disease: an intravascular ultrasonic study in vivo. *Coron Artery Dis* 4:981–6, 1993
- [37] Gerber TC, Erbel R, Gorge G et al. Extent of atherosclerosis and remodeling of the left main coronary artery determined by intravascular ultrasound. *Am J Cardiol* 73:666–71, 1994
- [38] Birgelen Cv, Hartmann M, Mintz GS et al. Remodeling index compared to actual vascular remodeling in atherosclerotic left main coronary arteries in assessment with long-term (> or = 12 months) serial intravascular ultrasound. *J Am Coll Cardiol* 47:1363–8, 2006
- [39] Birgelen Cv, Klinkhart W, Mintz GS et al. Plaque distribution and vascular remodeling of ruptured and nonruptured coronary plaques in the same vessel: an intravascular ultrasound study in vivo. *J Am Coll Cardiol* 37:1864–70, 2001
- [40] Düber C, Jungbluth A, Rumpelt HJ et al. Morphology of the coronary arteries after combined thrombolysis and percutaneous transluminal coronary angioplasty for acute myocardial infarction. *Am J Cardiol* (1986); 58(9):698–703
- [41] Kolesov VI. Coronary-thoracic artery anastomosis as a means of treating coronary heart disease. *Klin Med* 44:7–12, 1966
- [42] Perry D. History of cardiology: Vasilii Ivanovich Kolesov. *Circulation* f136–f38, 2007
- [43] Vineberg AM. Development of anastomosis between coronary vessels and transplanted internal mammary artery. *Can Med Assoc J* 55:117–19, 1945
- [44] Demikhova OV. Pioneers in Cardiology. VP Demikhov. *Circulation* f99–f102, 2008
- [45] Rohman M, Goetz RH, Dee R. Double coronary artery-internal mammary artery anastomoses, tantalum ring technique. *Surg Forum* 11:236–7, 1960
- [46] Favaloro RG. Saphenous vein autograft replacement of severe segmental coronary artery occlusion: operative technique. *Ann Thorac Surg* 5:334–39, 1968
- [47] Senning A. Strip grafting in coronary arteries: report of a case. *J Thorac Cardiovasc Surg* 41:543–49, 1961
- [48] Effler DB, Groves LK, Sones FM et al. Endarterectomy in the treatment of coronary artery disease. *J Thorac Cardiovasc Surg* 47:98–108, 1964
- [49] Sheldon WC, Sones FM, Shirey EK et al. Reconstructive coronary artery surgery: postoperative assessment. *Circulation* 39 (Suppl 1):I61–6, 1969
- [50] Favaloro RG. Landmarks in the development of coronary artery bypass surgery. *Circulation* 98:466–78, 1998

- [51] Swan HJ, Ganz W, Forrester J et al. Catheterization of the heart in man with use of a flow-directed balloon-tipped catheter. *N Engl J Med* 283:447–51, 1970
- [52] Ganz W, Donoso R, Marcus HS et al. A new technique for measurement of cardiac output by thermodilution in man. *Am J Cardiol* 27:392–96, 1971
- [53] Forrester JS, Diamond G, Swan HJ. Pulmonary artery catheterization. A new technique in treatment of acute myocardial infarction. *Geriatrics* 26:65–71, 1971
- [54] Merx W, Bleifeld W, Hanrath P et al. Acute myocardial infarct. II. Hemodynamics of the right ventricle. *Z Kardiol* 62:701–18, 1973
- [55] Merx W, Bleifeld W, Hanrath P et al. Acute myocardial infarction. IV. Relationship between left ventricular filling pressure and late diastolic pulmonary artery pressure. *Z Kardiol* 62:835–45, 1973
- [56] Bleifeld W, Hanrath P, Mathey D et al. Acute myocardial infarction. V: left and right ventricular haemodynamics in cardiogenic shock. *Br Heart J* 36:822–34, 1974
- [57] Bleifeld W, Mathey D, Hanrath P et al. Acute myocardial infarct. VII. Prognostic significance of a new shock index. *Dtsch Med Wochenschr* 98:1355–57, 1973
- [58] Bleifeld W, Hanrath P, Mathey D. Acute myocardial infarction. X. Changes in the haemodynamics of the right and left ventricles from the acute stage to convalescence. *Dtsch Med Wochenschr* 99:1049–57, 1974
- [59] Hanrath P, Bleifeld W, Merx W et al. Acute myocardial infarct. 3. Significance of central venous pressure for function of the left ventricle. *Z Kardiol* 62:718–28, 1973
- [60] Hanrath P, Bleifeld W, Mathey D. Acute myocardial infarct. 8. Correlation of haemodynamic values with left and right-ventricular injection time. *Z Kardiol* 63:328–38, 1974
- [61] Meyer J, Erbel R, Rupprecht HJ et al. Relation between admission time, haemodynamic measurements and prognosis in acute myocardial infarction. *Br Heart J* 46:647–56, 1981
- [62] Bleifeld WH, Hanrath P, Mathey D. Serial CPK determinations for evaluation of size and development of acute myocardial infarction. *Circulation* 53 (3 Suppl):I108–11, 1976
- [63] Essen Rv, Merx W, Doerr R et al. QRS mapping in the evaluation of acute anterior myocardial infarction. *Circulation* 62:266–76, 1980
- [64] Erbel R, Belz GG. Recent aspects on basic drug therapy of acute myocardial infarct. *Med Klin* 72:1341–60, 1977
- [65] Chazov El, Matveeva LS, Mazaev AV et al. Intracoronary administration of fibrinolytic in acute myocardial infarct. *Ter Arkh* 48:8–19, 1976. Russian
- [66] Rentrop P, Vivie ERd, Karsch KR et al. Acute coronary occlusion with impending infarction as an angiographic complication relieved by a guidewire recanalization. *Clin Cardiol* 1:101–6, 1978
- [67] Rentrop P, Blanke H, Karsch KR et al. Reopening of infarct-occluded vessel by transluminal recanalisation and intracoronary streptokinase application. *Dtsch Med Wochenschr* 104:1438–40, 1979
- [68] Rentrop P, Blanke H, Karsch KR et al. Changes in left ventricular function after intracoronary streptokinase infusion in clinically evolving myocardial infarction. *Am Heart J* 102:1188–93, 1981
- [69] Merx W, Dörr R, Rentrop P et al. Evaluation of the effectiveness of intracoronary streptokinase infusion an acute myocardial infarction: postprocedure management and hospital course in 204 patients. *Am Heart J* 102:1181–7, 1981
- [70] Mathey DG, Rodewald G, Rentrop P et al. Intracoronary streptokinase thrombolytic recanalization and subsequent surgical bypass of remaining atherosclerotic stenosis in acute myocardial infarction: complementary combined approach effecting reduced infarct size, preventing reinfarction, and improving left ventricular function. *Am Heart J* 102:1194–201, 1981
- [71] Rutsch W, Scharlt M, Mathey D et al. Percutaneous transluminal coronary recanalization: procedure, results, and acute complications. *Am Heart J* 102:1178–81, 1981
- [72] Schröder R, Biamino G, Leitner ERv et al. Intravenous streptokinase infusions in acute myocardial infarction. Restoring patency of occluded thrombotic coronary vessels. *Dtsch Med Wochenschr* 106:294–301, 1981
- [73] Neuhaus KL, Tebbe U, Sauer G et al. High dose intravenous streptokinase in acute

- myocardial infarction. *Clin Cardiol* 6:426–34, 1983
- [74] ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. *Lancet* 2:349–60, 1988
- [75] The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. *N Engl J Med* 329:1615–22, 1993. Erratum in: *N Engl J Med* 330:516, 1994
- [76] Meyer J, Merx W, Dörr R et al. Successful treatment of acute myocardial infarction shock by combined percutaneous transluminal coronary recanalization (PTCR) and percutaneous transluminal coronary angioplasty (PTCA). *Am Heart J* 103:132–4, 1982
- [77] Erbel R, Pop T, Henrichs KJ et al. Percutaneous transluminal coronary angioplasty after thrombolytic therapy: a prospective controlled randomized trial. *J Am Coll Cardiol* 8:485–95, 1986
- [78] Erbel R, Pop T, Diefenich C et al. Long-term results of thrombolytic therapy with and without percutaneous transluminal coronary angioplasty. *J Am Coll Cardiol* 14:276–85, 1989
- [79] Grines CL, Browne KF, Marco J et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. *N Engl J Med* 328:673–9, 1993
- [80] Grines CL, Cox DA, Stone GW et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. *N Engl J Med* 341:1949–56, 1999
- [81] Waller BF, Rothbaum DA, Pinkerton CA et al. Status of the myocardium and infarct-related coronary artery in 19 necropsy patients with acute recanalization using pharmacologic (streptokinase, r-tissue plasminogen activator), mechanical (percutaneous transluminal coronary angioplasty) or combined types of reperfusion therapy. *J Am Coll Cardiol* 9:785–801, 1987
- [82] Assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary intervention (ASSENT-4PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4PCI): randomised trial. *Lancet* 367:569–78, 2006
- [83] Werf Fvd, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J* 29:2909–45, 2008
- [84] Mauri L, Silbaugh TS, Garg P et al. Drug-eluting or bare-metal stents for acute myocardial infarction. *N Engl J Med* 359:1330–42, 2008
- [85] Koslowski B. Namen des Herzinfarktverbundes Essen. The Essen myocardial infarction network as a model of integrated medical care in the realization of the therapy of acute ST segment elevation myocardial infarction corresponding to guidelines. *Herz* 30:715–20, 2005
- [86] Jacksch R, Naber CK, Koslowski B et al. Herzinfarktverbund Essen. Coronary Intervention (PCI) within the myocardial infarction network system in a German city (Essen). *Herz* 33:110–4, 2008
- [87] Buchholz J, Naber CK, Budde T et al. Herzinfarktverbund Essen. STEMI network Essen-in-hospital results. *Herz* 33:148–52, 2008
- [88] Hailer B, Naber CK, Koslowski B et al. Herzinfarktverbund Essen. STEMI network Essen – results after 1 year. *Herz* 33:153–7, 2008
- [89] Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. *Circulation* 101:366–71, 2000
- [90] Erbel R, Heusch G. Coronary microembolization. *J Am Coll Cardiol* 36:22–4, 2000
- [91] Limbruno U, Caterina Rd. EMERALD, AIMI, and PROMISE: is there still a potential for embolic protection in primary PCI? *Eur Heart J* 27:1139–45, 2006
- [92] Heusch G. Postconditioning: old wine in a new bottle? *J Am Coll Cardiol* 44:1111–2, 2004

- [93] Skyschally A, Caster Pv, Iliodromitis EK et al. Ischemic postconditioning: experimental models and protocol algorithms. *Basic Res Cardiol*, 2009 (Epub ahead of print)
- [94] Kin H, Zhao ZQ, Sun HY et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. *Cardiovasc Res* 62:74–85, 2004
- [95] Cung TT, Morel O, Cayla G et al. Cyclosporine before PCI in patients with acute myocardial infarction. *N Engl J Med* 373:1021–31, 2015
- [96] Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med* 349:1893–906, 2003
- [97] Brehm M, Zeus T, Strauer BE. Therapy with adult stem cells in myocardial infarct. *Internist (Berl)* 43 (Suppl 1):S96–8, 2002
- [98] Strauer BE, Brehm M, Schannwell CM. The therapeutic potential of stem cells in heart disease. *Cell Prolif* 41 (Suppl 1):126–45, 2008
- [99] Schächinger V, Erbs S, Elsässer A et al. REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. *N Engl J Med* 355:1210–21, 2006
- [100] Limbourg FP, Ringes-Lichtenberg S, Schaefer A et al. Haematopoietic stem cells improve cardiac function after infarction without permanent cardiac engraftment. *Eur J Heart Fail* 7:722–9, 2005
- [101] Guan K, Hasenfuss G. Do stem cells in the heart truly differentiate into cardiomyocytes? *J Mol Cell Cardiol* 43:377–87, 2007
- [102] Dotter CT. Two decades of transluminal angioplasty. An overview. *J Mal Vasc* 7 (Suppl 4):357–61, 1982
- [103] Dotter CT. Transluminal angioplasty: a long view. *Radiology* 135:561–4, 1980
- [104] Grüntzig A. Transluminal dilatation of coronary-artery stenosis. *Lancet* 1:263, 1978
- [105] Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. *N Engl J Med* 301:61–8, 1979
- [106] Gleichmann U, Mannebach H, Lichtlen P. Ergebnis einer Umfrage im Auftrag der Kommission für Klinische Kardiologie im Jahr 1995. 22. Bericht über die Leistungszahlen der Herzkatheterlabore in der Bundesrepublik Deutschland. *Der Kardiologe* 2:320–324, 2008
- [107] McAuley BJ, Oesterle S, Simpson JB. Advances in guidewire technology. *Am J Cardiol* 53:94C–96C, 1984
- [108] Simpson JB. How atherectomy began: a personal history. *Am J Cardiol* 72:3E–5E, 1993
- [109] Yock PG, Linker DT, White NW et al. Clinical applications of intravascular ultrasound imaging in atherectomy. *Int J Card Imaging* 4:117–25, 1989
- [110] Ge J, Koch L, Roth Th, Erbel R. Vision-guided laser atherectomy. *Min Invas Ther & Allied Technol* 6:209–212, 1997
- [111] Clas W, Erbel R, Seelen Wv et al. Ein neu entwickelter Ballonkatheter zur Reduzierung der myokardialen Ischämie während transluminaler Angioplastie. *Biomed Technik* 29:195–196, 1984
- [112] Erbel R, Clas W, Busch U et al. New balloon catheter for prolonged percutaneous transluminal coronary angioplasty and bypass flow in occluded vessels. *Cathet Cardiovasc Diagn* 12:116–23, 1986
- [113] Stack RS, Quigley PJ, Collins G et al. Perfusion balloon catheter. *Am J Cardiol* 61:77G–80G, 1988
- [114] Armstrong B, Sketch MH, Stack RS. The role of the perfusion balloon catheter after an initially unsuccessful coronary intervention. *J Interv Cardiol* 8:309–17, 1995
- [115] Gorge G, Haude M, Ge J et al. How does a continuous coronary perfusion catheter work in coronary artery dissection? Assessment by intravascular ultrasound. *Eur Heart J* 17:151–2, 1996
- [116] Bonzel T, Wollschläger H, Just H. A new catheter system for the mechanical dilatation of coronary stenosis with exchangeable intracoronary catheters, fast flow of the contrast agent and improved control. *Biomed Tech (Berl)* 31:195–200, 1986
- [117] Meyer J, Erbel R, Rupprecht HJ. Improvement of myocardial perfusion. *M. Nijhoff, Dordrecht*, 1985
- [118] Erbel R, O'Neill W, Auth D et al. High-frequency rotablation of occluded coronary artery during heart catheterization. *Cathet Cardiovasc Diagn* 17:56–8, 1989

- [119] Mohr-Kahaly S, Erbel R, Zotz R et al. Left ventricular contrast echocardiography using Gelifundol-assessment of hemodynamics, contractility and ECG. *Z Kardiol* 76:699–705, 1987
- [120] Zotz R, Stähr P, Erbel R et al. Analysis of high-frequency rotational angioplasty-induced echo contrast. *Cathet Cardiovasc Diagn* 22:137–44, 1991
- [121] Zotz RJ, Erbel R, Philipp A et al. High-speed rotational angioplasty-induced echo contrast in vivo and in vitro optical analysis. *Cathet Cardiovasc Diagn* 26:98–109, 1992
- [122] Dill T, Dietz U, Hamm CW et al. A randomized comparison of balloon angioplasty versus rotational atherectomy in complex coronary lesions (COBRA study). *Eur Heart J* 21:1759–66, 2000
- [123] Topol EJ, Leya F, Pinkerton CA et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. *N Engl J Med* 329:221–7
- [124] Bittl JA, Chew DP, Topol EJ et al. Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty. *J Am Coll Cardiol* 43:936–42, 2004
- [125] Puel J, Juilliere Y, Bertrand ME et al. Early and late assessment of stenosis geometry after coronary arterial stenting. *Am J Cardiol* 61:546–53, 1988
- [126] Schatz RA. Coronary stenting, report of the initial clinical experience with the Palmaz-Schatz TM balloon expandable stent. In: Reiber JHC, Serruys PW (Eds) *Quantitative Coronary Arteriography*. (Developments in Cardiovascular Medicine, vol 117) Springer, Dordrecht 1991
- [127] Erbel R, Schatz R, Dietz U et al. Balloon dilatation and coronary vascular stent implantation. *Z Kardiol* 78:71–7, 1989
- [128] Swars H, Hafner G, Erbel R et al. Prothrombin fragments and thrombotic occlusion of coronary stents. *Lancet* 337:59–60, 1991
- [129] Haude M, Hafner G, Jablonka A et al. Guidance of anticoagulation after intracoronary implantation of Palmaz-Schatz stents by monitoring prothrombin and prothrombin fragment 1 + 2. *Am Heart J* 130:228–38, 1995
- [130] Serruys PW, Strauss BH, Beatt KJ et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. *N Engl J Med* 324:13–7, 1991
- [131] Görges G, Haude M, Ge J et al. Intravascular ultrasound after low and high inflation pressure coronary artery stent implantation. *J Am Coll Cardiol* 26:725–30, 1995
- [132] Colombo A, Hall P, Nakamura S et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. *Circulation* 91:1676–88, 1995
- [133] Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. *N Engl J Med* 331:496–501, 1994
- [134] Serruys PW, Jaegere Pd, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. *N Engl J Med* 331:489–95, 1994
- [135] Erbel R, Haude M, Höpp HW et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. *N Engl J Med* 339:1672–8, 1998
- [136] Haude M, Konorza TF, Kalnins U et al. Heparin-coated stent placement for the treatment of stenosis in small coronary arteries of symptomatic patients. *Circulation* 107:1265–70, 2003
- [137] Haude M, Hopp HW, Rupprecht HJ et al. STENT-BY study group. Immediate stent implantation versus conventional techniques for the treatment of abrupt vessel closure or symptomatic dissections after coronary balloon angioplasty. *Am Heart J* 140:e26, 2000
- [137] Verin V, Urban P, Popowski Y et al. Feasibility of intracoronary beta irradiation to reduce restenosis after balloon angioplasty – a clinical pilot study. *Circulation* 95:1138–44, 1997
- [139] Teirstein PS, Massullo V, Jani S et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. *N Engl J Med* 336:1697–703, 1997
- [140] Waksman R, White RL, Chan RC et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in pa-

- tients with in-stent restenosis. *Circulation* 101:2165–71, 2000
- [141] Leon MB, Teirstein PS, Moses JW et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. *N Engl J Med* 344:250–6, 2001
- [142] Baumgart D, Sauerwein W, Naber C et al. Dose finding in intracoronary brachytherapy – consequences from empirical trials. *Z Kardiol* 91 (Suppl 3):23–30, 2002
- [143] Verin V, Popowski Y, Bruyne Bd et al. Dose-Finding Study Group. Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. The Dose-Finding Study Group. *N Engl J Med* 344:243–9, 2001
- [144] Urban P, Serruys P, Baumgart D et al. RENO Investigators. A multicentre European registry of intraluminal coronary beta brachytherapy. *Eur Heart J* 24:604–12, 2003
- [145] Naber CK, Baumgart D, Bonan R et al. Intracoronary brachytherapy, a promising treatment option for diabetic patients: Results from a European multicenter registry (RENO). *Catheter Cardiovasc Interv* 61:173–8, 2004
- [146] Morice MC, Serruys PW, Sousa JE et al. RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med* 346:1773–80, 2002
- [147] Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. *N Engl J Med* 356:998–1008, 2007
- [148] Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): a randomised non-inferiority trial. *Lancet* 372:1163–73, 2008
- [149] Degertekin M, Serruys PW, Tanabe K et al. Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis. *Circulation* 108:2747–50, 2003
- [150] Hoffmann R, Morice MC, Moses JW et al. Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials. *Heart* 94:322–8, 2008
- [151] Opolski MP, Pracon R, Mintz GS et al. Relation of drug-eluting stent strut distribution to stent thrombosis in coronary arteries. *Am J Cardiol* 104:343–8, 2009
- [152] Schulz S, Schuster T, Mehilli J et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4 year period. *Eur Heart J*, 2009 (Epub ahead of print)
- [153] Park DW, Yun SC, Lee SW et al. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. *JACC Cardiovasc Interv* 1:494–503, 2008
- [154] Wijns W. Late stent thrombosis after drug-eluting stent. Seeing is understanding. *Circulation* 2009 (Epub ahead of print)
- [155] Cook S, Windecker S. Early stent thrombosis: past, present and future. *Circulation* 119:657–9, 2009
- [156] Nebeker JR, Virmani R, Bennett CL et al. Hypersensitivity cases associated with drug-eluting coronary stents. A review of available cases from the research on adverse drug events and reports (RADAR) project. *J Am Coll Cardiol* 47:175–81, 2006
- [157] Cheneau E, Leborgne L, Mintz GS et al. Predictors of subacute stent thrombosis. Results of a systematic intravascular ultrasound study. *Circulation* 108:43–47, 2003
- [158] Maier W, Windecker S, Küng A et al. Exercise-induced coronary artery vasodilation is not impaired by stent placement. *Circulation* 105:2373–2377, 2002
- [159] Togni M, Windecker S, Cocchia R et al. Sirolimus-eluting stents associated with paradoxical coronary vasoconstriction. *J Am Coll Cardiol* 46:231–6, 2005
- [160] Hofma SH, Giessen WJvd, Dalen BMv et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. *European Heart Journal* 27:166–170, 2006
- [161] Erbel R, Clas W, Busch U et al. New balloon catheter for prolonged percutaneous transluminal coronary angioplasty and bypass flow in occluded vessels. *Cathet Cardiovasc Diagn* 12:116–23, 1986

- [162] Stack RS, Quigley PJ, Collins G et al. Perfusion balloon catheter. *Am J Cardiol* 61:77 G–80 G, 1988
- [163] Armstrong B, Sketch MH Jr, Stack RS. The role of the perfusion balloon catheter after an initially unsuccessful coronary intervention. *J Interv Cardiol* 8:309–17, 1995
- [164] Görges G, Erbel R, Haude M et al. Continuous coronary perfusion balloon catheters in coronary dissections after percutaneous transluminal coronary angioplasty. Acute clinical results and 6-months follow-up. *Eur Heart J* 15:908–14, 1994
- [165] Gaspard P, Didier B, Lienhart Y et al. Temporary stenting for abrupt closure during coronary angioplasty. *Lancet* 337:1226–7, 1991
- [166] Heuser RR, Mehta S, Strumpp RK. ACS RX Flow Support Catheters as a temporary stent for dissection or occlusion during balloon angioplasty: initial experience. *Cathet Cardiovasc Diag* 27:66–74, 1992
- [167] Gibbs JS, Sigwart U, Buller NP. Temporary stents as a bail-out device during percutaneous transluminal coronary angioplasty: preliminary clinical experience. *BR Heart J* 71:372–7, 1994
- [168] Eigler NL, Khorsandi MJ, Forrester JS et al. Implantation and recovery of temporary metallic stents in canine coronary arteries. *J Am Coll Cardiol* 22:1207–1213, 1993
- [169] Rechavia E, Fishbein MC, DeFrance T et al. Temporary arterial stenting: comparison to permanent stenting and conventional balloon injury in a rabbit carotid artery model. *Cathet Cardiovasc Diag* 41:85–92, 1997
- [170] Schwartz RS. Bioabsorbable stents. In: Ellis S, Holmes D (Eds), *Strategic approaches in coronary intervention*. Williams & Wilkins. Baltimore, 626–645, 1996
- [171] Murphy JG, Schwarz RS, Edwards WD et al. Percutaneous polymeric stents in porcine coronary arteries. Initial experience with polyethylene terephthalate stents. *Circulation* 86:1596–1604, 1992
- [172] Zidar J, Mohammed S, Culp S et al. In vitro thrombogenicity of a new bioabsorbable, balloon-expandable, endovascular stent. *J Am Coll Cardiol* 21:483 A, 1993
- [173] Zidar J, Gammon R, Chapman G et al. Short- and long-term tissue response to the Duke bioabsorbable stent. *J Am Coll Cardiol* 21:439A, 1993
- [174] Bostman O, Hirvensalo E, Mäkinen J. Foreign-body reactions to fracture fixation implants of biodegradable synthetic polymers. *J Bone Joint Surg* 72-B:592–596, 1991
- [175] Vogt F, Stein A, Rettemeier G et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polyactide stent. *Eur Heart J* 25:1330–40, 2004
- [176] Tamai H, Igaki K, Kyo E et al. Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. *Circulation* 102:399–404, 2000
- [177] Kukreja N, Otsuka M, Miegheem Cv et al. Biodegradable drug eluting stents: invasive and non-invasive imaging. *Euro Interv* 2:403, 2006
- [178] Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. *Catheter Cardiovasc Interv* 69:128–31, 2007
- [179] Onuma Y, Serruys PW, Ormiston JA et al. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. *EuroIntervention* 2010; 6:447–53
- [180] Brugaletta S, Garcia-Garcia HM, Garg S et al. Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. *Int J Cardiovasc Imaging*. 27(6):859–66, 2011
- [181] Ormiston JA, Serruys PW. Bioabsorbable coronary stents. *Circ Cardiovasc Interv*. 2:255–60, 2009
- [182] Gunatillake PA, Adhikari R. Biodegradable synthetic polymers for tissue engineering. *Eur Cell Mater* 2003, 5:1–16
- [183] Commandeur S, Beusekom MMv, Giesen Jvd. Polymers, Drug Release, and Drug-Eluting Stents. *J Interv Cardiol* 6:500–506, 2006
- [184] Serruys PW, Chevalier B, Sotomi Y et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. *Lancet* 388:2479–2491, 2016

- [185] Peuster M, Wohlsein P, Brugmann M et al. A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal-results 6–18 months after implantation into New Zealand white rabbits. *Heart* 86:563–9, 2001
- [186] Peuster M, Hesse C, Schloo T et al. Long-term biocompatibility of a corrodible peripheral iron stent in the porcine descending aorta. *Biomaterial* 27:4955–62, 2006
- [187] Haferkamp H, Bach FW, Juchmann P et al. Corrosion of Al- or Ca-Alloyed Mg LI-Alloys in Gaseous and Aqueous Media. In: Mordike BL, Kainer KU. *Magnesium Alloys and their Applications*. Werkstoff-Informationsgesellschaft, Frankfurt, 1998, 433–438
- [188] Haferkamp H, Kaese V, Niemeyer M et al. Korrosionssteuerung von Magnesiumlegierungen mittels Lithium. 6. Magnesiumguß. Abnehmerseminar & Automotive Seminar, Aalen, 30.09–01.10.1998
- [189] Heublein B, Rohde BR, Niemeyer M et al. Degradation of magnesium-alloys – a new principle in cardiovascular implant technology. *Transcatheter Cardiovascular Therapeutics Symposium*, TCT 99, 22.–26.09.1999, Washington, zugl. In: Roberts WC, Smith C, Jenkins BS. *AJ* 1999, Sappe 29 P
- [190] Haferkamp H, Kaese V, Niemeyer M et al. Magnesium-Base-Alloys as Implant-Material. 2nd Interdisciplinary Essen Symposium of the Working Group „Biomaterials and Tissue Compatibility“, Biomaterials: Fundamental and Clinical Applications, 6.–8.10.1999, Essen
- [191] Heublein B, Rohde R, Hausdorf G et al. Bio-corrosion – a new principle for temporary cardiovascular implants. *Eur Heart J* 21:286, 2000
- [192] Weissenburger J, Davy JM, Chezalviel F. Experimental models of torsades de pointes. *Fundam Clin Pharmacol* 7:29–38, 1993
- [193] Smetana R, Wink K. Magnesium, acute myocardial infarction and reperfusion injury. *Clin Calcium* 15:261–4, 2005
- [194] ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. *Lancet* 345:669–85, 1995
- [195] Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the magnesium in coronaries (MAGIC) trial: a randomised controlled trial. *Lancet* 360:1189–96, 2002
- [196] Roth A, Eshchar Y, Keren G et al. Effect of magnesium on restenosis after percutaneous transluminal coronary angioplasty: a clinical and angiographic evaluation in a randomized patient population. A pilot study. *Eur Heart Jour* 15; 1164–1173, 1994
- [197] Heublein B, Rohde R, Kaese V et al. Bio-corrosion of magnesium alloys: a new principle in cardiovascular implant technology? *Heart* 89:651–656, 2003
- [198] Nicole R. Metallschädigung bei Osteosynthesen. *Helv Chir Acta* 14 (Suppl III): 5–70, 1947
- [199] Ferrando WA. Review of corrosion and corrosion control of magnesium alloys and composites. *J Mater Eng* 11:4, 1989
- [200] Waksman R, Pakala R, Kuchulakanti PK et al. Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. *Catheter Cardiovasc Interv* 68:607–17, 2006
- [201] Peeters P, Bosiers M, Verbist J et al. Preliminary results after application of absorbable metal stents in patients with critical limb ischemia. *J Endovasc Ther* 12:1–5, 2005
- [202] Zartner P, Cesnjevar R, Singer H et al. First successful implantation of a biodegradable metal stent into the left pulmonary artery of a preterm baby. *Cathet Cardiovasc Interv* 66:590–594, 2005
- [203] Schranz D, Zartner P, Michel-Behnke I et al. Bioabsorbable metal stents for percutaneous treatment of critical reocclusion of the aorta in a newborn. *Catheter Cardiovasc Interv* 67:671–673, 2006
- [204] Erbel R, Rodermann J, Böse D et al. First absorbable metal stent implantation in human coronary arteries. *Am Coll Cardiol* 45 (3 Suppl 1): 7. Abstract 1058–1, 2005
- [205] Erbel R, Di Mario C, Bartunek J et al. PROGRESS-AMS (Clinical Performance and Angiographic Results of Coronary Stenting with Absorbable Metal Stents) Investigators. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective,

- non-randomised multicentre trial. *Lancet*. 369(9576):1869–75, 2007
- [206] Böse D, Eggebrecht H, Haude M et al. First absorbable metal stent implantation in human coronary arteries. *Am Heart Hosp J* 4:128–130, 2006
- [207] Eggebrecht H, Rodermann J, Hunold P et al. Images in cardiovascular medicine. Novel magnetic resonance-compatible coronary stent: the absorbable magnesium-alloy stent. *Circulation* 112:e303–4, 2005
- [208] Lind AY, Eggebrecht H, Erbel R. The invisible stent: imaging of an absorbable metal stent with multislice spiral computed tomography. *Heart* 91:1604, 2005
- [209] Böse D, Eggebrecht H, Erbel R. Absorbable metal stent in human coronary arteries: imaging with intravascular ultrasound. *Heart* 92:892, 2006
- [210] Waksman R, Erbel R, Di Mario C et al. Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. *JACC Cardiovasc Interv* 2:312–20, 2009
- [211] Erbel R, Böse D, Haude H et al. Absorbable coronary stents. New promising technology. *Herz*. 32(4):308–19, 2007
- [212] Di Mario C, Griffiths H, Goktekin O et al. Drug-Eluting bioabsorbable magnesium stent. *J Interv Cardiol* 17:391–395, 2004
- [213] Haude M, Erbel R, Erne P et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. *Lancet*. 381(9869):836–44, 2013
- [214] Haude M, Ince H, Abizaid A et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. *Lancet*. 387(10013):31–9, 2016
- [215] Rupprath G, Neuhaus KL. Valvuloplasty of congenital aortic stenosis. *Herz* 13:24–31, 1988
- [216] Rupprath G, Neuhaus KL. Percutaneous balloon valvuloplasty for aortic valve stenosis in infancy. *Am J Cardiol* 55(13 Pt 1):1655–6, 1985
- [217] Holmes DR, Nishimura RA, Reeder GS. Aortic and mitral balloon valvuloplasty: emergence of a new percutaneous technique. *Int J Cardiol* 16:227–33, 1987
- [218] Pop T, Erbel R, Henrichs KJ et al. Percutaneous angioplasty of the stenotic aortic valve: results, hemodynamic effects and complications. *Z Kardiol* 77:337–45, 1988
- [219] Sack S, Henrichs KJ, Erbel R et al. Echocardiographic and angiographic evaluation of left ventricular function during percutaneous transluminal aortic valvuloplasty. *Cathet Cardiovasc Diagn* 26:82–91, 1992
- [220] Sack S, Kahlert P, Khandanpour S et al. Revival of an old method with new techniques: balloon aortic valvuloplasty of the calcified aortic stenosis in the elderly. *Clin Res Cardiol* 97:288–97, 2008
- [221] Meier B, Friedli B, Oberhaensli I et al. Trefoil balloon for percutaneous valvuloplasty. *Cathet Cardiovasc Diagn* 12:277–81, 1986
- [222] Meier B, Friedli B, Oberhaensli I. Trefoil balloon for aortic valvuloplasty. *Br Heart J* 56:292–3, 1986
- [223] Andersen HR. History of percutaneous aortic valve prosthesis. *Herz* (2009); 34(5):343–346
- [224] Lung B, Baron G, Butchart EG et al. Prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. *Eur Heart J* 24:1231–1243, 2003
- [225] Bouma BJ, Brink RBvd, Meulen JHvd et al. To operate or not on elderly patients with aortic stenosis: the decision and its consequences. *Heart* 82:143, 1998
- [226] Ross J Jr, Braunwald E. Aortic stenosis. *Circulation* 38 (1 Suppl):61–7, 1968
- [227] Otto CM. Timing of aortic valve surgery. *Heart* 84:211–8, 2000
- [228] Erbel R, Jakob H. Aktueller Stand der interventionellen und chirurgischen Aortenklappenimplantation. *Herz* 34:1–8, 2009
- [229] Cribier A, Eltchaninoff H, Bash A et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. *Circulation* 106:3006–8, 2002
- [230] Sack S, Naber C, Kahlert P et al. Die perkutane Herzklappenimplantation in Aortenposition. *Herz* 30:433–7, 2005
- [231] Cribier A, Litzler PY, Eltchaninoff H et al. Technique of transcatheter aortic valve

- implantation with the Edwards-Sapien heart valve using the transfemoral approach. *Herz* (2009); 34(5):347–356
- [232] Sack S, Schofer J. Transcatheter based aortic valve implantation and future technologies. *Herz* (2009); 34(5):357–366
- [233] Al-Attar N, Nataf P. Development of aortic valve implantation. *Herz* (2009); 34(5):367–373
- [234] Bleiziffer S, Bauernschmitt R, Ruge H et al. Kathetergestützte Aortenklappenimplantation aus chirurgischer Sicht. *Herz* (2009); 34:374–380
- [235] Wendt D, Eggebrecht H, Kahlert P et al. Successful transapical aortic valve implantation four weeks before 97th birthday. *Interact Cardiovasc Thorac Surg* 8:684–6, 2009
- [236] Wendt D, Eggebrecht H, Kahlert P et al. Erfahrungen und Lernkurve mit der transapikalen Aortenklappenimplantation. *Herz* (2009); 34(5):388–397
- [237] Walther T, Dewey T, Borger MA et al. Transapical aortic valve implantation: step by step. *Ann Thorac Surg* 87:276–83, 2009
- [238] Falk V, Schwammenthal EE, Kempfert J et al. New anatomically oriented transapical aortic valve implantation. *Ann Thorac Surg* 87:925–6, 2009
- [239] Ye J, Cheung A, Lichtenstein SV et al. Transapical transcatheter aortic valve implantation: 1-year outcome in 26 patients. *J Thorac Cardiovasc Surg* 137:167–73, 2009
- [240] Greenbaum AB, Babaliaros VC, Chen MY et al. Transcaval access and closure for transcatheter aortic valve replacement: a prospective investigation. *J Am Coll Cardiol* 69:511–521, 2017
- [241] Webb JG, Munt B, Makkar RR et al. Percutaneous stent-mounted valve for treatment of aortic or pulmonary valve disease. *Catheter Cardiovasc Interv* 63:89–93, 2004
- [242] Webb JG, Altwegg L, Boone RH et al. Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes. *Circulation* 119:3009–16, 2009
- [243] Grube E, Laborde JC, Zickmann B et al. First report on a human percutaneous transluminal implantation of a self-expanding valve prosthesis for interventional treatment of aortic valve stenosis. *Catheter Cardiovasc Interv* 66:465–9, 2005
- [244] Grube E, Schuler G, Buellesfeld L et al. Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. *J Am Coll Cardiol* 50:69–76, 2007
- [245] Piazza N, Grube E, Gerckens U et al. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) CoreValve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. *Euro-Intervention* 4:242–9, 2008
- [246] Kälisch H, Sack S, Erbel R et al. Acute massive pulmonary embolism detected with angiography and intravascular ultrasound treated by pulmonary embolectomy. The hybrid concept. *Herz* 31:366–7, 2006
- [247] Jakob H, Tsagakis K, Szabo A et al. Rapid and safe direct cannulation of the true lumen of the ascending aorta in acute type A aortic dissection. *J Thorac Cardiovasc Surg* 134:244–5, 2007
- [248] Bonhoeffer P, Boudjemline Y, Oureshi SA et al. Percutaneous insertions of the pulmonary valve. *J Am Coll Cardiol* 39:1664–9, 2002
- [249] Frigiola A, Nordmeyer J, Bonhoeffer P. Percutaneous pulmonary valve replacement. *Coron Artery Dis* 20:189–91, 2009
- [250] Lurz P, Gaudin R, Taylor AM et al. Percutaneous pulmonary valve implantation. *Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu* 112–7, 2009
- [251] Comas GM, Widmann WD, Hardy MA. The legacy of Sir Henry Souttar: pioneer of the first mitral valvulotomy. *Curr Surg* 63:476–81, 2006
- [252] Effert S. Pre- and postoperative evaluation of mitral stenosis by ultrasound. *Am J Cardiol* 19:59–65, 1967
- [253] Matsuura Y, Fukunaga S, Ishihara H et al. Mechanics of percutaneous balloon valvotomy for mitral valvular stenosis. *Heart Vessels* 4:179–83, 1988
- [254] Inoue K. Percutaneous transvenous mitral commissurotomy (PTMC) by using Inoue-balloon. *Kyobu Geka* 42 (Suppl 8):596–602, 1989
- [255] Hernández García JM, Castillo Castro JL, Alonso Briaes JH et al. Actuarial follow-up after percutaneous mitral valvulotomy.

- Incidence and event-predicting factors. *Rev Esp Cardiol* 52:503–11, 1999
- [256] Miche E, Bogunovic N, Fassbender D et al. Predictors of unsuccessful outcome after percutaneous mitral valvulotomy including a new echocardiographic scoring system. *J Heart Valve Dis* 5:430–5, 1996
- [257] Padial LR, Freitas N, Sagie A et al. Echocardiography can predict which patients will develop severe mitral regurgitation after percutaneous mitral valvulotomy. *J Am Coll Cardiol* 27:1225–31, 1996
- [258] Schofer J, Siminiak T, Haude M et al. Percutaneous Mitral Annuloplasty for Functional Mitral Regurgitation. Results of the CARILLON Mitral Annuloplasty Device European Union Study. *Circulation* 2009 (Epub ahead of print)
- [259] Silvestry FE, Rodriguez LL, Herrmann HC et al. Echocardiographic guidance and assessment of percutaneous repair for mitral regurgitation with the Evalve MitraClip: lessons learned from EVEREST I. *J Am Soc Echocardiogr* 20:1131–40, 2007
- [260] Sack S, Kahlert P, Erbel R. Percutaneous mitral valve: A non-stented coronary sinus device for the treatment of functional mitral regurgitation in heart failure patients. *Minim Invasive Ther Allied Technol* 1:156–163, 2009
- [261] Herrmann HC, Rohatgi S, Wasserman HS et al. Mitral valve hemodynamic effects of percutaneous edge-to-edge repair with the MitraClip device for mitral regurgitation. *Catheter Cardiovasc Interv* 68:821–8, 2006
- [262] Bonis Md, Lapenna E, La Canna G et al. Mitral valve repair for functional mitral regurgitation in end-stage dilated cardiomyopathy: role of the „edge-to-edge“ technique. *Circulation* 112 (9 Suppl): I402–8, 2005
- [263] Cheung A, Webb JG, Barbanti M et al. 5-year experience with transcatheter transapical mitral valve-in-valve implantation for bioprosthetic valve dysfunction. *JACC* 61:1759–66, 2013
- [264] Lozonschi L, Quaden R, Edwards NM et al. Transapical mitral valve stent implantation. *Ann Thorac Surg* 86:745–8, 2008
- [265] Lutter G, Lozonschi L, Ebner A et al. First-in-Human off-pump transcatheter mitral valve replacement. *JACC CV Interv* 7:1077–1078, 2014
- [266] Lee SI, Kim HJ, Kim JB et al. Medtronic Duran AnCore versus Edwards MC3 rings for tricuspid annuloplasty. *Interact Cardiovasc Thorac Surg* 2017. doi: 10.1093/icvts/ivx005
- [267] Lee H, Sung K, Kim WS et al. Clinical and hemodynamic influences of prophylactic tricuspid annuloplasty in mechanical mitral valve replacement. *J Thorac Cardiovasc Surg* 151:788–95, 2016
- [268] David TE, David CM, Manhiot CJ. When is tricuspid valve annuloplasty necessary during mitral valve surgery? *Thorac Cardiovasc Surg* 150:1043–4, 2015
- [269] Choi JW, Park EA, Lee W et al. Changes in right ventricular volume and function after tricuspid valve surgery – tricuspid annuloplasty vs. tricuspid valve replacement. *Circ J* 80:1142–7, 2016
- [270] Lauten A, Figulla HR, Willich C et al. Percutaneous caval stent valve implantation: investigation of an interventional approach for treatment of tricuspid regurgitation. *Eur Heart J* 1:1274–81, 2010
- [271] Lauten A, Doenst T, Hamadanchi A et al. Percutaneous bicaval valve implantation for transcatheter treatment of tricuspid regurgitation: clinical observations and 12-month follow-up. *Circ Cardiovasc Interv.* 7:268–72, 2014
- [272] Laule M, Stangl V, Sanad W et al. Percutaneous transfemoral management of severe secondary tricuspid regurgitation with Edwards Sapien XT bioprosthesis: first-in-man experience. *J Am Coll Cardiol* 61:1929–1931, 2013
- [273] Campelo-Parada F, Perlman G, Philippon F et al. First-in-Man Experience of a Novel Transcatheter Repair System for Treating Severe Tricuspid Regurgitation. *J Am Coll Cardiol* 66:2475–2483, 2015
- [274] Schofer J, Tiburtius C, Hammerstingl C et al. Transfemoral Tricuspid Valve Repair Using a Percutaneous Mitral Valve Repair System. *J Am Coll Cardiol* 67:889–90, 2016
- [275] Schofer J, Bijuklic K, Tiburtius C et al. First-in-human transcatheter tricuspid valve repair in a patient with severely regurgitant tricuspid valve. *J Am Coll Cardiol* 65:1190–1195, 2015
- [276] Latib A, Agricola E, Pozzoli A et al. First-in-Man Implantation of a Tricuspid Annular Remodeling Device for Functional Tri-

- cuspid Regurgitation. *JACC Interv* 8:e211–4, 2015
- [277] Malesa M, Werner N, Nickenig G, Hammerstingl C et al. Transcatheter tricuspid valve repair in a patient with isolated functional tricuspid valve regurgitation. *Eur Heart J* 37:855, 2016
- [278] Latib A, Mangieri A, Vicentini L et al. Percutaneous Tricuspid Valve Annuloplasty Under Conscious Sedation (With Only Fluoroscopic and Intracardiac Echocardiography Monitoring). *JACC Cardiovasc Interv* 10:620–621, 2017
- [279] Hahn RT, Meduri CU, Davidson CJ et al. Early Feasibility Study of a Transcatheter Tricuspid Valve Annuloplasty: SCOUT Trial 30-Day Results. *J Amer Coll Cardiol* 69:1795–1806, 2017
- [280] Lahib A, Mangieri A. Transcatheter Tricuspid Valve Repair: New Valve, New Opportunities, New Challenges. *J Amer Coll Cardiol* 69:1807–1810, 2017
- [281] Yang Y, Bartel T, Caspari G et al. Echocardiographic detection of coronary artery fistula into the pulmonary artery. *Eur J Echocardiogr* 2:292–4, 2001
- [282] Oldenburg O, Philipp T, Forsting M et al. Percutaneous, catheter-based coil embolization of coronary fistula: determination of hemodynamic relevance. *J Interv Cardiol* 16:343–6, 2003
- [283] Kim MS, Casserly IP, Garcia JA et al. Percutaneous transcatheter closure of prosthetic mitral paravalvular leaks: are we there yet? *JACC Cardiovasc Interv* 2:81–90, 2009
- [284] Turi ZG. Fitting a round plug in a crescent-shaped hole: the percutaneous approach to paravalvular leaks. *Catheter Cardiovasc Interv* 73:842–3, 2009
- [285] Pate GE, Al Zubaidi A, Chandavimol M et al. Percutaneous closure of prosthetic paravalvular leaks: case series and review. *Catheter Cardiovasc Interv* 68:528–33, 2006
- [286] Uppstrom EL, Kern MJ, Mezei L et al. Balloon catheter closure of patent foramen ovale complicating right ventricular infarction: improvement of hypoxia and intracardiac venous shunting. *Am Heart J* 116:1092–7, 1988
- [287] Engelhardt W, Messmer BJ, Bernuth Gv. Transient transcatheter balloonclosure of patent foramen ovale following surgical repair of critical pulmonary stenosis. *Thorac Cardiovasc Surg* 38:377–8, 1990
- [288] Ende DJ, Chopra PS, Rao PS. Transcatheter closure of atrial septal defect or patent foramen ovale with the buttoned device for prevention of recurrence of paradoxical embolism. *Am J Cardiol* 78:233–6, 1996
- [289] Windecker S, Wahl A, Chatterjee T et al. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. *Circulation* 101:893–8, 2000
- [290] Wahl A, Tai T, Praz F et al. Late results after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism using the Amplatzer PFO occluder without intraprocedural echocardiography: effect of device size. *JACC Cardiovasc Interv* 2:116–23, 2009
- [291] Walsh KP, Wilmshurst PT, Morrison WL. Transcatheter closure of patent foramen ovale using the Amplatzer septal occluder to prevent recurrence of neurological decompression illness in divers. *Heart* 81:257–61, 1999
- [292] Bartel T, Konorza T, Arjumand J et al. Intracardiac echocardiography is superior to conventional monitoring for guiding device closure of interatrial communications. *Circulation* 107:795–7, 2008
- [293] Wahl A, Praz F, Stinimann J et al. Safety and feasibility of percutaneous closure of patent foramen ovale without intra-procedural echocardiography in 825 patients. *Swiss Med Wkly* 138:567–72, 2008
- [294] Ruiz CE, Kipshidze N, Chiam PT et al. Feasibility of patent foramen ovale closure with no-device left behind: first-in-man percutaneous suture closure. *Catheter Cardiovasc Interv* 71:921–6, 2008
- [295] Wahl A, Praz F, Findling O et al. Percutaneous closure of patent foramen ovale for migraine headaches refractory to medical treatment. *Catheter Cardiovasc Interv* 74:124–9, 2009
- [296] Patel ME et al. Implantable atrial flow regulator for severe, irreversible pulmonary arterial hypertension. *EuroIntervention* 11(6):706–9,
- [297] Feldman T, Komtebedde J, Burkhoof D et al. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure: Rationale and Design of the Randomized Trial to REDUCE Elevated Left Atrial Pres-

- sure in Heart Failure (REDUCE LAP-HF I). *Circ Heart Fail.* 9, 2016. pii:e003025
- [298] Kuhn H, Loogen F. Use of beta-receptor blockers in hypertrophic obstructive cardiomyopathy (HOCM). *Internist (Berl)* 19:527–31, 1978
- [299] Schulte HD, Bircks W, Körfer R et al. Surgical aspects of typical subaortic and atypical midventricular hypertrophic obstructive cardiomyopathy (HOCM). *Thorac Cardiovasc Surg* 29:375–80, 1981
- [300] Kuhn H, Gietzen F, Leuner C et al. Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Studies to develop a new catheter-based concept of treatment. *Eur Heart J* 18:846–51, 1997
- [301] Inoue H, Waller BF, Zipes DP. Intracoronary ethyl alcohol or phenol injection ablates aconitine-induced ventricular tachycardia in dogs. *J Am Coll Cardiol* 10:1342–9, 1987
- [302] Kay GN, Epstein AE, Buben RS et al. Intracoronary ethanol ablation for the treatment of recurrent sustained ventricular tachycardia. *J Am Coll Cardiol* 19:159–68, 1992
- [303] Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. *Lancet* 346:211–4, 1995
- [304] Gietzen F, Leuner C, Gerenkamp T et al. Katheterinterventionelle Therapie der hypertrophisch obstruktiven Kardiomyopathie durch Alkoholablation des ersten Septalastes der linken Koronararterie. *Z Kardiol (Suppl 2)*:3, 1996
- [305] Seggewiss H, Gleichmann U, Fassbender D et al. Catheter treatment of hypertrophic cardiomyopathy: acute hemodynamic and clinical results. *Circulation* 94 (Suppl 1):617, 1996
- [306] Kuhn HJ. Induced septal infarction/non-surgical septal reduction for hypertrophic obstructive cardiomyopathy. *Circulation* 97:708–9, 1998
- [307] Kuhn H, Seggewiss H, Gietzen FH et al. Catheter-based therapy for hypertrophic obstructive cardiomyopathy. First in-hospital outcome analysis of the German TASH Registry. *Z Kardiol* 93:23–31, 2004
- [308] Kuhn H, Lawrenz T, Lieder F et al. Survival after transcatheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience. *Clin Res Cardiol* 97:234–43, 2008
- [309] Faber L, Seggewiss H, Gietzen FH et al. Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German Cardiac Society. *Z Kardiol* 94:516–23, 2005
- [310] Lawrenz T, Lieder F, Bartelsmeier M et al. Predictors of complete heart block after transcatheter ablation of septal hypertrophy: results of a prospective electrophysiological investigation in 172 patients with hypertrophic obstructive cardiomyopathy. *J Am Coll Cardiol* 49:2356–63, 2007
- [311] Konorza TFM, Kaelsch H, Elstermann v. Elster C et al. Interventionelle Behandlung der Hypertrophen Obstruktiven Kardiomyopathie mit einer neuen Generation von Mikrosphären. *Clin Res Cardiol* 98, V650, 2009
- [312] Singer MI, Rowen M, Dorsey TJ. Transluminal aortic balloon angioplasty for coarctation of the aorta in the newborn. *Am Heart J* 103:131–2, 1982
- [313] D'Souza VJ, Velasquez G, Weesner KM et al. Transluminal angioplasty of aortic coarctation with a two-balloon technique. *Am J Cardiol* 54:457–8, 1984
- [314] Attia IM, Lababidi ZA. Early results of balloon angioplasty of native aortic coarctation in young adults. *Am J Cardiol* 61:930–1, 1988
- [315] Erbel R, Sievert H, Bussmann WD et al. Aortic isthmus stenosis-dilatation in adulthood. A German cooperative study. *Z Kardiol* 77:797–804, 1988
- [316] McCrindle BW, Jones TK, Morrow WR et al. Acute results of balloon angioplasty of native coarctation versus recurrent aortic obstruction are equivalent. Valvuloplasty and Angioplasty of Congenital Anomalies (VACA) Registry Investigators. *J Am Coll Cardiol* 28:1810–7, 1996
- [317] Rao PS, Kosciak R. Validation of risk factors in predicting recoarctation after initially successful balloon angioplasty for native aortic coarctation. *Am Heart J* 130:116–21, 1995
- [318] Erbel R, Bednarczyk I, Pop T et al. Detection of dissection of the aortic intima and media after angioplasty of coarctation of the aorta. An angiographic, computer tomographic, and echocardiographic comparative study. *Circulation* 81:805–14, 1990

- [319] Erbel R, Gorge G, Gerber T et al. Dissection following balloon angioplasty of aortic coarctation: review of the literature. *I Interv Cardiol* 5:99–109, 1992
- [320] Rao PS. Aortic rupture after balloon angioplasty of aortic coarctation. *Am Heart J* 125:1205–6, 1993
- [321] Aydogan U, Dindar A, Gurgan L et al. Late development of dissection aneurysm following balloon angioplasty of native aortic coarctation. *Cathet Cardiovasc Diagn* 36:226–9, 1995
- [322] Ozawa A, Predescu D, Chaturvedi R et al. Cutting balloon angioplasty for aortic coarctation. *J Invasive Cardiol* 21:295–9, 2009
- [323] Bulbul ZR, Bruckheimer E, Love JC et al. Implantation of balloon-expandable stents for coarctation of the aorta: implantation data and short-term results. *Cathet Cardiovasc Diagn* 39:36–42, 1996
- [324] Suárez de Lezo J, Pan M, Romero M et al. Balloon-expandable stent repair of severe coarctation of aorta. *Am Heart J* 129:1002–8, 1995
- [325] Fletcher SE, Cheatham JP, Froeming S. Aortic aneurysm following primary balloon angioplasty and secondary endovascular stent placement in the treatment of native coarctation of the aorta. *Cathet Cardiovasc Diagn* 44:40–4, 1998
- [326] Suárez de Lezo J, Pan M, Romero M et al. Immediate and follow-up findings after stent treatment for severe coarctation of aorta. *Am J Cardiol* 83:400–6, 1999
- [327] Forbes TJ, Moore P, Pedra CA et al. Intermediate follow-up following intravascular stenting for treatment of coarctation of the aorta. *Catheter Cardiovasc Interv* 70:569–77, 2007
- [328] Golden AB, Hellenbrand WE. Coarctation of the aorta: stenting in children and adults. *Catheter Cardiovasc Interv* 69:289–99, 2007
- [329] Mahadevan VS, Vondermuhll IF, Mullen MJ. Endovascular aortic coarctation stenting in adolescents and adults: angiographic and hemodynamic outcomes. *Catheter Cardiovasc Interv* 67:268–75, 2006
- [330] Kay JD, Chan KC. Aortic pseudo aneurysm complicating coarctation stenting successfully treated with a PTFE balloon expandable covered stent. *Congenit Heart Dis* 3:209–12, 2008
- [331] Börner N, Erbel R, Braun B et al. Diagnosis of aortic dissection by transoesophageal echocardiography. *Am J Cardiol* 54:1157–8, 1984
- [332] Erbel R, Börner N, Steller D et al. Detection of aortic dissection by transoesophageal echocardiography. *Br Heart J* 58:45–51, 1987
- [333] Erbel R, Engberding R, Daniel W et al. Echocardiography in diagnosis of aortic dissection. *Lancet* 1:457–61, 1989
- [334] Seybold-Epting W, Meyer J, Hallman GL et al. Surgical treatment of acute dissection of the ascending aorta (author's transl). *Thoraxchir Vask Chir* 23:187–91, 1975
- [335] Erbel R, Oelert H, Meyer J et al. Effect of medical and surgical therapy on aortic dissection evaluated by transesophageal echocardiography. Implications for prognosis and therapy. The European Cooperative Study Group on Echocardiography. *Circulation* 87:1604–15, 1993
- [336] Matsumura JS, Katzen BT, Sullivan TM et al. Excluder Bifurcated Endoprosthesis Investigators. Predictors of survival following open and endovascular repair of abdominal aortic aneurysms. *Ann Vasc Surg* 23:153–8, 2009
- [337] Razavi M, Semba C, Dake M. Stents match surgery in treating aortic aneurysms. *Diagn Imaging (San Franc)* 20:54–6, 1998
- [338] Demers P, Miller C, Scott Mitchell R et al. Chronic traumatic aneurysms of the descending thoracic aorta: mid-term results of endovascular repair using first and second-generation stent-grafts. *Eur J Cardiothorac Surg* 25:394–400, 2004
- [339] Conrad MF, Cambria RP. Contemporary management of descending thoracic and thoracoabdominal aortic aneurysms: endovascular versus open. *Circulation* 117:841–52, 2008
- [340] Nesser HJ, Eggebrecht H, Baumgart D et al. Emergency stent-graft placement for impending rupture of the descending thoracic aorta. *J Endovasc Ther* 9 (Suppl 2):II72–8, 2002
- [341] Buhr C, Eggebrecht H, Erbel R. Percutaneous occlusion of posttraumatic aortic arch pseudoaneurysm by catheter-based delivery of thrombin. *Catheter Cardiovasc Interv* 70:713–7, 2007

- [342] Seo Y, Kaneko M, Kato M et al. Transcatheter stent-graft implantation for the treatment of acute aortic dissection – rupture of aneurysm because of perigraft leakage. *Jpn J Thorac Cardiovasc Surg* 46:179–84, 1998
- [343] Dake MD, Kato N, Mitchell RS et al. Endovascular stent-graft placement for the treatment of acute aortic dissection. *N Engl J Med* 340:1546–52, 1999
- [344] Nienaber CA, Fattori R, Lund G et al. Nonsurgical reconstruction of thoracic aortic dissection by stent-graft placement. *N Engl J Med* 340:1539–45, 1999
- [345] Eggebrecht H, Nienaber CA, Neuhäuser M et al. Endovascular stent-graft placement in aortic dissection: a meta-analysis. *Eur Heart J* 27:489–98, 2006
- [346] Huptas S, Mehta RH, Kühl H et al. Aortic remodeling in type B aortic dissection: effects of endovascular stent-graft repair and medical treatment on true and false lumen volumes. *Endovasc Ther* 16:28–38, 2009
- [347] Eggebrecht H, Kahlert P, Kaiser GM et al. Technical Development and Initial Animal Experience with a Novel Uncovered Self-Expanding, Highly Flexible Aortic Stent Prosthesis with Improved Side Branch Access. *Cath Cardiovasc Int* (2009), 16, 539–545
- [348] Jakob H, Tsagakis K, Leyh R et al. Development of an integrated stent graft-dacron prosthesis for intended one-stage repair in complex thoracic aortic disease. *Herz* 30:766–8, 2005
- [349] Jakob H, Jakob H, Tsagakis K et al. Combining classic surgery with descending stent grafting for acute DeBakey type I dissection. *Ann Thorac Surg* 86:95–101, 2008
- [350] Borst HG, Walterbusch G, Schaps D. Extensive aortic replacement using „elephant trunk“ prosthesis. *J Thorac Cardiovasc Surg* 31:37–40, 1983
- [351] Eggebrecht H, Mehta RH, Metzounve H et al. Clinical implications of systemic inflammatory response syndrome following thoracic aortic stent-graft placement. *J Endovasc Ther* 15:135–43, 2008
- [352] Gorla R, Erbel R, Kahlert P et al. Clinical features and prognostic value of stent-graft-induced post-implantation syndrome after thoracic endovascular aortic repair in patients with type B acute aortic syndromes. *Eur J Cardiothorac Surg* 49:1239–47, 2016
- [353] Kuehl H, Eggebrecht H, Boes T et al. Detection of inflammation in patients with acute aortic syndrome: comparison of FDG-PET/CT imaging and serological markers of inflammation. *Heart* 94:1472–7, 2008
- [354] Gorla R, Erbel R, Kuehl H et al. Prognostic value of (18)F-fluorodeoxyglucose PET-CT imaging in acute aortic syndromes: comparison with serological biomarkers of inflammation. *Int J Cardiovasc Imaging* 31:1677–85, 2015
- [355] Eggebrecht H, Mehta RH, Dechene A et al. Aortoesophageal fistula after thoracic aortic stent-graft placement: a rare but catastrophic complication of a novel emerging technique. *JACC Cardiovasc Interv* 2:570–6, 2009
- [356] Engelhardt H, Paul A, Niebel W et al. Successful treatment of secondary aortoesophageal fistula after thoracic endovascular aortic repair]. *Dtsch Med Wochenschr* 135:2076–80, 2010
- [357] Eggebrecht H, Nienaber CA, Neuhäuser M et al. Endovascular stent-graft placement in aortic dissection: a meta-analysis. *Eur Heart J* 27:489–98, 2006
- [358] Eggebrecht H, Pamler R, Zipfel B et al. Stent-graft implantation in the thoracic aorta. Results of an interdisciplinary survey in Germany. *Dtsch Med Wochenschr* 131:730–4, 2006
- [359] Eggebrecht H, Kühl H, Kaiser GM et al. Feasibility of real-time magnetic resonance-guided stent-graft placement in a swine model of descending aortic dissection. *Eur Heart J* 27:613–20, 2006
- [360] Erbel R, Aboyans V, Boileau C et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). *Eur Heart J* 35:2873–926, 2014. Erratum in: *Eur Heart J* 36:2779, 2015
- [361] Benichoux R. The surgical treatment of massive pulmonary embolism; report of 22 cases of Trendelenburg's operation. *J Int Chir* 11:464–91, 1951
- [362] Crafoord C, Benichoux R. The surgical treatment of massive embolism of the pul-

- monary artery. *Rev Med Nancy* 77:523–45, 1952
- [363] Cooley DA, Beall AC Jr, Alexander JK. Acute massive pulmonary embolism. Successful surgical treatment using temporary cardiopulmonary bypass. *JAMA* 177:283–6, 1961
- [364] Cooley DA, Beall AC Jr. Surgical treatment of acute massive pulmonary embolism using temporary cardiopulmonary bypass. *Dis Chest* 41:102–4, 1962
- [365] Rosenberg DM, Ekman PJ, Pearce CW. Surgical treatment of massive pulmonary embolism with the use of extracorporeal circulation. *J Cardiovasc Surg (Torino)* 3:428–35, 1962
- [366] Beall AC Jr, Cooley DA. Use of cardiopulmonary bypass for resuscitation and treatment of acute massive pulmonary embolism. *Pac Med Surg* 75:67–70, 1967
- [367] Taguchi K, Okumori M, Kay JH. Treatment of massive pulmonary embolism with pulmonary artery aspiration employing cardiopulmonary bypass. An experimental study. *J Thorac Cardiovasc Surg* 59:645–54, 1970
- [368] Miller GA, Sutton GC, Kerr IH et al. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. *Br Med J* 2:681–4, 1971
- [369] Renkes-Hegendörfer U, Hermann K. Successful treatment of a case of fulminant massive pulmonary embolism with streptokinase. *Circulation* 77:253–60, 1988
- [370] Greenfield LJ, Elkins RC, Brown PP. Treatment of acute massive pulmonary embolism by transvenous catheter embolectomy and a new filter device. *Bull Soc Int Chir* 34:57–60, 1975
- [371] Nakao M, Haruna H, Okamura M et al. Surgical treatment of massive pulmonary embolism – an experience of using ECMO in cardiopulmonary failure. *Kyobu Geka* 40:721–5, 1987
- [372] Cuccia C, Campana M, Franzoni P et al. Effectiveness of intravenous rtPA in the treatment of massive pulmonary embolism and right heart thromboembolism. *Am Heart J* 126:468–72, 1993
- [373] Sigmund M, Rubart M, Vom Dahl J et al. Successful treatment of massive pulmonary embolism by combined mechanical and thrombolytic therapy. *J Interv Cardiol* 4:63–8, 1991
- [374] Tomkowski W, Borowiec B, Hajduk B et al. Low doses of rtPA administered as a bolus in treatment of clinically acute massive pulmonary embolism. *Pneumonol Alergol Pol* 64 (Suppl 2):161–5, 1996
- [375] Uflacker R, Strange C, Vujic I. Massive pulmonary embolism: preliminary results of treatment with the Amplatz thrombectomy device. *J Vasc Interv Radiol* 7:519–28, 1996
- [376] Schmitz-Rode T, Janssens U, Duda SH et al. Massive pulmonary embolism: percutaneous emergency treatment by pigtail rotation catheter. *J Am Coll Cardiol* 36:375–80, 2000
- [377] Taskinen P, Mosorin M, Lepojrvi M. Treatment of massive pulmonary embolism through embolectomy. *Duodecim* 120:1256–60, 2004
- [378] Zeni PT Jr, Blank BG, Peeler DW. Use of rheolytic thrombectomy in treatment of acute massive pulmonary embolism. *J Vasc Interv Radiol* 14:1511–5, 2003
- [379] Kadner A, Schmidli J, Schönhoff F et al. Excellent outcome after surgical treatment of massive pulmonary embolism in critically ill patients. *J Thorac Cardiovasc Surg* 136:448–51, 2008
- [380] Pieri S, Agresti P. Hybrid treatment with angiographic catheter in massive pulmonary embolism: mechanical fragmentation and fibrinolysis. *Radiol Med* 112:837–49, 2007
- [382] Barbosa MA, Oliveira DC, Barbosa AT et al. Treatment of massive pulmonary embolism by percutaneous fragmentation of the thrombus. *Arq Bras Cardiol* 88:279–84, 2007
- [383] Kucher N, Boekstegers P, Müller OJ et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. *Circulation* 129:479–86, 2014
- [384] Kälsch H, Sack S, Erbel R et al. Acute massive pulmonary embolism detected with angiography and intravascular ultrasound treated by pulmonary embolectomy. The hybrid concept. *Herz* 31:366–7, 2006
- [385] Konorza T, Plicht B, Aidonidis G et al. Percutaneous dilatation of the pulmonary arteries and combined selective lysis with urokinase and heparin as a new treatment option in patients with chronic embolic

- lung embolism. *EuroIntervention*, 5:E–62, 2009
- [386] Konstantinides SV, Torbicki A, Agnelli G et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. *Eur Heart J* 35:3033–69, 2014. Erratum in: *Eur Heart J* 36:2666, 2015. *Eur Heart J* 36:2642, 2015
- [387] Erbel R, Konorza T, Haude M et al. Rolle der interventionellen Kardiologie in der Therapie der koronaren Herzerkrankung. *Herz* 27:471–80, 2002
- [388] Wieneke H, Dirsch O, Sawitowski T et al. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. *Catheter Cardiovasc Interv* 60:399–407, 2003
- [389] Tunstall-Pedoe H, Vanuzzo D, Hobbs M et al. for the MONICA project. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. *Lancet* 355:688–700, 2000

2 Vorbereitungen der Herzkatheteruntersuchung

- [1] Hamm CW et al. Leitlinie Diagnostische Herzkatheteruntersuchung. Clin Res Cardiol 97:475–512, 2008
- [2] Bonzel T et al. Leitlinie Perkutane Koronarinterventionen (PCI), Clin Res Cardiol 97:513–547, 2008
- [3] Campeau L. Grading of angina pectoris. Circulation 54:522–3, 1976
- [4] Hamm CW, Braunwald E. A classification of unstable angina revisited. Circulation 102: 118–122, 2000
- [5] The Criteria Committee of the New York Heart Association, Inc. (Kossmann CE, chairman). Nomenclature and criteria for diagnosis. In: Diseases of the heart and blood vessels, 6th ed. Boston, Little, Brown & Company, 1964:110–4
- [6] Sechtem U, Achenbach S, Gitt AK et al. Kommentar zu den 2013 Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management der stabilen koronaren Herzkrankheit (KHK). Kardiologie 9:159–164, 2015
- [7] Nensa F, Poeppel T, Tezgah E et al. Integrated FDG PET/MR Imaging for the Assessment of Myocardial Salvage in Reperused Acute Myocardial Infarction. Radiology 2015 Aug; 276(2):400–7
- [8] Zhang S, Joseph AA, Voit D et al. Real-time magnetic resonance imaging of cardiac function and flow-recent progress. Quant Imaging Med Surg 4(5):313–29, 2014
- [9] Roffi M, Patrono C, Collet JP et al. Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37:267–315, 2016
- [10] Gueant-Rodriguez RM, Romano A, Barbaud A et al. Hypersensitivity reactions to iodinated contrast media, Curr Pharm Des 12/29:3359–72, 2006
- [11] Hamasaki O, Nakahara T, Katoh Y et al. Experience of cerebral angiography using gadolinium for renal insufficiency. No To Shinkei 55:167–71, 2003
- [12] Strunk HM, Schild H. Actual clinical use of gadolinium-chelates for non MRI applications. Eur Radiol 14:1055–62, 2004
- [13] Kälsch H, Kälsch T, Eggebrecht H et al. Gadolinium-based coronary angiography in patients with contraindication for iodinated x-ray contrast medium: A word of caution. J Interv Cardiol 21:167–74, 2008
- [14] Hammer FD, Goffette PP, Malaise J et al. Gadolinium dimeglumine: An alternative contrast agent for digital subtraction angiography. Eur Radiol 9:128–36, 1999
- [15] Albrecht T, Dawson P. Gadolinium-DTPA as x-ray contrast media in clinical studies. Br J Radiol 73:878–82, 2000
- [16] Gupta R, Uretsky BF. Gadodiamide-based coronary angiography in a patient with severe renal insufficiency. J Interv Cardiol 18:379–83, 2005
- [17] Briguori C, Colombo A, Airolidi F et al. Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Cath Cardiovasc Interv 67:175–80, 2006
- [18] Bartolini ME, Pekar J, Chettle D et al. An investigation of the toxicity of gadolinium based MRI contrast agents using neutron activation analysis. J Magn Reson Imaging 21:541–44, 2003
- [19] Nelson KL, Gifford LM, Lauber-Huber C et al. Clinical safety of gadopentetate dimeglumine. Radiology 196:439–43, 1995
- [20] Tishler S, Hoffman JC. Anaphylactoid reactions to i.v. gadopentetate dimeglumine. Am J Neuroradiol 11:1167–69, 1990

- [21] Cho KJ. Carbon Dioxide Angiography: Scientific Principles and Practice. *Vasc Specialist Int* 2015 Sep; 31(3):67–80
- [22] Bartorelli AL, Marenzi G. Contrast-Induced Nephropathy. *J Intervent Cardiol* 21:74–85, 2008
- [23] Cox CD, Tsikouris P. Preventing Contrast Nephropathy: What is the best strategy? A review of the literature. *J Clin Pharmacol* (2004); 44:327–337
- [24] Matuszczyk A, Hahn S, Böse D et al. Gadolinium as an alternative contrast agent during cardiac catheterization in patient with iodine-induced hyperthyroidism. *Exp Clin Endocrinol Diabetes* (2006); 114(6):336–338
- [25] Plicht B, Lind A, Erbel R. Infective endocarditis: New ESC guidelines 2015. *Internist* 57: 675–90, 2016
- [26] Achenbach S, Naber C, Levenson B et al. Indikationen zur invasiven Koronardiagnostik und Revaskularisation. *Kardiologie* 11:272–84, 2017
- [27] Laufs U, Anker SD, Falk V et al. Kommentar zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnostik und Behandlung der akuten und chronischen Herzinsuffizienz. *Kardiologie* 11:183–92, 2017
- [28] Kastrati A, Baldus S, Cremer J et al. Kommentar zu den „2014 ESC/EACTS Guidelines on Myocardial Revascularization“ der European Society of Cardiology (ESC) und der European Association for Cardio-Thoracic Surgery (EACTS). *Kardiologie* 10:359, 2016
- [29] Mehilli J, Hamm, CW, Landmesser U et al. Kommentar zu den 2015-Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management des akuten Koronarsyndroms ohne ST-Hebungen (NSTEMI-ACS). *Kardiologie* 10:351, 2016
- [30] Delgado V, Marsan NA, de Waha S et al. 2023 ESC Guidelines for the management of endocarditis: Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM), *Eur Heart J* 2023; ehad193
- [31] Reinecke H, Braun M, Frankenstein L et al. Kriterien für die Notwendigkeit und Dauer von Krankenhausbehandlungen bei Koronarangiografien und -interventionen. *Kardiologie* 9:295–302, 2015
- [32] Byrne RA, Roscello X, Coughlan JJ et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC), *Eur Heart J* 2023; ehad191
- [33] Schächinger V, Nef H, Achenbach S et al. Leitlinie zum Einrichten und Betreiben von HKL und Hybridoperationssälen/Hybridlaboren, 3. Auflage. *Kardiologie* 9:89–123, 2015
- [33a] Schächinger V, Kelm M. Addendum zur Leitlinie zum Einrichten und Betreiben von Herzkatheterlaboren und Hybridoperationssälen/Hybridlaboren Neue Strahlenschutzgesetzgebung 2019 und Aktualisierung der Arbeitsanweisung. *Kardiologie* 13:193–197, 2019
- [34] Schächinger V, Nef H, Achenbach S et al. Arbeitsanweisung in HKL und Hybridoperationssaal. *Kardiologie* 9:29–34, 2015

3 Punktionstechniken und Verschlusssysteme

- [1] Schnyder G et al. Common femoral artery anatomy is influenced by demographics and comorbidity: implications for cardiac and peripheral invasive studies. *Cathet Cardiovasc Intervent* 2001; 53:289–295
- [1a] Stone PA, Campbell JE, AbuRahma AF. Femoral pseudoaneurysms after percutaneous access. *J Vasc Surg* 2014; 60(5): 1359–1366
- [2] Dotter CT, Rösch J, Robinson M. Fluoroscopic guidance in femoral artery puncture. *Radiology* 1978; 127:266–7
- [3] Bashore TM et al. Cardiac catheterization laboratory standards: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents (ACC/SCA & I Committee to Develop an Expert Consensus Document on Cardiac Catheterization Laboratory Standards). *J Am Coll Cardiol* 2001; 37:2170–2214
- [4] Kahlert P et al. A modified „preclosure technique“ after percutaneous aortic valve replacement. *Catheter Cardiovasc Interv* 2008; 72:877–84
- [5] Petroglou D, Didagelos M, Chalikias G et al. Manual versus mechanical compression of the radial artery after transradial coronary angiography: the MEMORY Multicenter Randomized Trial. *JACC Cardiovasc Interv* 2018; 11:1050–1058
- [6] Kwok CS, Kontopantelis E, Kinnaird T et al. British Cardiovascular Intervention Society (BCIS) and National Institute of Cardiovascular Outcomes Research (NICOR). Retroperitoneal hemorrhage after percutaneous coronary intervention: incidence, determinants, and outcomes as recorded by the British Cardiovascular Intervention Society. *Circ Cardiovasc Interv* 2018; 11(2):e005866
- [7] Eggebrecht H et al. Impact of gender on femoral access complications secondary to application of a collagen-based vascular closure device. *J Invasive Cardiol* 2004; 16:247–250
- [8] Amer O, Binger S, Desch S et al. Incidence, predictors, and treatment options of critical limb ischaemia after use of collagen plug-based vascular closure devices. *Euro-Intervention* 2015; 11:816–823
- [9] Leibundgut G, Pache J, Schulz S et al. Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non st-segment elevation myocardial infarction. *J Interv Cardiol* 2013; 26:623–629
- [10] Rao AK, Pratt C, Berke A et al. Thrombolysis in myocardial infarction (TIMI) trial – phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. *J Am Coll Cardiol* 1988; 11:1–11
- [11] The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. *N Engl J Med* 1993; 329:673–682
- [12] Serebruany VL, Atar D. Assessment of bleeding events in clinical trials – proposal of a new classification. *Am HJ Cardiol* 2007; 99:288–290
- [13] Mehran R, Rao SV, Bhatt DL et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. *Circulation* 2011; 123:2736–2747
- [14] Chan YC, Morales JP, Reidy JF et al. Management of spontaneous and iatrogenic retroperitoneal haemorrhage: conservative management, endovascular intervention or open surgery? *Int J Clin Pract* 2008; 62:1604–1613
- [15] Chatterjee T, Do DD, Kaufmann U et al. Ultrasound-guided compression repair for treatment of femoral artery pseudoaneu-

- rysm: acute and follow-up results. *Cathet Cardiovasc Diagn* 1996; 38:335–340
- [16] Webber GW, Jang J, Gustavson S et al. Contemporary management of postcatheterization pseudoaneurysms. *Circulation* 2007; 115:266–274
 - [17] Omoigui NA, Califf RM, Pieper K et al. Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). *J Am Coll Cardiol* 1995; 26:922–930
 - [18] Tisi PV, Callam MJ. Surgery versus non-surgical treatment for femoral pseudoaneurysm. *Cochrane Database Syst Rev* 2006; 25(1):CD004981
 - [19] Tisi PV, Callam MJ. Treatment for femoral pseudoaneurysms. *Cochrane Database Syst Rev* 2009; 5(2)
 - [20] Schaub F, Theiss W, Busch R et al. Management of 219 consecutive cases of postcatheterization pseudoaneurysm. *J Am Coll Cardiol* 1997; 30(3):670–675
 - [21] Schaub F, Theiss W, Heinz M et al. New aspects in ultrasound-guided compression repair of postcatheterization femoral artery injuries. *Circulation* 1994; 90(4):1861–1865
 - [22] Waksman R, King SB III, Douglas JS et al. Predictors of groin complications after balloon and new-device coronary intervention. *Am J Cardiol* 1995; 75(14):886–889
 - [23] Lumsden AB, Miller JM, Kosinski AS et al. A prospective evaluation of surgically treated groin complications following percutaneous cardiac procedures. *Am Surg* 1994; 60(2):132–137
 - [24] Zahn R, Thoma S, Fromm E et al. Do 5-F catheters reduce the incidence of a pseudoaneurysm? *Int Angiol* 1996; 15(3):257–260
 - [25] Kent KC, McArdle CR, Kennedy B et al. Accuracy of clinical examination in the evaluation of femoral false aneurysm and arteriovenous fistula. *Cardiovasc Surg* 1993; 1(5):504–507
 - [26] Hanson JM, Atri M, Power N. Ultrasound guided thrombin injection of iatrogenic groin pseudoaneurysm: Doppler features and technical tips. *Radiology* 2008; 127(1):154–163
 - [27] Kang SS, Labropoulos N, Mansour MA et al. Percutaneous ultrasound guided thrombin injection: a new method for treating postcatheterization femoral pseudoaneurysms. *J Vasc Surg* 1998; 27(6):1032–1038
 - [28] Powell A, Benenati JF, Becker GJ et al. Percutaneous ultrasound-guided thrombin injection for the treatment of pseudoaneurysms. *J Am Coll Surg* 2002; 194(1 Suppl):S53–S57
 - [29] Babu SC, Piccorelli GO, Shah PM et al. Incidence and results of arterial complications among 16,350 patients undergoing cardiac catheterization. *J Vasc Surg* 1989; 10(2):113–116
 - [30] Dangas G, Mehran R, Kokolis S et al. Vascular complications after percutaneous coronary interventions following hemostasis with manual compression versus arteriotomy closure devices. *J Am Coll Cardiol* 2001; 38(3):638–641
 - [31] Roberts SR, Main D, Pinkerton J. Surgical therapy of femoral artery pseudoaneurysm after angiography. *Am J Surg* 1987; 154(6):676–680
 - [32] Jain SP, Roubin GS, Iyer SS et al. Closure of an iatrogenic femoral artery pseudoaneurysm by transcatheter coil embolization. *Cathet Cardiovasc Diagn* 1996; 39(3):317–319
 - [33] Owen RJ, Haslam PJ, Elliott ST et al. Percutaneous ablation of peripheral pseudoaneurysms using thrombin: a simple and effective solution. *Cardiovasc Intervent Radiol* 2000; 23(6):441–446
 - [33] Samal AK, White CJ, Collins TJ et al. Treatment of femoral artery pseudoaneurysm with percutaneous thrombin injection. *Catheter Cardiovasc Interv* 2001; 53(2):259–263
 - [34] Brummer U, Salcuni M, Salvati F et al. Repair of femoral postcatheterization pseudoaneurysm and arteriovenous fistula with percutaneous implantation of endovascular stent. *Nephrol Dial Transplant* 2001; 16(8):1728–1729
 - [35] Rath J, Marx R, Ganschow US et al. Formation, therapy and prevention of false aneurysm of the femoral artery following diagnostic and interventional heart catheterization. *Dtsch Med Wochenschr* 1997; 122(24):771–777
 - [36] Heis HA, Bani-Hani KE, Elheis MA et al. Postcatheterization femoral artery pseudoaneurysms: therapeutic options: A case-controlled study. *Int Surg* 2008; 6(3):214–219

- [37] Heis HA, Bani-Hani KE, Elheis MA et al. Postcatherization femoral artery pseudoaneurysms: therapeutic options: A case-controlled study. *Int Surg* 2008; 6(3):214–219
- [38] Samuels D, Orron DE, Kessler A et al. Femoral artery pseudoaneurysm: Doppler sonographic features predictive for spontaneous thrombosis. *J Clin Ultrasound* 1997; 25(9):497–500
- [39] Feld R, Patton GM, Carabasi RA et al. Treatment of iatrogenic femoral artery injuries with ultrasound-guided compression. *J Vasc Surg* 1992; 16(6):832–840
- [40] Fellmeth BD, Baron SB, Brown PR et al. Repair of postcatheterization femoral pseudoaneurysms by colour flow ultrasound guided compression. *Am Heart J* 1992; 123(2):547–551
- [41] Zahn R, Thoma S, Fromm E et al. Pseudoaneurysm after cardiac catheterization: therapeutic interventions and their sequelae: experience in 86 patients. *Cathet Cardiovasc Diagn* 1997; 0(1):9–15
- [42] Görges G, Kunz T, Kirstein M. Non-surgical therapy of iatrogenic false aneurysms. *Dtsch Med Wochenschr* 2003; 128(1–2):36–40
- [43] Brophy DP, Sheiman RG, Amatulle P et al. Iatrogenic femoral pseudoaneurysms: thrombin injection after failed US-guided compression. *Radiology* 2000; 214(1):278–282
- [44] Fellmeth BD, Roberts AC, Bookstein JJ et al. Postangiographic femoral artery injuries: nonsurgical repair with US-guided compression. *Radiology* 1991; 178(3):671–675
- [45] Schaub F, Theiss W, Heinz M et al. New aspects in ultrasound-guided compression repair of postcatheterization femoral artery injuries. *Circulation* 1994; 90(4):1861–1865
- [46] Vazquez V, Reus M, Pinero A et al. Human thrombin for treatment of pseudoaneurysms: comparison of bovine and human thrombin sonogram-guided injection. *AJR Am J Roentgenol* 2005; 184:1665–1671
- [47] Rath J, Marx R, Ganschow US et al. Formation, therapy and prevention of false aneurysm of the femoral artery following diagnostic and interventional heart catheterization. *Dtsch Med Wochenschr* 1997; 122(24):771–777
- [48] Carroll JF, Moskowitz KA, Edwards NM et al. Immunologic assessment of patients treated with bovine fibrin as a hemostatic agent. *Thromb Haemost* 1996; 76(6):925–931
- [49] Görges G, Kunz T. Thrombin injection for treatment of false aneurysms after failed compression therapy in patients on full-dose antiplatelet and heparin therapy. *Catheter Cardiovasc Interv* 2003; 58(4):505–509
- [50] Görges G, Kunz T, Kirstein M. A prospective study on ultrasound-guided compression therapy of thrombin injection for treatment of iatrogenic false aneurysms in patients receiving full-dose anti-platelet therapy. *Z Kardiol* 2003; 92(7):564–570
- [51] Görges G, Kunz T. Management of complex, two chamber false aneurysm by thrombin injections. *Heart* 2003 May; 89(5):564. doi:10.1136/heart.89.5.564
- [52] Maleux G, Hendrickx S, Vaninbrouckx J et al. Percutaneous injection of human thrombin to treat iatrogenic femoral pseudoaneurysms: short- and midterm ultrasound follow-up. *Eur Radiol* 2003; 13:209–212
- [53] Cope C, Zeit R. Coagulation of aneurysms by direct percutaneous thrombin injection. *AJR Am J Roentgenol* 1986; 147(2):383–387.
- [53a] Chen DH, Sammel AM, Jain P et al. Cardiologist operated ultrasound guided thrombin injection as a safe and efficacious first line treatment for iatrogenic femoral artery pseudoaneurysms. *Heart Lung Circ* 2015; 24(2):165–72
- [54] Ferguson JD, Whatling PJ, Martin V et al. Ultrasound guided percutaneous thrombin injection of iatrogenic femoral artery pseudoaneurysms after coronary angiography and intervention. *Heart* 2001; 85(4):E5
- [55] Tsetis D, Kochiadakis G, Hamilos M et al. Ultrasound guided percutaneous thrombin injection for the treatment of post-catheterisation femoral pseudoaneurysm. *Hellenic J Cardiol* 2006 Mar-Apr; 47(2):112–3
- [56] Paulson EK, Nelson RC, Mayes CE et al. Sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms: further experience of a single institution. *AJR Am J Roentgenol* 2001; 177(2):309–316

- [57] Sackett WR, Taylor SM, Coffey CB et al. Ultrasound-guided thrombin injection of iatrogenic femoral pseudoaneurysms: a prospective analysis. *Am Surg* 2000 Oct; 66(10):937–40; Discussion 940–942
- [58] Sheiman RG, Brophy DP. Treatment of iatrogenic femoral pseudoaneurysms with percutaneous thrombin injection: experience in 54 patients. *Radiology* 2001; 219(1):123–127
- [59] Taylor BS, Rhee RY, Muluk S et al. Thrombin injection versus compression of femoral artery pseudoaneurysms. *J Vasc Surg* 1999; 30(6):1052–1059
- [60] Pope M, Johnston KW. Anaphylaxis after thrombin injection of a femoral pseudoaneurysm: recommendations for prevention. *J Vasc Surg* 2000; 32(1):190–191
- [61] Sadiq S, Ibrahim W. Thromboembolism complicating thrombin injection of femoral artery pseudoaneurysm: management with intraarterial thrombolysis. *J Vasc Interv Radiol* 2001; 12(5):633–636
- [62] Tamim WZ, Arbid EJ, Andrews LS et al. Percutaneous induced thrombosis of iatrogenic femoral pseudoaneurysms following catheterization. *Ann Vasc Surg* 2000; 14(3):254–259
- [63] Sievert H, Baser A, Pfeil W et al. The treatment of iatrogenic spurious aneurysm of the femoral artery by direct thrombin injection. *Dtsch Med Wochenschr* 2000; 125(27):822–825
- [64] Ortel TL, Charles LA, Keller FG et al. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. *Am J Hematol* 1994; 45(2):128–135
- [65] Spotnitz WD, Dalton MS, Baker JW et al. Successful use of fibrin glue during 2 years of surgery at a university medical center. *Am Surg* 1989; 55(3):166–168
- [66] Zins M, Vilgrain V, Gayno S et al. US-guided percutaneous liver biopsy with plugging of the needle track: a prospective study in 72 high-risk patients. *Radiology* 1992; 84(3):841–843
- [67] Dorion RP, Hamati HF, Landis B et al. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. *Arch Pathol Lab Med* 1998; 122(10):887–894
- [68] Ortel TL, Moore KD, Quinn-Allen MA et al. Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations. *Blood* 1998; 91(11):4188–4196

4 Strahlenschutz im Herzkatheterlabor – praktische Aspekte

- [1] Ernst-Elz A. Referat Strahlenschutz außerhalb kerntechnischer Anlagen. https://www.tuev-nord.de/fileadmin/Content/TUEV_NORD_DE/pdf//euratom-grundnorm-2013-berlin.pdf (abgerufen am 17.10.2020)
- [2] Shope TB. Radiation-induced skin injuries from fluoroscopy. *Radiographics* 16:1195–1199, 1996
- [3] Chen J, Einstein AJ, Fazel R et al. Cumulative exposure to ionizing radiation from diagnostic and therapeutic cardiac imaging procedures – a population-based analysis. *J Am Coll Cardiol* 56:702–711, 2010
- [4] Bundesamt für Strahlenschutz. Röntgen: Nutzen und Risiken. 11. Auflage, 2018
- [5] Kuon E, Dahm JB, Empen K et al. Identification of less-irradiating tube angulations in invasive cardiology. *J Am Coll Cardiol* 44:1420–1428, 2004
- [6] Shope TB. Radiation-induced skin injuries from fluoroscopy. *RadioGraphics* 6:1195–1199, 1996
- [7] Hamm CE, Albrecht A, Bonzel T et al. Diagnostische Herzkatheteruntersuchung. *Clin Res Cardiol* 97:475–512, 2008
- [8] Boetticher Hv, Lachmund J, Hoffmann W et al. Optimierung des Strahlenschutzes für den Untersucher im Herzkatheterlabor auf Grundlage der effektiven Dosis. *Clin Res Cardiol* 8 (Suppl 2):P129, 2009
- [9] Elmaraezy A, Morra ME, Mohammed AT et al. Risk of cataract among interventional cardiologists and catheterization lab staff: a systematic review and meta-analysis. *Catheter Cardiovasc Interv* 90:1–9, 2017
- [10] Henry TD, Henry CR. The importance of vision. *Catheter Cardiovasc Interv* 90(1):10–11, 2017
- [11] Maeder M, Brunner-La Rocca HP, Wolber T et al. Impact of a lead glass screen on scatter radiation to eyes and hands in interventional cardiologists. *Catheter Cardiovasc Interv* 57:18–23, 2006
- [12] Ichimoto E, Kadohira T, Nakayama T et al. Efficacy of radiation dose reduction due to real-time monitoring and visualization of peak skin dose during coronary angiography and PCI. *Catheter Cardiovasc Interv* 92(4):717–722, 2018
- [13] Faroux L, Blanpain T, Nazeyrollas P et al. Effect of modern dose-reduction technology on the exposure of Interventional cardiologists to radiation in the catheterization laboratory. *JACC Cardiovasc Interv* 11:222–223, 2018
- [14] Lange HW, Boetticher Hv. Randomized comparison of operator radiation exposure during coronary angiography and intervention by radial of femoral approach. *Catheter Cardiovasc Interv* 67:12–16, 2006
- [15] Salaun E, Carles S, Bigand E et al. High radiation exposure of the imaging specialist during structural heart interventions with echocardiographic guidance. *JACC Cardiovasc Interv* 10:626–627, 2017
- [16] Madder RD, LaCombe A, VanOosterhout S et al. Radiation exposure among scrub technologists and nurse circulators during cardiac catheterization: the impact of accessory lead shields. *Cardiovasc Interv* 11:206–212, 2018
- [17] RS-Handbuch. Stand 07/16. Strahlenschutzverordnung. Seite 1 von 129. Verordnung über den Schutz vor Schäden durch ionisierende Strahlen. https://www.base.bund.de/SharedDocs/Downloads/BASE/DE/rsh/1a-atomrecht/1A-8-StrlSchV.pdf?__blob=publicationFile&v=1 (abgerufen 21.5.2021)
- [18] Cardis E, Vrijheid M, Blettner M et al. Risk of cancer after low doses of ionising radiation – retrospective cohort study in 15 countries. *BMJ* 331(7508):77, 2005
- [19] Council Directive 2013/59/Euratom of 5 December 2013 laying down basic safety standards for protection against the dangers arising from exposure to ionising ra-

- diation, and repealing Directives 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom and 2003/122/Euratom. OJ of the EU L13(57):1–73, 2014
- [20] European Society of Radiology (ESR). Summary of the European Directive 2013/59/Euratom; essentials for health professionals in radiology. Insights Imaging 6:411–417, 2015
- [21] Schächinger V, Nef H, Achenbach S et al. Leitlinie zum Einrichten und Betreiben von Herzkatheterlaboren und Hybridoperationssälen/Hybridlaboren, 3. Aufl. Kardiologie 9:89–123, 2015
- [22] Ebermann L. Schwerpunkt Strahlenschutz. Bundesamt für Strahlenschutz, Salzgitter 2016
- [23] Schächinger V, Kelm M. Addendum zur Leitlinie zum Einrichten und Betreiben von Herzkatheterlaboren und Hybrid-Operationssälen/Hybrid-Laboren. Neue Strahlenschutzgesetzgebung 2019 und Aktualisierung der Arbeitsanweisung. Kardiologie 13:193, 2019
- [24] Walz M, Wucherer M, Loose R. Was bringt die neue Strahlenschutzverordnung? Radiologie 59:457–466, 2019
- [25] Andreassi MG, Piccaluga E, Guagliumi G et al. Occupational health risks in cardiac catheterization laboratory workers. Circ Cardiovasc Interv 9:e003273, 2016
- [26] Schegerer A, Loose R, Heuser LJ et al. Diagnostische Referenzwerte für diagnostische und interventionelle Röntgenanwendungen in Deutschland: Aktualisierung und Handhabung. Röfo 191:739–751, 2019
- [27] Balter S, Hopewell JW, Miller DL et al. Fluoroscopically guided interventional procedures: A review of radiation effects on patients' skin and hair. Radiology 254:326–341, 2010
- [28] Bundesamt für Strahlenschutz. Berufliche Strahlenschutzüberwachung in Deutschland. 16.07.2020. <https://www.bfs.de/DE/themen/ion/strahlenschutz/beruf/einfuehrung/einfuehrung.html> (abgerufen am 26.04.2021)
- [29] Sobetzko T, Maushart R. Strahlenschutz am Arbeitsplatz VII. https://www.haufe.de/arbeitschutz/arbeitschutz-office/strahlenschutz-am-arbeitsplatz-vii-technik-und-handhabu-124-stab-oder-fuellhalterdosimeter_idesk_PI957_HI3677811.html (abgerufen am 28.04.2021)
- [30] Landesanstalt für Personendosimetrie und Strahlenschutz Ausbildung Mecklenburg-Vorpommern. Betriebliche Dosimetrie. <https://www.lps-berlin.de/personendosis-messstelle/elektronische-dosimetrie> (abgerufen 28.04.2021)
- [31] Stellungnahme des Bundesrates: Entwurf eines Ersten Gesetzes zur Änderung des Strahlenschutzgesetzes. Drucksache 24/21. 12.02.2021. [https://www.bundesrat.de/SharedDocs/drucksachen/2021/0001-0100/24-21\(B\).pdf?__blob=publicationFile&v=1](https://www.bundesrat.de/SharedDocs/drucksachen/2021/0001-0100/24-21(B).pdf?__blob=publicationFile&v=1)
- [32] Wohlaue M. Surgery is a contact sport. Vascular News 83:15, 2019

5 Diagnostische Koronarangiografie

- [1] Dodge JT Jr, Brown BG, Bolson EL et al. Lumen diameter of normal human coronary arteries. Influence of age, sex, anatomic variation, and left ventricular hypertrophy or dilation. *Circulation* 6:232–246, 1992
- [2] Hamm CW, Albrecht A, Bonzel T et al. Diagnostische Herzkatheteruntersuchung. *Clin Res Cardiol* 97:475–512, 2008. Erratum in: *Clin Res Cardiol* 97:925, 2008
- [3] Buck T. Manual zur Indikation und Durchführung der Echokardiographie. *Clin Res Cardiol Suppl* 4:3–51, 2009
- [4] Krause W. Über den Ursprung einer akzessorischen A. coronaria cordis aus der A. pulmonalis. *Z Ratl Med* 24:225–227, 1865
- [5] Said SA, Landman GH. Coronary-pulmonary fistula: long-term follow-up in operated and non-operated patients. *Int J Cardiol* 27:203–210, 1990
- [6] Alkhulaifi AM, Horner SM, Pugsley WB et al. Coronary artery presenting with bacterial endocarditis. *Ann Thorac Surg* 60:202–204, 1995
- [7] Willerson JT. Coronary artery anomalies. Coronary morphogenesis. From diagnosis to surgical management. *Texas Heart Institut J* 29:241–313, 2002
- [8] Gräni C, Buechel RR, Kaufmann PA et al. Multimodality imaging in individuals with anomalous coronary arteries. *JACC Cardiovasc Imag* 10:471–481, 2017
- [9] Cheezum MK, Liberthson RR, Shah NR et al. Anomalous aortic origin of a coronary artery from the inappropriate sinus of valsalva. *J Am Coll Cardiol* 69:1592–1608, 2017
- [10] Hillis LD, Smith PK, Anderson JL et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. *J Am Coll Cardiol* 58:e123–210, 2011
- [11] Warnes CA, Williams RG, Bashore TM et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). *J Am Coll Cardiol* 52:e143–263, 2008
- [12] Van Hare GF, Ackerman MJ, Evangelista JA et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 4: congenital heart disease: a scientific statement from the American Heart Association and American College of Cardiology. *J Am Coll Cardiol* 66:2372–2384, 2015
- [13] Erbel R, Neuhaus KL, Spiller P et al. The effect of contrast medium injection into the left ventricle on systolic and diastolic ventricle function. *Z Kardiol* 5:305–318, 1976
- [14] Erbel R, Schweizer P, Lambertz H et al. Echoventriculography – a simultaneous analysis of two-dimensional echocardiography and cineventriculography. *Circulation* 67:205–215, 1983
- [15] Weinsaft JW, Kim HW, Crowley AL et al. LV thrombus detection by routine echocardiography: insights into performance characteristics using delayed enhancement CMR. *JACC Cardiovasc Imaging* 4:702–712, 2011
- [16] Herman MV, Haniel RA, Klein MD et al. Localized disorders in myocardial contraction. Asynergy and its role in congestive heart failure. *N Engl J Med* 277:222–232, 1967
- [17] Dyer R. Thoracic aortography. In: *Handbook of basic vascular and interventional radiology*. Churchill Livingstone. New York 1993
- [18] Natsis KI, Tsitouridis IA, Didagelos MV et al. Anatomical variations in the branches of the human aortic arch in 633 angiographies: clinical significance and lite-

- ature review. *Surg Radiol Anat* 31:319–323, 2009
- [19] Sarkar K, Sharma SK, Kini SA. Catheter selection for coronary angiography and intervention in anomalous right coronary arteries. *J Interv Cardiol* 22:234–239, 2009
- [19a] Donisan T, Sayed L. Dual ostia right coronary artery: a newly described coronary anomaly. *JACC Cardiovasc Interv* 14:e69–70, 2021
- [20] Kuon E, Dahm JB, Robinson DM et al. Radiation-reducing planning of cardiac catheterisation. *Z Kardiol* 94:663–673, 2005
- [21] Kuon E, Weitmann K, Hoffmann W et al. Efficacy of a mini course in radiation-reducing techniques in invasive cardiology: a multicenter field study. *JACC Cardiovasc Interv* 7:382–390, 2014
- [22] Kuon E, Weitmann K, Hummel A et al. Latest-generation catheterization systems enable invasive submillisievert coronary angiography. *Herz* 40 Suppl 3:233–239, 2015
- [23] Kuon E, Felix SB, Weitmann K et al. Long-term strategies support autonomy in radiation safety in invasive cardiology. *J Kardiol* 68:43–48, 2016
- [24] King SB 3rd, Smith SC Jr, Hirshfeld JW Jr et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. *J Am Coll Cardiol* 51:172–209, 2008
- [25] West R, Ellis G, Brooks N. Complications of diagnostic cardiac catheterization: results from a confidential inquiry into cardiac catheter complications. *Heart* 2:810–814, 2006
- [26] Applegate RJ, Sacrinty MT, Kutcher MA et al. Trends in vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention via the femoral artery, 1998 to 2007. *JACC Cardiovasc Interv* 1:317–326, 2008
- [27] Gregory D, Midodzi W, Pearce N. Complications with Angio-Seal™ vascular closure devices compared with manual compression after diagnostic cardiac catheterization and percutaneous coronary intervention. *J Interv Cardiol* 26:630–638, 2013
- [28] El-Ghanem M, Malik AA, Azzam A et al. Occurrence of femoral nerve injury among patients undergoing transfemoral percutaneous catheterization procedures in the United States. *J Vasc Interv Neurol* 9:54–58, 2017
- [29] Scanlon PJ, Faxon DP, Audet AM et al. ACC/AHA guidelines for coronary angiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions. *Circulation* 99:2345–2357, 1999
- [30] TIMI study group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase 1 findings. *N Engl J Med* 312:932–936, 1985
- [31] Gibson CM, Cannon CO, Murphy SA et al. Relationship of TIMI Myocardial Perfusion Grade to mortality after administration of thrombolytic drugs. *Circulation* 101:125–130, 2000
- [32] Gibson CM, Cannon CP, Daley WL et al. TIMI frame count: a quantitative method of assessing coronary artery flow. *Circulation* 3:879–888, 1996
- [33] Medina A, Suarez de Lezo J, Pan M. A new classification of coronary bifurcation lesions. *REV Esp Cardiol* 8:199–204, 2006
- [34] Louvard Y, Thomas M, Dzavik V et al. Classification of coronary artery bifurcation lesions and treatments: time for a consensus. *Catheter Cardiovasc Interv* 71:175–183, 2008
- [35] Zlotnick DM, Ramanath VS, Brown JR et al. Classification and treatment of coronary artery bifurcation lesions: putting the Medina classification to the test. *Cardiovasc Revasc Med* 13:228–233, 2012
- [36] Ferenc M, Neumann FJ. Towards a lesion-specific approach to percutaneous coronary intervention for bifurcation lesions, *Eur Heart J* 41:2537–2540, 2020
- [37] Rentrop K, Cohen M, Blanke H et al. Changes in collateral filling immediately following controlled coronary occlusion by an angioplasty balloon in man. *J Am Coll Cardiol* 5:587–592, 1985
- [38] Serruys PW, Morice MC, Kappetein P et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. *N Engl J Med* 60:961–972, 2009
- [39] Reyman HC. Dissertationem inauguralem de vasis cordis propriis, 1–32. Medizini-

- sche Dissertation. Universität Göttingen, 1737
- [40] Black S. A case of angina pectoris with a dissection. *Men Med Soc Lond* 6–41, 1805
- [41] Geiringer E. The mural coronary. *Am Heart J* 41:359–368, 1951
- [42] Möhlenkamp S, Eggebrecht H, Ebraldize T et al. Muskelbrücken der Koronararterien: mögliche ischämierelevante Normvarianten. *Herz* 30:37–47, 2005
- [43] Ge J, Erbel E, Gorge G et al. High wall shear stress proximal to myocardial bridging and atherosclerosis: intracoronary ultrasound and pressure measurements. *Heart* 73:462–465, 1995
- [44] Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. *JAMA* 282:2035–2042, 1999
- [45] Erbel R, Ge J, Möhlenkamp S. Myocardial bridging: a congenital variant as an anatomic risk factor for myocardial infarction? *Circulation* 120:357–359, 2009
- [46] Ge J, Jeremias A, Rupp A et al. New signs characteristic of myocardial bridging demonstrated by intracoronary ultrasound and Doppler. *Eur Heart J* 20:1707–1716, 1999
- [47] Böse D, Philipp S. High-resolution imaging of myocardial bridging. *N Engl J Med* 358:392, 2008
- [48] Eggebrecht H, Möhlenkamp S. Myocardial bridging. *N Engl J Med* 349:1047, 2003
- [49] Qian JY, Zhang F, Dong M et al. Prevalence and characteristics of myocardial bridging in coronary angiogram – data from consecutive 5525 patients. *Chin Med J (Engl)* 122:632–635, 2009
- [50] Wang MH, Sun AJ, Qian JY et al. Myocardial bridging detection by non-invasive multi-slice spiral computed tomography: comparison with intravascular ultrasound. *Chin Med J (Engl)* 121:17–21, 2008
- [51] Klues HG, Schwarz ER, vom Dahl J et al. Disturbed intracoronary hemodynamics in myocardial bridging: early normalization by intracoronary stent placement. *Circulation* 96:2905–2913, 1997
- [52] Jeremias A, Haude M, Ge J et al. Notfallmäßige Stent-Implantation in dem Bereich einer ausgedehnten Muskelbrücke des Ramus interventricularis anterior nach postinterventioneller Dissektion. *Z Kardiol* 6:367–372, 1997
- [53] Tandar A, Whisenant BK, Michaels AD. Stent fracture following stenting of a myocardial bridge: a report of two cases. *Catheter Cardiovasc Interv* 71:191–196, 2008
- [54] Daoud AS, Pankin D, Tulgan H et al. Aneurysms of the coronary artery: report of ten cases and review of literature. *Am J Cardiol* 11:228–237, 1963
- [55] Ge J, Liu F, Kearney P et al. Intravascular ultrasound approach to the diagnosis of coronary artery aneurysms. *Am Heart J* 130:765–771, 1995
- [56] Fukazawa R, Kobayashi T, Mikami M et al. Nationwide survey of patients with giant coronary aneurysm secondary to kawasaki disease 1999–2010 in Japan. *Circ J* 82:239–246, 2017
- [57] Chen PT, Lin MT, Chen YS et al. Computed tomography predict regression of coronary artery aneurysm in patients with Kawasaki disease. *J Formos Med Assoc* 116:806–814, 2017
- [58] Jurado-Román A, López-Lluya MT, Sánchez-Pérez I et al. Coronary artery aneurysm after mini-crush drug-eluting stent technique in a chronic total occlusion. *J Invasive Cardiol* 29:e81–82, 2017
- [59] Wainstein RV, Araujo GN, Valle FH et al. Coronary artery aneurysm after bioresorbable scaffold implantation. *J Invasive Cardiol* 29:e79–80, 2017
- [60] Mehran R, Ambrose JA, Bongu RM et al. Angioplasty of complex lesions in ischemic rest angina: results of the Thrombolysis and Angioplasty in Unstable Angina (TAUSA) trial. *J Am Coll Cardiol* 26:961–966, 1995
- [61] Breuckman F, Nassenstein K, Boese D et al. Successful nitinol stent implantation in a large coronary aneurysm: post-interventional patency assessment by magnetic resonance imaging. *Intern J Cardiovasc Imag* 22:501–505, 2006
- [62] Núñez-Gil JJ, Nombela-Franco L, Bagur R et al. Rationale and design of a multicenter, international and collaborative Coronary Artery Aneurysm Registry (CAAR). *Clin Cardiol* 40:580–585, 2017
- [63] Vanzetto G, Berger-Coz E, Barone-Rochette G et al. Prevalence, therapeutic management and medium-term prognosis of spontaneous coronary artery dissection: results from a database of 11,605 patients. *Eur J Cardiothorac Surg* 35:250–254, 2009

- [64] Hering D, Piper C, Hohmann C et al. Prospective study of the incidence, pathogenesis and therapy of spontaneous, by coronary angiography diagnosed coronary artery dissection, *Z Kardiol* 87:961–970, 1998
- [65] Tweet MS, Hayes SN, Codsí E et al. Spontaneous coronary artery dissection associated with pregnancy. *J Am Coll Cardiol* 70:426–435, 2017
- [66] Pretty HC. Dissecting aneurysm of coronary artery in a woman aged. *Brit Med J* 42:1, 1931
- [67] Saw J. Spontaneous coronary artery dissection. *Can J Cardiol* 29:1027–1033, 2013
- [68] Kwon TG, Gulati R, Matsuzawa Y et al. Proliferation of coronary adventitial vasa vasorum in patients with spontaneous coronary artery dissection. *JACC Cardiovasc Imaging* 9:891–892, 2016
- [69] Saw J, Poulter R, Fung A et al. Spontaneous coronary artery dissection in patients with fibromuscular dysplasia: a case series. *Circ Cardiovasc Interv* 5:134–137, 2012
- [70] Fahmy P, Prakash R, Starovoytov A et al. Pre-disposing and precipitating factors in men with spontaneous coronary artery dissection. *JACC Cardiovasc Interv* 9:866–868, 2016
- [71] Henkin S, Negrotto SM, Tweet MS et al. Spontaneous coronary artery dissection and its association with heritable connective tissue disorders. *Heart* 102:876–881, 2016
- [72] Goel K, Tweet M, Olson TM et al. Familial spontaneous coronary artery dissection: evidence for genetic susceptibility. *JAMA Intern Med* 175:821–826, 2015
- [73] Böse D, Eggebrecht H, Churzidse S et al. 1-antitrypsin deficiency associated iatrogenic coronary artery dissection during intracoronary ultrasound examination. *Herz* 28:779, 2003
- [74] Kordish I, Philipp S, Böse D et al. Dissection of the right coronary artery as a complication after the IVUS procedure. *Herz* 32:573–577, 2007
- [75] Adlam D, Alfonso F, Maas A et al., Writing Committee. European Society of Cardiology, acute cardiovascular care association, SCAD study group: a position paper on spontaneous coronary artery dissection. *Eur Heart J* 39:3353–3368, 2018
- [76] Luong C, Starovoytov A, Heydari M et al. Clinical presentation of patients with spontaneous coronary artery dissection. *Catheter Cardiovasc Interv* 89:1149–1154, 2017
- [77] Saw J. Coronary angiogram classification of spontaneous coronary artery dissection. *Catheter Cardiovasc Interv* 84:1115–1122, 2014
- [78] Saw J, Sedlak T, Ganesh SK et al. Cardiology patient page. Spontaneous coronary artery dissection (SCAD). *Circulation* 131:e3–5, 2015
- [79] Arnold JR, West NE, van Gaal WJ et al. The role of intravascular ultrasound in the management of spontaneous coronary artery dissection. *Cardiovasc Ultrasound* 6:24, 2008
- [80] Kearney P, Erbel R, Ge J et al. Assessment of spontaneous coronary artery dissection by intravascular ultrasound in a patient with unstable angina. *Cathet Cardiovasc Diagn* 32:58–61, 1994
- [81] Baumgart D, Liu F, Haude M et al. Acute plaque rupture and myocardial stunning in patient with normal coronary arteriography. *Lancet* 346(8968):193–194, 1995
- [82] Maehara A, Mintz GS, Castagna MT et al. Intravascular ultrasound assessment of spontaneous coronary artery dissection. *Am J Cardiol* 89:466–468, 2002
- [83] Auer J, Punzengruber C, Berent R et al. Spontaneous coronary artery dissection involving the left main stem: assessment by intravascular ultrasound. *Heart* 90:e39, 2004
- [84] Ohlmann P, Weigold G, Kim SW et al. Images in cardiovascular medicine. Spontaneous coronary dissection: computed tomography appearance and insights from intravascular ultrasound examination. *Circulation* 113:e403–405, 2006
- [85] Alfonso F, Canales E, Aleong G. Spontaneous coronary artery dissection: diagnosis by optical coherence tomography. *Eur Heart J* 30:385, 2009
- [86] Ishibashi K, Kitabata H, Akasaka T. Intracoronary optical coherence tomography assessment of spontaneous coronary artery dissection. *Heart* 95:818, 2009
- [87] Poon K, Bell B, Raffel OC et al. Spontaneous coronary artery dissection: utility of intravascular ultrasound and optical coherence tomography during percutaneous

- coronary intervention. *Circ Cardiovasc Interv* 4:e5–7, 2011
- [88] Alfonso F, Paulo M, Gonzalo N et al. Diagnosis of spontaneous coronary artery dissection by optical coherence tomography. *J Am Coll Cardiol* 59:1073–1079, 2012
- [89] Paulo M, Sandoval J, Lennie V et al. Combined use of OCT and IVUS in spontaneous coronary artery dissection. *JACC Cardiovasc Imaging* 6:830–832, 2013
- [90] Giacoppo D, Capodanno D, Dangas G et al. Spontaneous coronary artery dissection. *Int J Cardiol* 175:8–20, 2014
- [91] Hoshi T, Sato A, Hiraya D et al. Multimodality intracoronary imaging in spontaneous coronary artery dissection: impacts of intravascular ultrasound, optical coherence tomography, and coronary angiography. *Catheter Cardiovasc Interv* 81:e151–154, 2013
- [92] Torres-Ayala SC, Maldonado J, Bolton JS et al. Coronary computed tomography angiography of spontaneous coronary artery dissection: a case report and review of the literature. *Am J Case Rep* 16:130–135, 2015
- [93] Manghat NE, Morgan-Hughes GJ, Roobottom CA. Spontaneous coronary artery dissection: appearance and follow-up on multi-detector row CT coronary angiography. *Clin Radiol* 60:1120–1125, 2005
- [94] Russo V, Marrozzini C, Zompatori M. Spontaneous coronary artery dissection: role of coronary CT angiography. *Heart*, 99:672–673, 2013
- [95] Tweet MS, Gulati R, Williamson EE et al. Multimodality imaging for spontaneous coronary artery dissection in women. *JACC Cardiovasc Imaging* 9:436–450, 2016
- [96] Eleid MF, Tweet MS, Young PM et al. Spontaneous coronary artery dissection: challenges of coronary computed tomography angiography. *Eur Heart J Acute Cardiovasc Care* 7(7):609–613, 2018
- [97] Alzand BSN, Vanneste L, Fonck D et al. Spontaneous coronary artery dissection undissolved using cardiac computed tomography. *Int J Cardiol* 222:1040–1041, 2017
- [98] Nakashima T1, Noguchi T, Morita Y et al. Detection of intramural hematoma and serial non-contrast T1-weighted magnetic resonance imaging findings in a female patient with spontaneous coronary artery dissection. *Circ J* 77:2844–2845, 2013
- [99] Saw J, Aymong E, Sedlak T et al. Spontaneous coronary artery dissection: association with predisposing arteriopathies and precipitating stressors and cardiovascular outcomes. *Circ Cardiovasc Interv* 7:645–655, 2014
- [100] Rogowski S, Maeder MT, Weilenmann D et al. Spontaneous coronary artery dissection: angiographic follow-up and long-term clinical outcome in a predominantly medically treated population. *Catheter Cardiovasc Interv* 89:59–68, 2017
- [101] Nakashima T, Noguchi T, Haruta S et al. Prognostic impact of spontaneous coronary artery dissection in young female patients with acute myocardial infarction: A report from the Angina Pectoris-Myocardial Infarction Multicenter Investigators in Japan. *Int J Cardiol* 207:341–348, 2016
- [102] Saw J, Humphries K, Aymong E et al. Spontaneous coronary artery dissection: clinical outcomes and risk of recurrence. *J Am Coll Cardiol* 70:1148–1158, 2017
- [103] Marijona E, Fressonnet R, Haggui A et al. Spontaneous coronary dissection of the left main stem after intense physical activity – Regression under conservative strategy. *Int J Cardiol* 128:e16–18, 2018
- [104] Zupan I, Noc M, Trinkaus D et al. Double vessel extension of spontaneous left main coronary artery dissection in young women treated with thrombolytics. *Catheter Cardiovasc Interv* 52:226–230, 2001
- [105] Goh AC, Lundstrom RJ. Spontaneous coronary artery dissection with cardiac tamponade. *Tex Heart Inst J* 42:479–482, 2015
- [106] Shamloo BK, Chintala RS, Nasur A et al. Spontaneous coronary artery dissection: aggressive vs. conservative therapy. *J Invasive Cardiol* 22:222–228, 2010
- [107] Byrne RA, Rossello X, Coughlan JJ et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur Heart J* 44:3720–3826, 2023
- [108] Saw J, Mancini GB, Humphries KH. Contemporary review on spontaneous coronary artery dissection. *J Am Coll Cardiol* 68:297–312, 2016

- [109] Tweet MS, Gulati R, Hayes SN. Spontaneous coronary artery dissection. *Curr Cardiol Rep* 18:60 (1–6), 2016
- [110] Combaret N, Souteyrand G, Amonchot A et al. Contribution of guidance by optical coherence tomography (OCT) in rescue management of spontaneous coronary artery dissection. *Eur Heart J Cardiovasc Imaging* 14:714, 2013
- [111] Bento AP, Fernandes RG, Neves DC et al. Spontaneous coronary dissection: „Live Flash“ optical coherence tomography guided angioplasty. *Case Rep Cardiol* 2016:5643819, 2016
- [112] Mori H, Kutys R, Romero M et al. Stenting of spontaneous coronary artery dissection from a pathological point of view. *Circ Cardiovasc Interv* 9(12):e004549, 2016
- [113] Mahr P, Ge J, Haude M et al. Extramural vessel wall hematoma causing a reduced vessel diameter after coronary stenting: diagnosis by intravascular ultrasound and treatment by stent implantation. *Cathet Cardiovasc Diagn* 43:438–443, 1998
- [114] Lempereur M, Fung A, Saw J. Stent malapposition with resorption of intramural hematoma with spontaneous coronary artery dissection. *Cardiovasc Diagn Ther* 5:323–329, 2015
- [114a] Motreff P, Ronchard T, Sanguineti F et al. Coronary artery fenestration: a promising technique for rescue management of spontaneous intramural hematoma with luminal compression. *JACC Cardiovasc Interv* 11:1902–1907, 2018
- [115] Martins JL, Afreixo V, Santos L et al. Medical treatment or revascularisation as the best approach for spontaneous coronary artery dissection: A systematic review and meta-analysis. *Eur Heart J Acute Cardiovasc Care* 7(7):614–623, 2018
- [116] Tweet MS, Hayes SN, Pitta SR et al. Clinical features, management, and prognosis of spontaneous coronary artery dissection. *Circulation* 126:579–588, 2012
- [117] Lettieri C, Zavalloni D, Rossini R et al. Management and long-term prognosis of spontaneous coronary artery dissection. *Am J Cardiol* 116:66–73, 2015
- [118] Tweet MS, Hayes SN, Pitta SR et al. Clinical features, management, and prognosis of spontaneous coronary artery dissection. *Circulation* 126:579–588, 2012
- [119] Eleid MF, Guddeti RR, Tweet MS et al. Coronary artery tortuosity in spontaneous coronary artery dissection: angiographic characteristics and clinical implications. *Circ Cardiovasc Interv* 7:656–662, 2014
- [120] Toggweiler S, Puck M, Thalhammer C et al. Associated vascular lesions in patients with spontaneous coronary artery dissection. *Swiss Med Wkly* 142:w13538, 2012
- [121] Liang JJ, Prasad M, Tweet MS et al. A novel application of CT angiography to detect extracoronary vascular abnormalities in patients with spontaneous coronary artery dissection. *J Cardiovasc Comput Tomogr* 8:189–197, 2014
- [122] Prasad M, Tweet MS, Hayes SN et al. Prevalence of extracoronary vascular abnormalities and fibromuscular dysplasia in patients with spontaneous coronary artery dissection. *Am J Cardiol* 115:1672–1677, 2015
- [123] Persu A, Van der Niepen P, Touze E et al. Revisiting fibromuscular dysplasia: rationale of the European fibromuscular dysplasia initiative. *Hypertension* 68:832–839, 2016
- [123a] Khiatah B, Jazayeri S, Yamamoto N et al. Cardiovascular disease in women: A review of spontaneous coronary artery dissection. *Medicine (Baltimore)*. 101:e30433, 2022
- [123b] Alfonso F, de la Torre Hernández JM, Ibáñez B et al. Rationale and design of the BA-SCAD (Beta-blockers and Antiplatelet agents in patients with Spontaneous Coronary Artery Dissection) randomized clinical trial. *Rev Esp Cardiol (Engl Ed)*. 75:515–522, 2022
- [124] Iga K, Gen H, Tomonaga G et al. Reversible left ventricular wall motion impairment caused by pheochromocytoma: a case report. *Jpn Circ J* 53:813–818, 1989
- [125] Sato TH, Uchida T, Dote K et al. Tako-tsubo-like left ventricular dysfunction due to multivessel coronary spasm. In: Kodama K, Haze K, Hori M (Eds), *Clinical Aspect of Myocardial Injury: From Ischemia to Heart Failure*. Tokyo, Japan: Kagakuhyoronsha Publishing Co; 56–64, 1990
- [126] Ghadri J-R, Wittstein IS, Prasad A et al. International expert consensus document on takotsubo syndrome (part i): clinical characteristics, diagnostic criteria, and pa-

- thophysiology. *Eur Heart J* 39:2032–2046, 2018
- [127] Natterson-Horowitz B, Bowers K. Wir sind Tier. Was wir von den Tieren für unsere Gesundheit lernen können. München: Knaus 2014
- [128] Ghadri JR, Sarcon A, Diekmann J et al. Happy heart syndrome: role of positive emotional stress in Takotsubo syndrome. *Eur Heart J* 37, 2823–2829, 2016
- [129] Desmet WJ, Adriaenssens BF, Dens JA. Apical ballooning of the left ventricle: first series in white patients. *Heart* 89:1027–1031, 2003
- [130] Wittstein IS, Thiemann DR, Lima JA et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. *N Engl J Med* 352:539–548, 2005
- [131] Prasad A, Dangas G, Srinivasan M et al. Incidence and angiographic characteristics of patients with apical ballooning syndrome (takotsubo/stress cardiomyopathy) in the HORIZONS-AMI trial: an analysis from a multicenter, international study of ST-elevation myocardial infarction. *Catheter Cardiovasc Interv* 83:343–348, 2014
- [132] Bybee KA, Prasad A, Barsness GW et al. Clinical characteristics and thrombolysis in myocardial infarction frame counts in women with transient left ventricular apical ballooning syndrome. *Am J Cardiol* 94:343–346, 2004
- [133] Redfors B, Vedad R, Angerås O et al. Mortality in takotsubo syndrome is similar to mortality in myocardial infarction – A report from the SWEDEHEART registry. *Int J Cardiol* 185:282–289, 2015
- [134] Nascimento FO, Larrauri-Reyes MC, Santana O et al. Comparison of stress cardiomyopathy in hispanic and non-hispanic patients. *Rev Esp Cardiol (Engl Ed)* 66:67–68, 2013
- [135] Schlossbauer SA, Ghadri JR, Templin C. Takotsubo-Syndrom – ein häufig verkannntes Krankheitsbild. *Praxis (Bern 1994)* 105(20):1185–1192, 2016
- [136] Amariles P, Cifuentes L. Drugs as possible triggers of Takotsubo cardiomyopathy: a comprehensive literature search-update 2015. *Curr Clin Pharmacol* 11:95–109, 2016
- [137] Ederhy S, Cautela J, Ancedy Y et al. Takotsubo-like syndrome in cancer patients treated with immune check-point inhibitors. *JACC Cardiovasc Imaging* 11:1187–1190, 2018
- [138] Berton E, Vitali-Serdoz L, Vallon P et al. Young girl with apical ballooning heart syndrome. *Int J Cardiol* 161:e4–6, 2012
- [139] Topal Y, Topal H, Doğan C et al. Tako-tsubo (stress) cardiomyopathy in childhood. *Eur J Pediatr* 179(4):619–625, 2020
- [140] Kumar G, Holmes DR Jr, Prasad A. “Familial” apical ballooning syndrome (Takotsubo cardiomyopathy). *Int J Cardiol* 144:444–445, 2010
- [141] El-Battrawy I, Santoro F, Stiermaier T et al. Incidence and clinical impact of recurrent Takotsubo syndrome: results from the GEIST registry. *J Am Heart Assoc* 8(9):e010753, 2019
- [142] Ghadri J-R, Wittstein IS, Prasad A et al. International Expert Consensus Document on Takotsubo syndrome (Part II): Diagnostic Workup, Outcome, and Management. *Eur Heart J* 39:2047–2062, 2018
- [143] Akashi YJ, Nef HM, Lyon AR. Epidemiology and pathophysiology of Takotsubo syndrome. *Nat Rev Cardiol* 12:387–397, 2015
- [144] Mansencal N, Auvert B, N’Guetta R et al. Prospective assessment of incidence of Tako-Tsubo cardiomyopathy in a very large urban agglomeration. *Int J Cardiol* 168:2791–2795, 2013
- [145] Pelliccia F, Kaski JC, Crea F et al. Pathophysiology of Takotsubo syndrome. *Circulation* 135:2426–2441, 2017
- [146] Heusch G. Alpha-adrenergic mechanisms in myocardial ischemia. *Circulation* 81:1–13, 1990
- [147] Ancona F, Bertoldi LF, Ruggieri F et al. Takotsubo cardiomyopathy and neurogenic stunned myocardium: similar albeit different. *Eur Heart J* 37:2830–2832, 2016
- [148] Sattler S, Couch LS, Harding SE. Takotsubo syndrome. Latest addition to the expanding family of immune-mediated diseases? *JACC: Basic Transl Sci* 3:779–781, 2018
- [149] Heubach JF, Ravens U, Kaumann AJ. Epinephrine activates both Gs and Gi pathways, but norepinephrine activates only the Gs pathway through human beta2-adrenoceptors overexpressed in mouse heart. *Mol Pharmacol* 65:1313–1322, 2004

- [150] Paur H, Wright PT, Sikkell MB et al. High levels of circulating epinephrine trigger apical cardiodepression. *Circulation* 126:697–706, 2012
- [150a] Mihailescu T, Kikuni G, Awada A et al. Latent left ventricular outflow tract obstruction in Takotsubo cardiomyopathy. *Eur Heart J Cardiovasc Imaging* 20(3):368, 2018
- [150b] Fefer P, Chelvanathan A, Dick AJ et al. Takotsubo cardiomyopathy and left ventricular outflow tract obstruction. *J Interv Cardiol* 22(5):444–452, 2009
- [151] Ueyama T, Ishikura F, Matsuda A et al. Chronic estrogen supplementation following ovariectomy improves the emotional stress-induced cardiovascular responses by indirect action on the nervous system and by direct action on the heart. *Circ J* 71:565–573, 2007
- [151a] Gupta S, Goyal P, Idrees S et al. Association of endocrine conditions with Takotsubo cardiomyopathy: a comprehensive review. *J Am Heart Assoc* 7:e009003, 2018
- [152] Nef HM, Möllmann H, Kostin S et al. Tako-Tsubo cardiomyopathy: intraindividual structural analysis in the acute phase and after functional recovery. *Eur Heart J* 28:2456–2464, 2007
- [153] Herraes P, Espinosa de los Monteros A, Fernandez A et al. Capture myopathy in live-stranded cetaceans. *Veter J* 196:181–188, 2013
- [154] Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P et al. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. *JAMA* 306:277–286, 2011
- [155] Ferreira VM, Marcelino M, Piechnik SK et al. Pheochromocytoma is characterized by catecholamine-mediated myocarditis, focal and diffuse myocardial fibrosis, and myocardial dysfunction. *J Am Coll Cardiol* 67:2364–2374, 2016
- [156] Scally C, Abbas H, Ahearn T et al. Myocardial and systemic inflammation in acute stress-induced (Takotsubo) cardiomyopathy. *Circulation* 139:1581–1592, 2019
- [157] Stirrat CG, Alam SR, MacGillivray TJ et al. Ferumoxytol-enhanced magnetic resonance imaging in acute myocarditis. *Heart* 104:300–305, 2018
- [158] Lüscher TF, Templin C. Is takotsubo syndrome a microvascular acute coronary syndrome? Towards a new definition. *Eur Heart J* 37:2816–2820, 2016
- [159] Thygesen K, Alpert JS, Jaffe AS et al., ESC Scientific Document Group. Fourth universal definition of myocardial infarction. *Eur Heart J* 40:237–269, 2019
- [160] Koeth O, Zeymer U, Schiele R et al. Inferior ST-elevation myocardial infarction associated with Takotsubo cardiomyopathy. *Case Rep Med* 2010:467867, 2010
- [161] Rechavia E, de Silva R, Nihoyannopoulos P et al. Hyperdynamic performance of remote myocardium in acute infarction. Correlation between regional contractile function and myocardial perfusion. *Eur Heart J* 16:1845–1850, 1995
- [162] Tavazzi G, Zanierato M, Via G et al. Are neurogenic stress cardiomyopathy and Takotsubo different syndromes with common pathways? Etiopathological insights on dysfunctional hearts. *JACC Heart Failure* 5:940–942, 2017
- [163] Guglin M, Novotorova I. Neurogenic stunned myocardium and Takotsubo cardiomyopathy are the same syndrome: a pooled analysis. *Congest Heart Fail* 17:127–132, 2011
- [164] Madias JE. „Neurogenic stress cardiomyopathy in heart donors“ is a form of Takotsubo syndrome. *Int J Cardiol* 184:612–613, 2015
- [165] Ravi Y, Campagna R, Rosas PC et al. Successful heart transplantation using a donor heart afflicted by takotsubo cardiomyopathy. *Proc (Bayl Univ Med Cent)* 29:73–74, 2016
- [166] Moussouttas M, Mearns E, Walters A et al. Plasma catecholamine profile of subarachnoid hemorrhage patients with neurogenic cardiomyopathy. *Cerebrovasc Dis Extra* 5:57–67, 2015
- [167] Cammann VC, Sarcon A, Ding KJ et al. Clinical features and outcomes of patients with malignancy and Takotsubo syndrome: observations from the International Takotsubo Registry. *J Am Heart Assoc* 6;8(15):e010881, 2019
- [168] Isogai T, Yasunaga H, Matsui H et al. Out-of-hospital versus in-hospital Takotsubo cardiomyopathy: analysis of 3719 patients in the Diagnosis Procedure Combination database in Japan. *Int J Cardiol* 176:413–417, 2014
- [169] Ludhwani D, Rahaby M, Patel V et al. Implications of left bundle branch block

- in Takotsubo cardiomyopathy: propensity match analysis from the National Inpatient Sample. *Cardiol Ther* 8:253–265, 2019
- [170] Haghi D, Athanasiadis A, Papavassiliu T et al. Right ventricular involvement in Takotsubo cardiomyopathy. *Eur Heart J* 27:2433–2439, 2006
- [171] Citro R, Bossone E, Parodi G et al. Clinical profile and in-hospital outcome of Caucasian patients with takotsubo syndrome and right ventricular involvement. *Int J Cardiol* 219:455–461, 2016
- [172] Ding KJ, Cammann VL, Szawan KA et al. Intraventricular thrombus formation and embolism in Takotsubo syndrome. Insights from the International Takotsubo Registry. *Arterioscler Thromb Vasc Biol* 40(1):279–287, 2020
- [173] Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (tako-tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. *Am Heart J* 2008; 155: 408–417, 2008
- [174] Stiermaier T, Santoro F, Graf T et al. Prognostic value of NTpro-BNP in Takotsubo syndrome. *Clin Res Cardiol* 107:597–606, 2018
- [175] Templin C, Ghadri JR, Diekmann J et al. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. *N Engl J Med* 373:929–938, 2015
- [176] Ponikowski P, Voors AA, Anker S et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 37:2129–2200, 2016
- [177] Izumi Y, Okatani H, Shiota M et al. Effects of metoprolol on epinephrine-induced Takotsubo-like left ventricular dysfunction in non-human primates. *Hypertens Res* 32:339–346, 2009
- [178] D’Ascenzo F, Gili S, Bertaina M et al. Impact of aspirin on takotsubo syndrome: a propensity score-based analysis of the InterTAK Registry. *Eur J Heart Fail* 22(2):330–337, 2020
- [179] Santoro F, Ieva R, Ferraretti A et al. Safety and feasibility of levosimendan administration in Takotsubo cardiomyopathy: a case series. *Cardiovasc Ther* 31:e133–137, 2013
- [180] Madias JE. If-channel blocker ivabradine vs. beta-blockers for sinus tachycardia in patients with Takotsubo syndrome. *Int J Cardiol* 223:877–878, 2016
- [181] Elesber A, Lerman A, Bybee KA et al. Myocardial perfusion in apical ballooning syndrome correlate of myocardial injury. *Am Heart J* 152:469, 2006
- [182] Tornvall P, Collste O, Ehrenborg E et al. A case-control study of risk markers and mortality in Takotsubo stress cardiomyopathy. *JACC* 67:1931–1936, 2016
- [183] Gili S, Cammann VL, Schlossbauer SA et al. Cardiac arrest in Takotsubo syndrome: results from the InterTAK registry. *Eur Heart J* 40:2142–2151, 2019
- [184] Jurisic S, Gili S, Cammann VL et al. Clinical predictors and prognostic impact of recovery of wall motion abnormalities in Takotsubo Syndrome: results from the International Takotsubo Registry. *J Am Heart Assoc* 8:e011194, 2019
- [185] Ghadri JR, Cammann VL, Jurisic S et al. A novel clinical score (InterTAK Diagnostic Score) to differentiate takotsubo syndrome from acute coronary syndrome: results from the International Takotsubo Registry. *Eur J Heart Fail* 19:1036–1042, 2017
- [186] Böhm M, Cammann VL, Ghadri JR et al. Interaction of systolic blood pressure and resting heart rate with clinical outcomes in takotsubo syndrome: insights from the International Takotsubo Registry. *Eur J Heart Fail* 20:1021–1030, 2018
- [187] Stiermaier T, Santoro F, El-Battrawy I et al. Prevalence and prognostic impact of diabetes in Takotsubo syndrome: insights from the international, multicenter GEIST registry. *Diabetes Care* 41:1084–1088, 2018
- [188] Wischnowsky MB, Candreva A, Bacchi B et al. Prediction of short- and long-term mortality in takotsubo syndrome: the InterTAK Prognostic Score. *Eur J Heart Failure* 21(11):1469–1472, 2019
- [189] Citro R, Radano I, Parodi G et al. Long-term outcome in patients with Takotsubo syndrome presenting with severely reduced left ventricular ejection fraction. *Eur J Heart Fail* 21:781–789, 2019
- [190] Scally C, Rudd A, Mezincescu A et al. Persistent long-term structural, functional,

- and metabolic changes after stress-induced (Takotsubo) cardiomyopathy. *Circulation* 137:1039–1048, 2018
- [191] Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. *JACC* 20:1391–1396, 2019
- [192] Roffi M, Patrono C, Collet JP et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J* 37:267–315, 2016
- [193] Byrne RA, Rossello X, Coughlan JJ et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur Heart J* 44:3720–3826, 2023
- [194] Campeau L. Entry sites for coronary angiography and therapeutic interventions: from the proximal to the distal radial artery. *Canad J Cardiol* 17:319–25, 2001
- [195] Otaki M. Percutaneous transradial approach for coronary angiography. *Cardiology* 81:330–3, 1992
- [196] Kiemeneij F, Laarman GJ. Percutaneous transradial artery approach for coronary stent implantation. *Catheter Cardiovasc Diag* 30:173–8, 1993
- [197] Kiemeneij F, Laarman GJ, Odekerken D et al. A randomized comparison of percutaneous transluminal coronary angioplasty by the radial, brachial and femoral approaches: the access study. *J Amer Coll Cardiol* 29:1269–75, 1997
- [198] Hess CN, Peterson ED, Neely ML et al. The learning curve for transradial percutaneous coronary intervention among operators in the United States: a study from the National Cardiovascular Data Registry. *Circulation* 129:2277–86, 2014
- [199] Barbash IM, Minha S, Gallino R et al. Operator learning curve for transradial percutaneous coronary interventions: implications for the initiation of a transradial access program in contemporary US practice. *Cardiovasc Revasc Med* 15:195–9, 2014
- [200] Hamon M, Pristipino C, Di Mario C et al. Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care and Thrombosis of the European Society of Cardiology. *EuroIntervention* 8:1242–51, 2013
- [201] Langer C, Riehle J, Wuttig H et al. Efficacy of a one-catheter concept for transradial coronary angiography. *PLoS One* 13:e0189899, 2018
- [202] Kedev S, Zafirovska B, Dharma S et al. Safety and feasibility of transulnar catheterization when ipsilateral radial access is not available. *Catheter Cardiovasc Interv* 83:e51–60, 2014
- [203] Pancholy SB, Bernat I, Bertrand OF et al. Prevention of radial artery occlusion after transradial catheterization: The PROPHET-II Randomized Trial. *JACC Cardiovasc Intervent* 9:1992–9, 2016
- [204] Stella PR, Kiemeneij F, Laarman GJ et al. Incidence and outcome of radial artery occlusion following transradial artery coronary angioplasty. *Catheter Cardiovasc Diag* 40:156–8, 1997
- [204a] Babunashvili A und Dundua N. Recanalization and reuse of early occluded radial artery within 6 days after previous transradial diagnostic procedure. *Catheter Cardiovasc Interv* 77:530–6, 2011
- [204b] Kiemeneij F. Left distal transradial access in the anatomical snuffbox for coronary angiography (IdTRA) and interventions (IdTRI). *Eurointervention* 13:851–7, 2017
- [204c] Soydan E, Akin M. Coronary angiography using the left distal radial approach – An alternative site to conventional radial coronary angiography. *Anatol J Cardiol* 19:243–8, 2018
- [204d] Schenke A, Prog DR, Matthiesen T, Rafflenbeul E, Grönefeld G, Viertel A. Ein neuer Weg zum Herz durch die distale Arteria radialis. Erste Erfahrungen mit dem Zugang durch die distale Arteria radialis in der Tabatière für Herzkatheteruntersuchungen und -interventionen. Daten aus der DRAGON (Distal Radial Access for coronary anGiOgraphy and iNtervention)-Register. *Kardiologie* 14:217–25, 2020

- [205] Saito S, Tanaka S, Hiroe Y et al. Usefulness of hydrophilic coating on arterial sheath introducer in transradial coronary intervention. *Cath Cardio Inter* 56:328–32, 2002
- [206] Kiemeneij F, Fraser D, Slagboom T et al. Hydrophilic coating aids radial sheath withdrawal and reduces patient discomfort following transradial coronary intervention: a randomized double-blind comparison of coated and uncoated sheaths. *Cathet Cardiovasc Intervent* 59:161–4, 2003
- [207] Varenne O, Jegou A, Cohen R et al. Prevention of arterial spasm during percutaneous coronary interventions through radial artery: the SPASM study. *Cathet Cardiovasc Intervent* 68(2):231–5, 2006
- [208] Chen CW, Lin CL, Lin TK et al. A simple and effective regimen for prevention of radial artery spasm during coronary catheterization. *Cardiology* 105:4 3–7, 2006
- [209] Deftereos S, Giannopoulos G, Raisakis K et al. Moderate procedural sedation and opioid analgesia during transradial coronary interventions to prevent spasm: a prospective randomized study. *JACC Cardiovasc Interv* 6:267–73, 2013
- [210] Pancholy SB, Coppola J, Patel T. Subcutaneous administration of nitroglycerin to facilitate radial artery cannulation. *Catheter Cardiovasc Interv* 68:389–91, 2006
- [211] Ouadhour A, Sideris G, Smida W et al. Usefulness of subcutaneous nitrate for radial access. *Catheter Cardiovasc Interv* 72:343–6, 2008
- [212] Lo TS, Nolan J, Fountzopoulos E et al. Radial artery anomaly and its influence on transradial coronary procedural outcome. *Heart* 95:410–5, 2009
- [213] Valsecchi O, Vassileva A, Musumeci G et al. Failure of transradial approach during coronary interventions: anatomic considerations. *Cathet Cardiovasc Intervent* 67:870–8, 2006
- [214] Chen O, Goel S, Acholonu M et al. Comparison of standard catheters versus radial artery-specific catheter in patients who underwent coronary angiography through transradial access. *Amer J Cardiol* 118:357–61, 2016
- [215] Jolly SS, Amlani S, Hamon M et al. Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. *A Heart J* 157:132–40, 2009
- [216] Plourde G, Pancholy SB, Nolan J et al. Radiation exposure in relation to the arterial access site used for diagnostic coronary angiography and percutaneous coronary intervention: a systematic review and meta-analysis. *Lancet* 386:2192–203, 2015
- [217] Becher T, Behnes M, Unsal M et al. Radiation exposure and contrast agent use related to radial versus femoral arterial access during percutaneous coronary intervention (PCI)-Results of the FERARI study. *Cardiovasc Revasc Med* 17:505–9, 2016
- [218] Xanthopoulou I, Stavrou K, Davlourous P et al. Randomised comparison of JUDKins vs. tiGER catheter in coronary angiography via the right radial artery: the JUDGE study. *EuroIntervention* 13:1950–8, 2018
- [219] Frizzell JD, Alkous M, Sheldon MW. Left ventricular perforation during ventriculogram using an optitorque tiger catheter. *JACC Cardiovasc Interv* 7:1456–7, 2014
- [220] Bernat I, Aminian A, Pancholy S et al. Best practices for the prevention of radial artery occlusion after transradial diagnostic angiography and intervention: an international consensus paper. *JACC Cardiovasc Interv* 12:2235–46, 2019
- [221] Rashid M, Kwok CS, Pancholy S et al. Radial artery occlusion after transradial interventions: a systematic review and meta-analysis. *J Am Heart Assoc* 5(1): e002686, 2016
- [222] Hahalis GN, Aznaouridis K, Tsigkas G et al. Radial artery and ulnar artery occlusions following coronary procedures and the impact of anticoagulation: ARTEMIS (radial and ulnar ARTEry occlusion Meta-analysis) systematic review and meta-analysis. *J Am Heart Assoc* 6(8):e005430, 2017
- [223] Mamas MA, Fraser DG, Ratib K et al. Minimising radial injury: prevention is better than cure. *EuroIntervention* 10: 824–32, 2014
- [224] Yonetsu T, Kakuta T, Lee T et al. Assessment of acute injuries and chronic intimal thickening of the radial artery after transradial coronary intervention by optical coherence tomography. *Eur Heart J* 31:1608–15, 2010
- [225] Abdelaal E, Molin P, Plourde G et al. Successive transradial access for coronary pro-

- cedures: experience of Quebec Heart-Lung Institute.. *Am Heart J* 165:325–31, 2013
- [225] Horie K, Tada N, Isawa T et al. A randomised comparison of incidence of radial artery occlusion and symptomatic radial artery spasm associated with elective transradial coronary intervention using 6.5 Fr SheathLess Eaucath Guiding Catheter vs. 6.0 Fr Glidesheath Slender. *EuroIntervention* 13:2018–25, 2018
- [226] Hahalis GN, Leopoulou M, Tsigkas G et al. Multicenter randomized valuation of high versus standard heparin dose on incident radial arterial occlusion after transradial coronary angiography: The SPIRIT OF ARTEMIS Study. *JACC Cardiovasc Interv* 11:2241–50, 2018
- [227] Pancholy S, Coppola J, Patel T et al. Prevention of radial artery occlusion-patent hemostasis evaluation trial (PROPHET study): a randomized comparison of traditional versus patency documented hemostasis after transradial catheterization. *Catheter Cardiovasc Interv* 72:335–40, 2008
- [228] Cubero JM, Lombardo J, Pedrosa C et al. Radial compression guided by mean artery pressure versus standard compression with a pneumatic device (RACOMAP). *Catheter Cardiovasc Interv* 73:467–72, 2009
- [229] Barbeau GR, Arsenault F, Dugas L et al. Evaluation of the ulnopalmar arterial arches with pulse oximetry and plethysmography: comparison with the Allen's test in 1010 patients. *Am Heart J* 147:489–93, 2004
- [230] Kotowycz MA, Dzavík V. Radial artery patency after transradial catheterization. *Circ Cardiovasc Interv* 5:127–33, 2012
- [231] Valgimigli M, Gagnor A, Calabro P et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. *Lancet* 385:2465–76, 2015
- [232] Ando G, Capodanno D. Radial access reduces mortality in patients with acute coronary syndromes: results from an updated trial sequential analysis of randomized trials. *JACC Cardiovasc Interv* 9:660–70, 2016
- [233] Fastner C, Behnes M, Unsal M et al. Clinical outcomes of femoral closure compared to radial compression devices following percutaneous coronary intervention: the FERARI study. *Heart Vessels* 32:520–30, 2017
- [234] Kolkailah AA, Alreshq RS, Muhammed AM et al. Transradial versus transfemoral approach for diagnostic coronary angiography and percutaneous coronary intervention in people with coronary artery disease. *Cochrane Database Syst Rev* 4:CD012318, 2018
- [235] Sirker A, Kwok CS, Kotronias R et al. Influence of access site choice for cardiac catheterization on risk of adverse neurological events: A systematic review and meta-analysis. *Am Heart J* 181:107–19, 2016
- [236] Dziewierz A, Siudak Z, Tokarek T et al. Determinants of stroke following percutaneous coronary intervention in acute myocardial infarction (from ORPKI Polish National Registry). *Int J Cardiol* 223:236–8, 2016
- [237] Dziewierz A, Siudak Z, Rakowski T et al. Transradial access and the risk of periprocedural stroke. *Am Heart J* 186:e5–6, 2017
- [238] Rashid M, Lawson C, Potts J et al. Incidence, determinants, and outcomes of left and right radial access use in patients undergoing percutaneous coronary intervention in the United Kingdom: a national perspective using the BCIS dataset. *JACC Cardiovasc Interv* 11:1021–33, 2018

6 Erweiterte morphologische und funktionelle Koronardiagnostik

6.1 Quantitative Koronarangiografie (QCA)

- [1] Feyter PJd, Serruys PW, Davies MJ et al. Quantitative coronary angiography to measure progression and regression of coronary atherosclerosis. Value, limitations, and implications for clinical trials. *Circulation* 84:412–423, 1991
- [2] Tonino PA, Bruyne Bd, Pijls NH et al. FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. *N Engl J Med* 60(3):213–224, 2009
- [3] Liao R, Luc D, Sun Y et al. 3-D reconstruction of the coronary artery tree from multiple views of a rotational X-ray angiography. *Int J Cardiovasc Imaging* 26:733–749, 2010
- [4] Pijls NH, van Son JAM, Kirkeeide RL et al. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. *Circulation* 87: 1354–1367, 1993
- [5] Pellicano M, Lavi I, De Bruyne B et al. Validation study of image-based fractional flow reserve during coronary angiography. *Circ Cardiovasc Interv* 10:e005259, 2017
- [3] Cole JS, Hartley CJ. The pulsed Doppler coronary artery catheter: Preliminary report of a new technique for measuring rapid changes in coronary artery flow velocity in man. *Circulation* 56:18–25, 1977
- [4] Wilson RF, Laughlin DE, Ackell PH et al. Transluminal, subselective measurement of coronary artery blood flow velocity and vasodilator reserve in man. *Circulation* 72:82–92, 1985
- [5] Sibley DH, Millar HD, Hartley CJ et al. Subselective measurement of coronary blood flow velocity using a steerable Doppler catheter. *J Am Coll Cardiol* 8:1332–40, 1986
- [6] Serruys PW, Juillière Y, Zijlstra F et al. Coronary blood flow velocity during percutaneous transluminal coronary angioplasty as a guide for assessment of the functional result. *Am J Cardiol* 61:253–9, 1988
- [7] Johnson EL, Yock PG, Hargrave VK et al. Assessment of severity of coronary stenoses using a Doppler catheter. Validation of a method based on the continuity equation. *Circulation* 80:625–35, 1989
- [8] McGinn AL, White CW, Wilson RF. Interstudy variability of coronary flow reserve. Influence of heart rate, arterial pressure, and ventricular preload. *Circulation* 81:1319–30, 1990
- [9] Di Mario C, Slager CJ, Linker DT et al. Quantitative assessment of coronary artery stenosis by intravascular Doppler catheter technique. *Circulation* 86:2016–7, 1992

6.2 Intrakoronarer Doppler (ICD)

- [1] White CW, Wright CB, Doty DB et al. Does visual interpretation of the coronary arteriogram predict the physiologic importance of a coronary stenosis? *N Engl J Med* 310:819–24, 1984
- [2] Hartley CJ, Cole JS. An ultrasound pulsed Doppler system for measuring blood flow in small vessels. *J Am Physiol* 37:626–9, 1974
- [10] Erbel R, Rupprecht HJ, Ge J et al. Coronary artery shape and flow changes induced by myocardial bridging. *Echocardiography* 10:71–7, 1993
- [11] Ge J, Erbel R, Rupprecht HJ et al. Comparison of intravascular ultrasound and angiography in the assessment of myocardial bridging. *Circulation* 89:1725–32, 1994

- [12] Doucette JW, Corl PD, Payne HM et al. Validation of a Doppler guide for intravascular measurement of coronary artery flow velocity. *Circulation* 85:1899–911, 1992
- [13] Dagres N, Haude M, Kurreck S et al. The EchoMap System: online integration of intracoronary ultrasound and Doppler images into angiographic images during cardiac catheterization. Influence on radiation exposure and procedure parameters. *J Interv Cardiol* 17:321–5, 2004
- [14] Baumgart D, Haude M, Ge J et al. New modular system for the determination of coronary blood flow velocity. *Cathet Cardiovasc Diagn* 35:378–9, 1995
- [15] Qian J, Ge J, Baumgart D et al. Safety of intracoronary Doppler flow measurement. *Am Heart J* 140:501–10, 2000
- [16] Klocke FJ. Coronary blood flow in man. *Prog Cardiovasc Dis* 19:117–66, 1976
- [17] Hoffman JI. Maximal coronary flow and the concept of coronary vascular reserve. *Circulation* 70:153–9, 1984
- [18] Baumgart D, Haude M, Liu F et al. Current concepts of coronary flow reserve for clinical decision making during cardiac catheterization. *Am Heart J* 136:136–49, 1998
- [19] Hoffman JI. Determinants and prediction of transmural myocardial perfusion. *Circulation* 8:381–91, 1978
- [20] Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. *Am J Cardiol* 33:87–94, 1974
- [21] Gould KL, Lipscomb K. Effects of coronary stenoses on coronary flow reserve and resistance. *Am J Cardiol* 34:48–55, 1974
- [22] Gould KL, Kelley KO, Bolson EL. Experimental validation of quantitative coronary arteriography for determining pressure-flow characteristics of coronary stenosis. *Circulation* 66:930–7, 1982
- [23] Gould KL. Assessment of coronary stenoses with myocardial perfusion imaging during pharmacologic coronary vasodilatation. IV. Limits of detection of stenosis with idealized experimental cross-sectional myocardial imaging. *Am J Cardiol* 42:761–8, 1978
- [24] Gould KL. Coronary flow reserve and pharmacologic stress perfusion imaging: beginnings and evolution. *JACC Cardiovasc Imaging* 2:664–9, 2009
- [25] Dayanikli F, Grambow D, Muzik O et al. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. *Circulation* 90:808–17, 1994
- [26] Gould KL, Schlebert HR, Phelps ME et al. Noninvasive assessment of coronary stenosis with myocardial perfusion imaging during pharmacologic coronary vasodilatation. V. Detection of 47 percent diameter coronary stenosis with intravenous nitrogen-13 ammonia and emission-computed tomography in intact dogs. *Am J Cardiol* 3(2):200–8, 1979
- [27] Zeiher AM, Drexler H, Saurbier J et al. Endothelium-mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia and hypertension. *J Clin Invest* 92:652–62, 1993
- [28] Erbel R, Ge J, Bockisch A et al. Value of intracoronary ultrasound and Doppler in the differentiation of angiographically normal coronary arteries: a prospective study in patients with angina pectoris. *Eur Heart J* 17:880–9, 1996
- [29] Qian JY, Ge JB, Fan B et al. Identification of syndrome X using intravascular ultrasound imaging and Doppler flow mapping. *Chin Med J* 17:521–7, 2004
- [30] Haude M, Caspari G, Baumgart D et al. Comparison of myocardial perfusion reserve before and after coronary balloon predilatation and after stent implantation in patients with postangioplasty restenosis. *Circulation* 94:286–97, 1996
- [31] Kern MJ. Applying coronary physiology for the nuclear cardiologist: new observations from intracoronary flow velocity and reserve in patients. *J Nucl Cardiol* 1:561–6, 1994
- [32] Kern MJ. Meaning of relative coronary flow reserve. *Am J Cardiol* 77:329–30, 1996
- [33] Miller DD, Donohue TJ, Wolford TL et al. Assessment of blood flow distal to coronary artery stenoses. Correlations between myocardial positron emission tomography and poststenotic intracoronary Dopp-

- ler flow reserve. *Circulation* 94(10):2447–54, 1996
- [34] Kern MJ, Puri S, Craig WR et al. Hemodynamic rounds series II: Coronary hemodynamics for angioplasty and stenting after myocardial infarction: use of absolute, relative coronary velocity and fractional flow reserve. *Cathet Cardiovasc Diagn* 45:174–82, 1998
- [35] Kern MJ, Puri S, Bach RG et al. Abnormal coronary flow velocity reserve after coronary artery stenting in patients: role of relative coronary reserve to assess potential mechanisms. *Circulation* 100:2491–8, 1999
- [36] Jeremias A, Whitbourn RJ, Filardo SD et al. Adequacy of intracoronary versus intravenous adenosine-induced maximal coronary hyperemia for fractional flow reserve measurements. *Am Heart J* 140: 651–7, 2000
- ### 6.3 Intrakoronare Druckmessung (ICP): Bestimmung von FFR, iFR und QFR
- [1] Freudenberg H, Lichtlen PR. The normal wall segment in coronary stenoses – a postmortal study (author's transl). *Z Kardiol* 70:863–9, 1981
- [2] Arnett EN, Isner JM, Redwood DR et al. Coronary artery narrowing in coronary heart disease: comparison of cineangiographic and necropsy findings. *Ann Intern Med* 91:350–6, 1979
- [3] Isner JM, Kishel J, Kent KM et al. Accuracy of angiographic determination of left main coronary arterial narrowing Angiographic – histologic correlative analysis in 28 patients. *Circulation* 63:1056–64, 1981
- [4] Bergelson BA, Tommaso CL. Left main coronary artery disease: assessment, diagnosis, and therapy. *Am Heart J* 129:350–9, 1995
- [5] Lee Th, Boucher CA. Clinical practice. Noninvasive tests in patients with stable coronary artery disease. *N Engl J Med* 344:1840–5, 2001
- [6] Aarnoudse WH, Botman KJ, Pijls NH. False-negative myocardial scintigraphy in balanced three-vessel disease, revealed by coronary pressure measurement. *Int J Cardiovasc Intervent* 5:67–71, 2003
- [7] Fisher LD, Judkins MP, Lesperance J et al. Reproducibility of coronary arteriographic reading in the coronary artery surgery study (CASS). *Cathet Cardiovasc Diagn* 8:565–75, 1982
- [8] Jandt U, Schäfer D, Grass M et al. Automatic generation of 3D coronary artery centerlines using rotational X-ray angiography. *Med Image Anal* 13:846–58, 2009
- [9] Chaitman BR, Fisher LD, Bourassa MG et al. Effect of coronary bypass surgery on survival patterns in subsets of patients with left main coronary artery disease. Report of the Collaborative Study in Coronary Artery Surgery (CASS). *Am J Cardiol* 48:765–77, 1981
- [10] Campeau L, Corbara F, Crochet D et al. Left main coronary artery stenosis: the influence of aortocoronary bypass surgery on survival. *Circulation* 57:1111–5, 1978
- [11] Taylor HA, Deumite NJ, Chaitman BR et al. Asymptomatic left main coronary artery disease in the Coronary Artery Surgery Study (CASS) registry. *Circulation* 79:1171–9, 1989
- [12] Caracciolo EA, Davis KB, Sopko G et al. Comparison of surgical and medical group survival in patients with left main coronary artery disease. Long-term CASS experience. *Circulation* 91:2325–34, 1995
- [13] Stone GW, Sabik JF, Serruys PW et al. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. *N Engl J Med* 375:2223–35, 2016
- [14] Mäkilä T, Holm NR, Lindsay M et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. *Lancet* 388:2743–52, 2016
- [15] Pijls NH, van Son JAM, Kirkeeide RL et al. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. *Circulation* 87:1354–1367, 1993
- [16] Pijls NH, Kern MJ, Yock PG et al. Practice and potential pitfalls of coronary pressure measurement. *Catheter Cardiovasc Interv* 2000 Jan; 9(1):1–16. Review. Erratum in: *Catheter Cardiovasc Interv* 50:157, 2000

- [17] Pijls N, De Bruyne B. Coronary pressure. Kluwer Academic Publishers, Dordrecht, 1997
- [18] Baumgart D, Haude M, Gorge G et al. Improved assessment of coronary stenosis severity using the relative flow velocity reserve. *Circulation* 98:40–6, 1998
- [19] van de Hoef TP, van Lavieren MA, Dammann P et al. Physiological basis and long-term clinical outcome of discordance between fractional flow reserve and coronary flow velocity reserve in coronary stenoses of intermediate severity. *Circ Cardiovasc Interv* 7:301–11, 2014
- [20] Matsuo H, Kawase Y. FFR and iFR guided percutaneous coronary intervention. *Cardiovasc Interv and Ther* 31:183–95, 2016
- [21] De Bruyne B, Fearon WF, Pijls NH et al., and FAME 2 Trial Investigators. Fractional flow reserve-guided PCI for stable coronary artery disease. *N Engl J Med* 371:1208–17, 2014; Erratum in: *N Engl J Med* 371:1465, 2014
- [22] Bech GJ, Droste H, Pijls NH et al. Value of fractional flow reserve in making decisions about bypass surgery for equivocal left main coronary artery disease. *Heart* 86:547–52, 2001
- [23] Kern MJ. Coronary physiology revisited: practical insights from the cardiac catheterization laboratory. *Circulation* 101:1344–51, 2000
- [24] Klauss V, Erdin P, Rieber J et al. Fractional flow reserve for the prediction of cardiac events after coronary stent implantation: results of a multivariate analysis. *Heart* 91:203–6, 2005
- [25] Lindstaedt M, Yazar A, Germing A et al. Clinical outcome in patients with intermediate or equivocal left main coronary artery disease after deferral of surgical revascularization on the basis of fractional flow reserve measurements. *Am Heart J* 152:156.e1–9, 2006
- [26] Tamita K, Akasaka T, Takagi T et al. Effects of microvascular dysfunction on myocardial fractional flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction. *Catheter Cardiovasc Interv* 57:452–9, 2002
- [27] Yanagisawa H, Chikamori T, Tanaka N et al. Correlation between thallium-201 myocardial perfusion defects and the functional severity of coronary artery stenosis as assessed by pressure-derived myocardial fractional flow reserve. *Circ J* 66:1105–9, 2002
- [28] Davies RF, Goldberg AD, Forman S et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. *Circulation* 95:2037–43, 1997
- [29] Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. *J Nucl Cardiol* 11:171–85, 2004
- [30] Shaw LJ, Berman DS, Maron DJ et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. *Circulation* 117:1283–91, 2008
- [31] Matsumoto H, Ushimaru S, Matsuda T et al. Is caffeine abstention necessary before adenosine-induced fractional flow reserve measurement? *J Am Coll Cardiol* 66:1943–5, 2015
- [32] Rzczuch K, Jankowska E, Kaczmarek A et al. Measurement of coronary fractional flow reserve. Standard doses of intracoronary adenosine are insufficient to induce maximal hyperaemia. *Kardiologia Pol* 58:269–74, 2003
- [33] Murtagh B, Higano S, Lennon R et al. Role of incremental doses of intracoronary adenosine for fractional flow reserve assessment. *Am Heart J* 146:99–105, 2003
- [34] Casella G, Rieber J, Schiele TM et al. A randomized comparison of 4 doses of intracoronary adenosine in the assessment of fractional flow reserve. *Z Kardiologie* 92:627–32, 2003
- [35] Usui Y, Chikamori T, Yanagisawa H et al. Reliability of pressure-derived myocardial fractional flow reserve in assessing coronary artery stenosis in patients with previous myocardial infarction. *Am J Cardiol* 92:699–702, 2003
- [36] Lopez-Palop R, Saura D, Pinar E et al. Adequate intracoronary adenosine doses to achieve maximum hyperaemia in coronary functional studies by pressure derived fractional flow reserve: a dose response study. *Heart* 90:95–6, 2004
- [37] Bishop AH, Samady H. Fractional flow reserve: critical review of an important physiologic adjunct to angiography. *Am Heart J* 147:792–802, 2004

- [38] Berger A, Botman KJ, MacCarthy PA et al. Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. *J Am Coll Cardiol* 46:438–42, 2005
- [39] Wongpraparut N, Yalamanchili V, Pasnoori V et al. Thirty-month outcome after fractional flow reserve-guided versus conventional multivessel percutaneous coronary intervention. *Am J Cardiol* 96:877–84, 2005
- [40] Legalery P, Schiele F, Seronde MF et al. One-year outcome of patients submitted to routine fractional flow reserve assessment to determine the need for angioplasty. *Eur Heart J* 26:2623–9, 2005
- [41] Pijls NH, Schaardenburgh Pv, Manoharan G et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. *J Am Coll Cardiol* 49:2105–11, 2007
- [42] Tonino PA, De Bruyne B, Pijls NH et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. *N Engl J Med* 360:213–24, 2009
- [43] Lim HS, Tonino PA, De Bruyne B et al. The impact of age on fractional flow reserve-guided percutaneous coronary intervention: a FAME (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) trial substudy. *Int J Cardiol* 177:66–70, 2014
- [43] Fearon WF, Nishi T, De Bruyne B et al. Clinical outcomes and cost-effectiveness of fractional flow reserve-guided percutaneous coronary intervention in patients with stable coronary artery disease: three-year follow-up of the FAME 2 Trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation). *Circulation* 137:480–7, 2018
- [44] Nijjer SS, de Waard GA, Sen S et al. Coronary pressure and flow relationships in humans: phasic analysis of normal and pathological vessels and the implications for stenosis assessment: a report from the Iberian-Dutch-English (IDEAL) collaborators. *Eur Heart J* 37:2069–80, 2016
- [45] Jeremias A, Kirtane AJ, Stone GW. A test in context: fractional flow reserve: accuracy, prognostic implications, and limitations. *J Am Coll Cardiol* 69:2748–58, 2017
- [46] Zimmermann FM, De Bruyne B, Pijls NH et al. Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: a comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease. *Am Heart J* 170:619–26.e2, 2015
- [46a] Kobayashi Y, Takahashi T, Zimmermann FM et al. FAME 3 Trial Investigators. Outcomes Based on Angiographic vs Functional Significance of Complex 3-Vessel Coronary Disease: FAME 3 Trial. *JACC Cardiovasc Interv* 16:2112–2119, 2023
- [47] Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J* 34:2949–3003, 2013
- [48] Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 35:2541–619, 2014
- [49] Matsuo H, Kawase Y. FFR and iFR guided percutaneous coronary intervention. *Cardiovasc Interv Ther* 31:183–95, 2016
- [50] Sen S, Asress KN, Nijjer S et al. Diagnostic classification of the instantaneous wave-free ratio is equivalent to fractional flow reserve and is not improved with adenosine administration. Results of CLARIFY (Classification Accuracy of Pressure-Only Ratios Against Indices Using Flow Study). *J Am Coll Cardiol* 61:1409–20, 2013
- [51] Petraco R, Escaned J, Sen S et al. Classification performance of instantaneous wave-free ratio (iFR) and fractional flow reserve in a clinical population of intermediate coronary stenoses: results of the ADVISE registry. *EuroIntervention* 9:91–101, 2013
- [52] Sen S, Escaned J, Malik IS et al. Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis: results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation)

- study. *J Am Coll Cardiol* 59:1392–402, 2012
- [53] Davies JE, Sen S, Broyd C et al. Arterial pulse wave dynamics after percutaneous aortic valve replacement: fall in coronary diastolic suction with increasing heart rate as a basis for angina symptoms in aortic stenosis. *Circulation* 124:1565–72, 2011
- [54] Maini R, Moscona J, Katigbak P et al. Instantaneous wave-free ratio as an alternative to fractional flow reserve in assessment of moderate coronary stenosis: a meta-analysis of diagnostic accuracy studies. *Cardiovasc Revasc Med* 19(5 Pt B):613–20, 2018
- [55] Davies JE, Sen S, Dehbi HM et al. Use of the instantaneous wave-free ratio or fractional flow reserve in PCI. *N Engl J Med* 376:1824–34, 2017
- [56] Götzberg M, Christiansen EH, Gudmundsdottir IJ et al., and iFR-SWEDEHEART investigator. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. *N Engl J Med* 376:1813–23, 2017
- [57] Berry C, McClure JD, Oldroyd KG. Meta-analysis of death and myocardial infarction in the DEFINE-FLAIR and iFR-SWEDEHEART Trials. *Circulation* 136:2389–91, 2017
- [58] Pijls NH. Optimum guidance of complex PCI by coronary pressure measurement. *Heart* 90:1085–93, 2004
- [59] Iwasaki K, Matsumoto T. Coronary pressure measurement identifies patients with diffuse coronary artery disease who benefit from coronary revascularization. *Coron Artery Dis* 22:81–6, 2011
- [60] Bhatt DL. Fractional flow reserve measurement for the physiological assessment of coronary artery stenosis severity. *JAMA* 320:1275–76, 2018
- [60a] De Rosa S, Polimeni A, Petraco R et al. Diagnostic Performance of the Instantaneous Wave-Free Ratio: Comparison With Fractional Flow Reserve. *Circ Cardiovasc Interv* 11:e004613, 2018
- [60b] DEFINE-FLAIR Trial Investigators et al. Comparison of Major Adverse Cardiac Events Between Instantaneous Wave-Free Ratio and Fractional Flow Reserve-Guided Strategy in Patients With or Without Type 2 Diabetes: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Cardiol* 4:857–864, 2019
- [60c] Modi BN, Rahman H, Ryan M et al. Comparison of fractional flow reserve, instantaneous wave-free ratio and a novel technique for assessing coronary arteries with serial lesions. *EuroIntervention* 16:577–583, 2020
- [61] Fermor U, Huber H, Neuhaus KL et al. Measurement of flow velocity in the model circulation by videodensitometry. *Methodological investigations. Basic Res Cardiol* 74:361–77, 1979
- [62] Schmiel FK, Hackbarth W, Körfer R et al. Flow measurements and simultaneously performed angiography of aorto-coronary bypass grafts during bypass surgery. *Thorac Cardiovasc Surg* 27:386–9, 1979
- [63] Block M, Jehle J, Pölit B et al. [Determination of phasic flow speeds in the coronary vessels by means of a simple photo-densitometric technique (author's transl)]. *Rofo* 136:283–90, 1982
- [64] Spiller P, Schmiel FK, Pölit B et al. Measurement of systolic and diastolic flow rates in the coronary artery system by x-ray densitometry. *Circulation* 68:337–47, 1983
- [65] Sauer G, Krause H, Burmeister A et al. [Determination of flow velocities in the human coronary system using a computer-assisted cine-videodensitometric system]. *Z Kardiol* 72:207–14, 1983
- [66] Machnig T, Jehle J, Pölit B et al. [The determination of myocardial perfusion parameters from coronary angiograms by analysing the passage of contrast media through the myocardium]. *Rofo* 153:252–9, 1990
- [67] Pellicano M, Lavi I, De Bruyne B et al. Validation study of image-based fractional flow reserve during coronary angiography. *Circ Cardiovasc Interv* 10:e005259, 2017
- [68] Smit JM, El Mahdiui M, van Rosendaal AR et al. Comparison of diagnostic performance of quantitative flow ratio in patients with versus without diabetes mellitus. *Am J Cardiol* 123:1722–8, 2019
- [69] Zhang Y, Zhang S, Westra J et al. Automatic coronary flow computation: validation in quantitative flow ratio from coronary angiography. *Int J Cardiol* 35:587–95, 2019
- [70] Morris PD, Gunn JP. Computing fractional flow reserve from invasive coronary angiography. *Circ Cardiovasc Interv* 10:e005806, 2017
- [71] Morris PD1, Ryan D, Morton AC et al. Virtual fractional flow reserve from coronary

- angiography: modeling the significance of coronary lesions: results from the VIRTU-1 (VIRTUal Fractional Flow Reserve From Coronary Angiography) study. *JACC Cardiovasc Interv* 6:149–57, 2013
- [72] Morris PD, Silva Sato DA, Feher JFA et al. Fast virtual fractional flow reserve based upon steady-state computational fluid dynamics analysis: results from the VIRTU-Fast study. *JACC Basic Transl Sci* 2:34–446, 2017
- [73] Papafakis MI, Muramatsu T, Ishibashi Y et al. Fast virtual functional assessment of intermediate coronary lesions using routine angiographic data and blood flow simulation in humans: comparison with pressure wire – fractional flow reserve. *EuroIntervention* 10:574–83, 2014
- [74] Schuurbiers JC, Lopez NG, Ligthart J et al. In vivo validation of CAAS QCA-3D coronary reconstruction using fusion of angiography and intravascular ultrasound (ANGUS). *Catheter Cardiovasc Interv* 73:620–6, 2009
- [75] Kern MJ, Bach RG, Mechem CJ et al. Variations in normal coronary vasodilatory reserve stratified by artery, gender, heart transplantation and coronary artery disease. *J Am Coll Cardiol* 28:1154–60, 1996
- [76] Tu S, Barbato E, Köszegi Z et al. Fractional flow reserve calculation from 3-dimensional quantitative coronary angiography and TIMI (Thrombolysis in Myocardial Infarction) frame count: a fast computer model to quantify the functional significance of moderately obstructed coronary arteries. *J Am Coll Cardiol Interv* 7:768–77, 2014
- [77] Tu S, Westra J, Yang J et al., FAVOR Pilot Trial Study Group. diagnostic accuracy of fast computational approaches to derive fractional flow reserve from diagnostic coronary angiography: the international multicenter FAVOR Pilot Study. *JACC Cardiovasc Interv* 9:2024–35, 2016
- [78] Dodge JT Jr, Rizzo M, Nykiel M et al. Impact of injection rate on the Thrombolysis in Myocardial Infarction (TIMI) trial frame count. *Am J Cardiol* 81:1268–70, 1998
- [79] Stoel MG, Zijlstra F, Visser CA. Frame count reserve. *Circulation* 107:3034–9, 2003
- [80] Zhang Y, Zhang S, Westra J et al. Automatic coronary blood flow computation: validation in quantitative flow ratio from coronary angiography. *Int J Cardiovasc Imaging* 35:587–95, 2019
- [80a] Biscaglia S, Tebaldi M, Brugaletta S et al. Prognostic value of QFR measured immediately after successful stent implantation: the international multicenter prospective HAWKEYE Study. *JACC Cardiovasc Interv* 12:2079–88, 2019
- [80b] Cerrato E, Mejía-Rentería H, Franzè A et al. Quantitative flow ratio as a new tool for angiography-based physiological evaluation of coronary artery disease: a review. *Future Cardiol Future Cardiol* 17:1435–1452, 2021
- [81] Tröbs M, Achenbach S, Röther J et al. Comparison of fractional flow reserve based on computational fluid dynamics modeling using coronary angiographic vessel morphology versus invasively measured fractional flow reserve. *Am J Cardiol* 117:29–35, 2016
- [82] Ammon F, Tröls M, Bittner D et al. Diagnostic accuracy of on-site FFRCT and the new concept of FFRangio: a head to head comparison with invasively measured FFR. *J Cardiovasc Comput Tomogr* 13(1)(Suppl):S28, 2019
- [83] Pellicano M, Lavi I, De Bruyne B et al. Validation study of image-based fractional flow reserve during coronary angiography. *Circ Cardiovasc Interv* 10(9):e005259, 2017
- [84] Kirkeeide RL. Coronary obstructions, morphology physiologic significance. In: Reiber JHC, Serruys PW (Eds), *Quantitative coronary arteriography*. Kluwer Academic Publishers, Dordrecht, pp. 229–244, 1991
- [85] Tu S, Westra J, Yang J et al. Diagnostic accuracy of fast computational approaches to derive fractional flow reserve from diagnostic coronary angiography: the international multicenter FAVOR Pilot Study. *JACC Cardiovasc Interv* 9:2024–35, 2016
- [86] Ties D, van Dijk R, Pundziute G et al. Computational quantitative flow ratio to assess functional severity of coronary artery stenosis. *Int J Cardiol* 271:36–41, 2018
- [87] Johnson NP, Jeremias A, Zimmermann FM et al. Continuum of vasodilator stress from rest to contrast medium to adenosine hyperemia for fractional flow reserve assessment. *JACC Cardiovasc Interv* 9:757–67, 2016

- [88] Westra J, Tu S, Campo G et al. Diagnostic performance of quantitative flow ratio in prospectively enrolled patients: An individual patient-data meta-analysis. *Catheter Cardiovasc Interv* 94:693–701, 2019
- [89] Westra J, Andersen BK, Campo G et al. Diagnostic performance of in-procedure angiography-derived quantitative flow reserve compared to pressure-derived fractional flow reserve: The FAVOR II Europe-Japan Study. *J Am Heart Assoc* 7(14):e009603, 2018
- [90] Westra J, Tu S, Winther S et al. Evaluation of coronary artery stenosis by quantitative flow ratio during invasive coronary angiography: the WIFI II Study (Wire-Free Functional Imaging II). *Circ Cardiovasc Imaging* 11:e007107, 2018
- [91] Xu B, Tu S, Qiao S et al. Diagnostic accuracy of angiography-based quantitative flow ratio measurements for online assessment of coronary stenosis. *J Am Coll Cardiol* 70:3077–87, 2017
- heit des intraluminalen Ultraschalls. *Z Kardiol* 80:595–601, 1991
- [8] Lookwood G, Ryan L, Gotlieb A et al. In vitro high resolution intravascular imaging in muscular and elastic arteries. *J Am Coll Cardiol* 20:153–160, 1992
- [9] Tobis JM, Mallery J, Mahon D. Intravascular ultrasound imaging of human coronary arteries in vivo. *Circulation* 83:913–926, 1991
- [10] Sievers B, Böse D, Sack S et al. Online PC-based integration of digital intracoronary ultrasound images into angiographic images during cardiac catheterization. *Int J Cardiol* 128:289–293, 2008
- [11] Di Mario C, The SH, Madretsma S et al. Detection and characterization of vascular lesions by intravascular ultrasound: an in vitro study correlated with histology. *J Am Echocardiogr* 5:135–146, 1992
- [12] Friedewald VE, Ambrose JA, Stone GW et al. The editor's roundtable: the vulnerable plaque. *Am J Cardiol* 102:1644–1653, 2008
- [13] Görges G, Erbel R, Schuster S et al. Intravascular ultrasound in diagnosis of acute pulmonary embolism. *Lancet* 337:623–624, 1991

6.4 Intravaskulärer Ultraschall (IVUS)

- [1] Freudenberg H, Lichtlen PR. The normal wall segment in coronary stenoses. A post-mortal study. *Z Kardiol* 70:863–869, 1981
- [2] Isner JM, Kishel J, Kent KM. Accuracy of angiographic determination of the left main coronary arterial narrowing. *Circulation* 63:1065–1061, 1981
- [3] Vlodover Z, Edwards JE. Pathology of coronary atherosclerosis. *Progr Cardiovasc Dis* 14:256–274, 1971
- [4] Glagov S, Weisenberg E, Zarins CK et al. Compensatory enlargement of human atherosclerotic coronary arteries: *New Engl J Med* 316:1371–1375, 1987
- [5] Zarins CK, Weisenberg E, Kolettis G et al. Differential enlargement of artery segments in response to enlarging atherosclerotic plaques. *J Vasc Surg Suppl* 7:386–394, 1988
- [6] Di Mario C, The SHK, Madretsma S. Detection and characterization of vascular lesions by intravascular ultrasound. An in vitro study correlated with histology. *J Am Soc Echocard* 5:135–146, 1992
- [7] Ge J, Erbel R, Seidel I et al. Experimentelle Überprüfung der Genauigkeit und Sicherheit des intraluminalen Ultraschalls. *Z Kardiol* 80:595–601, 1991
- [8] Lookwood G, Ryan L, Gotlieb A et al. In vitro high resolution intravascular imaging in muscular and elastic arteries. *J Am Coll Cardiol* 20:153–160, 1992
- [9] Tobis JM, Mallery J, Mahon D. Intravascular ultrasound imaging of human coronary arteries in vivo. *Circulation* 83:913–926, 1991
- [10] Sievers B, Böse D, Sack S et al. Online PC-based integration of digital intracoronary ultrasound images into angiographic images during cardiac catheterization. *Int J Cardiol* 128:289–293, 2008
- [11] Di Mario C, The SH, Madretsma S et al. Detection and characterization of vascular lesions by intravascular ultrasound: an in vitro study correlated with histology. *J Am Echocardiogr* 5:135–146, 1992
- [12] Friedewald VE, Ambrose JA, Stone GW et al. The editor's roundtable: the vulnerable plaque. *Am J Cardiol* 102:1644–1653, 2008
- [13] Görges G, Erbel R, Schuster S et al. Intravascular ultrasound in diagnosis of acute pulmonary embolism. *Lancet* 337:623–624, 1991
- [14] Boksch WG, Scharl M, Beckmann SH et al. Intravascular ultrasound imaging in patients with acute myocardial infarction: comparison with chronic stable angina pectoris. *Coron Artery Dis* 5:727–735, 1994
- [15] Kearney P, Erbel R, Rupprecht HJ et al. Differences in morphology of unstable coronary lesions and their impact on the mechanisms of angioplasty – An in vivo study with intravascular ultrasound. *Eur Heart J* 17:721–730, 1996
- [16] Ge J, Chirillo F, Schwedtmann J et al. Screening of ruptured plaques in patients with coronary artery disease by intravascular ultrasound. *Heart* 81:621–627, 1999
- [17] Gussenhoven WJ, Essed CE, Frietman P et al. Intravascular echographic assessment of vessel wall characteristics: a correlation with histology. *Int J Card Imag* 4:105–116, 1989
- [18] Erbel R, Ge J, Kearney P et al. Intravaskuläre Sonographie bei koronarer Herzkrankheit. *DMW* 120:847–854, 1995
- [19] Erbel R, Ge J, Görges G et al. Intravascular ultrasound classification of atherosclerotic lesions according to American Heart Asso-

- ciation recommendation. *Coron Artery Dis* 10:489–499, 1999
- [20] Zamorano J, Erbel R, Ge J et al. Spontaneous plaque rupture visualized by intravascular ultrasound examination. *Eur Heart J* 15:710–712, 1994
- [21] Ge J, Liu F, Kearney P et al. Intravascular ultrasound approach to the diagnosis of coronary artery aneurysms. *Am Heart J* 130:765–771, 1995
- [22] Montenegro MR, Eggen DA. Topography of atherosclerosis in the coronary arteries. *Lab Invest* 18:586–593, 1968
- [23] Wolhoff K. Über die Atherosklerose der Koronararterien des Herzens. *Beitr Path Anat* 82:555–596, 1929
- [24] Stary HC. The sequency of cell and matrix chatges in atherosclerotic lesions of coronary arteries in the first forty years of life. *Europ Heart J* 11(Suppl):3–19, 1990
- [25] Stary HC, Chandler AB, Dinsmore RE et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. *Circulation* 92:1355–1374, 1995
- [26] Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a Comprehensive Morphological Classification Scheme for Atherosclerotic Lesions. *Arterioscler, Thromb Vasc Biol* 20:1262–1275, 2000
- [27] Schaar JA, Regar E, Mastik F et al. Incidence of high-strain patterns in human coronary arteries: assessment with three-dimensional intravascular palpography and correlation with clinical presentation. *Circulation* 109:2716–2719, 2004
- [28] Schaar JA, van der Steen AF, Mastik F et al. Intravascular palpography for vulnerable plaque assessment. *J Am Cardiol* 28 (Suppl 8):C86–91, 2006
- [29] Nair A, Kuban BD, Tuzcu EM et al. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. *Circulation* 106:2200–2206, 2002
- [30] Nair A, Margolis M, Kuban B et al. Automated coronary plaque characterisation with intravascular ultrasound backscatter: ex vivo validation. *EuroIntervention* 3:113–120, 2007
- [31] Philipp S, Böse D, Wijns W et al. Do systemic risk factors impact invasive findings from virtual histology? Insights from the international virtual histology registry. *Eur Heart J* 31(2):196–202, 2010
- [32] Qian J, Maehara A, Mintz GS et al. Relation between individual plaque components and overall plaque burden in the prospective, multicenter virtual histology intravascular ultrasound registry. *Am J Cardiol* 104:501–506, 2009
- [33] Qian J, Maehara A, Mintz GS et al. Impact of gender and age on in vivo virtual histology-intravascular ultrasound imaging plaque characterization (from the global Virtual Histology Intravascular Ultrasound [VH-IVUS] registry). *Am J Cardiol* 103:1210–1214, 2009
- [34] Garcia-Garcia HM, Gonzalo N, Regar E et al. Virtual histology and optical coherence tomography: from research to a broad clinical application. *Heart* 95:1362–1374, 2009
- [35] Pundziute G, Schuijff JD, Jukema JW et al. Type 2 diabetes is associated with more advanced coronary atherosclerosis on multislice computed tomography and virtual histology intravascular ultrasound. *J Nucl Cardiol* 16:376–383, 2009
- [36] Nasu K, Tsuchikane E, Katoh O et al. Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology intravascular ultrasound. *JACC Cardiovasc Interv* 2:689–696, 2009
- [37] Böse D, von Birgelen C, Zhou XY et al. Impact of atherosclerotic plaque composition on coronary microembolization during percutaneous coronary interventions. *Basic Res Cardiol* 103:587–597, 2008
- [38] Garcia-Garcia H, Mintz G, Lerman A et al. Tissue characterization using intravascular radiofrequency data analysis: recommendations for acquisition, analysis, interpretation and reporting. *Eur Interv* 5:177–189, 2009
- [39] Zarins CK, Zatina MA, Giddens DP et al. Shear stress regulation of artery lumen diameter in experimental atherogenesis. *J Vasc Surg* 5:413–420, 1987
- [40] Ge J, Erbel R, Zamorano J et al. Coronary artery remodeling in atherosclerotic disease: an intravascular ultrasonic study in vivo. *Coron Artery Dis* 4:981–986, 1993
- [41] Gerber T, Erbel R, Gorge G et al. Extent of atherosclerosis and remodelling of the left main coronary artery determined by intravascular ultrasound. *Am J Cardiol* 73:666–671, 1994
- [42] Gerber TC, Erbel R, Gorge G et al. Classification of morphologic effects of percuta-

- neous transluminal coronary angioplasty assessed by intravascular ultrasound. *Am J Cardiol* 70:1546–1554, 1992
- [43] von Birgelen C, Mintz GS, Eggebrecht H et al. Preintervention arterial remodeling affects vessel stretch and plaque extrusion during coronary stent deployment as demonstrated by three-dimensional intravascular ultrasound. *Am J Cardiol* 92:130–135, 2003
- [44] von Birgelen C, Mintz GS, Sieling C et al. Relation between plaque composition and vascular remodeling in coronary lesions with different degrees of lumen narrowing as assessed with three-dimensional intravascular ultrasound in patients with stable angina pectoris. *Am J Cardiol* 91:1103–1107, 2003
- [45] von Birgelen C, Hartmann M, Mintz GS et al. Remodeling index compared to actual vascular remodeling in atherosclerotic left main coronary arteries as assessed with long-term (> or = 12 months) serial intravascular ultrasound. *J Am Coll Cardiol* 47:1363–1368, 2006
- [46] Mintz GS, Nissen SE, Anderson WD et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol* 37:1478–1492, 2001
- [47] Hong MK, Mintz GS, Lee CW et al. Intravascular ultrasound assessment of patterns of arterial remodeling in the absence of significant reference segment plaque burden in patients with coronary artery disease. *J Am Coll Cardiol* 42:806–810, 2003
- [48] Mintz GS, Popma JJ, Pichard AD et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. *Circulation* 94:35–43, 1996
- [49] Abizaid AS, Mintz GS, Mehran R et al. Long-term follow-up after percutaneous transluminal coronary angioplasty was not performed based on intravascular ultrasound findings: importance of lumen dimensions. *Circulation* 100:256–261, 1999
- [50] Hong MK, Mintz GS, Lee CW et al. The site of plaque rupture in native coronary arteries: a three-vessel intravascular ultrasound analysis. *J Am Coll Cardiol* 46:261–265, 2005
- [51] von Birgelen C, Mintz GS, de Vrey EA et al. Atherosclerotic coronary lesions with inadequate compensatory enlargement have smaller plaque and vessel volumes: observations with three dimensional intravascular ultrasound in vivo. *Heart* 79:137–143, 1998
- [52] Ge J, Erbel R, Gerber T et al. Intravascular ultrasound imaging of angiographically normal coronary arteries: a prospective study in vivo. *Br Heart J* 71:572–578, 1994
- [53] Hausmann D, Erbel R, Alibelli-Chemarin MJ et al. The safety of intracoronary ultrasound. a multicenter survey of 2207 examinations. *Circulation* 91:623–630, 1995
- [54] Ge J, Liu F, Kearney P et al. Acute coronary artery closure following intracoronary ultrasound examination. *Cathet Cardiovasc Diagn* 35:232–235, 1995
- [54] Parise H, Maehara A, Stone GW et al. Meta-analysis of randomized studies comparing intravascular ultrasound versus angiographic guidance of percutaneous coronary intervention in pre-drug-eluting stent era. *Am J Cardiol* 107:374–382, 2011
- [55] Steinvil A, Zhang Y, Lee SA et al. Intravascular ultrasound-guided drug eluting stent implantation: an updated meta-analysis of randomized control trials and observational studies. *Int J Cardiol* 216:133–139, 2016
- [56] Bavishi C, Sardar P, Chatterjee S et al. Intravascular ultrasound-guided vs angiography-guided drug-eluting stent implantation in complex coronary lesions: met-analysis of randomized trials. *Am Heart J* 185:26–34, 2017
- [57] de la Torre Hernandez JM, Hernandez Hernandez F, Alfonso F et al. Prospective application of pre-defined intravascular ultrasound criteria for assessment of intermediate left main coronary artery lesions results from the multicenter LITRO study. *J Am Coll Cardiol* 58:351–358, 2011
- [58] Neumann FJ, Sousa-Uva M, Ahlsson A et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 40:87–165, 2019
- [59] Waksman R, Legutko J, Singh J et al. FIRST: Fractional Flow Reserve and Intravascular Ultrasound Relationship Study. *J Am Coll Cardiol* 61:917–923, 2013

- [60] Fassa AA, Wagatsuma K, Higano ST et al. Intravascular ultrasound-guided treatment for angiographically indeterminate left main coronary artery disease: A long-term follow-up study. *J Am Coll Cardiol* 45:204–211, 2005
- [61] Erbel R. Diagnosis and prevention of cardiovascular diseases, Part 2. Herz 32(7):527–528, 2007
- [62] Velican D, Velican C. Comparative study on age-related changes and atherosclerotic involvement of the coronary arteries of male and female subjects up to 40 years of age. *Atherosclerosis* 38:39–50, 1981

6.5 Optische Kohärenztomografie (OCT)

- [1] Leistner DM, Landmesser U, Frohlich GM. FD-OCT and IVUS for detection of incomplete stent apposition in heavily calcified vessels: novel insights. *Open Heart* 2:e000292, 2015
- [2] Kuku KO, Ekanem E, Azizi V et al. Optical coherence tomography-guided percutaneous coronary intervention compared with other imaging guidance: a meta-analysis. *Int J Cardiovasc Imaging* 34: 503–513, 2018
- [3] Leistner DM, Boeckel JN, Reis SM et al. Transcoronary gradients of vascular miRNAs and coronary atherosclerotic plaque characteristics. *Eur Heart J* 37:1738–1749, 2016
- [4] Kubo T, Imanishi T, Kashiwagi M et al. Multiple coronary lesion instability in patients with acute myocardial infarction as determined by optical coherence tomography. *Am J Cardiol* 105:318–322, 2010
- [5] Jia H, Abtahian F, Aguirre AD et al. In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. *J Am Coll Cardiol* 62: 1748–1758, 2013
- [6] Mizukoshi M, Imanishi T, Tanaka A et al. Clinical classification and plaque morphology determined by optical coherence tomography in unstable angina pectoris. *Am J Cardiol* 106:323–328, 2010
- [7] Hu S, Zhu Y, Zhang Y et al. Management and outcome of patients with acute coronary syndrome caused by plaque rupture versus plaque erosion: an intravascular optical coherence tomography study. *J Am Heart Assoc* 6:e004730, 2017
- [8] Tearney GJ, Regar E, Akasaka T et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. *J Am Coll Cardiol* 59:1058–1072, 2012
- [9] Sinclair H, Bourantas C, Bagnall A et al. OCT for the identification of vulnerable plaque in acute coronary syndrome. *JACC Cardiovasc Imaging* 8:198–209, 2015
- [10] Niccoli G, Montone RA, Di Vito L et al. Plaque rupture and intact fibrous cap assessed by optical coherence tomography portend different outcomes in patients with acute coronary syndrome. *Eur Heart J* 36:1377–1384, 2015
- [11] Ali ZA, Maehara A, Genereux P et al. Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial. *Lancet* 388:2618–2628, 2016
- [12] Chamie D, Bezerra HG, Attizzani GF et al. Incidence, predictors, morphological characteristics, and clinical outcomes of stent edge dissections detected by optical coherence tomography. *JACC Cardiovasc Interv* 6:800–813, 2013
- [13] Leistner DM, Riedel M, Steinbeck L et al. Real-time optical coherence tomography coregistration with angiography in percutaneous coronary intervention-impact on physician decision-making: The OPTICO-integration study. *Catheter Cardiovasc Interv* 92:30–37, 2018
- [14] Di Vito L, Yoon JH, Kato K et al. Comprehensive overview of definitions for optical coherence tomography-based plaque and stent analyses. *Coron Artery Dis* 25:172–185, 2014
- [15] Porto I, Di Vito L, Burzotta F et al. Predictors of periprocedural (type IVa) myocardial infarction, as assessed by frequency-domain optical coherence tomography. *Circulation Cardiovasc Interv* 5:89–96, S1–6, 2012
- [16] Cook S, Wenaweser P, Togni M et al. Incomplete stent apposition and very late

- stent thrombosis after drug-eluting stent implantation. *Circulation* 115:2426–2434, 2007
- [17] Sethi A, Singbal Y, Rastogi U et al. Late incomplete stent apposition is associated with late/very late stent thrombosis: a meta-analysis. *Catheter Cardiovasc Interv* 91:365–375, 2018
 - [18] Souteyrand G, Amabile N, Mangin L et al. Mechanisms of stent thrombosis analysed by optical coherence tomography: insights from the national PESTO French registry. *Eur Heart J* 37:1208–1216, 2016
 - [19] Hong SJ, Kim BK, Shin DH et al. Effect of intravascular ultrasound-guided vs angiography-guided everolimus-eluting stent implantation: the IVUS-XPL Randomized Clinical Trial. *JAMA* 314:2155–2163, 2015
 - [20] Serruys PW, Deshpande NV. Is there MUSIC in IVUS guided stenting? Is this MUSIC going to be a MUST? Multicenter Ultrasound Stenting in Coronaries Study. *Eur Heart J* 19:1122–1124, 1998
 - [21] Kolh P, Windecker S, Alfonso F et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur J Cardio-thorac Surg* 46:517–592, 2014
 - [22] Komukai K, Kubo T, Kitabata H et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. *J Am Coll Cardiol* 64:2207–2217, 2014
 - [23] Meneveau N, Souteyrand G, Motreff P et al. Optical coherence tomography to optimize results of percutaneous coronary intervention in patients with non-ST-elevation acute coronary syndrome: results of the multicenter, randomized DOCTORS Study (Does Optical Coherence Tomography Optimize Results of Stenting). *Circulation* 134:906–917, 2016
 - [24] Sheth TN, Kajander OA, Lavi S et al. Optical coherence tomography-guided percutaneous coronary intervention in ST-segment-elevation myocardial infarction: a prospective propensity-matched cohort of the Thrombectomy Versus Percutaneous Coronary Intervention Alone Trial. *Circ Cardiovasc Interv* 9:e003414, 2016
 - [25] Taniwaki M, Radu MD, Garcia-Garcia HM et al. Long-term safety and feasibility of three-vessel multimodality intravascular imaging in patients with ST-elevation myocardial infarction: the IBIS-4 (integrated biomarker and imaging study) sub-study. *Int J Cardiovasc Imaging* 31:915–926, 2015
 - [26] Burzotta F, Dato I, Trani C et al. Frequency domain optical coherence tomography to assess non-ostial left main coronary artery. *EuroIntervention* 10:e1–8, 2015
 - [27] Wijns W, Shite J, Jones MR et al. Optical coherence tomography imaging during percutaneous coronary intervention impacts physician decision-making: ILUMIEN I study. *Eur Heart J* 36:3346–3355, 2015
 - [28] Amabile N, Trouillet C, Meneveau N et al. Mechanical abnormalities associated with first- and second-generation drug-eluting stent thrombosis analyzed by optical coherence tomography in the national PESTO French registry. *Int J Cardiol* 227:161–165, 2016
 - [29] Piroth Z, Toth GG, Tonino PAL et al. Prognostic value of fractional flow reserve measured immediately after drug-eluting stent implantation. *Circ Cardiovasc Interv* 10:e005233, 2017
 - [30] Prati F, Di Vito L, Biondi-Zoccai G et al. Angiography alone versus angiography plus optical coherence tomography to guide decision-making during percutaneous coronary intervention: the Centro per la Lotta contro l'Infarto-Optimisation of Percutaneous Coronary Intervention (CLI-OPCI) study. *EuroIntervention* 8:823–829, 2012
 - [31] Prati F, Romagnoli E, Burzotta F et al. Clinical impact of OCT findings during PCI: the CLI-OPCI II Study. *JACC Cardiovasc Imag* 8:1297–1305, 2015
 - [32] Kubo T. Optical frequency domain imaging vs. intravascular ultrasound in percutaneous coronary intervention. *EuroPCR* 2016
 - [33] Saia F, Komukai K, Capodanno D et al. Eroded versus ruptured plaques at the culprit site of STEMI: in vivo pathophysiological features and response to primary PCI. *JACC Cardiovasc Imag* 8:566–575, 2015

- [34] Wang L, Parodi G, Maehara A et al. Variable underlying morphology of culprit plaques associated with ST-elevation myocardial infarction: an optical coherence tomography analysis from the SMART trial. *Eur Heart J Cardiovasc Imag* 16:1381–1389, 2015
- [35] Higuma T, Soeda T, Abe N et al. A Combined optical coherence tomography and intravascular ultrasound study on plaque rupture, plaque erosion, and calcified nodule in patients with st-segment elevation myocardial infarction: incidence, morphologic characteristics, and outcomes after percutaneous coronary intervention. *JACC Cardiovasc Interv* 8:1166–1176, 2015
- [36] Souteyrand G, Arbustini E, Motreff P et al. Serial optical coherence tomography imaging of ACS-causing culprit plaques. *Euro-Intervention* 11:319–324, 2015
- [37] Jia H, Dai J, Hou J et al. Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion (the EROSION study). *Eur Heart J* 38:792–800, 2017
- [38] Burzotta F, Leone AM, Aurigemma C et al. Fractional flow reserve or optical coherence tomography to guide management of angiographically intermediate coronary stenosis: a single-center trial. *JACC Cardiovasc Interv* 13:49–58, 2020
- [4] Arbogast R, Bourassa MG. Myocardial function during atrial pacing in patients with angina pectoris and normal coronary arteriograms. Comparison with patients having significant coronary artery disease. *Am J Cardiol* 32:257–263, 1973
- [5] Cannon RO III. 'Microvascular angina' a cause of chest pain in patients with normal coronary angiograms: the eye of the beholder. *Am J Cardiol* 62:306–308, 1988
- [6] Temkin LP, Marcus FI. Nonatherosclerotic myocardial ischemia. *J Am Coll Cardiol* 1:1534–1535, 1983
- [7] Bugiardini R, Manfrini O, De Ferrari GM. Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography. *Arch Intern Med* 166:1391–1395, 2006
- [8] Jespersen L, Hvelplund A, Abildstrom SZ et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. *Eur Heart J* 33:734–744, 2012
- [9] Maddox TM, Stanislawski MA, Grunwald GK et al. Nonobstructive coronary artery disease and risk of myocardial infarction. *Jama* 312:1754–1763, 2014
- [10] Douglas PS, Hoffmann U, Patel MR et al. Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med* 372:1291–1300, 2015
- [11] Bairey Merz CN, Pepine CJ, Walsh MN et al. Ischemia and no obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade. *Circulation* 135:1075–1092, 2017
- [12] Rahmann H, Corcoran D, Aetesam-ur-Rahman M et al. Diagnosis of patients with angina and non-obstructive coronary disease in the catheter laboratory. *Heart* 105:1536–1542, 2019
- [13] Bugiardini R, Pozzati A, Ottani F et al. Vasotonic angina: a spectrum of ischemic syndromes involving functional abnormalities of the epicardial and microvascular coronary circulation. *J Am Coll Cardiol* 22:417–425, 1993
- [14] Reis SE, Holubkov R, Conrad Smith AJ et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery

6.6 Nichtobstruktive KHK (NOCAD/INOCA), mikrovaskuläre Myokarderkrankung, „Syndrom X“

- [1] Patel MR, Peterson ED, Dai D et al. Low diagnostic yield of elective coronary angiography. *N Engl J Med* 362:886–895, 2010
- [2] Sullivan AK, Holdright DR, Wright CA et al. Chest pain in women: clinical, investigative and prognostic features. *BMJ* 308:883–886, 1994
- [3] Pepine CJ, Ferdinand KC, Shaw LJ et al. Emergence of nonobstructive coronary artery disease: a woman's problem and need for change in definition on angiography. *J Am Coll Cardiol* 66:1918–1933, 2015

- disease: results from the NHLBI WISE study. *Am Heart J* 141:735–741, 2001
- [15] Hasdai D, Gibbons RJ, Holmes DR Jr et al. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. *Circulation* 96:3390–3395, 1997
 - [16] Erbel R, Ge J, Bockisch A et al. Value of intracoronary ultrasound and Doppler in the differentiation of angiographically normal coronary arteries: a prospective study in patients with angina pectoris. *Eur Heart J* 17:880–889, 1996
 - [17] Qian J, Ge J, Baumgart D et al. Prevalence of microvascular disease in patients with significant coronary artery disease. *Herz* 24:548–57, 1999
 - [18] Qian JY, Ge JB, Fan B et al. Identification of syndrome X using intravascular ultrasound imaging and Doppler flow mapping. *Chin Med J* 17:521–527, 2004
 - [19] van de Hoef TP, van Lavieren MA, Damman P et al. Physiological basis and long-term clinical outcome of discordance between fractional flow reserve and coronary flow velocity reserve in coronary stenoses of intermediate severity. *Circ Cardiovasc Interv* 7:301–311, 2014
 - [20] Vogt M, Motz W, Scheler S et al. Disorders of coronary microcirculation and arrhythmias in systemic arterial hypertension. *Am J Cardiol* 65:45G–50G, 1990
 - [21] Motz W, Strauer BE. Therapy of hypertensive cardiac hypertrophy and impaired coronary microcirculation. *J Cardiovasc Pharmacol* 24(Suppl 1):S34–S38, 1994
 - [22] Bartel T, Yang Y, Müller S et al. Noninvasive assessment of microvascular function in arterial hypertension by transthoracic Doppler harmonic echocardiography. *J Am Coll Cardiol* 39:2012–2018, 2002
 - [23] Zeiher AM, Drexler H, Wollschläger H et al. Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. *Circulation* 84:1984–1992, 1991
 - [24] Baumgart D, Haude M, Gorge G et al. Augmented alpha-adrenergic constriction of atherosclerotic human coronary arteries. *Circulation* 99:2090–2097, 1999
 - [25] Heusch G, Baumgart D, Camici P et al. Alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans. *Circulation* 101(6):689–694, 2000
 - [26] Lanza GA, Stazi F, Colonna G et al. Circadian variation of ischemic threshold in syndrome X. *Am J Cardiol* 75:683–686, 1955
 - [27] Balady G, Weiner DA, McCabe CH et al. Value of arm exercise testing in detecting coronary artery disease. *Am J Cardiol* 55:37–39, 1985
 - [28] Harris KF, Matthews KA. Interaction between autonomic nervous system activity and endothelial function: a model for the development of cardiovascular disease. *Psychosom Med* 66:153–164, 2004
 - [29] Kaski JC, Elliott PM, Salomone O et al. Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms. *Br Heart J* 74:620–624, 1995
 - [30] Tousoulis D, Davies GJ, Asimakopoulos G et al. Vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X). *Clin Cardiol* 24:301–304, 2001
 - [31] Lerman A, Edwards BF, Hallett JW et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. *N Engl J Med* 325:997–1001, 1991
 - [32] Suwaidi JA, Hamasaki S, Higano ST et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. *Circulation* 101:948–954, 2000
 - [33] Mering GOv, Arant CB, Wessel TR et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). *Circulation* 109:722–725, 2004
 - [34] Suwaidi JA, Hamasaki S, Higano ST et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. *Circulation* 101:948–954, 2000
 - [35] Bugiardini R, Manfrini O, De Ferrari GM. Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography. *Arch Intern Med* 166:1391–1395, 2006
 - [36] Bugiardini R. Women, 'non-specific' chest pain, and normal or near-normal coro-

- nary angiograms are not synonymous with favourable outcome. *Eur Heart J* 27:1387–1389, 2006
- [37] Wieneke H, Schmermund A, Ge J et al. Increased heterogeneity of coronary perfusion in patients with early coronary atherosclerosis. *Am Heart J* 142:691–697, 2001
- [38] Ong P, Camici PG, Beltrame JF et al., the Coronary Vasomotion Disorders International Study Group (COVADIS). International standardization of diagnostic criteria for microvascular angina. *Int J Cardiol* 250:16–20, 2018
- [39] Brainin P, Frestad D, Prescott E. The prognostic value of coronary endothelial and microvascular dysfunction in subjects with normal or non-obstructive coronary artery disease: a systematic review and meta-analysis. *Int J Cardiol* 254:1–9, 2018
- [40] Ong P, Athanasiadis A, Sechtem U. Pharmacotherapy for coronary microvascular dysfunction. *Eur Heart J Cardiovasc Pharmacother* 1:65–71, 2015
- [41] Baumgart D, Haude M, Gorge G et al. Improved assessment of coronary stenosis severity using the relative flow velocity reserve. *Circulation* 98:40–46, 1998
- [42] Lamendola P, Lanza GA, Spinelli A et al. Long-term prognosis of patients with cardiac syndrome X. *Int J Cardiol* 140:197–199, 2010
- [43] Erbel R, Ge J, Gorge G et al. Intravascular ultrasound classification of atherosclerotic lesions according to American Heart Association recommendation. *Coron Artery Dis* 10:489–499, 1999
- [44] Glagov S, Weisenberg E, Zarins CK et al. Compensatory enlargement of human atherosclerotic coronary arteries. *N Engl J Med* 316:1371–1375, 1987
- [45] Zarins CK, Weisenberg E, Kolettis G et al. Differential enlargement of artery segments in response to enlarging atherosclerotic plaques. *J Vasc Surg Suppl* 7:386–394, 1988
- [46] Ge J, Erbel R, Gerber T et al. Intravascular ultrasound imaging of angiographically normal coronary arteries: a prospective study in vivo. *Br Heart J* 71:572–578, 1994
- [47] Gerber TC, Erbel R, Gorge G et al. Extent of atherosclerosis and remodeling of the left main coronary artery determined by intravascular ultrasound. *Am J Cardiol* 73:666–671, 1994
- [48] Haude M, Caspari G, Baumgart D et al. Comparison of myocardial perfusion reserve before and after coronary balloon predilatation and after stent implantation in patients with postangioplasty restenosis. *Circulation* 94:286–297, 1996
- [48a] Haude M, Baumgart D, Verna E et al. Intracoronary Doppler- and quantitative coronary angiography-derived predictors of major adverse cardiac events after stent implantation. *Circulation* 103:1212–1217, 2001
- [49] Bowers TR, Stewart RE, O'Neill WW et al. Effect of Rotablator atherectomy and adjunctive balloon angioplasty on coronary blood flow. *Circulation* 95:1157–1164, 1997
- [50] Hori M, Inoue M, Kitakaze M et al. Role of adenosine in hyperemic response of coronary blood flow in microembolization. *Am J Physiol* 250(3 Pt 2):H509–H518, 1986
- [51] von Liebergen RA, Piek JJ, Koch KT et al. Immediate and long-term effect of balloon angioplasty or stent implantation on the absolute and relative coronary blood flow velocity reserve. *Circulation* 98:2133–2140, 1998
- [52] Piek JJ, Boersma E, Voskuil M et al. The immediate and long-term effect of optimal balloon angioplasty on the absolute coronary blood flow velocity reserve. A subanalysis of the DEBATE study. *Doppler Endpoints Angioplasty Trial Europe*. *Eur Heart J* 2:1725–1732, 2001
- [53] Bahrman P, Werner GS, Heusch G et al. Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris undergoing elective percutaneous coronary interventions. *Circulation* 115:600–608, 2007
- [54] Herrmann J, Haude M, Lerman A et al. Abnormal coronary flow velocity reserve after coronary intervention is associated with cardiac marker elevation. *Circulation* 103:2339–2345, 2001
- [55] Erbel R, Heusch G. Coronary microembolization – its role in acute coronary syndromes and interventions. *Herz* 24:558–575, 1999
- [56] Okamura A, Ito H, Iwakura K et al. Detection of embolic particles with the Doppler guide wire during coronary intervention in patients with acute myocardial infarction.

- tion: efficacy of distal protection device. *J Am Coll Cardiol* 5:212–215, 2005
- [57] Erbel R, Heusch G. Coronary microembolization. *J Am Coll Cardiol* 36:22–24, 2000
- [58] Skyschally A, Schulz R, Erbel R et al. Reduced coronary and inotropic reserves with coronary microembolization. *Am J Physiol Heart Circ Physiol* 282:H611–H614, 2002
- [60] Heusch G, Schulz R, Baumgart D et al. Coronary microembolization. *Prog Cardiovasc Dis* 44:217–230, 2001
- [61] Dörge H, Schulz R, Belosjorow S et al. Coronary microembolization: the role of TNF-alpha in contractile dysfunction. *J Mol Cell Cardiol* 34:51–62, 2002
- [62] Skyschally A, Haude M, Dörge H et al. Glucocorticoid treatment prevents progressive myocardial dysfunction resulting from experimental coronary microembolization. *Circulation* 109:2337–2342, 2004
- [63] Thielmann M, Dörge H, Martin C et al. Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine. *Circ Res* 90:807–813, 2002
- [64] Böse D, von Birgelen C, Zhou XY et al. Impact of atherosclerotic plaque composition on coronary microembolization during percutaneous coronary interventions. *Basic Res Cardiol* 103:587–597, 2008
- [65] Baumgart D, Liu F, Haude M et al. Acute plaque rupture and myocardial stunning in patient with normal coronary arteriography. *Lancet* 346:193–194, 1995
- [66] Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J* 34:2949–3003, 2013
- [67] Knuuti J, Wijns W, Saraste A et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J* 41:407–477, 2020
- relation with lipid profile. *Herz* 32:329–335, 2007
- [2] Ong P, Athanasiadis A, Hill S et al. Coronary artery spasm as a frequent cause of acute coronary syndrome: The CASPAR (Coronary Artery Spasms in Patients With Acute Coronary Syndrome) Study. *J Am Coll Cardiol* 52:523–527, 2008
- [3] Gutersohn A, Zimmermann U, Bartel T et al. A rare case of “infective” myocardial infarction triggered by acute parvovirus B19 myocarditis. *Nat Clin Pract Cardiovasc Med* 2:167–171, 2005
- [4] Yilmaz A, Marholdt H, Athanasiadis A et al. Coronary vasospasm as the underlying cause for chest pain in patients with PVB19 myocarditis. *Heart* 94:1456–1463, 2008
- [5] Beltrame JF, Crea F, Kaski JC et al. Coronary Vasomotion Disorders International Study Group (COVADIS). International standardization of diagnostic criteria for vasospastic angina. *Eur Heart J* 38:2565–2568, 2017
- [6] Da Costa A, Isaaz K, Faure E et al. Clinical characteristics, aetiological factors and long-term prognosis of myocardial infarction with an absolutely normal coronary angiogram: a 3-year follow-up study of 91 patients. *Eur Heart J* 22:1459–1465, 2001
- [7] Igarashi Y, Tamura Y, Tanabe Y et al. Angina-linked syncope and lack of calcium antagonist therapy predict cardiac arrest before definitive diagnosis of vasospastic angina. *Coron Artery Dis* 5:881–887, 1994
- [8] Igarashi Y, Tamura Y, Suzuki K et al. Coronary artery spasm is a major cause of sudden cardiac arrest in survivors without underlying heart disease. *Coron Artery Dis* 4:177–185, 1993
- [9] Sato K, Kaikita K, Nakayama N et al. Coronary vasomotor response to intracoronary acetylcholine injection, clinical features, and long-term prognosis in 873 consecutive patients with coronary spasm: analysis of a single-center study over 20 years. *J Am Heart Assoc* 2:e000227, 2013
- [10] Nobuyoshi M, Abe M, Nosaka H et al. Statistical analysis of clinical risk factors for coronary artery spasm: identification of the most important determinant. *Am Heart J* 124:32–38, 1992
- [11] Miller D, Waters DD, Warnica W et al. Is variant angina the coronary manifesta-

6.7 Vasospastische Angina (VSA)

- [1] Nedeljkovic MA, Ostojic MC, Beleslin BD et al. Ergonovine-induced changes of coronary artery diameter in patients with nonsignificant coronary artery stenosis:

- tion of a generalized vasospastic disorder? *N Engl J Med* 304:763–766, 1981
- [12] Nakamura Y, Shinozaki N, Hirasawa M et al. Prevalence of migraine and Raynaud's phenomenon in Japanese patients with vasospastic angina. *Jpn Circ J* 64:239–242, 2000
- [13] Prinzmetal M, Kennamer R, Merliss R et al. Angina pectoris. I. A variant form of angina pectoris: preliminary report. *Am J Med* 27:375–388, 1959
- [14] Erbel R, Effert S. Coronary spasm. Clinical significance and therapeutic consequences. *Dtsch Med Wochenschr.* 106:586–592, 1981
- [15] Schmiert G, Schimmler W, Schwalb H et al. Die Coronarerkrankungen. In: von Bergmann G, Frey W, Schwieck H (Hrsg), *Handbuch der Inneren Medizin*, Bd. 9. 4. Aufl. Springer, Berlin, S. 653, 1960
- [16] Osler W. The lumleian lectures on angina pectoris. *Lancet* I: 697, 1910
- [17] Elsner R, Millard RW, Kjekshus JK et al. Coronary blood flow and myocardial segment dimensions during simulated dives in seals. *Am J Physiol* 249:H1119–1126, 1985
- [18] Nelson C, Nowak B, Childs H et al. Provocative testing for coronary arterial spasm: rationale, risk and clinical illustrations. *Am J Cardiol* 40:614–619, 1977
- [19] Bussmann WD, Klug W, Scriba U et al. The influence of ergonovine on coronary artery diameter and hemodynamics in patients with angina pectoris at rest. *Z Kardiol* 69:478–487, 1980
- [20] Buxton A, Goldberg S, Hirshfeld JW et al. Refractory ergonovine-induced coronary vasospasm: importance of intracoronary nitroglycerin. *Amer J Cardiol* 46:329–334, 1980
- [21] JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013). *Circ J* 78:2779–2801, 2014
- [22] Ong P, Athanasiadis A, Borgulya G et al. Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. *Circulation* 129:1723–1730, 2014
- [23] Heupler FA Jr, Proudfit WL, Razavi M et al. Ergonovine maleate provocative test for coronary arterial spasm. *Am J Cardiol* 41:631–640, 1978
- [24] Okumura K, Yasue H, Matsuyama K et al. Sensitivity and specificity of intracoronary injection of acetylcholine for the induction of coronary artery spasm. *J Am Coll Cardiol* 12:883–888, 1988
- [25] Wei J, Mehta PK, Johnson BD et al. Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study. *JACC Cardiovasc Interv* 5:646–653, 2012
- [26] Takagi Y, Yasuda S, Takahashi J et al. Clinical implications of provocation tests for coronary artery spasm: safety, arrhythmic complications, and prognostic impact: multicentre registry study of the Japanese Coronary Spasm Association. *Eur Heart J* 34:258–267, 2013

7 Rechtsherzkatheter

- [1] Olschewski H, Hoeper MM, Borst MM et al. Diagnostik und Therapie der chronischen pulmonalen Hypertonie. Clin Res Cardiol 96:301–330, 2007
- [2] Bayer O, Loogen F, Wolter HH. Die Herzkatheterisierung bei angeborenen und erworbenen Herzfehlern, 2. Aufl. Thieme, Stuttgart, S. 54–56, 1967
- [3] Galiè N, Humbert M, Vachiery JL et al., ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37:67–119, 2016
- [4] Humbert M, Kovacs G, Hoeper MM et al. ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 43:3618–3731, 2022. Erratum in: Eur Heart J 44:1312, 2023
- [4a] Rosenkranz S. 2022 ESC/ERS-Leitlinien zur Diagnostik und Therapie der pulmonalen Hypertonie: Ein fokussierter Überblick [2022 ESC/ERS guidelines on the diagnostics and treatment of pulmonary hypertension : A focussed review]. Herz 48:23–30, 2023
- [5] Miller GAH, Sutton GC, Kerr IH et al. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Med J 2:681–684, 1971
- [6] Deutsche Gesellschaft für Kardiotechnik e.V. Formelsammlung. <https://dgfkt.de/fortbildung/formelsammlung/> (25.10.2021)
- [7] Bartel T. Interventionelle Kardiologie, Angiologie und Kardiovaskularchirurgie. Schattauer, Stuttgart, S. 18, 2001
- [8] Reynolds A, Bartelt N, Taepke RT et al. Measurement of pulmonary artery diastolic pressure from the right ventricle. J Am Coll Cardiol 25:1176–1182, 1995
- [9] Ohlsson A, Bennett T, Nordlander R et al. Monitoring of pulmonary arterial diastolic pressure through a right ventricular pressure transducer. J Card Fail 1:161–168, 1995
- [10] Ohlsson A, Kubo SH, Steinhaus D et al. Continuous ambulatory monitoring of absolute right ventricular pressure and mixed venous oxygen saturation in patients with heart failure using an implantable haemodynamic monitor: results of a 1 year multicentre feasibility study. Eur Heart J 22:942–954, 2001
- [11] Steinhaus DM, Lemery R, Bresnahan DR Jr et al. Initial experience with an implantable hemodynamic monitor. Circulation 93:745–752, 1996
- [12] Magalski A, Adamson P, Gadler F et al. Continuous ambulatory right heart pressure measurements with an implantable hemodynamic monitor: a multicenter, 12-month follow-up study of patients with chronic heart failure. J Card Fail 8:63–70, 2002
- [13] Bourge RC, Abraham WT, Adamson PB et al. COMPASS-HF Study Group. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol 51:1073–1079, 2008
- [14] Ritzema J, Melton I C, Richards AM et al. Direct left atrial pressure monitoring in ambulatory heart failure patients: initial experience with a new permanent implantable device. Circulation 116:2952–2959, 2007

- [15] Troughton RW, Ritzema J, Eigler NL et al. Direct left atrial pressure monitoring in severe heart failure: long-term sensor performance. *J Cardiovasc Transl Res* 4:3–13, 2011
- [16] Mooney DM, Fung E, Doshi RN et al. Evolution from electrophysiologic to hemodynamic monitoring: the story of left atrial and pulmonary artery pressure monitors. *Front Physiol* 6:271–278, 2015
- [17] Maurer MS, Adamson PB, Costanzo MR et al. Rationale and design of the left atrial pressure monitoring to optimize heart failure therapy study (LAPTOP-HF). *J Card Fail* 21:479–488, 2015
- [18] Herrmann E, Fichtlscherer S, Hohnloser SH et al. Implantierbare Sensoren zur ambulanten Beurteilung des ventrikulären Füllungsdrucks bei fortgeschrittener Herzinsuffizienz. *Herzschr Elektrophys* 27:371–377, 2016
- [18a] Mullens W, Sharif F, Dupont M et al. Digital health care solution for proactive heart failure management with the Cordella Heart Failure System: results of the SIRONA first-in-human study. *Eur J Heart Fail* 22:1912–1919, 2020
- [18b] Angermann CE, Assmus B, Anker SD et al., MEMS-HF Investigators. Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). *Eur J Heart Fail* 22: 1891–1901, 2020
- [18c] Shavelle DM, Desai AS, Abraham WT et al., CardioMEMS Post-Approval Study Investigators. Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: one-year outcomes from the CardioMEMS Post-Approval Study. *Circ Heart Fail* 13:e006863, 2020
- [19] Shavelle D, Jermyn R. The CardioMEMS Heart Failure Sensor: a procedural guide for implanting physicians. *J Invasive Cardiol* 28:273–279, 2016
- [20] Rali AS, Shah Z, Sauer AJ et al. Hemoptysis after CardioMEMS implantation: case report and review. *Am J Case Rep* 19:382–385, 2018
- [21] Vaduganathan M, DeFilippis EM, Fonarow GC et al. Postmarketing adverse events related to the CardioMEMS HF system. *JAMA Cardiol* 2:1277–1279, 2017
- [22] Adamson PB, Abraham WT, Aaron M et al. CHAMPION trial rationale and design: the long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system. *J Card Fail* 17:3–10, 2011
- [23] Abraham WT, Adamson P, Bourge RC et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. *Lancet* 377:658–666, 2011
- [24] Givertz MM, Stevenson LW, Costanzo MR et al., CHAMPION Trial Investigators. Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction. *J Am Coll Cardiol* 70:1875–1886, 2017
- [25] Costanzo MR, Stevenson LW, Adamson PB et al. Interventions linked to decreased heart failure hospitalizations during ambulatory pulmonary artery pressure monitoring. *JACC Heart Fail* 4:333–344, 2016
- [26] Desai AS, Bhimaraj A, Bharmi R et al. Ambulatory hemodynamic monitoring reduces heart failure hospitalizations in “real-world” clinical practice. *J Am Coll Cardiol* 69:2357–2365, 2017
- [27] Loh JP, Barbash IM, Waksman R. Overview of the 2011 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee Meeting on the CardioMEMS Champion Heart Failure Monitoring System. *J Am Coll Cardiol*. 61:1571–1576, 2013
- [28] Schmier JK, Ong KL, Fonaro GC. Cost-effectiveness of remote cardiac monitoring with the CardioMems heart failure system. *Clin Cardiol* 40:430–436, 2017
- [29] Lesyuk W, Kriza C, Kolominsky-Rabas P. Cost-of-illness studies in heart failure: a systematic review 2004–2016. *BMC Cardiovasc Disord* 18:74, 2018
- [29a] Lindenfeld J, Zile MR, Desai AS et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. *Lancet* 398: 991–1001, 2021
- [30] Gorlin R, Gorlin SG. Hydraulic formula for calculation of the area of the stenotic mitral valve, other cardiac valves, and central circulatory shunts. *Am Heart J* 1:1–29, 1951
- [31] Sellers RD, Levy MJ, Amplatz K et al. Left retrograde cardioangiography in acquired cardiac disease. technic, indications and

- interpretations in 700 cases. *Amer J Card* 14:437–447, 1964
- [32] Oh JK, Seward JB, Tajik AJ. The echo manual. 2nd ed. Lippincott, Philadelphia, pp 181–194, 1999
- [33] Hurell DG, Nishimura RA, Higano ST et al. Value of dynamic respiratory changes in left and right ventricular pressures for the diagnosis of constrictive pericarditis. *Circulation* 93:1007–1013, 1996
- [34] Maisch B, Seferović PM, Ristić AD et al. Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. Guidelines on the diagnosis and management of pericardial diseases executive summary. *Eur Heart J* 25:587–610, 2004
- [35] Ling LH, Oh JK, Breen JF et al. Calcific constrictive pericarditis: is it still with us? *Ann Intern Med* 132:444–450, 2000. Erratum in: *Ann Intern Med* 133:659, 2000
- [36] Vaitkus PT, Kussmaul WG. Constrictive pericarditis versus restrictive cardiomyopathy: a reappraisal and update of diagnostic criteria. *Am Heart J* 122:1431–1441, 1991
- [37] Myers RB, Spodick DH. Constrictive pericarditis: clinical and pathophysiologic characteristics. *Am Heart J* 38(2 Pt 1):219–232, 1999
- [38] Oh JK, Hatle LK, Seward JB et al. Diagnostic role of Doppler echocardiography in constrictive pericarditis. *J Am Coll Cardiol* 23:154–162, 1994
- [39] Elliott P, Andersson B, Arbustini E et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. *Europ Heart J* 9:270–276, 2008
- [40] Hancock EW. Subacute effusive-constrictive pericarditis. *Circulation* 43:183–192, 1971
- [41] Steinberg I. Effusive-constrictive radiation pericarditis. Two cases illustrating value of angiocardiology in diagnosis. *Am J Cardiol* 19:434–439, 1967
- [42] Zurick AO, Klein AL. Effusive-constrictive pericarditis. *J Amer Coll Cardiol* 56:86, 2010
- [43] Low RI, Arthur A, Kelly PB et al. Clotted hemopericardium post myocardial infarction presenting as effusive constrictive pericarditis. *Am Heart J* 109:905–908, 1985

8 Myokardbiopsie

- [1] Goldberger E. Endomyocardial biopsy. *Am J Cardiol* 14:723, 1964
- [2] Sutton DC, Sutton GC. Needle biopsy of the human ventricular myocardium: review of 54 consecutive cases *Am Heart J* 60:364–70, 1960
- [3] Gleichmann U, Vlachakis N, Tsilos T. Zur Entstehung des Herzspitzenstoßes und Deutung systolischer Formveränderungen des Apexkardiogramms. *Z Kreislaufforsch* 60:789–807, 1971
- [4] Brock R, Milstein BB, Ross DN. Percutaneous left ventricular puncture in the assessment of aortic stenosis. *Thorax* 11:163–70, 1956
- [5] Sakakibara S, Konno S. Endomyocardial biopsy. *Jpn Heart J* 3:537–43, 1962
- [6] Bercu B, Heinz J, Choudhry AS et al. Myocardial biopsy. A new technic utilizing the ventricular septum. *Am J Cardiol* 14:675–8, 1964
- [7] Caves PK, Stinson EB, Graham AF et al. Percutaneous transvenous endomyocardial biopsy. *JAMA* 225:288–91, 1973
- [8] Richardson PJ. King's endomyocardial biptome. *Lancet* 1(7859):660–1, 1974
- [9] Anderson JL, Marshall HW. The femoral venous approach to endomyocardial biopsy: comparison with internal jugular and transarterial approaches. *Am J Cardiol* 53:833–7, 1984
- [10] Singh V, Mendirichaga R, Savani GT et al. Comparison of utilization trends, indications, and complications of endomyocardial biopsy in native versus donor hearts (from the Nationwide Inpatient Sample 2002 to 2014). *Am J Cardiol* 121:356–63, 2018
- [11] Elbadawi A, Elgendy IY, Ha LD et al. National trends and outcomes of endomyocardial biopsy for patients with myocarditis: from the National Inpatient Sample Database. *J Card Fail* 24:337–41, 2018
- [12] Yilmaz A, Kindermann I, Kindermann M et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. *Circulation* 122:900–9, 2010
- [13] Killu AM, Mehta N, Zheng Q et al. Endomyocardial biopsy at the time of ablation or device implantation. *J Interv Card Electrophysiol* 52:163–9, 2018
- [14] Schäufele TG, Spittler R, Karagianni A et al. Transradial left ventricular endomyocardial biopsy: assessment of safety and efficacy. *Clin Res Cardiol* 104:773–81, 2015
- [15] Drury JH, Labovitz AJ, Miller LW. Echocardiographic guidance for endomyocardial biopsy. *Echocardiography* 14:469–74, 1997
- [16] Hiramitsu S, Hiroe M, Uemura A et al. National survey of the use of endomyocardial biopsy in Japan. *Jpn Circ J* 62:909–12, 1998
- [17] Han J, Park Y, Lee H et al. Complications of 2-D echocardiography guided transfemoral right ventricular endomyocardial biopsy. *J Korean Med Sci* 21:989–94, 2006
- [18] Sloan KP, Bruce CJ, Oh JK et al. Complications of echocardiography-guided endomyocardial biopsy. *J Am Soc Echocardiogr* 22:324.e1–4, 2009
- [19] From AM, Maleszewski JJ, Rihal CS. Current status of endomyocardial biopsy. *Mayo Clin Proc* 86:1095–102, 2011
- [20] Liang JJ, Hebl VB, DeSimone CV et al. Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis. *JACC Heart Fail* 2:466–73, 2014
- [21] Casella M, Pizzamiglio F, Dello Russo A et al. Feasibility of combined unipolar and bipolar voltage maps to improve sensitivity of endomyocardial biopsy. *Circ Arrhythm Electrophysiol* 8:625–32, 2015
- [22] Yankah AC, Musci M, Weng Y et al. Tricuspid valve dysfunction and surgery after

- orthotopic cardiac transplantation. *Eur J Cardiothorac Surg* 17:343–8, 2000
- [23] Nguyen V, Cantarovitch M, Cecere R et al. Tricuspid regurgitation after cardiac transplantation: how many biopsies are too many? *J Heart Lung Transplant* 24(7 Suppl):S227–31, 2005
- [24] Tucker PA II, Jin BS, Gaos CM et al. Flail tricuspid leaflet after multiple biopsies following orthotopic heart transplantation: echocardiographic and hemodynamic correlation. *J Heart Lung Transplant* 13:466–72, 1994
- [25] Burgess MI, Aziz T, Yonan N. Clinical relevance of subclinical tricuspidal regurgitation after orthotopic cardiac transplantation. *J Am Soc Echocardiogr* 12:164, 1999
- [26] Jeevanandam V, Russell H, Mather P et al. Donor tricuspid annuloplasty during orthotopic heart transplantation: long-term results of a prospective controlled study. *Ann Thorac Surg* 82:2089–95, 2006
- [27] Sandhu JS, Uretsky BF, Zerbe TR et al. Coronary artery fistula in the heart transplant patient. A potential complication of endomyocardial biopsy. *Circulation* 79:350–6, 1989
- [28] Assomull RG, Lyne JC, Keenan N et al. The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. *Eur Heart J* 28:1242–9, 2007
- [29] Baccouche H, Mahrholdt H, Meinhardt G et al. Diagnostic synergy of non-invasive cardiovascular magnetic resonance and invasive endomyocardial biopsy in troponin-positive patients without coronary artery disease. *Eur Heart J* 30:2869–79, 2009
- [30] Gutberlet M, Lücke C, Krieghoff C et al. MRI für die Myokarditis-Diagnose. *Radio- loge* 53:30–7, 2013
- [30] Meléndez-Ramírez G, de Micheli A, Soto ME et al. Agreement between ST elevation and late enhancement evaluated by MRI in patients with acute myocarditis. *J Electrocardiol* 47:212–8, 2014
- [31] Besler C, Schuler G, Lurz P. Myocarditis in the differential diagnosis of cardiomyopathies. Endomyocardial biopsy or MRI? *Herz* 40:607–15, 2015
- [32] Finsterer J, Stöllberger C. Consider differentials of MRI myocarditis in noncompaction. *J Clin Diagn Res* 10:OL01–2, 2016
- [33] Gutersohn A, Zimmermann U, Bartel T et al. A rare case of acute 'infective' myocardial infarction triggered by acute parvovirus B19 myocarditis. *Nat Clin Pract Cardiovasc Med* 2:167–71, 2005
- [34] Yilmaz A, Mahrholdt H, Athanasiadis A et al. Coronary vasospasm as the underlying cause for chest pain in patients with PVB19 myocarditis. *Heart* 94:1456–63, 2008
- [35] Cooper LT, Baughman KL, Feldman AM et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. *Eur Heart J* 28:3076–93, 2007
- [36] Deckers JW, Hare JM, Baughman KL. Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center. *J Am Coll Cardiol* 19:43–7, 1992

9 Periinterventionelle Ultraschalldiagnostik

- [1] Bartel T, Müller S, Caspari G et al. Intracardiac and intraluminal echocardiography: indications and standard approaches. *Ultrasound Med Biol* 8(8):997–1003, 2002
- [2] Caspari GH, Müller S, Bartel T et al. Full performance of modern echocardiography within the heart: in-vivo feasibility study with a new intracardiac, phased-array ultrasound-tipped catheter. *Eur J Echocardiography* 2:100–107, 2001
- [3] Neskovic AN, Skinner H, Price S et al. Focus cardiac ultrasound core curriculum and core syllabus of the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 19:475–481, 2018
- [4] Nielsen MB, Cantisani V, Sidhu PS et al. The use of hand held ultrasound devices: an EFSUMB Position Paper. *Ultraschall Med* 40:30–39, 2019
- [5] Cardim N, Dalen H, Voigt JU et al. The use of handheld ultrasound devices: a position statement of the European Association of Cardiovascular Imaging (2018 update). *Eur Heart J Cardiovasc Imaging* 20:245–252, 2019
- [6] Haji K, Wong C, Neil C et al. Handheld ultrasound to reduce requests for inappropriate echocardiogram (HURRIE). *Echo Res Pract* 6:91–96, 2019
- [7] Savino K, Ambrosio G. Handheld ultrasound and focused cardiovascular echocardiography: use and information. *Medicina (Kaunas)* 55:423, 2019
- [8] Evangelista A, Galuppo V, Méndez J et al. Hand-held cardiac ultrasound screening performed by family doctors with remote expert support interpretation. *Heart* 102:376–382, 2016
- [9] Vitulano N, Pazzano V, Pelargonio G et al. Technology update: intracardiac echocardiography: a review of the literature. *Med Devices (Auckl)* 8:231–239, 2015
- [10] Enriquez A, Saenz LC, Rosso R et al. Use of intracardiac echocardiography in interventional cardiology: working with the anatomy rather than fighting it. *Circulation* 137:2278–2294, 2018
- [11] Ribeiro J, Braga P, Gama V. New catheter, wide angle imaging, 3D intracardiac echocardiography. *Rev Esp Cardiol* 71:293, 2018
- [12] Glassman E, Kronzon I. Transvenous intracardiac echocardiography. *Am J Cardiol* 47:1255–1259, 1981
- [13] Hijazi Z, Wang Z, Cao Q et al. Transcatheter closure of atrial septal defects and patent foramen ovale under intracardiac echocardiographic guidance: feasibility and comparison with transesophageal echocardiography. *Catheter Cardiovasc Interv* 52:194–199, 2001
- [14] Bartel T, Konorza T, Arjumand J et al. Intracardiac echocardiography is superior to conventional monitoring for guiding device closure of interatrial communications. *Circulation* 107:795–797, 2003
- [15] Mullen MJ, Dias BF, Walker F et al. Intracardiac echocardiography guided device closure of atrial septal defects. *J Am Coll Cardiol* 41:285–292, 2003
- [16] Boccalandro F, Baptista E, Muench A et al. Comparison of intracardiac echocardiography versus transesophageal echocardiography guidance for percutaneous transcatheter closure of atrial septal defect. *Am J Cardiol* 93:437–440, 2004
- [17] Koenig P, Cao QL. Echocardiographic guidance of transcatheter closure of atrial septal defect: is intracardiac echocardiography better than transesophageal echocardiography? *Pediatr Cardiol* 6:135–139, 2005
- [18] Themistoclakis S, Rossillo A, Bonso A et al. Intracardiac echocardiography for implantation of LAA occlusion devices: a further step toward the ICE era? *Heart Rhythm* 4:572–574, 2007
- [19] Holmes DR, Reddy VY, Turi ZG et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for preven-

- tion of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. *Lancet* 74:534–542, 2009
- [20] Ge J, Erbel R, Gorge G et al. Intravascular ultrasound imaging of arterial wall architecture. *Echocardiography* 5:475–483, 1992
- [21] Gorge G, Erbel R, Gerber T et al. Intravascular ultrasound in patients with suspected aortic dissection: comparison with transesophageal echocardiography. *Z Kardiol* 1:37–43, 1992
- [22] Weintraub AR, Erbel R, Gorge G et al. Intravascular ultrasound imaging in acute aortic dissection. *J Am Coll Cardiol* 24:495–503, 1994
- [23] Alfonso F, Goicolea J, Aragoncillo P et al. Diagnosis of aortic intramural hematoma by intravascular ultrasound imaging. *Am J Cardiol* 76:735–738, 1995
- [24] Yamada E, Matsumura M, Kyo S et al. Usefulness of a prototype intravascular ultrasound imaging in evaluation of aortic dissection and comparison with angiographic study, transesophageal echocardiography, computed tomography, and magnetic resonance imaging. *Am J Cardiol* 5(2):161–165, 1995
- [25] Svensson LG, Labib SB, Eisenhauser AC et al. Intimal tear without haematoma. *Circulation* 99:331–336, 1999
- [26] Erbel R, Aboyans V, Boileau C et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). *Eur Heart J* 35:2873–2926, 2014
- [27] Gorge G, Erbel R. Intravasaler Ultraschall zur Steuerung der perkutanen Fenestration einer Aortendissektionsmembran. *Dtsch Med Wschr* 121:1598–1602, 1996
- [28] Bartel T, Eggebrecht H, Ebradlidze T et al. Optimal guidance for intimal flap fenestration in aortic dissection by transvenous two-dimensional and Doppler ultrasonography. *Circulation* 107:e17–18, 2003
- [29] Gorge G, Ge J, Haude M et al. Initial experience with a steerable intravascular ultrasound catheter in the aorta and pulmonary artery. *Am J Card Imaging* 9:180–184, 1995
- [30] Gorge G, Schuster S, Ge J et al. Intravascular ultrasound in patients with acute pulmonary embolism after treatment with intravenous urokinase and high-dose heparin. *Heart* 77:73–77, 1997
- [31] Gorge G, Erbel R, Schuster S et al. Intravascular ultrasound in diagnosis of acute pulmonary embolism. *Lancet* 337:623–624, 1991
- [32] Kälsch H, Sack S, Erbel R et al. Acute massive pulmonary embolism detected with angiography and intravascular ultrasound treated by pulmonary embolectomy. The hybrid concept. *Herz* 31:366–367, 2006
- [33] Jánosi RA, Kahlert P, Plicht B et al. Guidance of percutaneous transcatheter aortic valve implantation by real-time three-dimensional transesophageal echocardiography: a single-center experience. *Minim Invasive Ther Allied Technol* 18:142–148, 2009
- [34] Kahlert P, Plicht B, Jánosi RA et al. The role of imaging in percutaneous mitral valve repair. *Herz* 4:458–467, 2009

10 Postinterventionelles Prozedere

10.1 Medikamentöse Therapie nach HKU

- [1] Zhang ZJ, Marroquin OC, Weissfeld JL et al. Beneficial effects of statins after percutaneous coronary intervention. *Europ J Cardiovasc Prev Rehab* 16:445–450, 2009
- [2] Jastrow H, Weber AA. Grundlagen der Thrombozytenpharmakologie. *Pharmakologie in unserer Zeit* 38:302–304, 2009
- [3] Valgimigli M, Bueno H, Byrne RA et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 39:213–260, 2018
- [4] Valgimigli M, Costa F, Byrne R et al. Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. *EuroIntervention* 11:68–74, 2015
- [5] Yeh RW, Secemsky EA, Kereiakes DJ et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. *JAMA* 315:1735–1749, 2016
- [6] Costa F, van Klaveren D, James S et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. *Lancet* 389:1025–1034, 2017
- [7] Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 361:1045–1057, 2009
- [8] Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 357:2001–2015, 2007
- [9] Agewall S, Cattaneo M, Collet JP et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. *Eur Heart J* 34:1708–1713, 2013
- [10] Bhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without omeprazole in coronary artery disease. *N Engl J Med* 363:1909–1917, 2010
- [11] Gargiulo G, Costa F. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study trial. *Am Heart J* 174: 95–102, 2016
- [12] Moukarbel GV, Bhatt DL. Antiplatelet therapy and proton pump inhibition: clinician update. *Circulation* 125:375–380, 2012
- [13] Fortuna LA, Pawloski PA, Parker ED et al. Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events. *Eur Heart J Cardiovasc Pharmacother* 2:13–19, 2016
- [14] Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 324:71–86, 2002
- [15] Rothwell PM, Cook NR, Gaziano JM et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. *Lancet* 392:387–399, 2018
- [16] Theken KN, Grosser T. Weight-adjusted aspirin for cardiovascular prevention. *Lancet* 392:361–362, 2018

- [17] Mehta SR, Tanguay JF, Eikelboom JW et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. *Lancet* 376:1233–1243, 2010
- [18] Wiviott S, Braunwald E, McCabe CH et al., TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 357:2001–2015, 2007
- [19] Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 361:1045–1057, 2009
- [20] Schömig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. *N Engl J Med* 334:1084–1089, 1996
- [21] Silber S, Borggrefe M, Böhm M et al. Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamenten freisetzen-den Koronarstents (DES). Eine evidenzbasierte Analyse von 71 randomisierten Studien mit 28 984 Patienten. *Kardiologie* 1:84–111, 2007
- [22] Gwon HC, Hahn JY, Park KW et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. *Circulation* 125:505–513, 2012
- [23] Valgimigli M, Campo G, Monti M et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. *Circulation* 125:2015–2026, 2012
- [24] Schulz-Schupke S, Byrne RA, Ten Berg JM et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. *Eur Heart J* 36:1252–1263, 2015
- [25] Han Y, Xu B, Xu K et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized sub-study of the I-LOVE-IT 2 trial. *Circ Cardio-vasc Interv* 9:e003145, 2016
- [26] Kim BK, Hong MK, Shin DH et al. A new strategy for discontinuation of dual anti-platelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual anti-platelet Therapy following Endeavor zotarolimus-eluting stent implantation). *J Am Coll Cardiol* 60:1340–1348, 2012
- [27] Feres F, Costa RA, Abizaid A et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. *JAMA* 310:2510–2522, 2013
- [28] Urban P, Meredith IT, Abizaid A et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. *N Engl J Med* 373:2038–2047, 2015
- [29] Valgimigli M, Patialiakas A, Thury A et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. *J Am Coll Cardiol* 65:805–815, 2015
- [30] Palmerini T, Benedetto U, Bacchi-Reggiani L et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. *Lancet* 385:2371–2382, 2015
- [31] Vranckx P, Valgimigli M, Jüni P et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. *Lancet* 392(10151):940–949, 2018
- [32] Costa F, Tijssen JG, Ariotti S et al. Incremental value of the CRUSADE, ACUITY, and HAS-BLED risk scores for the prediction of hemorrhagic events after coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy. *J Am Heart Assoc* 2015
- [33] Costa F, van Klaveren D, James S et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. *Lancet* 389:1025–1034, 2017
- [34] Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent

- acute coronary syndrome. *N Engl J Med* 366:9–19, 2012
- [35] Eikelboom JW, Connolly SJ, Bosch J. Rivaroxaban with or without aspirin in stable cardiovascular disease. *N Engl J Med* 377: 1319–1330, 2017
- [36] Connolly SJ, Eikelboom JW, Bosch J et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. *Lancet* 391(10117):205–218, 2018
- [37] Hess CN, James S, Lopes RD et al. Apixaban plus mono versus dual antiplatelet therapy in acute coronary syndromes: Insights from the APPRAISE-2 Trial. *J Am Coll Cardiol* 66:777–787, 2015
- [38] Dewilde WJ, Oirbans T, Verheugt FW et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. *Lancet* 381(9872):1107–1115, 2013
- [39] Gibson CM, Mehran R, Bode C et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. *N Engl J Med* 375:2423–2434, 2016
- [40] Cannon CP, Bhatt DL, Oldgren J et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. *N Engl J Med* 377:1513–1524, 2017
- [41] Bonzel T, Erbel R, Hamm CW et al. Leitlinie Perkutane Koronarinterventionen (PCI). *Clin Res Cardiol* 28:513–547, 2008
- [42] Jolly SS, Faxon DP, Fox KAA et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines – results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. *J Am Coll Cardiol* 4:468–476, 2009
- [43] Valgimigli, M, Frigoli E, Leonardi S et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. *N Engl J Med* 373:997–1009, 2015
- [44] Bolognese L, Falsini G, Liistro F et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. *J Am Coll Cardiol* 47:522–528, 2006
- [45] Kandzari DE, Kirtane AJ, Windecker S et al., Onyx ONE US/Japan Investigators. One-month dual antiplatelet therapy following percutaneous coronary intervention with zotarolimus-eluting stents in high-bleeding-risk patients. *Circ Cardiovasc Interv* 13(11):e009565, 2020
- [46] Mehran R, Baber U, Steg PG et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. *Lancet* 382(9906):1714–1722, 2013
- [46a] Byrne RA, Rossello X, Coughlan JJ et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur Heart J* 44:3720–826. Erratum in: *Eur Heart J* 2024

10.2 Dokumentation und Befundung

- [1] Schächinger V, Nef H, Achenbach S et al. Leitlinie zum Einrichten und Betreiben von Herzkatheterlaboren und Hybridoperationssälen/Hybridlaboren, 3. Aufl. 2015. *Kardiologie* 9:89–123, 2015

10.3 Qualitätsmanagement im HKL

- [1] Erbel R, Sommerfeld U, Ashry M et al. Qualitätsmanagement im Herzkatheterlabor. *Z Kardiol* 83(Suppl 6):43–55, 1994
- [2] Kamiske GF, Brauer JP. Qualitätsmanagement von A bis Z. Hanser, München, Wien, 1993
- [3] Deming WE. Out of the crisis. 2. Aufl. Massachusetts Institute of Technology Press, Cambridge/MA, 1986
- [4] Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTiG). Qualitätsreport 2019. https://iqtig.org/downloads/berichte/2018/IQTiG_Qualitaetsreport-2019_2019-09-25.pdf (23.05.2020)

11 Notfälle im Herzkatheterlabor

- [1] Criley JM, Niemann JT, Rosborough JP et al. Modifications of cardio-pulmonary resuscitation based on the cough. *Circulation* 4:IV42–50, 1986
- [2] Miller B, Lesnefsky E, Heyborne T et al. Cough-cardiopulmonary resuscitation in the cardiac catheterization laboratory: hemodynamics during an episode of prolonged hypotensive ventricular tachycardia. *Cathet Cardiovasc Diagn* 18:168–171, 1989
- [3] Robertson C. The precordial thump and cough techniques in advanced life support. A statement for the Advanced Life Support Working Party of the European Resuscitation Council. *Resuscitation* 24:133–135, 1992
- [4] Saba SE, David SW. Sustained consciousness during ventricular fibrillation: case report of cough cardiopulmonary resuscitation. *Cathet Cardiovasc Diagn* 37:47–48, 1996
- [5] Ginsky MJ, Criley JM. Images in cardiovascular medicine. Cough cardiopulmonary resuscitation revisited. *Circulation* 114:e530–531, 2006
- [6] Monsieurs KG, Nolan JP, Bossaert LL et al. European Resuscitation Council guidelines for resuscitation 2015: Section 1. Executive summary. *Resuscitation* 95:1–80, 2015
- [7] Monsieurs KG, Nolan JP, Bossaert LL et al. Kapitel 1 der Leitlinien zur Reanimation 2015 des European Resuscitation Council. *Notfall Rettungsmed* 18:655–747, 2015
- [8] Soar J, Nolan JP, Bottiger BW et al. European Resuscitation Council guidelines for resuscitation 2015: Section 3. Adult advanced life support. *Resuscitation* 95:100–147, 2015
- [9] Perkins GD, Olasveengen TM, Maconochie I et al. European Resuscitation Council guidelines for resuscitation: 2017 update. *Resuscitation* 128:43–50, 2018
- [9a] Priori SG, Blomström-Lundqvist C et al., ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. *Eur Heart J* 36:2793–2867, 2015
- [9b] Kirchhof P, Benussi S, Kotecha D et al., ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 37:2893–2962, 2016
- [9c] Hindricks G, Potpara T, Dagres N et al., ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 42:373–498, 2021. Erratum in: *Eur Heart J* 42:507, 2021. Erratum in: *Eur Heart J* 42:546–547, 2021. Erratum in: *Eur Heart J* 42:4194, 2021
- [9d] Rettungsdienst Factsheets 2022. <https://rd-factsheets.de/factsheets/bradykardie/> (10.01.2022)
- [10] Link MS, Atkins DL, Passman RS et al. Part 6: electrical therapies: automated external defibrillators, defibrillation, cardioversion, and pacing: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation* 122(Suppl 3):S706–719, 2010. Erratum in: *Circulation* 123:e235, 2011
- [11] Radke PW, Wolfrum S, Elsässer A et al. „Standard Operating Procedures“ für periprozedurale Komplikationen im Herzkatheterlabor. *Kardiologie* 5:27–37, 2011
- [12] Wieneke H, Konorza T, Breuckmann F et al. Automatic external defibrillator – mode of operation and clinical use. *Dtsch Med Wochenschr* 133:2163–2167, 2008
- [13] Soar J, Donnino MW, Maconochie I et al. 2018 International consensus on cardiopulmonary resuscitation and emergency

- cardiovascular care science with treatment recommendations summary. *Circulation* 138:e714–730, 2018
- [13a] Jörgens M, Königer J, Kanz KG et al. Testing mechanical chest compression devices of different design for their suitability for prehospital patient transport – a simulator-based study. *BMC Emerg Med* 21:1–8, 2021
- [14] Hallstrom AI, Rea TD, Sayre MR et al. Manual chest compression vs use of an automated chest compression device during resuscitation following out-of-hospital cardiac arrest: a randomized trial. *JAMA* 295:2620–2628, 2006
- [15] Perkins GD, Lall R, Quinn T et al. Mechanical versus manual chest compression for out-of-hospital cardiac arrest (PARAMEDIC): a pragmatic, cluster randomised controlled trial. *Lancet* 385:947–955, 2014
- [16] Rubertsson S, Lindgren E, Smekal D et al. Mechanical chest compressions and simultaneous defibrillation vs conventional cardiopulmonary resuscitation in out-of-hospital cardiac arrest. *JAMA* 311:353, 2014
- [17] Koster RW, Beenen LF, van der Boom EB et al. Safety of mechanical chest compression devices AutoPulse and LUCAS in cardiac arrest: a randomized clinical trial for non-inferiority. *Eur Heart J* 38:3006–3013, 2017
- [18] Cave DM, Gazmuri RJ, Otto CW et al. Part 7: CPR techniques and devices: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation* 122:(18 Suppl 3):S720–728, 2010
- [19] Soar J, Nolan JP, Bottiger BW et al. Erweiterte Reanimationsmaßnahmen für Erwachsene („adult advanced life support“). Kapitel 3 der Leitlinien zur Reanimation 2015 des European Resuscitation Council. *Notfall Rettungsmed* 20:S25–88, 2017
- [19a] Kudenchuk PJ, Brown SP, Daya M et al., Resuscitation Outcomes Consortium Investigators. Amiodarone, Lidocaine, or placebo in out-of-hospital cardiac arrest. *N Engl J Med* 374:1711–1722, 2016
- [19b] Soar J, Berg KM, Andersen LW et al., Adult Advanced Life Support Collaborators. Adult Advanced Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. *Resuscitation* 156:A80–A119, 2020
- [20] Wallbach M, Lach N, Stock J et al. Direct assessment of adherence and drug interactions in patients with hypertensive crisis: a cross-sectional study in the Emergency Department. *J Clin Hypertens* (Greenwich) 21:55–63, 2019
- [21] Zidek W. V.a. hypertensive Krise. *MMW Fortschritte der Medizin* 4:41–42, 2019
- [22] Williams B, Mancia G, Spiering W et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. *J Hypertens* 36:2284–2309, 2018
- [23] Nef HM, Achenbach S, Birekeyer R et al. Manual der Arbeitsgruppe Interventionelle Kardiologie (AGIK) der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. (DGK). Teil 1: Durchführung der diagnostischen Koronarographie. *Kardiologe* 15:370–403, 2021
- [23a] Nef HM, Achenbach S, Birekeyer R et al. Manual der Arbeitsgruppe Interventionelle Kardiologie (AGIK) der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. (DGK). Teil 2: Durchführung der perkutanen Koronarintervention. *Kardiologe* 15:542–584, 2021
- [24] Erbel R. Perkutane Perikarddrainage und Perikardfenestration. In: Günther RW, Theilen M (Hrsg), *Interventionelle Radiologie*. 2. Aufl. Thieme, Stuttgart, pp 384–390, 1996
- [25] Horowitz MS, Schultz CS, Stinson EB et al. Sensitivity and specificity of echocardiographic diagnosis of pericardial effusion. *Circulation* 50:239–247, 1974
- [25a] Maisch B, Seferović PM, Ristić AD et al., Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. Guidelines on the diagnosis and management of pericardial diseases executive summary. *Eur Heart J* 25:587–610, 2004
- [26] Adler Y, Charron P, Imazio M et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Tho-

- racic Surgery (EACTS). *Eur Heart J* 36:2921–2964, 2015
- [27] Klopfenstein HS, Cogswell TL, Bernath GA et al. Alterations in intravascular volume affect the relation between right ventricular diastolic collapse and the hemodynamic severity of cardiac tamponade. *J Am Coll Cardiol* 6:1057–1063, 1985
- [28] Schiller NB, Botvinick EH. Right ventricular compression as a sign of cardiac tamponade: an analysis of echocardiographic ventricular dimensions and their clinical implications. *Circulation* 56:774–779, 1977
- [29] Merx W, Schweizer P, Krebs W et al. Verbesserte Punktionstechnik des Perikards und Quantifizierung von Perikardergüssen mittels Ultraschall. *Dtsch Med Wschr* 104:19–21, 1979
- [30] Schweizer P, Merx W, Krebs W et al. Quantification of pericardial effusion by echocardiography. In: Tavers BM, Frey R, Anästhesiologie und Intensivmedizin 116:258–261, 1979
- [31] Pfeiffer C, Kerb T, Erbel R et al. Echokardiographische Volumenbestimmung von Perikardergüssen. *Klin Wschr* 63(Suppl IV):4–8, 1985
- [32] Settle HR, Adolph RJ, Fowler NO et al. Echocardiographic study of cardiac tamponade. *Circulation* 56:951–959, 1977
- [33] Gillam LD, Guyer E, Gibson TC et al. Hydrodynamic compression of the right atrium: a new echocardiographic sign of cardiac tamponade. *Circulation* 68:294–301, 1983
- [34] Kronzon JM, Cohen L, Winer HL. Diastolic atrial compression: a sensitive echocardiographic sign of cardiac tamponade. *J Am Coll Cardiol* 2:770–775, 1983
- [35] Singh SKL, Wann S, Klopfenstein S et al. Usefulness of right ventricular diastolic collapse in diagnosing cardiac tamponade and comparison to pulsus paradoxus. *Am J Cardiol* 57:652–656, 1986
- [36] Gaffney FA, Keller AM, Peshock RM et al. Pathophysiologic mechanism of cardiac tamponade and pulsus alternans shown by echocardiography. *Am J Cardiol* 53:1662–1666, 1984
- [37] Kwasnik EM, Koster EJ Jr, Lazarus JM et al. Conservative management of uremic pericardial effusions. *J Thorac Cardiovasc Surg* 76:629–632, 1978
- [38] Cikes J. Pericardiocentesis guided by ultrasound. *Echocardiography in cardiac interventions*. Klüwer, Dordrecht, pp 133–145, 1989
- [39] Erbel R. Perikarderguß – Überschätzung durch Sonographie. *Ultraschall Klin Prax* 1:41–42, 1986
- [40] Masumi RA, Rios CJ, Ross AM et al. Technique for insertion of an indwelling intrapericardial catheter. *Brit Heart J* 30:333–335, 1968
- [41] Bishop LH, Estes EH Jr, McIntosh HD. The electrocardiogram as a safeguard in pericardiocentesis. *J Am med Ass* 162:264–265, 1956
- [42] Glancy DL, Richter MA. Catheter drainage of the pericardial space. *Cathet Cardiovasc Diagn* 1:311–315, 1973
- [43] Nordenstrom B. Percutaneous catheterization of the pericardium. *Acta Radiol Diagn* 4:662, 1966
- [44] Wong B, Murphy J, Chang CJ et al. The risk of pericardiocentesis. *Am J Cardiol* 44:1110–1114, 1979
- [45] Callahan JA, Seward JB, Nishimura RA et al. Two-dimensional echocardiographically guided pericardiocentesis: experience in 117 consecutive patients. *Am J Cardiol* 55:476–479, 1985
- [46] Ristić AD, Wagner HJ, Maksimović R, Maisch B. Epicardial halo phenomenon: a guide for pericardiocentesis? *Heart Fail Rev* 18:307–316, 2013
- [47] Hoit BD, Gabel M, Fowler NO. Hemodynamic efficacy of rapid saline infusion and dobutamine versus saline infusion alone in a model of cardiac rupture. *Am J Cardiol* 16:1745–1749, 1990
- [48] Park SC, Pahl E, Ettedgui JA et al. Experience with a newly developed pericardiocentesis set. *Am J Cardiol* 66:1529–1531, 1990
- [49] Kopecky SL, Callahan JA, Tajik AJ et al. Percutaneous pericardial catheter drainage: report of 42 consecutive cases. *Am J Cardiol* 58:633–635, 1986
- [49a] Petri N, Ertel B, Gassenmaier T et al. “Blind” pericardiocentesis: a comparison of different puncture directions. *Catheter Cardiovasc Interv* 92:E327–E332, 2018
- [49b] Silvestry FE, Kerber RE, Brook MM et al. Echocardiography-guided interventions. *J Am Soc Echocardiogr* 22:213–231, 2009
- [49c] Ristić AD, Imazio M, Adler Y et al. Triage strategy for urgent management of cardiac

- tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J* 35:2279–2284, 2014
- [50] Hancock EW. Subacute effusive constrictive pericarditis. *Circulation* 43:183–192, 1971
- [51] Zurick AO, Klein AL. Effusive-constrictive pericarditis. *JACC* 56:86, 2000
- [52] Steinberg I. Effusive-constrictive radiation pericarditis. *Am J Cardiol* 19:434–439, 1967
- [53] Low RI, Arthur A, Kelly PB et al. Clotted hemopericardium post myocardial infarction presenting as effusive constrictive pericarditis. *Am Heart J* 109:905–918, 1985
- [54] van der Bijl P, Herbst P, Doubell AF. Redefining effusive-constrictive pericarditis with echocardiography. *J Cardiovasc Ultrasound* 24:317–323, 2016
- [55] Guberman BA, Fowler NO, Engel PJ et al. Cardiac tamponade in medical patients. *Circulation* 64:633–640, 1981
- [56] Krikorian JG, Hancock EW. Pericardiocentesis. *Am J Med* 65:808–814, 1978
- [57] Tsang TS, Barnes ME, Hayes SN et al. Clinical and echocardiographic characteristics of significant pericardial effusion following cardiothoracic surgery and outcomes of echo-guided pericardiocentesis for management: Mayo Clinic experience, 1979–1998. *Chest* 16:322–331, 1999
- [58] Zimmermann R. Perikarderguß und Punktion. *Dtsch Med Wschr* 118:1544, 1993
- [58a] Rafique AM, Patel N, Biner S et al. Frequency of recurrence of pericardial tamponade in patients with extended versus nonextended pericardial catheter drainage. *Am J Cardiol* 108:1820–1825, 2011
- [59] Ziskind AA, Pearce AC, Lemmon CC et al. Percutaneous balloon pericardiotomy for the treatment of cardiac tamponade and large pericardial effusions: Description of technique and report of the first 50 cases. *Clin Studies* 21:1–5, 1993
- [60] Beck CS. Two cardiac compression triads. *JAMA* 104:714–716, 1935
- [61] Palacios IF, Tuzcu EM, Ziskind AA et al. Percutaneous balloon pericardial window for patients with malignant pericardial effusion and tamponade. *Cather Cardiovasc Diagn* 48:244–249, 1991
- [62] Vora AM, Lokhandwala YY, Purshottam AK. Echocardiography guided creation of balloon pericardial window. *Cather Cardiovasc Diagn* 25:164–165, 1992
- [63] D'Cruz IA, Hoffman PK. A new cross sectional echocardiographic method for estimating the volume of large pericardial effusions. *Brit Heart J* 66:448–451, 1991
- [64] Chow L, Chow WH. Mechanism of pericardial window creation by balloon pericardiotomy. *Am J Cardiol* 72:1321–1322, 1993
- [65] Chow L, Chow TC, Yip ASB et al. Nonsurgical creation of a pericardial window: identification by echocardiography. *Echocardiography* 11:145–147, 1992
- [66] Ziskind AA, Pearce AC, Lemmon CC et al. Percutaneous balloon pericardiotomy for the treatment of cardiac tamponade and large pericardial effusions: description of technique and report of the first 50 cases. *Clin Studies* 21:1–5, 1993
- [67] Yoshida M, Sakiyama S, Kondo K et al. Thoracoscopic pericardial fenestration for effective long-term management of non-tuberculous mycobacterium pericarditis. *Gen Thorac Cardiovasc Surg* 63:49–51, 2015

12 Ambulanter Herzkatheter

- [1] Deutsche Herzstiftung e.V. (Hrsg) 32. Deutscher Herzbericht 2020. Frankfurt am Main, 2021
- [2] Hamm CW, Albrecht A, Bonzel T et al. Diagnostic heart catheterization. *Clin Res Cardiol* 97:475–512, 2008. Erratum in: *Clin Res Cardiol* 97:925, 2008
- [3] Nef HM, Achenbach S, Birkemeyer R et al. Manual der Arbeitsgruppe Interventionelle Kardiologie (AGIK) der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislafforschung e.V. (DGK). Teil 1: Durchführung der diagnostischen Herzkatheteruntersuchung. *Kardiologie* 15:370–403, 2021
- [4] Nef HM, Achenbach S, Birkemeyer R et al. Manual der Arbeitsgruppe Interventionelle Kardiologie (AGIK) der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislafforschung e.V. (DGK). Teil 2: Durchführung der perkutanen Koronarintervention. *Kardiologie* 2 Aug 2021. Epub ahead of print. <https://doi.org/10.1007/s12181-021-00504-6>
- [5] Neumann FJ, Sousa-Uva M, Ahlsson A et al., ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 40:87–165, 2019
- [6] Mason PJ, Shah B, Tamis-Holland JE et al., American Heart Association Interventional Cardiovascular Care Committee of the Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Peripheral Vascular Disease, Council on Genomic and Precision Medicine. An update on radial artery access and best practices for transradial coronary angiography and intervention in acute coronary syndrome: a scientific statement from the American Heart Association. *Circ Cardiovasc Interv* 11:e000035, 2018
- [7] Cantor WJ, Mehta SR, Yuan F et al. Radial versus femoral access for elderly patients with acute coronary syndrome undergoing coronary angiography and intervention: insights from the RIVAL trial. *Am Heart J* 170:880–886, 2015
- [8] Knuuti J, Wijns W, Saraste A et al., ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J* 41(3):407–444, 2020
- [9] Collet JP, Thiele H, Barbato E et al., ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 42:1289–1367, 2021
- [10] Byrne RA, Rossello X, Coughlan JJ et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur Heart J* 44:3720–3826, 2023
- [11] Cosentino F, Grant PJ, Aboyans V et al., ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J* 41(3):255–323, 2020
- [12] Juarez-Orozco LE, Saraste A, Capodanno D et al. Impact of a decreasing pre-test probability on the performance of diagnostic tests for coronary artery disease. *Eur Heart J Cardiovasc Imaging* 20:1198–1207, 2019
- [13] Reeh J, Thermoing CB, Heitmann M et al. Prediction of obstructive coronary artery disease and prognosis in patients with suspected stable angina. *Eur Heart J* 40:1426–1435, 2019
- [14] Cheng VY, Berman DS, Rozanski A et al. Performance of the traditional age, sex, and angina typicality-based approach for estimating pretest probability of angiographically significant coronary artery disease in patients undergoing coronary computed tomographic angiography: results from the multinational coronary CT angiography evaluation for clinical outcomes: an international multicenter registry

- (CONFIRM). *Circulation* 124:2423–2432, 2011
- [15] Foldyna B, Udelson JE, Karády J et al. Pretest probability for patients with suspected obstructive coronary artery disease: re-evaluating Diamond-Forrester for the contemporary era and clinical implications: insights from the PROMISE trial. *Eur Heart J Cardiovasc Imaging* 20:574–581, 2019
- [16] Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. *N Engl J Med* 300:1350–1358, 1979
- [17] Genders TS, Steyerberg EW, Alkadhi H et al., CAD Consortium. A clinical prediction rule for the diagnosis of coronary artery disease: validation, updating, and extension. *Eur Heart J* 32:1316–1330, 2011
- [18] Knuuti J, Ballo H, Juarez-Orozco LE et al. The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability. *Eur Heart J* 39:3322–3330, 2018
- [19] ISCHEMIA Trial Research Group, Maron DJ, Hochman JS, O'Brien SM et al. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: rationale and design. *Am Heart J* 201:124–135, 2018
- [20] Hochman JS, Reynolds HR, Bangalore S et al., ISCHEMIA Research Group. Baseline characteristics and risk profiles of participants in the ISCHEMIA randomized clinical trial. *JAMA Cardiol* 4:273–286, 2019
- [21] Maron DJ, Hochman JS, Reynolds HR et al., ISCHEMIA Research Group. Initial invasive or conservative strategy for stable coronary disease. *N Engl J Med* 382(15): 1395–1407, 2020
- [22] Spertus JA, Jones PG, Maron DJ et al., ISCHEMIA Research Group. Health-status outcomes with invasive or conservative care in coronary disease. *N Engl J Med* 382(15):1408–1419, 2020
- [23] Shroff A, Kupfer J, Gilchrist IC et al. Same-day discharge after percutaneous coronary intervention: current perspectives and strategies for implementation. *JAMA Cardiol* 1:216–223, 2016
- [24] Elfandi A, Safirstein JG. Transradial PCI and same day discharge. *Curr Treat Options Cardiovasc Med* 20:10, 2018
- [25] Rubimbura V, Rostain L, Duval AM et al. Outcomes and safety of same-day discharge after percutaneous coronary intervention: a 10-year single-center study. *Catheter Cardiovasc Interv* 94:105–111, 2019
- [26] Amin AH, Alqahtani F, Aljohani S et al. The feasibility and safety of same day discharge for all comers after elective percutaneous coronary interventions. *Cardiovasc Revasc Med* 21(5):588–591, 2019
- [27] Amin AP, Pinto D, House JA et al. Association of same-day discharge after elective percutaneous coronary intervention in the united states with costs and outcomes. *JAMA Cardiol* 3:1041–1049, 2018
- [28] Rymer JA, O'Donnell CI, Plomondon ME et al. Same-day discharge among patients undergoing elective PCI: Insights from the VA CART Program. *Am Heart J* 218:75–83, 2019
- [29] Madan M, Bagai A, Overgaard CB et al. Same-day discharge after elective percutaneous coronary interventions in Ontario, Canada. *J Am Heart Assoc* 8:e012131, 2019
- [30] Saad Y, Shugman IM, Kumar M et al. Safety and efficacy of same-day discharge following elective percutaneous coronary intervention, including evaluation of next day troponin T levels. *Heart Lung Circ* 24:368–376, 2015
- [31] Seto AH, Shroff A, Abu-Fadel M et al. Length of stay following percutaneous coronary intervention: an expert consensus document update from the society for cardiovascular angiography and interventions. *Catheter Cardiovasc Interv* 92:717–731, 2018

13 Angeborene Herzfehler im Erwachsenenalter

- [1] <http://www.kompetenznetz-ahf.de/wir/register> (21.2.2022)
- [2] <https://www.awmf.org/leitlinien/aktuelle-leitlinien/ll-liste/deutsche-gesellschaft-fuer-paediatrische-kardiologie-ev.html>
- [3] Bonhoeffer P, Boudjemline Y, Saliba Z et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. *Lancet* 356 (9239):1403–1405, 2000
- [4] Coats L, Tsang V, Khambadkone S et al. The potential impact of percutaneous pulmonary valve stent implantation on right ventricular outflow tract re-intervention. *Eur J Cardiothorac Surg* 27:536–543, 2005
- [5] Bergersen L, Benson LN, Gillespie MJ et al. Harmony feasibility trial: acute and short-term outcomes with a self-expanding transcatheter pulmonary valve. *JACC Cardiovasc Interv* 10:1763–1773, 2017
- [6] Kim GB. First human cases of new self-expandable percutaneous pulmonary valve implantation using knitted nitinol-wire stent mounted with a tri-leaflet porcine pericardial valve. *J Amer Coll Cardiol* 69:Suppl A-159, 2017
- [7] Vigl M et al. Sexuality and subjective well-being in male patients with congenital heart disease. *Heart* 14:1179–1183, 2009
- [8] Vigl M, Niggemeyer E, Hager A et al. The importance of socio-demographic factors for the quality of life of adults with congenital heart disease. *Quality Life Res* 20:169–177, 2011
- [9] Müller J, Amberger T, Berg A et al. Physical activity in adults with congenital heart disease and associations with functional outcomes. *Heart* 103:1117–1121, 2017
- [10] Bauer UMM, Körten MA, Diller GP et al. Cardiovascular risk factors in adults with congenital heart defects – recognised but not treated? An analysis of the German National Register for Congenital Heart Defects. *Int J Cardiol* 277:79–84, 2019
- [11] Reiner B, Oberhoffer R, Ewert P et al. Quality of life in young people with congenital heart disease is better than expected. *Arch Dis Child* 104:124–128, 2019
- [12] Baumgartner H, Bonhoeffer P, de Groot NM et al. ESC guidelines for the management of grown-up congenital heart disease (new version 2010). *Eur Heart J* 31:2915–2957, 2010
- [13] Bayer O, Loogen F, Wolter HH. Die Herzkatheterisierung bei angeborenen und erworbenen Herzfehlern, 2. Aufl. Thieme, Stuttgart, S. 54–56, 1967
- [14] Morray BH, Jones TK, Coe JY et al. Implantation of the Melody transcatheter pulmonary valve PB1016 in patients with dysfunctional right ventricular outflow tract conduits. *Catheter Cardiovasc Interv* 93:474–480, 2019
- [15] Hascoët S, Dalla Pozza R, Benthams J et al. Early outcomes of percutaneous pulmonary valve implantation using the Edwards SAPIEN 3 transcatheter heart valve system. *EuroIntervention* 14:1378–1385, 2019
- [16] Hascoët S, Karsenty C, Tortigue M et al. A modified procedure for percutaneous pulmonary valve implantation of the Edwards SAPIEN 3 valve. *EuroIntervention* 14:1386–1388, 2019
- [17] Plessis J, Hascoët S, Baruteau A et al. Edwards SAPIEN transcatheter pulmonary valve implantation: results from a french registry. *JACC Cardiovasc Interv* 11:1909–1916, 2018
- [18] Morgan G, Prachasilchai P, Promphan W et al. Medium-term results of percutaneous pulmonary valve implantation using the Venus P-valve™: international experience. *EuroIntervention* 14:1363–1370, 2019
- [19] Kim GB, Song MK, Bae EJ et al. Successful feasibility human trial of a new self-expandable percutaneous pulmonary valve (Pulsta Valve) implantation using knitted

- nitinol wire backbone and trileaflet α -gal-free porcine pericardial valve in the native right ventricular outflow tract. *Circ Cardiovasc Interv* 11:e006494, 2018
- [20] Lababidi Z, Wu JR, Walls TJ. Percutaneous balloon aortic valvuloplasty: results in 23 patients. *Am J Cardiol* 53:194–197, 1984
- [21] Walls JT, Lababidi Z, Curtes JJ et al. Assessment of percutaneous balloon pulmonary and aortic valvuloplasty. *J Thorac Cardiovasc Surg* 88:352–356, 1984
- [22] Rupprath G, Neuhaus KL. Percutaneous balloon valvuloplasty for aortic valve stenosis in infancy. *Am J Cardiol* 55:1655–1656, 1985
- [23] Vogt A, Rupprath G, Tebbe U et al. Verlaufsbeobachtung nach Dilatation angeborener und erworbener Aortenstenosen. *Dtsch Med Wochenschr* 113:1956–1959, 1988
- [24] Ten Harkel AD, Berkhout M, Hop WC et al. Congenital valvular aortic stenosis: limited progression during childhood. *Arch Dis Child* 94:531–535, 2009
- [25] van der Linde D, Andrinopoulou ER, Oechslin EN et al. Congenital valvular aortic stenosis in young adults: predictors for rate of progression of stenosis and aortic dilatation. *Int J Cardiol* 168:863–870, 2013
- [26] Sen S, Garg S, Rao SG et al. Native aortic coarctation in neonates and infants: immediate and midterm outcomes with balloon angioplasty and surgery. *Ann Pediatr Cardiol* 11:261–266, 2018
- [27] Bugeja J, Cutajar D, Zahra C et al. Aortic stenting for neonatal coarctation of the aorta – when should this be considered? *Images Paediatr Cardiol* 18:1–4, 2016
- [28] Ewert P, Berger F, Kretschmar O et al. Stentimplantation als Therapie der ersten Wahl bei Erwachsenen mit Aortenisthmusstenose? *Z Kardiol* 92:48–52, 2003
- [29] Haas NA, Lewin MA, Knirsch W et al. Initial experience using the NuMED Cheat-ham Platinum (CP) stent for interventional treatment of coarctation of the aorta in children and adolescents. *Z Kardiol* 94:113–120, 2005
- [30] Salcher M, Naci H, Law TJ et al., Cardio-proof Consortium. Balloon dilatation and stenting for aortic coarctation: a systematic review and meta-analysis. *Circ Cardiovasc Interv* 9:e003153, 2016
- [31] Morray HB. Ventricular septal defect closure devices, techniques, and outcomes. *Intervent Cardiol Clin* 8:1–10, 2019
- [32] Saurav A, Kaushik M, Mahesh Alla V et al. Comparison of percutaneous device closure versus surgical closure of peri-membranous ventricular septal defects: A systematic review and meta-analysis. *Catheter Cardiovasc Interv* 86:1048–1056, 2015
- [33] Gray RG, Menon SC, Johnson JT et al. Acute and midterm results following percutaneous device closure of muscular ventricular septal defects: a multicenter PICES investigation. *Catheter Cardiovasc Interv* 90:281–289, 2017
- [34] Agrawal H, Waller BR 3rd, Surendan S et al. New patent ductus arteriosus closure devices and techniques. *Interv Cardiol Clin* 8:23–32, 2019
- [35] Cesnjevar R, Dietrich S. S2k-Leitlinie: Persistierender Ductus arteriosus im Kindes- und Jugendalter. *Bayer Ärztzbl* 640–645, 2016
- [36] Fontan F, Baudet E. Surgical repair of tricuspid atresia. *Thorax* 6:240–249, 1971
- [36a] Rychik J, Atz AM, Celermajer DS et al., American Heart Association Council on Cardiovascular Disease in the Young and Council on Cardiovascular and Stroke Nursing. Evaluation and management of the child and adult with fontan circulation: a scientific statement from the American Heart Association. *Circulation* 140:e234–e284, 2019
- [36b] Freedom RM, Nykanen D, Benson LN. The physiology of the bidirectional cavopulmonary connection. *Ann Thorac Surg* 66:664–667, 1998
- [37] Taussig BH, Bing RJ. Complete transposition of the aorta and a levoposition of the pulmonary artery – clinical, physiological, and pathological findings. *Am Heart J* 37:551–559, 1949
- [38] Gaspardone A, De Marco F, Sgueglia GA et al. Novel percutaneous suture-mediated patent foramen ovale closure technique: early results of the NobleStitch EL Italian Registry. *EuroIntervention* 14:e272–279, 2018
- [39] Welch TR, Nugent AW, Veeram Reddy SR. Biodegradable stents for congenital heart disease. *Interv Cardiol Clin* 8:81–94, 2019
- [40] Sigler M, Söderberg B, Schmitt B et al. Carag bioresorbable septal occluder (CBSO):

- histopathology of experimental implants. *EuroIntervention* 13:1655–1661, 2018
- [41] Germans T, Wilde AA, Dijkmans PA et al. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. *J Am Coll Cardiol* 48:2518–2523, 2006
- [42] Johansson B, Maceira AM, Babu-Narayan SV et al. Clefts can be seen in the basal inferior wall of the left ventricle and the interventricular septum in healthy volunteers as well as patients by cardiovascular magnetic resonance. *J Am Coll Cardiol* 50:1294–1295, 2007
- [43] Aquaro GD, Di Bella G, Strata E. Cardiac magnetic resonance findings in isolated congenital left ventricular diverticuli. *Int J Cardiovasc Imaging* 23:43–47, 2007
- [44] Basso C, Marra MP, Thiene G. Myocardial clefts, crypts, or crevices: once again, you see only what you look for. *Circ Cardiovasc Imaging* 7:217–219, 2014
- [45] Teare D. Asymmetrical hypertrophy of the heart in young adults. *Br Heart J* 20:1–8, 1958
- [46] Wein M, Wolf-Puetz A, Niehues R et al. Multiple linksventrikuläre inferoseptale Clefts. *Herz* 36:438–443, 2011
- [47] Seraphim A, Papachristidis A, Bratt N et al. Significance of left ventricular clefts: a case report. *J Cardiol Cases* 9:138–142, 2014
- [48] Petryka J, Baksi AJ, Prasad SK et al. Prevalence of inferobasal myocardial crypts among patients referred for cardiovascular magnetic resonance. *Circ Cardiovasc Imaging* 7:259–264, 2014
- [49] Maron MS, Rowin EJ, Lin D et al. Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. *Circ Cardiovasc Imaging* 5:441–447, 2012
- [50] Child N, Muhr T, Sammut E et al. Prevalence of myocardial crypts in a large retrospective cohort study by cardiovascular magnetic resonance. *J Cardiovasc Magn Reson* 16:66, 2014
- [51] Deykina D, Merzhina EA, Arkhipova I et al. Occurrence and significance of myocardial clefts detected on coronary CTA. *ECR* 2012. doi: 10.1594/ecr2012/C-2232, 2012
- [52] Brouwer WP, Germans T, Head MC et al. Multiple myocardial crypts on modified long-axis view are a specific finding in pre-hypertrophic HCM mutation carriers. *Eur Heart J Cardiovasc Imaging* 13:292–297, 2012
- [53] Jenni R, Oechslin E, Schneider J et al. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy. *Heart* 86:666–671, 2001
- [54] Petersen SE, Selvanayagam JB, Wiesmann F et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. *J Am Coll Cardiol* 46:101–105, 2005
- [55] Srichai MB, Hecht EM, Kim DC et al. Ventricular diverticula on cardiac CT: more common than previously thought. *AJR Am J Roentgenol* 189:204–208, 2007
- [56] Ohlow MA. Congenital left ventricular aneurysms and diverticula: definition, pathophysiology, clinical relevance and treatment. *Cardiology* 106:63–72, 2006
- [57] Ohlow MA, Secknus MA, Geller JC et al. Prevalence and outcome of congenital left ventricular aneurysms and diverticula in an adult population. *Cardiology* 112:287–293, 2009
- [58] Krasemann T, Gehrmann J, Fenge H et al. Ventricular aneurysm or diverticulum? Clinical differential diagnosis. *Pediatr Cardiol* 22:409–411, 2001
- [59] Grant RT. An unusual anomaly of the coronary vessels in the malformed heart for a child. *Heart* 13:273–283, 1926
- [60] Engberding R, Bender F. Identification of a rare congenital anomaly of the myocardium by two-dimensional echocardiography: persistence of isolated myocardial sinusoids. *Am J Cardiol* 53:1733–1734, 1984
- [61] Engberding R, Stöllberger C, Ong P et al. Isolierte Noncompaction-Kardiomyopathie. *Dtsch Arztebl Int* 107:206–213, 2010
- [62] Chin TK, Perloff JK, Williams RG et al. Isolated noncompaction of left ventricular myocardium: a study of eight cases. *Circulation* 82:507–513, 1990
- [63] Dusek J, Ostádal B, Duskova M. Postnatal persistence of spongy myocardium with embryonic blood supply. *Arch Pathol* 99:312–317, 1975
- [64] Sedmera D, McQuinn T. Embryogenesis of the heart muscle. *Heart Fail Clin* 4:235–245, 2008

- [65] Shariati J, Schlosser T, Erbel R. „Non-compaction“-Kardiomyopathie. Herz 40:583–590, 2015
- [66] Murphy RT, Thaman R, Blanes JG et al. Natural history and familial characteristics of isolated left ventricular non-compaction. Eur Heart J 26:187–192, 2005
- [67] Towbin JA, Lorts A, Jefferies JL. Left ventricular non-compaction cardiomyopathy. Lancet 386(9995):813–825, 2015
- [68] Carrilho-Ferreira P, Almeida AG, Pinto FJ. Non-compaction cardiomyopathy: prevalence, prognosis, pathoetiology, genetics, and risk of cardioembolism. Curr Heart Fail Rep 11:393–403, 2014
- [69] Jenni R, Oechslin E, Schneider J et al. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy. Heart 86:666–671, 2001
- [70] Stöllberger C, Finsterer J. Left ventricular hypertrabeculation/noncompaction. J Am Soc Echocardiogr 17:91–100, 2004
- [71] Petersen SE, Selvanayagam JB, Wiesmann F et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol 46:101–105, 2005
- [72] Jacquier A, Thuny F, Jop B et al. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. Eur Heart J 31:1098–1104, 2010
- [73] Stacey RB, Andersen MM, St Clair M et al. Comparison of systolic and diastolic criteria for isolated LV noncompaction in CMR. JACC Cardiovasc Imaging 6:931–940, 2013
- [73a] Weir-McCall JR, Yeap PM, Papagiorcopulo C et al. Left ventricular noncompaction: anatomical phenotype or distinct cardiomyopathy? J Am Coll Cardiol 68:2157–2165, 2016
- [74] Captur G, Muthurangu V, Cook C et al. Quantification of left ventricular trabeculae using fractal analysis. J Cardiovasc Magn Reson 15:36, 2013
- [75] Kawel-Boehm N, McClelland RL, Zemrak F et al. Hypertrabeculated left ventricular myocardium in relationship to myocardial function and fibrosis: The Multi-Ethnic Study of Atherosclerosis. Radiology 284:667–675, 2017
- [76] Ivanov A, Dabiesingh DS, Bhumireddy GP et al. Prevalence and prognostic significance of left ventricular noncompaction in patients referred for cardiac magnetic resonance imaging. Circ Cardiovasc Imaging 10(9):e006174, 2017
- [77] Oechslin EN, Attenhofer Jost CH, Rojas JR et al. Long-term follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis. J Am Coll Cardiol 36:493–500, 2000
- [78] Mohrs OK, Magedanz A, Schlosser T. Non-compaction of the left ventricular myocardium detected by 64-slice multidetector computed tomography. Clin Cardiol 30:48, 2007
- [79] Melendez-Ramirez G, Castillo-Castellon F, Espinola-Zavaleta N et al. Left ventricular noncompaction: a proposal of new diagnostic criteria by multidetector computed tomography. J Cardiovasc Comput Tomogr 6:346–354, 2012
- [80] Engberding R, Yelbuz TM, Breithardt G. Isolated noncompaction of the left ventricular myocardium – a review of the literature two decades after the initial case description. Clin Res Cardiol 96:481–488, 2007
- [81] Steffel J, Duru F. Rhythm disorders in isolated left ventricular noncompaction. Ann Med 44:101–108, 2012
- [82] Onay OS, Yildirim I, Beken B et al. Successful implantation of an intracardiac defibrillator in an infant with long QT syndrome and isolated noncompaction of the ventricular myocardium. Pediatr Cardiol 34:189–193, 2013
- [83] Jefferies JL. Are we getting closer to risk stratification in left ventricular noncompaction cardiomyopathy? J Am Heart Assoc 7:e010608, 2018
- [84] Zemrak F, Ahlman MA, Captur G et al. The relationship of left ventricular trabeculation to ventricular function and structure over a 9.5-year follow-up: the MESA study. J Am Coll Cardiol 64:1971–1980, 2014
- [85] Thavendiranathan P, Dahiya A, Phelan D et al. Isolated left ventricular non-compaction controversies in diagnostic criteria, adverse outcomes and management. Heart 99:681–689, 2013
- [86] Columbus MR. De re anatomica. XV, 265, 1559

- [87] Auch-Schwelk W, Bonzel T, Krause T et al. Differential diagnosis of chest pain and diagnostic findings in pericardial defects combined with coronary artery disease. *Clin Cardiol* 11:650–657, 1988
- [87a] Johanssen L. Diseases of the pericardium. A. Development of the pericardial cavity. In: Derra E (Ed), *Handbuch der Thoraxchirurgie*, 614–615. Springer, Berlin, Göttingen, Heidelberg, 1959
- [88] Jaglan A, Leybiskis B, Tajik AJ. Topsy-turvy heart: a case of congenital absence of the pericardium. *Eur Heart J CV Imag* 21:269, 2020
- [89] Van Son JA, Danielson GK, Schaff HV et al. Congenital partial and complete absence of the pericardium. *Mayo Clin Proc* 68:743–747, 1993
- [90] Ellis K, Leeds NE, Himmelstein A. Congenital deficiencies in the parietal pericardium: a review with 2 new cases including successful diagnosis by plain roentgenography. *Am J Roentgenol Radium Ther Nucl Med* 82:125–137, 1959
- [91] Glover LB, Barcia A, Reeves TJ. Congenital absence of the pericardium. A review of the literature with demonstration of a previously unreported fluoroscopic finding. *Am J Roentgenol Radium Ther Nucl Med* 106:542–549, 1969
- [92] Palau P, Domínguez E, García-González P et al. Isolated partial congenital absence of the pericardium: a familial presentation. *Can J Cardiol* 32:1039.e1–2, 2016
- [93] Persigehl M, Erbel R. Die angeborene linksseitige Perikardaplasie. *Fortschr Röntgenstr* 135:541–547, 1981
- [93] Üzünlü I, Büyük Y, Pakiş I et al. Sudden death due to congenital pericardial defect: an autopsy case. *Am J Forensic Med Pathol* 29: 242–244, 2008
- [94] Foo JS, Koh CH, Sahlén A et al. Congenital partial absence of pericardium: a mimic of arrhythmogenic right ventricular cardiomyopathy. *Case Rep Med* 2018:4297280, 2018
- [95] Shah AB, Kronzon I. Congenital defects of the pericardium: a review. *Eur Heart J Cardiovasc Imaging* 16:821–827, 2015
- [96] Huang J, Slaughter MS. Congenital partial absence of the pericardium. *Ann Thorac Surg* 91:e28, 2011
- [97] Ren G, Juan YH, Fei H et al. Congenital absence of the pericardium and tricuspid regurgitation. *QJM* 111:895–897, 2018
- [98] von Bernuth G, Nissen H, Lang D et al. Angeborene Defekte des linksseitigen Perikards. *Z Kardiol* 65:1022–1032, 1976
- [99] Morgan JR, Rogers AK, Forker AD. Congenital absence of the left pericardium: clinical findings. *Ann Intern Med* 74:370–376, 1971
- [100] Han J, Xiang H, Ridley WE et al. Snoopy sign: congenital absence of the left pericardium. *J Med Imaging Radiat Oncol* 62(Suppl 1):47, 2018
- [101] Kim HJ, Cho YS, Cho GY et al. Congenital absence of the pericardium. *J Cardiovasc Ultrasound* 22:36–39, 2014
- [102] Jurko A Jr, Minarik M, Cisarikova V et al. Congenital complete and partial absence of the left pericardium. *Wien Med Wochenschr* 163:426–428, 2013
- [103] Marta L, Ferreira AM, Santos KR. Congenital absence of pericardium: a nomad heart. *Cardiol Young* 25:1415–1417, 2015
- [104] Gatzoulis MA, Munk MD, Merchant N et al. Isolated congenital absence of the pericardium: clinical presentation, diagnosis, and management. *Ann Thorac Surg* 69:1209–1215, 2000
- [105] Abbas AE, Appleton CP, Liu PT et al. Congenital absence of the pericardium: case presentation and review of literature. *Int J Cardiol* 98:21–25, 2005
- [106] Huang J, Slaughter MS. Congenital partial absence of the pericardium. *Ann Thorac Surg* 91:e28, 2011
- [107] De Brabandere K, Czaplaj J, Callens E et al. Coronary artery bypass surgery in a patient with congenital absence of the left pericardium. *Eur J Cardiothorac Surg* 41:e65, 2012
- [108] Tăbăran AF, Nagy AL, Cătoi C et al. Congenital diaphragmatic hernia with concurrent aplasia of the pericardium in a foal. *BMC Vet Res* 11:309, 2015

14 Technische und personelle Voraussetzungen für Herzkatheterdiagnostik und Intervention

- [1] Schächinger V, Nef H, Achenbach S et al. Leitlinie zum Einrichten und Betreiben von Herzkatheterlaboren und Hybridoperationssälen/Hybridlaboren. *Kardiologie* 9:89–123, 2015
- [2] Hamm CW, Albrecht A, Bonzel T et al. Diagnostische Herzkatheteruntersuchung. *Clin Res Cardiol* 97:475–512, 2008
- [3] Schächinger V, Naber CK, Kreuzer J et al. Curriculum Interventionelle Kardiologie (Curriculum Interventional Cardiology of the German Cardiac Society). *Kardiologie* 6:315–323, 2012
- [4] Strahlenschutzverordnung vom 29. November 2018 (BGBl. I S. 2034, 2036), die zuletzt durch Artikel 83 des Gesetzes vom 10. August 2021 (BGBl. I S. 3436) geändert worden ist
- [5] Kuon E, Glaser C, Dahm JB. Effective techniques for reduction of radiation dosage to patients undergoing invasive cardiac procedures. *Br J Radiol* 76:406–413, 2002
- [6] Schächinger V, Kelm M. Addendum zur Leitlinie zum Einrichten und Betreiben von Herzkatheterlaboren und Hybridoperationssälen/Hybridlaboren – Neue Strahlenschutzgesetzgebung 2019 und Aktualisierung der Arbeitsanweisung. *Kardiologie* 13:193–197, 2015
- [7] Arbeitskreis „Krankenhaus- & Praxishygiene“ der AWMF. Hygieneanforderungen bei invasiven Untersuchungen und Behandlungen im Herzkatheterlabor. *Hyg Med* 38:436, 2013
- [8] Cook S, Togni M, Walpoth N et al. Percutaneous coronary interventions in Europe 1992–2003. *EuroIntervention* 1:374–379, 2006
- [9] Richtlinie des Gemeinsamen Bundesausschusses über Maßnahmen zur Qualitätssicherung bei der Durchführung von minimalinvasiven Herzklappeninterventionen gemäß § 136 Absatz 1 Satz 1 Nummer 2 für nach § 108 SGB V zugelassene Krankenhäuser (Richtlinie zu minimalinvasiven Herzklappeninterventionen/MHIL). www.g-ba.de/downloads (19.03.20)
- [10] Dohle DS, Tzagakis K, Ibrahim S et al. Controlled delayed aortic repair in acute aortic syndrome and multiorgan failure: an option in selected cases. *Thorac Cardiovasc Surg Rep* 4:52–55, 2015
- [11] Spaziano M, Lefèvre T, Romano M et al. Transcatheter aortic valve replacement in the catheterization laboratory versus hybrid operating room – insights from the FRANCE TAVI registry. *J Am Coll Cardiol Interv* 11:2195–2203, 2018
- [12] Babaliaros V, Devireddy C, Lerakis S et al. Comparison of transfemoral transcatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach) – outcomes and cost analysis. *J Am Coll Cardiol Interv* 7:898–904, 2014
- [13] Patsalis P, Alotaibi S, Wolf A et al. Feasibility of transfemoral aortic valve implantation in patients with aortic disease and simultaneous or sequential endovascular aortic repair. *J Invasive Cardiol* 31:289–295, 2019 (Epub 2019 August 15)
- [14] Kälisch H, Sack S, Erbel R et al. Acute massive pulmonary embolism detected with angiography and intravascular ultrasound treated by pulmonary embolectomy. The hybrid concept. *Herz* 31:366–367, 2006
- [15] Umakanthan R, Leacche M, Petracek MR et al. Combined PCI and minimally invasive heart valve surgery for high-risk patients. *Curr Treat Options Cardiovasc Med* 11:492–498, 2008
- [16] Zhao DX, Leacche M, Balaguer JM et al. Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room. *Am Coll Cardiol* 53:232–241, 2009

15 Koronare Interventionen

15.1 Einleitung

- [1] Grüntzig A. Transluminal dilatation of coronary-artery stenosis. *Lancet* 1:263, 1978
- [2] Deutsche Herzstiftung e.V. 30./32./34. Herzbericht der Deutschen Herzstiftung, Frankfurt 2018/2020/2022
- [3] Görges G, Haude M, Ge J et al. Intravascular ultrasound after low and high inflation pressure coronary artery stent implantation. *J Am Coll Cardiol* 26:725–30, 1995
- [4] Colombo A, Hall P, Nakamura S et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. *Circulation* 91:1676–88, 1995
- [5] Morice MC, Zémour G, Benveniste E et al. Intracoronary stenting without coumadin: one month results of a French multicenter study. *Cathet Cardiovasc Diagn* 35:1–7, 1995
- [6] Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med* 346:1773–80, 2002
- [7] Bønaa KH, Mannsverk J, Wiseth R et al. Drug-eluting or bare-metal stents for coronary artery disease. *N Engl J Med* 375:1242–52, 2016
- [8] Ellis SG, Kereiakes DJ, Metzger DC et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. *N Engl J Med* 373:1905–15, 2015
- [9] Jeżewski MP, Kubisa MJ, Eyileten C et al. Bioresorbable vascular scaffolds – dead end or still a rough diamond? *J Clin Med* 8:2167, 2019
- [10] Serruys PW, Chevalier B, Sotomi Y et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. *Lancet* 388:2479–91, 2016
- [11] Wykrzykowska JJ, Kraak RP, Hofma SH et al. Bioresorbable scaffolds versus metallic stents in routine PCI. *N Engl J Med* 376:2319–28, 2017
- [12] Chevalier B, Cequier A, Dudek D et al. Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial) *EuroIntervention* 13:1561–4, 2018
- [13] Boeder NF, Weissner M, Blachutzik F et al. Incidental finding of strut malapposition is a predictor of late and very late thrombosis in coronary bioresorbable scaffolds. *J Clin Med* 8:580, 2019
- [14] Dimitriadis Z, Polimeni A, Anadol R et al. Procedural predictors for bioresorbable vascular scaffold thrombosis: analysis of the individual components of the „PSP“ technique. *J Clin Med* 8:93, 2019
- [15] Gori T, Polimeni A, Indolfi C et al. Predictors of stent thrombosis and their implications for clinical practice. *Nat Rev Cardiol* 16:243–56, 2019
- [16] Heublein B, Rohde R, Hausdorf G et al. Bio-corrosion – a new principle for temporary cardiovascular implants. *Eur Heart J* 21:286, 2000
- [17] Erbel R, Di Mario C, Bartunek J et al., PROGRESS-AMS (Clinical Performance and Angiographic Results of Coronary Stenting with Absorbable Metal Stents) Investigators. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. *Lancet* 369:1869–75, 2007
- [18] Böse D, Eggebrecht H, Erbel R. Absorbable metal stent in human coronary arteries: imaging with intravascular ultrasound. *Heart* 92:892, 2006
- [19] Lind AY, Eggebrecht H, Erbel R. The invisible stent: imaging of an absorbable me-

- tal stent with multislice spiral computed tomography. *Heart* 91:1604, 2005
- [20] Erbel R, Böse D, Haude M et al. Absorbierbare Stents: Eine vielversprechende Neuerung? *Herz* 32:308–19, 2007
- [21] Eggebrecht H, Rodermann J, Hunold P et al. Images in cardiovascular medicine. Novel magnetic resonance-compatible coronary stent: the absorbable magnesium-alloy stent. *Circulation* 112:e303–4, 2005
- [22] Haude M, Erbel R, Erne P et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. *Lancet* 381:836–44, 2013
- [23] Haude M, Ince H, Abizaid A et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. *Lancet* 387:31–9, 2016
- [24] Haude M, Ince H, Toelg R et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: three-year clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. *EuroIntervention* 15:e1375–82, 2020
- [25] Timmis A, Townsend N, Gale C et al., ESC Scientific Document Group. European Society of Cardiology: Cardiovascular Disease Statistics 2017. *Eur Heart J* 39:508–79, 2018
- [25a] Timmis A, Townsend N, Gale CP et al., European Society of Cardiology. European Society of Cardiology: Cardiovascular Disease Statistics 2019. *Eur Heart J* 41:12–85, 2020. Erratum in: *Eur Heart J* 41:4507, 2020
- [26] Meier B. The coronary stent saga. *Cardio-Update* 2E-800-1647-1:20–7, 2007
- [26a] Praz L, Cook S, Meier B, Working Group of Interventional Cardiology (WG 10) of the European Society of Cardiology/European Association of Percutaneous Cardiovascular Interventions (EAPCI). Percutaneous coronary interventions in Europe in 2005. *EuroIntervention* 3:442–6, 2008
- [27] Cook S, Togni M, Walpoth N et al. Percutaneous coronary interventions in Europe 1992–2003. *EuroIntervention* 1:374–9, 2006
- [28] Praz L, Cook S, Meier B. Percutaneous coronary interventions in Europe in 2005. *EuroIntervention* 3:442–6, 2008
- [29] Gajanana D, Weintraub WS, Kolm P et al. Trends in death rate 2009 to 2018 following percutaneous coronary intervention stratified by acuteness of presentation. *Am J Cardiol* 124:1349–56, 2019
- [30] Hulme WJ, Sperrin M, Martin GP et al., British Cardiovascular Intervention Society and the National Institute of Cardiovascular Outcomes Research. Temporal trends in relative survival following percutaneous coronary intervention. *BMJ Open* 9:e024627, 2019
- [31] Thygesen K, Alpert JS, Jaffe AS et al. Fourth universal definition of myocardial infarction (2018). *Eur Heart J* 40:237–69, 2019
- [32] Eggebrecht H, Ritzel A, von Birgelen C et al. Acute and long-term outcome after coronary artery perforation during percutaneous coronary interventions. *Z Kardiol* 93:791–8, 2004
- [33] Parsh J, Seth M, Green J et al. Coronary artery perforations after contemporary percutaneous coronary interventions: evaluation of incidence, risk factors, outcomes, and predictors of mortality. *Catheter Cardiovasc Interv* 89:966, 2017
- [34] Elison D, Dean LS. Cover up: Clinic outcomes of covered stent usage for coronary perforation during PCI. *Catheter Cardiovasc Interv* 96:1367–8, 2020
- [35] Verevkin A, von Aspern K, Leontyev S et al. Early and long-term outcomes in patients undergoing cardiac surgery following iatrogenic injuries during percutaneous coronary intervention. *J Am Heart Assoc* 8:e010940, 2019
- [36] Slottosch I, Liakopoulos O, Kuhn E et al. Outcome after coronary bypass grafting for coronary complications following coronary angiography. *J Surg Res* 210:69, 2017
- [37] Windecker S, Stortecky S, Stefanini GG et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. *BMJ* 348:g3859, 2014
- [38] Maron DJ, Hochman JS, Reynolds HR et al., ISCHEMIA Research Group. Initial invasive or conservative strategy for stable

- coronary disease. *N Engl J Med* 382:1395–407, 2020
- [39] Koslowski B. The Essen myocardial infarction network as a model of integrated medical care in the realization of the therapy of acute ST segment elevation myocardial infarction corresponding to guidelines. *Herz* 30:715–20, 2005
- [40] Scholz KH, Maier SK, Jung J et al. Reduction in treatment times through formalized data feedback: results from a prospective multicenter study of ST-segment elevation myocardial infarction. *JACC Cardiovasc Interv* 5:848–57, 2012
- [41] Scholz KH, Friede T, Meyer T et al. Prognostic significance of emergency department bypass in stable and unstable myocardial infarction. *Eur Heart J Acute Cardiovasc Care* 9 (Suppl 1):34–44, 2020
- [42] Löwel H, Meisinger C, Heier M et al. Herzinfarkt und koronare Sterblichkeit in Süddeutschland. *Dtsch Ärzteblatt* 103:527–33, 2006
- nary atherosclerosis: the Heinz Nixdorf Recall study. *J Am Coll Cardiol* 56:1397–406, 2010
- [6] Erbel R. The dawn of a new era – non-invasive coronary imaging. *Herz* 21:75–7 1996
- [7] Greenland P, Blaha MJ, Budoff MJ et al. Coronary calcium score and cardiovascular risk. *J Am Coll Cardiol* 72:434–47, 2018
- [8] Figulla HR, Lauten A, Maier LS et al. Percutaneous coronary intervention in stable coronary heart disease – is less more? *Dtsch Arztebl Int* 117:137–44, 2020
- [9] Erbel R, Budoff M. Improvement of cardiovascular risk prediction using coronary imaging: subclinical atherosclerosis: the memory of lifetime risk factor exposure. *Eur Heart J* 33:1201–13, 2012
- [10] Maron DJ, Hochman JS, Reynolds HR et al., ISCHEMIA Research Group. Initial invasive or conservative strategy for stable coronary disease. *N Engl J Med* 382:1395–407, 2020
- [11] Knuuti J, Wijns W, Saraste A et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J* 41:407–77, 2020
- [11a] Nef HM, Achenbach S, Birkemeyer R et al. Manual der Arbeitsgruppe interventionelle Kardiologie (AGIK) der Deutschen Gesellschaft für Kardiologie – Herz-Kreislaufforschung e.V. (DGK) Teil 2: Durchführung der perkutanen Koronarintervention. *Kardiologie* 15:542–584, 2021
- [12] Neumann FJ, Sousa-Uva M, Ahlsson A et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 40:87–165, 2019
- [13] Alfonso F, Pérez-Vizcayno MJ, Cárdenas A et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). *J Am Coll Cardiol* 63:1378–86, 2014
- [14] Alfonso F, Pérez-Vizcayno MJ, Cárdenas A et al. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV randomized clinical trial. *J Am Coll Cardiol* 66:23–33, 2015

15.2 Koronare interventionelle Revaskularisierung

- [1] Bonzel T, Erbel R, Hamm CW et al. Perkutane Koronarinterventionen (PCI). *Clin Res Cardiol* 97:513–47, 2008
- [2] Maseri A, L'Abbate A, Chierchia S et al. Significance of spasm in the pathogenesis of ischemic heart disease. *Am J Cardiol* 44:788–92, 1979
- [3] Sigwart U, Grbic M, Payot M et al. Ischemic events during coronary artery balloon obstruction. In: Rutishauser W, Roskamm H (Eds), *Silent myocardial ischemia*. 29–36. Springer, Berlin, 1984
- [3a] Conti CR, Bavry AA, Petersen JW. Silent ischemia: clinical relevance. *J Am Coll Cardiol* 59:435–41, 2012
- [4] Erbel R, Hüttemann M, Schreiner G et al. Ischemia tolerance of the heart in percutaneous transluminal coronary angioplasty. Controlled study of the effect of isosorbide dinitrate and nifedipine. *Herz* 12:302–11, 1987
- [5] Erbel R, Möhlenkamp S, Moebus S et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coro-

- [15] Siontis GC, Stefanini GG, Mavridis D et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. *Lancet* 386:655–64, 2015
- [17] Giacoppo D, Gargiulo G, Aruta P et al. Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. *BMJ* 351:h5392, 2015
- [18] Hachamovitch R, Rozanski A, Shaw LJ et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. *Eur Heart J* 32:1012–24, 2011
- [19] Parasca CA, Head SJ, Milojevic M et al. Incidence, characteristics, predictors, and outcomes of repeat revascularization after percutaneous coronary intervention and coronary artery bypass grafting: the SYN-TAX Trial at 5 years. *JACC Cardiovasc Interv* 9:2493–507, 2016
- [20] Flaker G, Lopes RD, Hylek E et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. *J Am Coll Cardiol* 64:1541–50, 2014
- [21] Barbato E, Toth GG, Johnson NP et al. A prospective natural history study of coronary atherosclerosis using fractional flow reserve. *J Am Coll Cardiol* 68:2247–55, 2016
- [22] Trikalinos TA, Alsheikh-Ali AA, Tatsioni A et al. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. *Lancet* 373:911–8, 2009
- [23] Velazquez EJ, Lee KL, Deja MA et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. *N Engl J Med* 364:1607–16, 2011
- [24] Pursnani S, Korley F, Gopaul R et al. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. *Circ Cardiovasc Interv* 5:476–90, 2012
- [24a] Collet JP, Thiele H, Barbato E et al., ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 42:1289–367, 2021. Erratum in: *Eur Heart J* 42:1908, 2021. Erratum in: *Eur Heart J* 42:1925, 2021. Erratum in: *Eur Heart J* 42:2298, 2021.
- [24b] Granger CB, Goldberg RJ, Dabbous O et al., Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the global registry of acute coronary events. *Arch Intern Med* 163:2345–53, 2003
- [25] Eagle KA, Lim MJ, Dabbous OH et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. *JAMA* 291:2727–33, 2004
- [26] Mehta SR, Granger CB, Boden WE et al. Early versus delayed invasive intervention in acute coronary syndromes. *N Engl J Med* 360:2165–75, 2009
- [27] Koslowski B. The Essen myocardial infarction network as a model of integrated medical care in the realization of the therapy of acute ST segment elevation myocardial infarction corresponding to guidelines. *Herz* 30:715–20, 2005
- [28] Hailer B, Naber CK, Koslowski B et al., Herzinfarktverbund Essen. STEMI network Essen – results after 1 year. *Herz* 33:153–7, 2008
- [29] Jacksch R, Naber CK, Koslowski B et al., Herzinfarktverbund Essen. Primary Coronary Intervention (PCI) within the myocardial infarction network system in a German city (Essen). *Herz* 33:110–4, 2008
- [30] Erbel R. Treatment of acute myocardial infarction. *Herz* 33:85–6, 2008
- [31] Scholz KH, Maier SKG, Maier LS et al. Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial. *Eur Heart J* 39:1065–74, 2018
- [32] Ibáñez B, James S, Agewall S et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of

- the European Society of Cardiology (ESC). *Eur Heart J* 39:119–77, 2018
- [32a] Thrane PG, Olesen KKW, Thim T et al. Mortality Trends After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. *J Am Coll Cardiol* 82:999–1010, 2023
- [33] Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. *Lancet* 361:13–20, 2006
- [34] Boersma E. Primary coronary angioplasty vs. thrombolysis group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. *Eur Heart J* 27:779–88, 2006
- [35] Thiele H, Akin I, Sandri M et al. One-year outcomes after PCI strategies in cardiogenic shock. *N Engl J Med* 379:1699–710, 2018
- [36] Armstrong PW, Gershlick AH, Goldstein P et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. *N Engl J Med* 368:1379–87, 2013
- [37] Armstrong PW, Gershlick AH, Van de Werf F, STREAM Study Group. Fibrinolysis or primary PCI in myocardial infarction. *N Engl J Med* 369:280–1, 2013
- [38] Zeymer U, Bueno H, Granger CB et al. Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: a document of the Acute Cardiovascular Care Association of the European Society of Cardiology. *Eur Heart J Acute Cardiovasc Care* 9:183–97, 2020
- [39] Thiele H, Zeymer U, Neumann FJ et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. *N Engl J Med* 367:1287–96, 2012
- [40] Thiele H, Zeymer U, Thelemann N et al. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long-term 6-year outcome of the randomized IABP-SHOCK II trial. 139:395–403, 2019
- [41] Thiele H, Akin I, Sandri M et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. *N Engl J Med* 377:2419–32, 2017
- [41a] Thiele H, Zeymer U, Akin I et al. ECLS-SHOCK Investigators. Extracorporeal Life Support in Infarct-Related Cardiogenic Shock. *N Engl J Med*. 2023. Epub ahead of print. PMID:37634145, 2023
- [42] Erbel R. Myokardinfarkt. In: Burchardi H, Larsen R, Schuster H-P, Intensivmedizin. 9. Aufl., 515–48. Springer, Berlin, 2008
- [42a] Meyer J, Merx W, Dörr R et al. Successful treatment of acute myocardial infarction shock by combined percutaneous transluminal coronary recanalization (PTCR) and percutaneous transluminal coronary angioplasty (PTCA). *Am Heart J* 103:132–134, 1982
- [42b] Ostadal P, Rokyta R, Karasek J et al. ECMO-CS Investigators. Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial. *Circulation* 147:454–464, 2023
- [43] Pöss J, Köster J, Fuernau G et al. Risk stratification for patients in cardiogenic shock after acute myocardial infarction. *J Amer Coll Cardiol* 69:1913–20, 2017
- [44] Thiele H, Akin I, Sandri M et al. One-year outcomes after PCI strategies in cardiogenic shock. *N Engl J Med* 379:1699–710, 2018
- [45] Branco F. The heart and circulation – an integrative model. 2nd ed. Springer, New York, 2019
- [46] Erbel R, Heusch G. Koronare Mikroembolisierung – Rolle bei akutem Koronarsyndrom und Intervention. *Herz* 24:558–75, 1999
- [47] Erbel R, Heusch G. Coronary microembolization. *J Am Coll Cardiol* 36:22–4, 2000
- [48] Erbel R. Spontaneous and interventional coronary microembolization. *Heart* 89:986–9, 2003
- [49] Erbel R, Heusch G. Distale Embolisierung: Manifestation und Konsequenzen. *Herz* 29:716–21, 2004
- [50] Skyschally A, Schulz R, Haude M et al. Koronare Mikroembolisierung – Manifestation und klinische Konsequenzen. *Herz* 29:777–8, 2004
- [51] Heusch G, Kleinbongard P, Böse D et al. Coronary microembolization: from bedside to bench and back to bedside. *Circulation* 120:1822–36, 2009
- [52] Dörge H, Neumann T, Behrends M et al. Perfusion-contraction mismatch with coronary microvascular obstruction: role of

- inflammation. *Am J Physiol* 279: H2587–92, 2000
- [53] Skyschally A, Haude M, Dörge H et al. Glucocorticoid treatment prevents progressive myocardial dysfunction resulting from experimental coronary microembolization. *Circulation* 109:2337–42, 2004
- [54] Horn P, Baars T, Kahlert P et al. Release of intracoronary microparticles during stent implantation into stable atherosclerotic lesions under protection with an aspiration device. *PLoS One* 10:e0124904, 2015
- [55] Kleinbongard P, Baars T, Mohlenkamp S et al. Aspirate from human stented native coronary arteries vs. saphenous vein grafts: more endothelin but less particulate debris. *Am J Physiol Heart Circ Physiol* 305: H1222–9, 2013
- [56] Haude M, Altmann C, Eick B et al. Analysis of vessel wall morphology, blood flow velocity, and the hemostatic system in a patient with a large intracoronary thrombus. *Cathet Cardiovasc Diagn* 43:298–305, 1998
- [57] Baars T, Kleinbongard P, Boese D et al. Saphenous vein aorto-coronary graft atherosclerosis in patients with chronic kidney disease: more plaque calcification and necrosis, but less vasoconstrictor potential. *Basic Res Cardiol* 107:303, 2012
- [58] Kleinbongard P, Böse D, Baars T et al. Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. *Circ Res* 108:344–52, 2011
- [59] Angelini A, Rubartelli P, Mistrorigo F et al. Distal protection with a filter device during coronary stenting in patients with stable and unstable angina. *Circulation* 110:515–21, 2004
- [60] Mahmood A, Khair T, Abdel-Karim AR et al. Contemporary approaches to saphenous vein graft interventions: a survey of 275 interventional cardiologists. *Catheter Cardiovasc Interv* 79:834–42, 2012
- [61] Shoaib A, Kinnaird T, Curzen N et al. Outcomes following percutaneous coronary intervention in saphenous vein grafts with and without embolic protection devices. *JACC Cardiovasc Interv* 12:2286–95, 2019
- [62] Eick B, Haude M, Altmann C et al. Behandlung eines großen intrakoronaren Thrombus mit Urokinase und einem chimären monoklonalen Thrombozytenaggregationshemmer. *Dtsch Med Wochenschr* 122:709–15, 1997
- [63] Eggebrecht H, Baumgart D, Naber C et al. Extraction of large intracoronary thrombus in acute myocardial infarction by percutaneous Fogarty maneuver: intentional abuse of a novel interventional device. *Catheter Cardiovasc Interv* 55:228–32, 2002
- [64] Behan MW, Haude M, Oldroyd KG et al. Will this trial change my practice? TOTAL: a randomised trial of thrombus aspiration in ST-elevation myocardial infarction. *EuroIntervention* 11:361–3, 2015
- [65] Fröbert O, Lagerqvist B, Olivecrona GK et al. TASTE Trial. Thrombus aspiration during ST-segment elevation myocardial infarction. *N Engl J Med* 369:1587–97, 2013
- [66] Jolly SS, Cairns JA, Yusuf S et al., TOTAL Investigators. Randomized trial of primary PCI with or without routine manual thrombectomy. *N Engl J Med* 372:1389–98, 2015
- [67] Ito N, Nanto S, Doi Y et al. Distal protection during primary coronary intervention can preserve the index of microcirculatory resistance in patients with acute anterior ST-segment elevation myocardial infarction. *Circ J* 75:94–8, 2011
- [68] Gamou T, Sakata K, Matsubara T et al. Impact of thin-cap fibroatheroma on predicting deteriorated coronary flow during interventional procedures in acute as well as stable coronary syndromes: insights from optical coherence tomography analysis. *Heart Vessels* 30:719–27, 2015
- [70] Porto I, Belloni F, Niccoli G et al. Filter no-reflow during percutaneous coronary intervention of saphenous vein grafts: incidence, predictors and effect of the type of protection device. *EuroIntervention* 7:955–61, 2011
- [71] Kitagawa K, Amano T, Uetani T et al. Association between plaque characteristics and the amount of debris captured by a filter-type distal protection device in patients with acute coronary syndrome. *Atherosclerosis* 258:72–8, 2017
- [72] Teramoto R, Sakata K, Miwa K et al. Impact of distal protection with filter-type device on long-term outcome after percutaneous coronary intervention for acute myocardial infarction: clinical results with

- Filtrap. *J Atheroscler Thromb* 23:1313–23, 2016
- [73] Hibi K, Kozuma K, Sonoda S et al. A randomized study of distal filter protection versus conventional treatment during percutaneous coronary intervention in patients with attenuated plaque identified by intravascular ultrasound. *JACC Cardiovasc Interv* 11:1545–55, 2018
- [74] Kereiakes DJ, Turco MA, Breall J et al. A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions: results of the AMethyst randomized controlled trial. *JACC Cardiovasc Interv* 1:248–57, 2008
- [75] de Bruyne B, Bartunek J, Sys SU et al. Simultaneous coronary pressure and flow velocity measurements in humans. Feasibility, reproducibility, and hemodynamic dependence of coronary flow velocity reserve, hyperemic flow versus pressure slope index, and fractional flow reserve. *Circulation* 94:1842–9, 1996
- [76] Pijls NH, van Schaardenburgh P, Manoharan G et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. *J Am Coll Cardiol* 49:2105–11, 2007
- [77] Xaplanteris P, Fournier S, Pijls NHJ et al. Five-year outcomes with PCI guided by fractional flow reserve. *N Engl J Med* 379:250–9, 2018
- [78] DEFINE-FLAIR Trial Investigators, Lee JM, Choi KH, Koo BK et al. Comparison of major adverse cardiac events between instantaneous wave-free ratio and fractional flow reserve-guided strategy in patients with or without Type 2 diabetes: a secondary analysis of a randomized clinical trial. *JAMA Cardiol* 4:857–64, 2019
- [79] Driessen RS, de Waard GA, Stuijzand WJ et al. Adverse plaque characteristics relate more strongly with hyperemic fractional flow reserve and instantaneous wave-free ratio than with resting instantaneous wave-free ratio. *JACC Cardiovasc Imaging* 13:746–56, 2020
- [80] Arashi H, Satomi N, Ishida et al. Hemodynamic and lesion characteristics associated with discordance between the instantaneous wave-free ratio and fractional flow reserve. *J Interv Cardiol* 2019:3765282, 2019
- [81] Cook CM, Howard JP, Ahmad Y et al. How do fractional flow reserve, whole-cycle PdPa, and instantaneous wave-free ratio correlate with exercise coronary flow velocity during exercise-induced angina? *Circ Cardiovasc Interv* 13:e008460, 2020
- [82] Hwang D, Choi KH, Lee JM et al. Diagnostic agreement of quantitative flow ratio with fractional flow reserve and instantaneous wave-free ratio. *J Am Heart Assoc* 8:e011605, 2019
- [83] Abizaid AS, Mintz GS, Mehran R et al. Long-term follow-up after percutaneous transluminal coronary angioplasty was not performed based on intravascular ultrasound findings – importance of lumen dimensions. *Circulation* 100:256–61, 1999
- [84] Riccardi MJ, Meyers S, Choi K et al. Angiographically silent left main disease detected by intravascular ultrasound: a marker for future adverse cardiac events. *Am Heart J* 146:507–12, 2003
- [85] Okabe T, Mintz GS, Lee SY et al. Five-year outcomes of moderate or ambiguous left main coronary artery disease and the intravascular ultrasound predictors of events. *J Invasive Cardiol* 20:635–9, 2008
- [86] Gyongyosi M, Yang P, Hassan A et al. Intravascular ultrasound predictors of major adverse cardiac events in patients with unstable angina. *Clin Cardiol* 23:507–15, 2000
- [87] Gil RJ, Gziut AI, Prati F et al. Threshold parameters of left main coronary artery stem stenosis based on intracoronary ultrasound examination. *Kardiol Pol* 63:223–31, 2005
- [87a] Stone GW, Maehara A, Lansky AJ et al., PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. *N Engl J Med* 364:226–35, 2011
- [88] Erbel R, Ge J, Bockisch A et al. Value of intracoronary ultrasound and Doppler in the differentiation of angiographically normal coronary arteries: a prospective study in patients with angina pectoris. *Eur Heart J* 17:880–9, 1996
- [89] Baumgart D, Haude M, Goerge G et al. Improved assessment of coronary stenosis severity using the relative flow velocity reserve. *Circulation* 98:40–6, 1998
- [90] Baumgart D, Haude M, Liu F et al. Current concepts of coronary flow reserve for clinical decision making during cardiac ca-

theterization. *Am Heart J* 136:136–49, 1998

- [91] Haude M, Baumgart D, Verna E et al. Intracoronary Doppler- and quantitative coronary angiography-derived predictors of major adverse cardiac events after stent implantation. *Circulation* 103:1212–7, 2001
- [92] Peterson ED, Dai D, DeLong ER et al. Contemporary mortality risk prediction for percutaneous coronary intervention – results from 588,398 procedures in the National Cardiovascular Data Registry. *J Am Coll Cardiol* 55:1923–1932, 2010

15.3 Materialien für koronare Interventionen

15.3.1–15.3.3 Koronare Interventionen

- [1] Alfonso F, Pérez-Vizcayno MJ, Cárdenas A et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). *J Am Coll Cardiol* 63:1378–86, 2014
- [1a] Burke MN. Wire strategy as a first option: properties of the tools. *Interv Cardiol Clin* 1:309–14, 2012
- [2] Pleva L, Kukla P, Kusnierova P et al. Comparison of the efficacy of paclitaxel-eluting balloon catheters and everolimus-eluting stents in the treatment of coronary in-stent restenosis: the treatment of in-stent restenosis study. *Circ Cardiovasc Interv* 9:e003316, 2016
- [3] Habara S, Iwabuchi M, Inoue N et al. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. *Am Heart J* 166:527–33, 2013
- [4] Byrne RA, Neumann FJ, Mehilli J et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. *Lancet* 381:461–7, 2013
- [5] Alfonso F, Pérez-Vizcayno MJ, Cárdenas A et al. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV Randomized Clinical Trial. *J Am Coll Cardiol* 66:23–33, 2015
- [6] Baan J Jr, Claessen BE, Dijk KB et al. A randomized comparison of paclitaxel-eluting balloon versus everolimus-eluting stent for the treatment of any in-stent restenosis: the DARE Trial. *JACC Cardiovasc Interv* 11:275–83, 2018
- [7] Neumann FJ, Sousa-Uva M, Ahlsson A et al. ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 40:87–165, 2019 Erratum in: *Eur Heart J* 40:3096, 2019
- [8] Kufner S, Joner M, Schneider S et al. Neointimal modification with scoring balloon and efficacy of drug-coated balloon therapy in patients with restenosis in drug-eluting coronary stents: a randomized controlled trial. *JACC Cardiovasc Interv* 10:1222–9, 2017
- [9] Siontis GC, Stefanini GG, Mavridis D et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. *Lancet* 386:655–64, 2015
- [10] Giacoppo D, Gargiulo G, Aruta P et al. Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. *BMJ* 351:h5392, 2015
- [11] Kufner S, Cassese S, Valeskini M et al. Long-term efficacy and safety of paclitaxel-eluting balloon for the treatment of drug-eluting stent restenosis: 3-year results of a randomized controlled trial. *JACC Cardiovasc Interv* 8:877–84, 2015
- [12] Xu B, Qian J, Ge J et al. Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis. *Catheter Cardiovasc Interv* 87(Suppl 1):624–9, 2016
- [13] Byrne RA, Cassese S, Windisch T et al. Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: in-

sights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. *EuroIntervention* 9:797–802, 2013

15.3.4 Koronare Stents

- [1] O'Brien B, Carroll W. The evolution of cardiovascular stent materials and surfaces in response to clinical drivers: a review. *Acta Materialia* 5:945–58, 2009
- [1a] Schmidt T, Abbott JD. Coronary stents: history, design, and construction. *J Clin Med* 7:126, 2018
- [2] Kastrati A, Mehilli J, Dirschinger J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STERO) trial. *Circulation* 103:2816–21, 2001
- [3] Hoffmann R, Mintz GS, Haager PK et al. Relation of stent design and stent surface material to subsequent in-stent intimal hyperplasia in coronary arteries determined by intravascular ultrasound. *Am J Cardiol* 89:1360–4, 2002
- [4] Hausleiter J, Kastrati A, Mehilli J et al. Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STERO trial. *Am Heart J* 146:882–6, 2003
- [5] Rittersma SZ, de Winter RJ, Koch KT et al. Impact of strut thickness on late luminal loss after coronary artery stent placement. *Am J Cardiol* 93:477–80, 2004
- [6] Turco MA, Ormiston JA, Popma JJ et al. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program. *JACC Cardiovasc Interv* 1:699–709, 2008
- [7] Haidopoulos M. Development of an optimized electrochemical process for subsequent coating of L316 stainless steel for stent application. *J Mater Sci Mater Med* 17:647–57, 2006
- [8] Noad RL, Hanratty CG, Walsh SJ. Clinical impact of stent design. *Interv Cardiol* 9:89–93, 2014
- [9] Watson T, Webster MWI, Ormiston JA et al. Long and short of optimal stent design. *Open Heart* 4:e000680, 2017
- [10] Borhani S, Hassanajili S, Ahmadi Tafti SH et al. Cardiovascular stents: overview, evolution, and next generation. *Prog Biomater* 7:175–205, 2018
- [11] Torii S, Jinnouchi H, Sakamoto A et al. Drug-eluting coronary stents: insights from preclinical and pathology studies. *Nat Rev Cardiol* 17:37–51, 2020
- [11a] Christ G. Stents und Scaffolds. *J Kardiologie* 27:229–36, 2020
- [12] Strupp G, Schreiner G, Bonzel T. Bauarten und Eigenschaften koronarer Stents – „Stentmanual 2005“. 9. Aufl. Klinikum Fulda, Medizinische Klinik I, 2005
- [13] Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. *N Engl J Med* 331:489–95, 1994
- [14] Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. *N Engl J Med* 331:496–501, 1994
- [15] Erbel R, Haude M, Höpp HW et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. *N Engl J Med* 339:1672–8, 1998
- [16] Haude M, Hopp HW, Rupprecht HJ et al. Immediate stent implantation versus conventional techniques for the treatment of abrupt vessel closure or symptomatic dissections after coronary balloon angioplasty. *Am Heart J* 140:e26, 2000
- [17] Iqbal J, Gunn J, Serruys PW. Coronary stents: historical development, current status and future directions. *Br Med Bull* 106:193–211, 2013
- [18] Schmidt W, Lanzer P, Behrens P et al. Direct comparison of coronary bare metal vs. drug-eluting stents: same platform, different mechanics? *Eur J Med Res* 23:1–12, 2018. Original publisher: BMC – BioMed Central Ltd, Part of Springer Nature
- [18a] <https://www.xiencestent.com/us/complex-pci/xience-sierra-large-vessel-lesion> (abgerufen 17.1.2023)
- [18b] <https://www.xiencestent.com/us/complex-pci/xience-sierra-side-branch-stent> (abgerufen 17.1.2023)
- [18c] <https://www.bostonscientific.com/en-EU/products/stents-coronary/synergy->

- stent-system/megatron/visibility.html (abgerufen 17.1.2023)
- [18d] Schenk CD, Gebker R, Berger A et al. Review of safety reports of cardiac MR-imaging in patients with recently implanted coronary artery stents at various field strengths. *Expert Rev Med Devices* 18:83–90, 2021
- [19] Möhlenkamp S, Pump H, Ge J et al. Ein neuer Titan Stent: In-vitro-Charakteristika in der Elektronenstrahltomographie. *Z Kardiol* 86:3, 1997
- [20] Karjalainen PP, Ylitalo A, Airaksinen JK et al. Five-year clinical outcome of titanium-nitride-oxide-coated bioactive stent implantation in a real-world population: a comparison with paclitaxel-eluting stents: the PORI registry. *J Interv Cardiol* 24:1–8, 2011
- [21] Karjalainen PP, Ylitalo A, Airaksinen JK et al. Titanium-nitride-oxide-coated Titan-2 bioactive coronary stent: a new horizon for coronary intervention. *Expert Rev Med Devices* 7:599–604, 2010
- [22] Karjalainen PP, Nammas W. Titanium-nitride-oxide-coated coronary stents: insights from the available evidence. *Ann Med* 49:299–309, 2017
- [23] Antoniucci D, Bartorelli A, Valenti R et al. Clinical and angiographic outcome after coronary arterial stenting with the carbo-stent. *Am J Cardiol* 85:821–5, 2000
- [24] Wieneke H, Dirsch O, Sawitowski T et al. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. *Cath Cardiovasc Interv* 60:399–407, 2003
- [24a] Takami Y, Nakazawa T, Makinouchi K et al. Biocompatibility of alumina ceramic and polyethylene as materials for pivot bearings of a centrifugal blood pump. *J Biomed Mater Res* 36:381–6, 1997
- [24b] Eckert KL, Mathey M, Mayer J et al. Preparation and in vivo testing of porous alumina ceramics for cell carrier applications. *Biomaterials* 21:63–9, 2000
- [24c] Edelman ER, Seifert P, Morss GA et al. Gold-coated NIR stents in porcine coronary arteries. *Circulation* 103:429–34, 2001
- [25] Tur DS, Korshak SV, Vinogradova NB. Investigation of the thermostability of poly[bis(trifluoroethoxy)phosphazene]. *Acta Polymerica* 36:627–31, 1985
- [26] Welle A, Grunze M, Tur D. Plasma protein adsorption and platelet adhesion on poly[bis(trifluoroethoxy)phosphazene] and reference material surfaces. *J Colloid Interface Sci* 197:263–74, 1998
- [27] Unterberg C, Sandrock D, Nebendahl K et al. Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty. *J Am Coll Cardiol* 26:174–54, 1995
- [28] Prati F, Cera M, Ramazzotti V et al. Safety and feasibility of a new non-occlusive technique for facilitated intracoronary optical coherence tomography (OCT) acquisition in various clinical and anatomical scenarios. *EuroInterv* 3:365–70, 2007
- [29] Tamburino C, La Manna A, Di Salvo ME et al. First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The Latest Non-Thrombogenic Angioplasty stent) trial. *JACC Cardiol Interv* 2:197–204, 2009
- [30] Pourmoghaddas M, Rohani HR, Sanei H et al. Undesired outcomes of the catania stent compared to the Xience stent in patients undergoing angioplasty: a double-blind randomized controlled trial. *Adv Biomed Res* 6:154–8, 2017
- [31] Hasebe T, Yohena S, Kamijo A et al. Fluorine doping into diamond-like carbon coatings inhibits protein adsorption and platelet activation. *J Biomed Mater Res A* 83:1192–9, 2007
- [32] Rogers C, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. *Circulation* 91:2995–3001, 1995
- [33] Price MJ, Shlofmitz RA, Spriggs DJ et al. Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: primary outcome of the RESOLUTE ONYX core trial. *Catheter Cardiovasc Interv* 92:253–9, 2018
- [34] Jensen LO, Thayssen P, Christiansen EH et al. Safety and efficacy of everolimus-versus sirolimus-eluting stents: 5-year results from SORT OUT IV. *J Am Coll Cardiol* 67:751–62, 2016
- [35] Otsuka F, Vorpahl M, Nakano M et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. *Circulation* 129:211–23, 2014

- [36] Kandzari DE, Smits PC, Love MP et al. Randomized comparison of ridaforolimus- and zotarolimus-eluting coronary stents in patients with coronary artery disease: primary results from the BIONICS Trial (BioNIR ridaforolimus-eluting coronary stent system in coronary stenosis). *Circulation* 136:1304–14, 2017
- [37] El-Hayek G, Bangalore S, Casso Dominguez A et al. Meta-analysis of randomized clinical trials comparing biodegradable polymer drug-eluting stent to second-generation durable polymer drug-eluting stents. *JACC Cardiovasc Interv* 10:462–73, 2017
- [38] Torii S, Virmani R, Finn A. An uncommon but important cause of stent thrombosis: Kounis syndrome. *Cardiovasc Revasc Med* 19:818–9, 2018
- [39] Wiemer M, Butz T, Schmidt W et al. Scanning electron microscopic analysis of different drug eluting stents after failed implantation: from nearly undamaged to major damaged polymers catheter. *Cardiovasc Interv* 75:905–11, 2010
- [40] Basalus MW, Tandjung K, van Westen T et al. Scanning electron microscopic assessment of coating irregularities and their precursors in unexpanded durable polymer-based drug-eluting stents. *Catheter Cardiovasc Interv* 79:644–53, 2012
- [41] Basalus MW, Tandjung K, van Apeldoorn AA et al. Effect of oversized partial postdilatation on coatings of contemporary durable polymer-based drug-eluting stents: a scanning electron microscopy study. *J Interv Cardiol* 24:149–61, 2011
- [42] Ladich E, Vorpahl M, Nakano M et al. Late test on the pathology of drug-eluting stents. *Interv Cardiol* 1:165–74, 2009
- [43] Middleton JC, Tipton AJ. Synthetic biodegradable polymers as orthopedic devices. *Biomaterials* 21:2335–46, 2000
- [44] Grube E, Hauptmann KE, Buellesfeld L et al. Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coating. *EuroIntervention* 1:53–7, 2005
- [45] Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): a randomised non-inferiority trial. *Lancet* 372:1163–73, 2008
- [46] Hamilos MI, Ostojic M, Beleslin B et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. *J Am Coll Cardiol* 51:2123–9, 2008
- [49] Kandzari DE, Mauri L, Koolen JJ et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. *Lancet* 390:1843–52, 2017; Erratum in: *Lancet* 390:1832, 2017
- [50] Wani MC, Taylor HL, Wall ME et al. Plant antitumor agents. VI. The isolated and structure of taxol, a novel antileukemic and antitumor agent from *Taxus brevifolia*. *J Am Chem Soc* 93:2325–7, 1971
- [51] Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. *Nature* 277:665–7, 1979
- [52] Wieneke H, Schmermund A, van Birgelen C et al. Therapeutic potential of active stent coating. *Expert Opin Investig Drugs* 12:1–9, 2003
- [53] Wilson GJ, Nakazawa G, Schwartz RS et al. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. *Circulation* 120:141–9, 2009
- [54] Farb A, Heller PF, Shroff S et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. *Circulation* 104:473–9, 2001
- [55] Drachman DE, Edelman ER, Seifert P et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. *J Am Coll Cardiol* 36:2325–32, 2000
- [56] Ahmed W, Zambahari R, Al-Rashdan I et al. One-year outcome with the TAXUS Liberté stent in the real world: The TAXUS OLYMPIA Registry (Phase I). *J Interv Cardiol* 21:512–8, 2008
- [57] Turco MA, Ormiston JA, Popma JJ et al. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program. *JACC Cardiovasc Interv* 1:699–709, 2008
- [58] Mahmud E, Ormiston JA, Turco MA et al. TAXUS Liberté attenuates the risk of re-

- nosis in patients with medically treated diabetes mellitus: results from the TAXUS ATLAS program. *JACC Cardiovasc Interv* 2:240–52, 2009
- [59] Turco M, Ormiston J, Mandinov L et al. TAXUS ATLAS and TAXUS ATLAS DIRECT STENT trials: Durable effectiveness of the TAXUS Liberté stent and long-term benefit of direct stenting. *Am J Cardiol* 102(Suppl 1):147i, 2008
- [60] Moses JW, Stone GW, Nikolsky E et al. Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials. *J Am Coll Cardiol* 47:2164–71, 2006
- [61] Dawkins KD, Stone GW, Colombo A et al. Integrated analysis of medically treated diabetic patients in the TAXUS program: benefits across stent platforms, paclitaxel release formulations, and diabetic treatments. *EuroIntervention* 2:61–8, 2006
- [62] Ellis SG, Colombo A, Grube E et al. Incidence, timing, and correlates of stent thrombosis with the polymeric Paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. *J Am Coll Cardiol* 49:1043–51, 2007
- [63] Escolar E, Mintz GS, Popma J et al. Meta-analysis of angiographic versus intravascular ultrasound parameters of drug-eluting stent efficacy (from TAXUS IV, V, and VI). *Am J Cardiol* 100:621–6, 2007
- [64] Stone GW, Ellis SG, Colombo A et al. Off-setting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. *Circulation* 115:2842–7, 2007
- [65] Vezina C, Kudelski A, Seghal SN. Rapamycin (AY-22, 989), a new antifungal antibiotic, I: toxoneme of the producing streptomycete and isolation of the active principle. *J Antibiot (Tokyo)* 28:721–6, 1975
- [66] Gregory CR, Huie P, Billingham ME et al. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. *Transplantation* 55:1409–18, 1993
- [67] Sadoshima J, Izumo S. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. *Circ Res* 77:1040–52, 1995
- [68] Poon M, Marx SO, Gallo R et al. Rapamycin inhibits vascular smooth muscle cell migration. *J Clin Invest* 98:2277–83, 1996
- [69] Burke SE, Lubbers NL, Chen YW et al. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. *J Cardiovasc Pharmacol* 33:829–35, 1999
- [70] Sousa JE, Costa MA, Abizaid A et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. *Circulation* 103:192–5, 2001
- [71] Morice MC, Serruys PW, Sousa JE et al., RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med* 46(23):1773–80, 2002
- [72] Moses J, Leon MB, Popma JJ et al. SIRIUS: A US multicenter, randomised, double-blind study of the sirolimus-stent in de novo native coronary lesions. 14th Annual Transcatheter Cardiovascular Therapeutics Meeting, Washington DC, USA, September 24–28, 2002
- [73] Sousa JE, Costa MA, Sousa AG et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. *Circulation* 107:381–3, 2003
- [74] Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? *Circulation* 109:701–5, 2004
- [75] Otsuka F, Yahagi K, Ladich E et al. Hypersensitivity reaction in the US Food and Drug Administration-approved second-generation drug-eluting stents: histopathological assessment with ex vivo optical coherence tomography. *Circulation* 131:322–4, 2015
- [76] Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. *N Engl J Med* 356:998–1008, 2007
- [77] Moses JW, Leon MB, Popma JJ et al. SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients

- with stenosis in a native coronary artery. *N Engl J Med* 349:1315–23, 2003
- [78] Togni M, Windecker S, Cocchia R et al. Sirolimus-eluting stents associated with paradoxical coronary vasoconstriction. *J Am Coll Cardiol* 46:231–6, 2005
- [79] Hofma SH, van der Giessen WJ, van Dalen BM et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. *Eur Heart J* 27:166–70, 2006
- [80] Marzocchi A, Saia F, Piovaccari G et al. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. *Circulation* 115:3181–8, 2007
- [81] Morice MC, Serruys PW, Barragan P et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. *J Am Coll Cardiol* 50:1299–304, 2007
- [82] Schampaert E, Moses JW, Schofer J et al. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. *Am J Cardiol* 98:36–41, 2006
- [83] Edelmann E, Falotico R, Parker T. Naevo sirolimus-eluting coronary stent. *Cardiac & Vascular update* 2:7–9, 2009
- [84] Wiemer M, Seth A, Chandra P et al. Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. *Am Heart J* 156:751.e1–7, 2008
- [85] Doros G, Massaro JM, Kandzari DE et al. Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach. *Am Heart J* 193:35–45, 2017
- [86] Saito S, Toelg R, Witzenbichler B et al. BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months. *EuroIntervention* 15:e1006–13, 2019
- [87] Kang SH, Chung WY, Lee JM et al. Angiographic outcomes of Orsiro biodegradable polymer sirolimus-eluting stents and Resolute Integrity durable polymer zotarolimus-eluting stents: results of the ORIENT trial. *EuroIntervention* 12:1623–31, 2017
- [88] van der Heijden LC, Kok MM, Zocca P et al. Bioresorbable polymer-coated orsiro versus durable polymer-coated Resolute Onyx stents (BIONYX): rationale and design of the randomized TWENTE IV multicenter trial. *Am Heart J* 198:25–32, 2018
- [89] von Birgelen C, Zocca P, Buiten RA et al. Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultra-thin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial. *Lancet* 392:1235–45, 2018
- [90] Godino C, Beneduce A, Ferrante G et al. One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in allcomers population. Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry). *Int J Cardiol* 260:36–41, 2018
- [91] de Winter RJ, Katagiri Y, Asano T et al. A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial. *Lancet* 391:431–40, 2018
- [92] Milewski K, Takahashi K, Asano T et al. Neointimal hyperplasia of ultra-thin stents with microcrystalline sirolimus or durable polymer everolimus-eluting stents: 6- and 24-month results of the DESSOLVE III OCT study. *EuroIntervention* 16:1187–94, 2021
- [93] Torguson R, Waksman R. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the Xience V everolimus-eluting coronary stent. *Am J Cardiol* 102:1624–30, 2008
- [94] Stone GW, Midei M, Newman W et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. *Circulation* 119:680–6, 2009

- [95] Onuma Y, Kukreja N, Piazza N et al. Interventional Cardiologists of the Thoraxcenter (2000 to 2007). The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry. *J Am Coll Cardiol* 54:269–76, 2009
- [96] Kedhi E, Joesoef KS, McFadden E et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. *Lancet* 375:201–9, 2000
- [97] Chang CC, Onuma Y, Achenbach S et al. Absorb bioresorbable scaffold versus Xience metallic stent for prevention of restenosis following percutaneous coronary intervention in patients at high risk of restenosis: rationale and design of the COMPARE ABSORB Trial. *Cardiovasc Res* 20:577–82, 2019
- [98] Nakamura M, Otsuji S, Nakagawa Y et al. Non-inferiority of Resolute Integrity drug-eluting stent to benchmark Xience drug-eluting stent. *Circ J* 82:2284–91, 2018
- [99] Vlachojannis GJ, Puricel S, Natsuaki M et al. Biolimus-eluting versus everolimus-eluting stents in coronary artery disease: a pooled analysis from the NEXT (NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent) and COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) randomised trials. *EuroIntervention* 12:1970–7, 2017
- [100] Windecker S, Stortecky S, Stefanini GG et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. *BMJ* 348:g3859, 2014
- [101] Mitsis A, Valgimigli M. Device profile of the XIENCE V and XIENCE Sierra stents for the treatment of coronary artery disease: an overview of safety and efficacy. *Expert Rev Med Devices* 17:383–90, 2020
- [102] Kogame N, Modolo R, Tomaniak M et al. Prasugrel monotherapy after PCI with the SYNERGY stent in patients with chronic stable angina or stabilised acute coronary syndromes: rationale and design of the ASET pilot study. *EuroIntervention* 15:e547–50, 2019
- [103] Shreenivas SS, Kereiakes DJ. Evolution of the SYNERGY bioresorbable polymer metallic coronary stent. *Future Cardiol* 14:307–17, 2018
- [104] Lopes RD, Heizer G, Aronson R et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. *N Engl J Med* 380:1509–24, 2019
- [105] Vranckx P, Valgimigli M, Jüni P et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. *Lancet* 392:940–9, 2018
- [106] Watanabe H, Domei T, Morimoto T et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial. *JAMA* 321:2414–27, 2019
- [107] Hahn JY, Song YB, Oh JH et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. *JAMA* 321:2428–37, 2019
- [108] Baber U, Dangas G, Cohen DJ et al. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: rationale and design of the TWILIGHT study. *Am Heart J* 182:125–34, 2016
- [108a] Escaned J, Cao D, Baber U et al. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. *Eur Heart J* 42:4624–34, 2021
- [109] Garcia-Touchard A, Burke SE, Toner JL et al. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. *Euro Heart J* 27:988–93, 2006
- [110] Lewis AL, Cumming ZL, Goreish HH et al. Cross-linkable coatings from phosphorylcholine-based polymers. *Biomaterials* 22:99–111, 2001
- [111] Lewis AL, Stratford PW. Phosphorylcholine-coated stents. *J Long Term Eff Med Implants* 12:231–50, 2002
- [112] Meredith IT, Ormiston J, Whitbourn R et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo na-

- tive coronary artery lesions: Endeavor I Trial. *EuroIntervention* 1:157–64, 2005
- [113] Meredith IT, Ormiston J, Whitbourn R et al., ENDEAVOR I Investigators. Five-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, first-in-human study. *Catheter Cardiovasc Interv* 74:989–95, 2009
- [114] Mehta RH, Leon MB, Sketch MH Jr. ENDEAVOR II Continued Access Registry. The relation between clinical features, angiographic findings, and the target lesion revascularization rate in patients receiving the endeavor zotarolimus-eluting stent for treatment of native coronary artery disease: an analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III. *Am J Cardiol* 100:62M–70M, 2007
- [115] Miyazawa A, Ako J, Hongo Y et al. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. *Am Heart J* 155:108–13, 2008
- [116] Leon MB, Nikolsky E, Cutlip DE et al. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease) trial. *JACC Cardiovasc Interv* 3:1043–50, 2010
- [117] Kirtane AJ, Leon MB, Ball MW et al. The „final“ 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. *JACC Cardiovasc Interv* 6:325–33, 2013
- [118] Vardi M, Burke DA, Bangalore S et al. Long-term efficacy and safety of zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials. *Catheter Cardiovasc Interv* 82:1031–8, 2013
- [119] Finn AV, Joner M, Nakazawa G et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialisation. *Circulation* 115:2435–41, 2007
- [120] Kim JW, Suh SY, Choi CU et al. Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus paclitaxel-eluting stent. *JACC Cardiovasc Interv* 1:65–71, 2008
- [121] Kim JW, Seo HS, Park JH et al. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction. *J Am Coll Cardiol* 53:1653–9, 2009
- [122] Okumura M, Ozaki Y, Ishii J et al. Restenosis and stent fracture following sirolimus-eluting stent (SES) implantation. *Circ J* 71(11):1669–77, 2007
- [123] Park JS, Cho IH, Kim YJ. Stent fracture and restenosis after zotarolimus-eluting stent implantation. *Int J Cardiol* 147:e29–31, 2011
- [124] Kim JS, Lee SY, Lee JM et al. Significant association of coronary stent fracture with in-stent restenosis in sirolimus-eluting stents. *Coron Artery Dis* 20:59–63, 2009
- [125] Watanabe T, Tamura A, Miyamoto K et al. Fracture of a paclitaxol-eluting stent implanted for in-stent restenosis at the site of sirolimus-eluting stent fracture. *Int J Cardiol* 140:e12–3, 2010
- [126] Bilen E, Saatci Yasar A, Bilge M et al. Acute coronary syndrome due to complete bare metal stent fracture in the right coronary artery. *Int J Cardiol* 139:e44–6, 2010
- [127] Toutouzas K, Patsa C, Tsiamis E et al. Everolimus- and zotarolimus-eluting stents for bare metal stent in-stent restenosis treatment: a prospective study. *J Interv Cardiol* 21:388–94, 2008
- [128] Meredith IT, Worthley SG, Whitbourn R et al. Long-term clinical outcomes with the next-generation Resolute Stent System: a report of the two-year follow-up from the RESOLUTE clinical trial. *Eurointervention* 5:692–7, 2010
- [129] Buiten RA, Ploumen EH, Zocca P et al. Thin composite-wire-strut zotarolimus-eluting stents versus ultrathin-strut sirolimus-eluting stents in BIONYX at 2 years. *JACC Cardiovasc Interv* 13:1100–9, 2020
- [130] Windecker S, Latib A, Kedhi E et al., on behalf of the ONYX ONE Investigators. Polymer-based or polymer-free stents in patients at high bleeding risk. *N Engl J Med* 382:1208–18, 2020
- [131] Ostojic M, Sagic D, Jung R et al. The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients

- with coronary artery disease: the NOBORI PK study. *Catheter Cardiovasc Interv* 72:901–8, 2008
- [132] Chevalier B, Serruys PW, Silber S et al. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. *Eurointervention* 2:426–34, 2007
- [133] Vetrovec GW, Rizik D, Williard C et al. Sirolimus PK trial: A pharmacokinetic study of the sirolimus-eluting Bx Velocity stent in patients with de novo coronary lesions. *Catheter Cardiovasc Interv* 67:32–7, 2006
- [134] Stella PR, Mueller R, Pavlakis G et al., Custom-II Investigators. One year results of a new in situ length-adjustable stent platform with a biodegradable biolimus A9 eluting polymer: results of the CUSTOM-II trial. *EuroIntervention* 4:200–7, 2008
- [135] Konishi A, Ho M, Shirai Y et al. First approval of improved medical device conditional on use-result survey in Japan – regulatory review of polymer-free drug-coated BioFreedom Coronary Stent. *Circ J* 82:1487–90, 2018
- [136] Lee SWL, Tam FCC, Chan KKW et al. Establishment of healing profile and neointimal transformation in the new polymer-free biolimus A9-coated coronary stent by longitudinal sequential optical coherence tomography assessments: the EGO-BIOFREEDOM study. *EuroIntervention* 14:780–8, 2018
- [137] Jensen LO, Maeng M, Raungaard B et al. Comparison of the polymer-free biolimus-coated BioFreedom stent with the thin-strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers population treated with percutaneous coronary intervention: rationale and design of the randomized SORT OUT IX trial. *Am Heart J* 213:1–7, 2019
- [137a] Jensen LO, Maeng M, Raungaard B et al., Sort Out IX Study Group. Randomized comparison of the polymer-free biolimus-coated BioFreedom stent with the ultrathin strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers population treated with percutaneous coronary intervention: the SORT OUT IX Trial. *Circulation* 141:2052–63, 2020
- [138] Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): a randomised non-inferiority trial. *Lancet* 372:1163–73, 2008
- [139] Stella PR, Mueller R, Pavlakis G et al., Custom-II Investigators. One year results of a new in situ length-adjustable stent platform with a biodegradable biolimus A9 eluting polymer: results of the CUSTOM-II trial. *EuroIntervention* 4:200–7, 2008
- [140] Verheye S, Agostoni P, Dubois CL et al. 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study. *J Am Coll Cardiol* 53:1031–9, 2009
- [141] Buysschaert I, Sanidas E, Hasegawa T et al. Baseline and 9 months IVUS analysis of the bifurcation-dedicated biolimus A9-eluting Axxess stent system: the DIVERGE IVUS substudy. *Catheter Cardiovasc Interv* 84:1062–70, 2014
- [142] Briguori C, Donahue M, Visconti G et al. Coronary artery bifurcation narrowing treated by Axxess stent implantation: the CARINAX registry. *Catheter Cardiovasc Interv* 89:e112–23, 2017
- [143] Borgia F, Niglio T, De Luca N et al. True double bifurcation lesions: new application of the self-expandable Axxess stent and review of literature with dedicated bifurcation devices. *Cardiovasc Revasc Med* 20:254–60, 2019
- [144] Buysschaert I, Verheye S. The Axxess stent. *EuroIntervention* 11(Suppl V): V143–4, 2015
- [145] Hamada N, Miyata M, Eto H et al. Tacrolimus-eluting stent inhibits neointimal hyperplasia via calcineurin/NFAT signaling in porcine coronary artery model. *Atherosclerosis* 208:97–103, 2010
- [146] Onuma Y, Serruys P, den Heijer P et al. MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de

- novo coronary stenoses. *Eur Heart J* 30:1477–85, 2009
- [147] Rinker A, Nusser T, Grossmann G et al. Angiographic results of a tacrolimus-eluting stent in acute coronary syndrome lesions. *Clin Res Cardiol* 98:89–93, 2009
- [148] Tamburino C, Di Salvo ME, Capodanno D et al. Real world safety and efficacy of the Janus tacrolimus-eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting STent (TEST) registry. *Catheter Cardiovasc Interv* 73:243–8, 2009
- [149] Aslanabadi N, Separham A, Beheshti R et al. OPTIMA tacrolimus-eluting stent: a twelve-month clinical follow up with two different periods of dual antiplatelet therapy; 2-month vs. 6-month approach. *J Cardiovasc Thorac Res* 4:81–4, 2012
- [150] Verheye S, Agostoni P, Dawkins KD et al. The GENESIS (randomized, multicenter study of the pimecrolimus-eluting and pimecrolimus/paclitaxel-eluting coronary stent system in patients with de novo lesions of the native coronary arteries) trial. *JACC Cardiovasc Interv* 2:205–14, 2009
- [151] Ormiston JA, Webster MW, Schwartz RS et al. Feasibility, safety, and efficacy of a novel polymeric pimecrolimus-eluting stent: traditional pre-clinical safety end points failed to predict 6-month clinical angiographic results. *JACC Cardiovasc Interv* 2:1017–24, 2009
- [152] Savvoulidis P, Perlman G, Bagur R. The EluNIRTM ridaforolimus eluting coronary stent system. *Expert Rev Med Devices* 16:71–6, 2019
- [153] Kandzari DE, Smits PC, Love MP et al. Randomized comparison of ridaforolimus- and zotarolimus-eluting coronary stents in patients with coronary artery disease: primary results from the BIONICS trial (BioNIR ridaforolimus-eluting coronary stent system in coronary stenosis). *Circulation* 136:1304–14, 2017
- [154] Paradies V, Ben-Yehuda O, Jonas M et al. A prospective randomised trial comparing the novel ridaforolimus-eluting BioNIR stent to the zotarolimus-eluting Resolute stent: six-month angiographic and one-year clinical results of the NIREUS trial. *EuroIntervention* 14:86–93, 2018
- [155] Konigstein M, Smits PC, Love MP et al. Randomized comparison of ridaforolimus-eluting and zotarolimus-eluting coronary stents 2-year clinical outcomes from the BIONICS and NIREUS Trials. *JACC Cardiovasc Interv* 13:86–93, 2020
- [156] Serruys PW, Ormiston JA, Sianos G et al., ACTION investigators. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. *J Am Coll Cardiol* 44:1363–7, 2004
- [157] Hildalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. *J Natl Cancer Inst* 93:178–93, 2001
- [158] Sierevogel MJ, Velema E, van der Meer FJ et al. Matrix metalloproteinase inhibition reduces adventitial thickening and collagen accumulation following balloon dilation. *Cardiovasc Res* 55:864–9, 2002
- [159] Pepine CJ, Hirshfeld JW, Macdonald RG et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group. *Circulation* 81:1753–61, 1990
- [160] Versaci F, Gaspardone A, Tomai F et al. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation study (IMPRESS Study). *J Am Coll Cardiol* 40:1935–42, 2002
- [161] New G, Moses JW, Roubin GS et al. Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model. *Catheter Cardiovasc Interv* 57:266–71, 2002
- [162] Chandrasekar B, Nattel S, Tanguay JF. Coronary artery endothelial protection after local delivery of 17 beta-estradiol during balloon angioplasty in a porcine model: a potential new pharmacologic approach to improve endothelial function. *J Am Coll Cardiol* 38:1570–6, 2001
- [163] Byrne RA, Kastrati A, Kufner S et al., Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Investigators. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. *Eur Heart J* 30:2441–9, 2009
- [164] Byrne R, Kastrati A, Massberg S et al. Bio-degradable polymer versus permanent po-

- lymer drug-eluting stents and everolimus-versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. *J Am Coll Cardiol* 58:1325–31, 2011
- [165] Stefanini G, Byrne RA, Serruys PW et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. *Eur Heart J* 33:1214–22, 2012
- [166] Kufner S, Joner M, Thannheimer A et al. Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease. *Circulation* 139:325–33, 2019
- [167] Xhepa E, Tada T, Cassese T et al. Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort. *Indian Heart J* 66:345–9, 2014
- [168] Aoki J, Serruys PW, van Beusekom H et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. *J Am Coll Cardiol* 45:1574–9, 2005
- [169] Nakazawa G, Granada JF, Alviar C. Anti-CD34 antibodies immobilized on the surface of sirolimus eluting stents enhances stent endothelialization. *JACC Cardiovasc Interv* 3:68–75, 2010
- [170] Woudstra P, Kalkman DN, den Heijer P et al. 1-year results of the REMEDEE Registry. Clinical outcomes after deployment of the abluminal sirolimus-coated bioengineered (Combo) stent in a multicenter, prospective all-comers registry. *JACC Cardiovasc Interv* 9:1127–34, 2016
- [171] Kalkman DN, Tijssen RYG, Kraak RP et al. 1-year clinical performance of COMBO stent versus Xience stent in all-comers patients with coronary artery disease. *JACC Cardiovasc Interv* 11:102–3, 2018 yyy
- [172] Chandrasekhar J, Kok MM, Kalkman DN et al. 1-year clinical outcomes of all-comers treated with 2 bioresorbable polymer-coated sirolimus-eluting stents: propensity score-matched comparison of the COMBO and ultrathin-strut Orsiro stents. *JACC Cardiovasc Interv* 13:820–30, 2020
- [172a] Christ G. Stents und Scaffolds. *J Kardiologie* 27:229–36, 2020
- [173] Nef HM, Abdel-Wahab M, Achenbach S et al. Medikamentenfreisetzende Koronarstents/Scaffolds und medikamentenbeschichtete Ballonkatheter. *Kardiologie* 12:12–26, 2017. Erratum in: *Kardiologie* 12:53–5, 2018
- [174] Vlaar PJ, Svilaas T, van der Horst IC et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. *Lancet* 371:1915–20, 2008
- [175] Awuor SO, Ettinger SE, Capecci LM et al. Graftmaster savior: Injury to a patent LIMA during pericardiectomy, when a covered stent came to the rescue. *Catheter Cardiovasc Interv* 93:e326–30, 2019
- [176] Stone GW, Abizaid A, Silber S et al. Prospective, randomized, multicenter evaluation of a polyethylene terephthalate micro-net mesh-covered stent (MGuard) in ST-segment elevation myocardial infarction: the MASTER Trial. *J Am Coll Cardiol* 60:1975–84, 2012
- [177] Dudek D, Brener SJ, Rakowski T et al. Efficacy of an embolic protection stent as a function of delay to reperfusion in ST-segment elevation myocardial infarction (from the MASTER Trial). *Am J Cardiol* 114:1485–9, 2014
- [178] Gracida M, Romaguera R, Jacobi F et al. The MGuard coronary stent: safety, efficacy, and clinical utility. *Vasc Health Risk Manag* 11:533–9, 2015
- [179] Wañha W, Mielczarek M, Gilis-Malinowska N et al. Safety and efficacy of embolic protection devices in saphenous vein graft interventions: a propensity score analysis-multicenter SVG PCI PROTECTA Study. *J Clin Med* 9:1198, 2020
- [180] Amoroso G, Vos NS, Van der Heyden JA et al. A prospective, postmarket study with the MGuard Prime Embolic Protection Stent in ST-segment elevation myocardial infarction: the International MGuard Prime Observational Study (IMOS Prime). *Catheter Cardiovasc Interv* 86(Suppl 1):S28–33, 2015
- [180a] <https://medscape.com.my/embolic-protection-stent/> (abgerufen 17.1.2023)

- [181] Secco GG, Serdoz R, Kilic ID et al. Indications and immediate and long-term results of a novel pericardium covered stent graft: Consecutive 5 year single center experience. *Catheter Cardiovasc Interv* 87:712–9, 2016
- [182] Lu H, Ijsselmuiden AJ, Grundeken MJ et al. First-in-man evaluation of the novel balloon delivery system STENTYS Xposition S for the self-apposing coronary artery stent: impact on longitudinal geographic miss during stenting. *EuroIntervention* 11:1341–5, 2016
- [183] van Geuns RJ, Tamburino C, Fajadet J et al. Self-expanding versus balloon-expandable stents in acute myocardial infarction: results from the APPOSITION II study: self-expanding stents in ST-segment elevation myocardial infarction. *JACC Cardiovasc Interv* 5:1209–19, 2012
- [184] Koch KT, Grundeken MJ, Vos NS et al. One-year clinical outcomes of the STENTYS Self-Apposing coronary stent in patients presenting with ST-segment elevation myocardial infarction: results from the APPOSITION III registry. *EuroIntervention* 11:264–71, 2015
- [185] van Geuns R-J, Yetgin T, La Manna A. STENTYS Self-Apposing sirolimus-eluting stent in ST-segment elevation myocardial infarction: results from the randomised APPOSITION IV trial. *EuroIntervention* 11:e1267–74, 2016
- [186] Naber CK, Pyxaras SA, Nef H et al. Final results of a self-apposing paclitaxel-eluting stent for the percutaneous treatment of de novo lesions in native bifurcated coronary arteries study. *EuroIntervention* 12:356–8, 2016
- [3] Haude M, Erbel R, Issa H et al. Subacute thrombotic complications after intracoronary implantation of Palmaz-Schatz stents. *Am Heart J* 126:15–22, 1993
- [4] Görges G, Haude M, Ge J et al. Intravascular ultrasound after low and high inflation pressure coronary artery stent implantation. *J Am Coll Cardiol* 26:725–30, 1995
- [5] Görges G, Ge J, Erbel R. Role of intravascular ultrasound in the evaluation of mechanisms of coronary interventions and restenosis. *Am J Cardiol* 81:91–5, 1998
- [6] Batchelor R, Dinh D, Brennan A et al., VCOR Investigators. Incidence, predictors and clinical outcomes of stent thrombosis following percutaneous coronary intervention in contemporary practice. *Heart Lung Circ* 29:1433–9, 2020
- [7] Rao K R, Reddy S, Kashyap JR et al. Acute coronary syndrome after 17 years of bare metal stent implantation: „very“ very late stent thrombosis. *Case Rep Cardiol* 2020:9628719, 2020
- [8] Cutlip DE, Windecker S, Mehran R et al., Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation* 115:2344–51, 2007
- [9] Watanabe Y, Sakakura K, Fujita H et al., REAL-ST Registry Investigators. Comparison of clinical characteristics of stent thrombosis between the right coronary artery and the left coronary artery – a sub-analysis of the REAL-ST Registry. *Circ J* 84:169–77, 2020
- [10] Taniwaki M, Räber L, Zaugg S et al. Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography. *Circulation* 133:650–60, 2016
- [11] Adriaenssens T, Joner M, Godschalk TC et al., Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort (PRESTIGE) Investigators. Optical coherence tomography findings in patients with coronary stent thrombosis: a report of the PRESTIGE consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort). *Circulation* 136:1007–21, 2016
- [12] Noaman S, O'Brien J, Andrianopoulos N et al., Melbourne Interventional Group Investigators. Clinical outcomes following ST-elevation myocardial infarction secondary to stent thrombosis treated by percu-

15.3.5–15.3.6 Stentthrombosen und -frakturen

- [1] Swars H, Hafner G, Erbel R et al. Prothrombin fragments and thrombotic occlusion of coronary stents. *Lancet* 337:59–60, 1991
- [2] Hafner G, Swars H, Erbel R et al. Monitoring prothrombin fragment 1+2 during initiation of oral anticoagulant therapy after intracoronary stenting. *Ann Hematol* 65:83–7, 1992

- taneous coronary intervention. *Catheter Cardiovasc Interv* 96:E406–14, 2020
- [13] Oba Y, Funayama H, Takahashi M et al. Stent fracture and thrombosis visualized by a combination of enhanced stent visualization and optical coherence tomography. *Coron Artery Dis* 31:660, 2020
- [14] Lopes RD, Leonardi S, Wojdyla DM et al. Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. *Circulation* 141:781–3, 2020
- [14a] Escaned J, Cao D, Baber U et al. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. *Eur Heart J* 42:4624–34, 2021
- [15] Açıkgoz SK, Açıkgoz E, Çiçek G. Value of CHA2DS2-VASc Score for prediction and ruling out of acute stent thrombosis after primary percutaneous coronary intervention. *Angiology* 71:411–6, 2020
- [15a] Wu H, Xu L, Zhao X et al., OPTION Investigators. Indobufen or Aspirin on top of Clopidogrel after coronary drug-eluting stent implantation (OPTION): a randomized, open-label, end point-blinded, noninferiority trial. *Circulation* 147:212–22, 2023
- [16] Virmani R, Kolodgie FD, Farb A. Drug-eluting stents: are they really safe? *Am Heart Hosp J* 2:85–8, 2004
- [17] Ladich E, Vorpahl M, Nakano M et al. Latest on the pathology of drug-eluting stents. *Interv Cardiol* 1:165–74, 2009
- [18] Cook S, Ladich E, Nakazawa G et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. *Circulation* 120:391–9, 2009
- [19] Ohno Y, Yamaji K, Kohsaka S et al. Incidence and in-hospital outcomes of patients presenting with stent thrombosis (from the Japanese Nationwide Percutaneous Coronary Intervention Registry). *Am J Cardiol* 125:720–6, 2020
- [20] Shite J, Matsumoto D, Yokoyama M. Sirolimus-eluting stent fracture with thrombus, visualization by optical coherence tomography. *Eur Heart J* 27:1389, 2006
- [21] Aoki J, Nakazawa G, Tanabe K et al. Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. *Catheter Cardiovasc Interv* 69:380–6, 2007
- [22] Lee MS, Jurewitz D, Aragon J et al. Stent fracture associated with drug-eluting stents: clinical characteristics and implications. *Catheter Cardiovasc Interv* 69:387–94, 2007
- [23] Lee SH, Park JS, Shin DG et al. Frequency of stent fracture as a cause of coronary restenosis after sirolimus-eluting stent implantation. *Am J Cardiol* 100:627–30, 2007
- [24] Shaikh F, Maddikunta R, Djelmami-Hani M et al. Stent fracture, an incidental finding or a significant marker of clinical in-stent restenosis? *Catheter Cardiovasc Interv* 71:614–8, 2008
- [25] Leong DP, Dundon BK, Puri R et al. Very late stent fracture associated with a sirolimus-eluting stent. *Heart Lung Circ* 17:426–8, 2008
- [26] Nakazawa G, Finn AV, Vorpahl M et al. Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis. *J Am Coll Cardiol* 54:1924–31, 2009
- [27] Park JS, Cho IH, Kim YJ. Stent fracture and restenosis after zotarolimus-eluting stent implantation. *Int J Cardiol* 147:e29–31, 2011
- [28] Park JS, Shin DG, Kim YJ et al. Acute myocardial infarction as a consequence of stent fracture and plaque rupture after sirolimus-eluting stent implantation. *Int J Cardiol* 134:e79–81, 2009
- [29] Popma JJ, Tiroch K, Almonacid A et al. A qualitative and quantitative angiographic analysis of stent fracture late following sirolimus-eluting stent implantation. *Am J Cardiol* 103:923–9, 2009
- [30] Biscaglia S, Tebaldi M, Tumscitz C et al. Prospective identification of stent fracture by enhanced stent visualization system during percutaneous coronary intervention. *Circ J* 81:82–9, 2017

15.4–15.10 PCI – Techniken, Nachbehandlung, Komplikationen, Fallbeispiel

- [1] Grüntzig A, Fischer M, Goebel N et al. Percutaneous transluminal coronary angioplasty (PTCA). Study of 147 patients. *Ann Radiol* 24:377–9, 1981
- [2] Meyer J, Schmitz H, Erbel R et al. Treatment of unstable angina pectoris with percutaneous transluminal coronary angioplasty (PTCA). *Cathet Cardiovasc Diagn* 7:361–71, 1981
- [3] Dorros G, Cowley MJ, Simpson J et al. Percutaneous transluminal coronary angioplasty: report of complications from the National Heart, Lung, and Blood Institute PTCA Registry. *Circulation* 67:723–30, 1983
- [4] Rupprecht HJ, Brennecke R, Kottmeyer M et al. Short- and long-term outcome after PTCA in patients with stable and unstable angina. *Eur Heart J* 11:964–73, 1990
- [5] Grüntzig A. Transluminal dilatation of coronary-artery stenosis. *Lancet* 1:263, 1978
- [6] Meier B, Bachmann D, Lüscher T. 25 years of coronary angioplasty: almost a fairy tale. *Lancet* 361:527, 2003
- [7] Schlumpf M. 30 Jahre Ballonkatheter: Andreas Grüntzig, ein Pionier in Zürich. *Schweiz Ärztezeitung* 85:347–51, 2004
- [8] Düber C, Jungbluth A, Rumpelt HJ et al. Morphology of the coronary arteries after combined thrombolysis and percutaneous transluminal coronary angioplasty for acute myocardial infarction. *Am J Cardiol* 58:698–703, 1986
- [9] Jungbluth A, Düber C, Rumpelt HJ et al. Morphology of the coronary arteries following percutaneous transluminal coronary angioplasty with hemopericardium. *Z Kardiol* 77:125–9, 1988
- [10] Waller BF. Morphologic observations in coronary arteries, aortocoronary saphenous vein bypass grafts and infant aortae following balloon angioplasty procedures. *Herz* 10:255–68, 1985
- [11] Waller BF, Orr CM, Pinkerton CA et al. Morphologic observations late after coronary balloon angioplasty: mechanisms of acute injury and relationship to restenosis. *Radiology* 174:961–7, 1990
- [12] Waller BF, Pinkerton CA, Orr CM et al. Morphological observations late (greater than 30 days) after clinically successful coronary balloon angioplasty. *Circulation* 83(Suppl 2):I28–41, 1991
- [13] Gerber TC, Erbel R, Gorge G et al. Classification of morphologic effects of percutaneous transluminal coronary angioplasty assessed by intravascular ultrasound. *Am J Cardiol* 70:1546–54, 1992
- [14] Schmitz HJ, Erbel R, Meyer J et al. Influence of vessel dilatation on restenosis after successful percutaneous transluminal coronary angioplasty. *Am Heart J* 131:884–91, 1996
- [15] Colombo A, Hall P, Nakamura S et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. *Circulation* 91:1676–88, 1995
- [16] Gorge G, Haude M, Ge J et al. Intravascular ultrasound after low and high inflation pressure coronary artery stent implantation. *J Am Coll Cardiol* 26:725–30, 1995
- [17] Frey AW, Hodgson JM, Müller C et al. Ultrasound-guided strategy for provisional stenting with focal balloon combination catheter: results from the randomized strategy for intracoronary ultrasound-guided PTCA and stenting (SIPS) trial. *Circulation* 102:2497–502, 2000
- [18] Cook S, Wenaweser P, Togni M et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. *Circulation* 115:2426–34, 2007
- [19] Fitzgerald PJ, Oshima A, Hayase M et al. Final results of the can routine ultrasound influence stent expansion (CRUISE) study. *Circulation* 102:523–30, 2000
- [20] Abizaid A, Kornowski R, Mintz G et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. *J Am Soc Cardiol* 2:584–9, 1998
- [21] Eyüboğlu M. In stent restenosis after percutaneous coronary intervention. *Anatol J Cardiol* 16:73, 2016
- [22] Rathore S, Terashima M, Katoh O et al. Predictors of angiographic restenosis after drug eluting stents in the coronary arteries: contemporary practice in real world patients. *EuroIntervention* 5:349–54, 2009
- [23] Kozuma K, Shinozaki T, Kozuma K et al. Impact of residual stenosis on the angiographic edge restenosis of a second-generation drug-eluting stent. *Int Heart J* 60:1050–60, 2019

- [24] Jiang H, Liu W, Liu Y et al. High levels of HB-EGF and interleukin-18 are associated with a high risk of in-stent restenosis. *Anatol J Cardiol* 15:907–12, 2015
- [25] Lee HY, Kim JH, Kim BO et al. Regular exercise training reduces coronary restenosis after percutaneous coronary intervention in patients with acute myocardial infarction. *Int J Cardiol* 167:2617–22, 2013
- [26] Choi JW, Goodreau LM, Davidson CJ. Resource utilization and clinical outcomes of coronary stenting: a comparison of intravascular ultrasound and angiographical guided stent implantation. *Am Heart J* 142:112–8, 2001
- [27] Russo RJ. Ultrasound-guided stent placement. *Cardiol Clin* 15:49–61, 1997
- [28] Gaster AL, Slothuus Skjoldborg U, Larsen J et al. Continued improvement of clinical outcome and cost effectiveness following intravascular ultrasound guided PCI: insights from a prospective, randomised study. *Heart* 89:1043–9, 2003
- [29] Schiele F, Meneveau N, Vuilleminot A et al. Impact of intravascular ultrasound guidance in stent deployment on 6-month restenosis rate: a multicenter, randomized study comparing two strategies – with and without intravascular ultrasound guidance. RESIST Study Group. REStenosis after Ivus guided STenting. *J Am Coll Cardiol* 32:320–8, 1998
- [30] Oemrawsingh PV, Mintz GS, Schali J et al. Intravascular ultrasound guidance improves angiographic and clinical outcome of stent implantation for long coronary artery stenoses: final results of a randomized comparison with angiographic guidance (TULIP Study). *Circulation* 107:62–7, 2003
- [31] Ge J, Erbel R, Gerber T et al. Intravascular ultrasound imaging of angiographically normal coronary arteries: a prospective study in vivo. *Br Heart J* 71:572–8, 1994
- [32] Moses JW, Weisz G, Mishkel G et al. The SIRIUS-DIRECT trial: a multi-center study of direct stenting using the sirolimus-eluting stent in patients with de novo native coronary artery lesions. *Catheter Cardiovasc Interv* 70:505–12, 2007
- [33] Ohlmann P, Mintz GS, Kim SW et al. Intravascular ultrasound findings in patients with restenosis of sirolimus- and paclitaxel-eluting stents. *Int J Cardiol* 125:11–5, 2008
- [34] Colombo A. Cutting balloon and the search for an optimal treatment for in-stent restenosis. *Ital Heart J* 5:280–1, 2004
- [35] de Ribamar Costa J Jr, Mintz GS, Carlier SG et al. Nonrandomized comparison of coronary stenting under intravascular ultrasound guidance of direct stenting without predilation versus conventional predilation with a semi-compliant balloon versus predilation with a new scoring balloon. *Am J Cardiol* 100:812–7, 2007
- [36] Biscaglia S, Tebaldi M, Tumscitz C et al. Prospective identification of stent fracture by enhanced stent visualization system during percutaneous coronary intervention. *Circ J* 81:82–9, 2016
- [37] Windecker S, Simon R, Lins M et al. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. *Circulation* 111:2617–22, 2005
- [38] Roy P, Torguson R, Okabe T et al. Angiographic and procedural correlates of stent thrombosis after intracoronary implantation of drug-eluting stents. *J Interv Cardiol* 20:307–13, 2007
- [39] Ali ZA, Maehara A, Genereux P et al. Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial. *Lancet* 388:2618–28, 2016
- [40] Kuku KO, Ekanem E, Azizi V et al. Optical coherence tomography-guided percutaneous coronary intervention compared with other imaging guidance: a meta-analysis. *Int J Cardiovasc Imaging* 34:503–13, 2018
- [41] Mudra H, Di Mario C, de Jaegere P et al., OPTICUS (OPTimization with ICUS to reduce stent restenosis) Study Investigators. Randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS Study). *Circulation* 104:1343–9, 2001
- [42] Koo BK, Kim YS, Park KW et al. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. *Lancet* 370:567–74, 2007

- [43] Sakurai R, Ako J, Morino Y et al., SIRIUS Trial Investigators. Predictors of edge stenosis following sirolimus-eluting stent deployment (a quantitative intravascular ultrasound analysis from the SIRIUS trial). *Am J Cardiol* 96:1251–3, 2005
- [44] Bagnall AJ, Spratt JC. The „buddy-in-jail“ technique – a novel method for increasing support during percutaneous coronary intervention. *Catheter Cardiovasc Interv* 4:6564–8, 2009

15.11 Bioabsorbierbare Stents

- [1] Byrne RA, Serruys PW, Baumbach A et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. *Eur Heart J* 36:2608–20, 2015
- [2] Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 35:2541–619, 2014
- [3] Wiebe J, Nef HM, Hamm CW. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. *J Am Coll Cardiol* 64:2541–51, 2014
- [4] Maeng M, Tilsted H, Jensen L et al. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre open-label, randomised superiority trial. *Lancet* 383:2047–56, 2014
- [5] Stone GW, Maehara A, Lansky AJ et al. A prospective natural-history study of coronary atherosclerosis. *N Engl J Med* 364:226–35, 2011
- [6] Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? *Eur Heart J* 33:16–25b, 2012
- [7] Otsuka F, Byrne RA, Yahagi K et al. Neo-atherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. *Eur Heart J* 36:2147–59, 2015
- [8] Serruys PW, Onuma Y, Dudek D et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. *J Am Coll Cardiol* 58 :1578–88, 2011
- [9] Serruys PW, Chevalier B, Sotomi Y et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. *Lancet* 388:2479–91, 2016
- [10] Ellis SG, Kereiakes DJ, Metzger DC et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. *N Engl J Med* 373:1905–15, 2015
- [11] Gao R, Yang Y, Han Y et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China Trial. *J Am Coll Cardiol* 66:2298–309, 2015
- [12] Kimura T, Kozuma K, Tanabe K et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. *Eur Heart J* 36:3332–42, 2015
- [13] Sabaté M, Windecker S, Iñiguez A et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. *Eur Heart J* 37:229–40, 2016
- [14] Wykrzykowska J, Kraak R, Hofman S et al. Bioresorbable scaffolds versus metallic stents in routine PCI. *N Engl J Med* 376:2319–28, 2017
- [15] Stone GW, Gao R, Kimura T et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. *Lancet* 387:1277–89, 2016
- [16] Sorrentino S, Giustino G, Mehran R et al. Everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents. *J Am Coll Cardiol* 69:3055–66, 2017

- [17] Ishibashi Y, Nakatani S, Sotomi Y et al. Relation between bioresorbable scaffold sizing using QCA-Dmax and clinical outcomes at 1 year in 1,232 patients from 3 study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). *JACC Cardiovasc Interv* 8:1715–26, 2015
- [18] Ormiston JA, Serruys PW, Onuma Y et al. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. *Circ Cardiovasc Interv* 5:620–63, 2012
- [19] Ellis SG, Kereiakes DJ, Metzger DC et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. *N Engl J Med* 373:1905–15, 2015
- [20] Suwannasom P, Sotomi Y, Ishibashi Y et al. The impact of post-procedural asymmetry, expansion, and eccentricity of bioresorbable everolimus-eluting scaffold and metallic everolimus-eluting stent on clinical outcomes in the ABSORB II Trial. *JACC Cardiovasc Interv* 9:1231–42, 2016
- [21] Puricel S, Cuculi F, Weissner M et al. Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. *J Am Coll Cardiol* 67:921–31, 2016
- [22] Abizaid A, Costa RA, Schofer J et al. Serial multimodality imaging and 2-year clinical outcomes of the novel DESolve novolimus-eluting bioresorbable coronary scaffold system for the treatment of single de novo coronary lesions. *JACC Cardiovasc Interv* 9:565–74, 2016
- [23] Wiebe J, Dörr O, Ilstad H et al. Everolimus- versus novolimus-eluting bioresorbable scaffolds for the treatment of coronary artery disease: a matched comparison. *JACC Cardiovasc Interv* 10:477–85, 2017
- [24] Haude M, Ince H, Abizaid A et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. *Lancet* 387:31–9, 2016
- [25] Haude M, Ince H, Abizaid A et al. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. *Eur Heart J* 37:2701–9, 2016
- [26] Haude M, Tölg R et al. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: 3-year clinical results and angiographic findings of the Biosolve-II first-in-man trial. *EuroIntervention* 23:432–9, 2017
- [27] Haude M, Erbel R, Erne P et al. Safety and performance of the Drug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. *EuroIntervention* 12:e160–6, 2016
- [28] Haude M, Ince H, Kische S et al. Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of Biosolve-II and Biosolve-III. *EuroIntervention* 13:432–9, 2017
- [29] Waksman R, Zumstein P, Pritsch M et al. Second-generation magnesium scaffold Magmaris: device design and preclinical evaluation in a porcine coronary artery model. *EuroIntervention* 13:440–9, 2017
- [30] Abizaid A, Carrié D, Frey N et al. 6-month clinical and angiographic outcomes of a novel radiopaque sirolimus-eluting bioresorbable vascular scaffold: The FANTOM II Study. *JACC Cardiovasc Interv* 10:1832–8, 2017
- [31] La Manna A, Chisari A, Giacchi G et al. Everolimus-eluting bioresorbable vascular scaffolds versus second generation drug-eluting stents for percutaneous treatment of chronic total coronary occlusions: technical and procedural outcomes from the GHOST-CTO registry. *Catheter Cardiovasc Interv* 88:e155–63, 2016
- [32] Kawamoto H, Ruparel N, Tanaka A et al. Bioresorbable scaffolds for the management of coronary bifurcation lesions. *JACC Cardiovasc Interv* 989–1000, 2016
- [33] Capodanno D, Gori T, Nef H et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. *EuroIntervention* 10:1144–53, 2015

- [34] Rottländer D, Schneider T, Degen H et al. Lesion preparation with cutting balloon angioplasty is associated with coronary aneurysm formation in polylactide biodegradable vascular scaffold implantation. *EuroIntervention* 13:e1483–6, 2017
- [35] Verheye S, Wlodarczak A, Montorsi P et al. BIOSOLVE-IV-registry: safety and performance of the Magmaris scaffold: 12-month outcomes of the first cohort of 1,075 patients. *Catheter Cardiovasc Interv* 98(1):E1–E8, 2021

16 Spezielle Koronarinterventionen

16.1 Intervention an aortokoronaren Bypässen

- [1] Baim DS, Wahr D, George B et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. *Circulation* 105:1285–90, 2002
- [2] Bonello L, De Labriolle A, Lemesle G et al. Prognostic value of procedure-related myocardial infarction according to the universal definition of myocardial infarction in saphenous vein graft interventions. *Am Heart J* 157:894–8, 2009
- [3] Brennan JM, Al-Hejily W, Dai D et al. Three-year outcomes associated with embolic protection in saphenous vein graft intervention: results in 49 325 senior patients in the Medicare-linked National Cardiovascular Data Registry CathPCI Registry. *Circ Cardiovasc Interv* 8:e001403, 2015
- [4] Brilakis ES, Lichtenwalter C, de Lemos JA et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. *J Am Coll Cardiol* 53:919–28, 2009
- [5] Brilakis ES, O'Donnell CI, Penny W et al. Percutaneous coronary intervention in native coronary arteries versus bypass grafts in patients with prior coronary artery bypass graft surgery: insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. *JACC Cardiovasc Interv* 9:884–93, 2016
- [6] Gaglia MA, Torguson R, Xue Z et al. Outcomes of patients with acute myocardial infarction from a saphenous vein graft culprit undergoing percutaneous coronary intervention. *Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv* 78:23–9, 2011
- [7] Gruberg L, Hellkamp AS, Thomas LE et al. The Association of Previous Revascularization with In-Hospital Outcomes in Acute Myocardial Infarction Patients: results from the National Cardiovascular Data Registry. *JACC Cardiovasc Interv* 8:1954–62, 2015
- [8] Halkin A, Masud AZ, Rogers C et al. Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial. *Am Heart J* 151:915.e1–7, 2006
- [9] Hofmann M, Störger H, Schwarz F et al. Percutaneous saphenous vein graft interventions with and without distal filter wire protection. *J Intervent Cardiol* 18:475–9, 2005
- [10] Hong YJ, Pichard AD, Mintz GS et al. Outcome of undersized drug-eluting stents for percutaneous coronary intervention of saphenous vein graft lesions. *Am J Cardiol* 105:179–85, 2010
- [11] Kohl LP, Garberich RF, Yang H et al. Outcomes of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction patients with previous coronary bypass surgery. *JACC Cardiovasc Interv* 7:981–7, 2014
- [12] Leborgne L, Cheneau E, Pichard A et al. Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft. *Am Heart J* 146:501–6, 2003
- [13] Lee MS, Park S-J, Kandzari DE et al. Saphenous vein graft intervention. *JACC Cardiovasc Interv* 4:831–43, 2011
- [14] Leineweber K, Böse D, Vogelsang M et al. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. *J Am Coll Cardiol* 47:981–6, 2006
- [15] Mauri L, Cox D, Hermiller J et al. The PROXIMAL trial: proximal protection du-

ring saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. *J Am Coll Cardiol* 50:1442–9, 2007

- [16] Mehilli J, Pache J, Abdel-Wahab M et al. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. *Lancet Lond Engl* 378:1071–8, 2011
- [17] Mehta SK, Frutkin AD, Milford-Beland S et al. Utilization of distal embolic protection in saphenous vein graft interventions (an analysis of 19 546 patients in the American College of Cardiology – National Cardiovascular Data Registry). *Am J Cardiol* 100:1114–8, 2007
- [18] Rigattieri S, Sciahbasi A, Brilakis ES et al. Meta-analysis of radial versus femoral artery approach for coronary procedures in patients with previous coronary artery bypass grafting. *Am J Cardiol* 117:1248–55, 2016
- [19] Rodés-Cabau J, Bertrand OF, Larose E et al. Comparison of plaque sealing with paclitaxel-eluting stents versus medical therapy for the treatment of moderate non-significant saphenous vein graft lesions: the moderate vein graft lesion stenting with the taxus stent and intravascular ultrasound (VELETI) pilot trial. *Circulation* 120:1978–86, 2009
- [20] Stone GW, Rogers C, Hermiller J et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. *Circulation* 108:548–53, 2003
- [21] Welsh RC, Granger CB, Westerhout CM et al., APEX AMI Investigators (2010). Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. *JACC Cardiovasc Interv* 3:343–51, 2010

16.2 PCI koronarer Bifurkationsstenosen

- [1] Medina A, Suarez de Lezo J, Pan M. A new classification of coronary bifurcation lesions. *Rev Esp Cardiol* 59:183, 2006
- [2] Murray CD. The physiological principle of minimum work applied to the angle of branching of arteries. *J Gen Physiol* 9:835–41, 1926
- [3] Neumann FJ, Sousa-Uva M, Ahlsson A et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 40:87–165, 2018
- [4] Koo BK, Park KW, Kang HJ et al. Physiological evaluation of the provisional side-branch intervention strategy for bifurcation lesions using fractional flow reserve. *Eur Heart J* 29:726–32, 2008
- [5] Mintz GS, Lefèvre T, Lassen JF et al. Intravascular ultrasound in the evaluation and treatment of left main coronary artery disease: a consensus statement from the European Bifurcation Club. *EuroIntervention* 14:e467–74, 2018
- [6] Manabe O, Naya M, Aikawa T et al. PET/CT scanning with 3D acquisition is feasible for quantifying myocardial blood flow when diagnosing coronary artery disease. *EJNMMI Res* 7:52, 2017
- [7] Colombo A, Moses JW, Morice MC et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. *Circulation* 109:1244–9, 2004
- [8] Steigen TK, Maeng M, Wiseth R et al. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic Bifurcation Study. *Circulation* 114:1955–61, 2006
- [9] Ferenc M, Gick M, Kienzle RP et al. Randomized trial on routine vs. provisional T-stenting in the treatment of de novo coronary bifurcation lesions. *Eur Heart J* 29:2859–67, 2008
- [10] Lassen JF, Burzotta F, Banning AP et al. Percutaneous coronary intervention for the left main stem and other bifurcation lesions: 12th consensus document from the European Bifurcation Club. *EuroIntervention* 13:1540–53, 2018
- [11] Colombo A, Bramucci E, Saccà S et al. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS

- (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study. *Circulation* 119:71–8, 2009
- [12] Hildick-Smith D, de Belder AJ, Cooter N et al. Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies. *Circulation* 121:1235–43, 2010
- [13] Chen SL, Ye F, Zhang JJ et al. DK crush technique: modified treatment of bifurcation lesions in coronary artery. *Chin Med J* 118:1746–50, 2005
- [14] Chen SL, Santoso T, Zhang JJ et al. A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions: results from the DKCRUSH-II (Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) trial. *J Am Coll Cardiol* 57:914–20, 2011
- [15] Chen SL, Xu B, Han YL et al. Clinical outcome after DK Crush versus Culotte stenting of distal left main bifurcation lesions: the 3-year follow-up results of the DKCRUSH-III Study. *JACC Cardiovasc Interv* 8:1335–42, 2015
- [16] Chen SL, Zhang JJ, Han Y et al. Double Kissing Crush versus provisional stenting for left main distal bifurcation lesions: DKCRUSH-V randomized trial. *J Am Coll Cardiol* 70:2605–17, 2017
- [16a] Hildick-Smith D, Egred M, Banning A et al. The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN). *Eur Heart J* 42:3829–3839, 2021
- [16b] Tarantini G, Fovino LN, Varbella F et al. A large, prospective, multicentre study of left main PCI using a latest-generation zotarolimus-eluting stent: the ROLEX study. *EuroIntervention* 18:e1108–e1119, 2023
- [17] Ferenc M, Gick M, Comberg T et al. Culotte stenting vs. TAP stenting for treatment of de-novo coronary bifurcation lesions with the need for side-branch stenting: the Bifurcations Bad Krozingen (BBK) II angiographic trial. *Eur Heart J* 37:3399–405, 2016
- [18] Zhang JJ, Ye F, Xu K et al. Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial. *Eur Heart J* 41:2523–36, 2020
- [19] Ferenc M, Neumann FJ. Towards a lesion-specific approach to percutaneous coronary intervention for bifurcation lesions. *Eur Heart J* 41:2537–40, 2020
- [20] Lassen JF, Holm NR, Banning A et al. Percutaneous coronary intervention for coronary bifurcation disease: 11th consensus document from the European Bifurcation Club. *EuroIntervention* 2:38–46, 2016
- [21] Suzuki G, Nozaki Y, Sakurai M. A novel guidewire approach for handling acute-angle bifurcations: reversed guidewire technique with adjunctive use of a double-lumen microcatheter. *J Invasive Cardiol* 25:48–54, 2013
- [22] Pan M, Medina A, Romero M et al. Assessment of side branch predilation before a provisional T-stent strategy for bifurcation lesions. A randomized trial. *Am Heart J* 16:374–80, 2014
- [23] Hoyer A. The proximal optimisation technique for intervention of coronary bifurcations. *Interv Cardiol* 1:110–5, 2017
- [24] Niemelä M, Kervinen K, Erglis A et al. Randomized comparison of final kissing balloon dilatation versus no final kissing balloon dilatation in patients with coronary bifurcation lesions treated with main vessel stenting: the Nordic-Baltic Bifurcation Study III. *Circulation* 123:79–86, 2011
- [25] Louvard Y, Medina A. Definitions and classifications of bifurcation lesions and treatment. *EuroIntervention* 11 Suppl V:V23–6, 2005
- [26] Toth GG, Sasi V, Franco D et al. Double-kissing Culotte technique for coronary bifurcation stenting – technical evaluation and comparison with conventional double stenting techniques. *EuroIntervention* 16:e724–33, 2020
- [27] Rab T, Sheiban I, Louvard Y et al. Current Interventions for the Left Main Bifurcation. *JACC Cardiovasc Interv* 10:849–865, 2017

16.3 PCI ostialer Läsionen

- [1] Pritchard CL, Mudd JG, Barner HB. Coronary ostial stenosis. *Circulation* 52:46–8, 1975

- [2] Yildirimturk O, Cansel M, Erdim R et al. Coexistence of left main and right coronary artery ostial stenosis: demographic and angiographic features. *Int J Angiol* 20:33–8, 2011
- [3] Wöhrle J, Markovic S. Percutaneous coronary interventions for ostial lesions. *Herz* 41:579–84, 2016
- [4] Neumann FJ, Sousa-Uva M, Ahlsson A et al., ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 40:87–165, 2019
- [5] Jokhi P, Curzen N. Percutaneous coronary intervention of ostial lesions. *EuroIntervention* 5:511–4, 2009
- [6] von Birgelen C, Hartmann M. Intravascular ultrasound assessment of coronary atherosclerosis and percutaneous interventions. *Minerva Cardioangiol* 52:391–406, 2004
- [7] Pesenti-Rossi D, Chouli M, Gharbi M et al. Coronary aorto-ostial stenosis analysed by multislice computed tomography: a new tool for percutaneous coronary intervention? *EuroIntervention* 6:717–21, 2011
- [8] Jaffe R, Halon DA, Shiran A et al. Percutaneous treatment of aorto-ostial coronary lesions: current challenges and future directions. *Int J Cardiol* 186:61–6, 2015
- [9] Hussain F, Kashour T, Rajaram M. Ostial RCA intervention: guiding catheter challenges and use of a buddy wire to perform focused-force angioplasty on a severely calcific ostial right coronary lesion. *J Invasive Cardiol* 18: E298–301, 2006
- [10] Palmer ND, Nair RK, Ramsdale DR. Treatment of calcified ostial disease by rotational atherectomy and adjunctive cutting balloon angioplasty prior to stent implantation. *Int J Cardiovasc Intervent* 6:134–6, 2004
- [11] Ko E, Natsuaki M, Toyofuku M et al. Sirolimus-eluting stent implantation for ostial right coronary artery lesions: five-year outcomes from the j-Cypher registry. *Cardiovasc Interv Ther* 29:200–8, 2014
- [12] Okabe T, Kawamura A, Maekawa Y et al. Can intravascular ultrasound guidance modify the efficacy of drug-eluting stent over bare-metal stent in an aorto-ostial lesion? *Cardiovasc Revasc Med* 12:105–10, 2011

16.4 PCI der In-Stent-Restenose (ISR)

- [1] Pleva L, Kukla P Hlinomaz O. Treatment of coronary in-stent restenosis: a systematic review. *J Geriatr Cardiol* 15:173–84, 2018
- [2] Giacoppo D, Gargiulo G, Aruta P et al. Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. *BMJ* 351:h5392, 2015; Erratum in: *BMJ* 351:h6364, 2015
- [3] Her AY, Shin ES. Current management of in-stent restenosis. *Korean Circ J* 48:337–49, 2018
- [4] Yin RX, Yang DZ, Wu JZ. Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis. *Theranostics* 4:175–200, 2014
- [5] Tepe G, Wendel HP, Khorchidi S et al. Thrombogenicity of various endovascular stent types: an in vitro evaluation. *J Vasc Interv Radiol* 13:1029–35, 2002
- [6] Hofma SH, van der Giessen WJ, van Dalen BM et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. *Eur Heart J* 27:166–70, 2006
- [7] Berliner JA, Navab M, Fogelman AM et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. *Circulation* 91:2488–96, 1995
- [8] Glagov S, Weisenberg E, Zarins CK et al. Compensatory enlargement of human atherosclerotic coronary arteries. *N Engl J Med* 316:1371–5, 1987
- [9] Dangas G, Fuster V. Management of restenosis after coronary intervention. *Am Heart J* 132:428–36, 1996
- [10] Welt FG, Rogers C. Inflammation and restenosis in the stent era. *Arterioscler Thromb Vasc Biol*, 22:1769–76, 2002
- [11] Farb A, Weber DK, Kolodgie FD et al. Morphological predictors of restenosis after coronary stenting in humans. *Circulation* 105:2974–80, 2002
- [12] Farb A, Kolodgie FD, Hwang JY et al. Extracellular matrix changes in stented human coronary arteries. *Circulation* 110:940–7, 2004
- [13] Riessen R, Wight TN, Pastore C et al. Distribution of hyaluronan during extracellular matrix remodeling in human resteno-

- tic arteries and balloon-injured rat carotid arteries. *Circulation* 93:1141–7, 1996
- [14] Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. *Circulation* 111:2257–73, 2005
 - [15] Pocock SJ, Lansky AJ, Mehran R et al. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. *J Am Coll Cardiol* 51:23–32, 2008
 - [16] Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. *Circulation* 111:3435–42, 2005
 - [17] Kasaoka S, Tobis JM, Akiyama T et al. Angiographic and intravascular ultrasound predictors of in-stent restenosis. *J Am Coll Cardiol* 32:1630–5, 1998
 - [18] Sonoda S, Morino Y, Ako J et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the SIRIUS trial. *J Am Coll Cardiol* 43:1959–63, 2004
 - [19] Gonzalo N, Serruys PW, Okamura T et al. Optical coherence tomography patterns of stent restenosis. *Am Heart J* 158:284–93, 2009
 - [20] Nef HM, Boeder NF, Abdel-Wahab M et al. Empfehlungen zur Anwendung von intravaskulärer Bildgebung (optische Kohärenztomographie). *Kardiologie* 11:8–15, 2017
 - [21] Andreini D, Pontone G, Mushtaq S et al. Coronary in-stent restenosis: assessment with CT coronary angiography. *Radiology* 265:410–7, 2012
 - [22] Sun Z, Davidson R, Lin CH. Multi-detector row CT angiography in the assessment of coronary in-stent restenosis: a systematic review. *Eur J Radiol* 69:489–95, 2009
 - [23] Sun Z, Almutairi AM. Diagnostic accuracy of 64 multislice CT angiography in the assessment of coronary in-stent restenosis: a meta-analysis. *Eur J Radiol* 73:266–73, 2010
 - [24] Kumbhani DJ, Ingelmo CP, Schoenhagen P et al. Meta-analysis of diagnostic efficacy of 64-slice computed tomography in the evaluation of coronary in-stent restenosis. *Am J Cardiol* 103:1675–81, 2009
 - [25] Bainey KR, Norris CM, Graham MM et al., APPROACH investigators. Clinical in-stent restenosis with bare metal stents: is it truly a benign phenomenon? *Int J Cardiol* 128:378–82, 2008
 - [26] Mehran R, Dangas G, Abizaid AS et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. *Circulation* 100:1872–8, 1999
 - [27] Alfonso F, Cequier A, Angel J et al. Value of the American College of Cardiology/American Heart Association angiographic classification of coronary lesion morphology in patients with in-stent restenosis. Insights from the Restenosis Intra-stent Balloon angioplasty versus elective Stenting (RIBS) randomized trial. *Am Heart J* 151:681.e1–e9, 2006
 - [28] Petretta M, Acampa W, Daniele S et al. Long-term survival benefit of coronary revascularization in patients undergoing stress myocardial perfusion imaging. *Circ J* 80:485–93, 2016
 - [29] Baschet L, Bourguignon S, Marque S et al. Cost-effectiveness of drug-eluting stents versus bare-metal stents in patients undergoing percutaneous coronary intervention. *Open Heart* 3:e000445, 2016
 - [30] Köster R, Vieluf D, Kiehn M et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. *Lancet* 356:1895–7, 2000
 - [31] Moustapha A, Assali AR, Sdringola S et al. Abciximab administration and clinical outcomes after percutaneous intervention for in-stent restenosis. *Catheter Cardiovasc Interv* 56:184–7, 2002
 - [32] Kufner S, Hausleiter J, Ndrepepa G et al. Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis. *JACC Cardiovasc Interv* 2:1142–8, 2009
 - [33] Alfonso F, Pérez-Vizcayno MJ, Cruz A et al. Treatment of patients with in-stent restenosis. *EuroIntervention* 5(D):D70–8, 2009
 - [34] Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 35:2541–619, 2014

- [35] Alfonso F, Byrne RA, Rivero F et al. Current treatment of in-stent restenosis. *J Am Coll Cardiol* 63:2659–73, 2014
- [36] Alfonso F, Pérez-Vizcayno MJ, Gómez-Reico M et al. Implications of the „watermelon seeding“ phenomenon during coronary interventions for in-stent restenosis. *Catheter Cardiovasc Interv* 66:521–7, 2005
- [37] Byrne R, Neumann FJ, Mehilli J et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. *Lancet* 381:461–7, 2013
- [38] Adamian M, Colombo A, Briguori C et al. Cutting balloon angioplasty for the treatment of in-stent restenosis: a matched comparison with rotational atherectomy, additional stent implantation and balloon angioplasty. *J Am Coll Cardiol* 38:672–9, 2001
- [39] Albiero R, Silber S, Di Mario C et al. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT). *J Am Coll Cardiol* 43:943–9, 2004
- [40] Kufner S, Joner M, Schneider S et al. Neointimal modification with scoring balloon and efficacy of drug-coated balloon therapy in patients with restenosis in drug-eluting coronary stents: a randomized controlled trial. *JACC Cardiovasc Interv* 10:1332–40, 2017
- [41] Mehran R, Dangas G, Mintz GS et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotational atherectomy: comparative mechanisms and results. *Circulation* 101:2484–9, 2000
- [42] vom Dahl J, Dietz U, Haager PK et al. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST). *Circulation* 105:583–8, 2002
- [43] Holmes DR Jr, Teirstein P, Satler L et al. Sirolimus-eluting stents vs. vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISr randomized trial. *JAMA* 295:1264–73, 2006
- [44] Leon MB, Teirstein PS, Moses JW et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. *N Engl J Med* 344:250–46, 2001
- [45] Alfonso F, Zueco J, Cequier A et al. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. *J Am Coll Cardiol* 42:796–805, 2003
- [46] Kastrati A, Dibra A, Eberle S et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs. balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. *JAMA* 293:165–171, 2005
- [47] Alfonso F, Pérez-Vizcayno MJ, Hernández R et al. Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study. *J Am Coll Cardiol* 52:1621–7, 2008
- [48] Byrne RA, Cassese S, Windisch T et al. Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. *EuroIntervention* 9:797–802, 2013
- [49] Alfonso F, Pérez-Vizcayno MJ, Dutary J et al. Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). *JACC Cardiovasc Interv* 5:728–37, 2012
- [50] Jamshidi P, Nyffenegger T, Sabti Z et al. A novel approach to treat in-stent restenosis: 6- and 12-month results using the everolimus-eluting bioresorbable vascular scaffold. *EuroIntervention* 11:1479–86, 2016
- [51] Longo G, Granata F, Capodanno D et al. Anatomical features and management of bioresorbable vascular scaffolds failure: a case series from the GHOST registry. *Catheter Cardiovasc Interv* 85:1150–61, 2015
- [52] Scheller B, Hehrlein C, Bocks W et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. *N Engl J Med* 355:2113–24, 2006

- [53] Unverdorben M, Vallbracht C, Cremers B et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. *Circulation* 119:2986–94, 2009
- [54] Alfonso F, Pérez-Vizcayno MJ, Cárdenas A et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). *J Am Coll Cardiol* 63:1378–86, 2014
- [55] Habara S, Mitsudo K, Kadota K et al. Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. *JACC Cardiovasc Interv* 4:149–54, 2011
- [56] Rittger H, Brachmann J, Sinha AM et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. *J Am Coll Cardiol* 59:1377–82, 2012
- [57] Xu B, Gao R, Wang J et al. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. *JACC Cardiovasc Interv* 7:204–11, 2014
- [58] Alfonso F, Pérez-Vizcayno MJ, Cárdenas A et al. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV randomized clinical trial. *J Am Coll Cardiol* 66:23–33, 2015
- [59] Siontis GC, Stefanini GG, Mavridis D et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. *Lancet* 386:655–64, 2015
- [60] Latib A, Mussardo M, Ielasi A et al. Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis. *JACC Cardiovasc Interv* 4:155–64, 2011
- [61] Habara S, Iwabuchi M, Inoue N et al. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. *Am Heart J* 166:527–33, 2013
- [62] Chorny M, Fishbein I, Yellen BB et al. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. *Proc Natl Acad Sci* 107:8346–51, 2010
- [63] Imaizumi S, Miura S, Takata K et al. Association between cholesterol efflux capacity and coronary restenosis after successful stent implantation. *Heart Vessels* 31:1257–65, 2016
- [64] Stone GW, Ellis SG, O'Shaughnessy CD et al. Paclitaxel-eluting stents vs. vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. *JAMA* 295:1253–63, 2006
- [65] Kawai K, Akahori H, Imanaka T et al. Coronary restenosis of in-stent protruding bump with rapid progression: optical frequency domain imaging and angioscopic observation. *J Cardiol Cases* 19:12–4, 2019
- [66] Alfonso F, Pérez-Vizcayno MJ, Hernandez R et al. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. *J Am Coll Cardiol* 47:2152–60, 2006
- [67] Scheller B, Hehrlein C, Bocks W et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. *Clin Res Cardiol* 97:773–81, 2008
- [68] Pleva L, Kukla P, Kusnierova P et al. Comparison of the efficacy of paclitaxel-eluting balloon catheters and everolimus-eluting stents in the treatment of coronary in-stent restenosis: the Treatment of in-stent Restenosis Study. *Circ Cardiovasc Interv* 9:e003316, 2016
- [69] Mehilli J, Byrne RA, Tiroch K et al. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. *J Am Coll Cardiol* 55:2710–6, 2010
- [70] Wöhrle J, Zadura M, Möbius-Winkler S et al. SeQuentPlease World Wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-

- scale, prospective registry study. *J Am Coll Cardiol* 60:1733–8, 2012
- [71] Stella PR, Belkacemi A, Waksman R et al. The Valentines Trial: results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation DIOR paclitaxel drug-eluting balloon for in-stent restenosis treatment. *EuroIntervention* 7:705–10, 2011
- [72] Loh J, Stella PR, Sangiorgi G et al. Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial. *Cardiovasc Revasc Med* 15:23–8, 2014
- [73] Naganuma T, Latib A, Costopoulos C et al. Drug-eluting balloon versus second-generation drug-eluting stent for the treatment of restenotic lesions involving coronary bifurcations. *EuroIntervention* 11:989–95, 2016
- [74] Hong SJ, Ahn CM, Kim BK et al. Prospective randomized comparison of clinical and angiographic outcomes between everolimus-eluting vs. zotarolimus-eluting stents for treatment of coronary restenosis in drug-eluting stents: intravascular ultrasound volumetric analysis (RESTENT-ISR trial). *Eur Heart J* 37:3409–18, 2016
- [75] Nijhoff F, Stella PR, Troost MS et al. Comparative assessment of the antirestenotic efficacy of two paclitaxel drug-eluting balloons with different coatings in the treatment of in-stent restenosis. *Clin Res Cardiol* 105:401–11, 2016
- [76] Pleva L, Kukla P, Zapletalova J et al. Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis. *BMC Cardiovasc Disord* 17:168, 2017
- [77] Assadi-Schmidt A, Mohring A, Liebsch E et al. SeQuent Please vs. Pantera Lux drug coated balloon angioplasty in real life: Results from the Dusseldorf DCB registry. *Int J Cardiol* 231:68–72, 2017
- [78] Masuda S, Nakano K, Funakoshi K et al. Imatinib mesylate-incorporated nanoparticle-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries. *J Atheroscler Thromb* 18:1043–53, 2011
- [79] Bhargava B, Reddy NK, Karthikeyan G et al. A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, non-polymeric cobalt-chromium stent: evaluation in a porcine model. *Catheter Cardiovasc Interv* 67:698–702, 2006
- [80] Tsukie N, Nakano K, Matoba T et al. Pita-vastatin-incorporated nanoparticle-eluting stents attenuate in-stent stenosis without delayed endothelial healing effects in a porcine coronary artery model. *J Atheroscler Thromb* 20:32–45, 2013
- [81] Acharya G, Lee CH, Lee Y. Optimization of cardiovascular stent against restenosis: factorial design-based statistical analysis of polymer coating conditions. *PLoS One* 7:e43100, 2012

16.5 Rotations- und orbitale (Kreisel-)Atherektomie

- [1] Schlumpf M. 30 Jahre Ballonkatheter: Andreas Grüntzig, ein Pionier in Zürich. *Schweiz Ärztezeitung* 85:346–51, 2004
- [2] Hansen DD, Auth DC, Vracko R et al. Rotational atherectomy in atherosclerotic rabbit iliac arteries. *Am Heart J* 115(1 Pt 1):160–5, 1988
- [3] Hansen DD, Auth DC, Hall M et al. Rotational endarterectomy in normal canine coronary arteries: preliminary report. *J Am Coll Cardiol* 11:1073–7, 1988
- [4] Ahn SS, Auth D, Marcus DR et al. Removal of focal atheromatous lesions by angioscopically guided high-speed rotary atherectomy. Preliminary experimental observations. *J Vasc Surg* 7:292–300, 1988
- [5] Kaltenbach M, Vallbracht C, Hartmann A. Recanalization of chronic coronary occlusions by low speed rotational angioplasty (ROTACS). *J Interv Cardiol* 4:155–65, 1991
- [6] Barbato E, Shlofmitz E, Milkas A et al. State of the art: evolving concepts in the treatment of heavily calcified and undilatable coronary stenoses – from debulking to plaque modification, a 40-year-long journey. *EuroIntervention* 13:696–705, 2015
- [6a] Rocha-Singh KJ, Sachar R, DeRubertis BG et al. Directional atherectomy before paclitaxel coated balloon angioplasty in complex femoropopliteal disease: the VIVA REALITY study. *Catheter Cardiovasc Interv* 98:549–58, 2021
- [6b] Wei L, Guo J, Guo L et al. Directional atherectomy and drug-coated balloon an-

- gioplasty vs. bare nitinol stent angioplasty for femoropopliteal artery lesions. *Vasa* 51: 275–81, 2022
- [7] Kini A, Marmur JD, Duvvuri S et al. Rotational atherectomy: improved procedural outcome with evolution of technique and equipment. Single-center results of first 1000 patients. *Catheter Cardiovasc Interv* 46:305–11, 1999
 - [8] Heuser RR. Treatment of lower extremity vascular disease: the Diamondback 360 degrees Orbital Atherectomy System. *Expert Rev Med Devices* 5:279–86, 2008
 - [9] Adams GL, Khanna PK, Staniloae CS et al. Optimal techniques with the Diamondback 360° System achieve effective results for the treatment of peripheral arterial disease. *J Cardiovasc Transl Res* 4:220–9, 2011
 - [10] Sotomi Y, Shlofmitz RA, Colombo A et al. Patient selection and procedural considerations for coronary orbital atherectomy system. *Interv Cardiol* 11:33–8, 2016
 - [11] Matsuo H, Watanabe S, Watanabe T et al. Prevention of no-reflow-/slow-flow phenomenon during rotational atherectomy – a prospective randomized study comparing intracoronary continuous infusion of verapamil and nicorandil. *Am Heart J* 154:994.e1–6, 2007
 - [12] Sharma SK, Tomey MI, Teirstein PS et al. North American expert review of rotational atherectomy. *Circ Cardiovasc Interv* 12:e007448, 2019
 - [13] Barbato E, Carrié D, Dardas P et al. European expert consensus on rotational atherectomy. *EuroIntervention*. 11:30–6, 2015
 - [14] Whitlow PL, Bass TA, Kipperman RM et al. Results of the study to determine rotablator and transluminal angioplasty strategy (STRATAS). *Am J Cardiol* 87:699–705, 2001
 - [15] Safian RD, Feldman T, Muller DW et al. Coronary Angioplasty and Rotablator Atherectomy Trial (CARAT): immediate and late results of a prospective multicenter randomized trial. *Catheter Cardiovasc Interv* 53:213–20, 2001
 - [16] <https://www.bostonscientific.com/en-US/products/atherectomy-systems/rotational-atherectomy-systems/rotapro.html> (21.12.21)
 - [17] Lee MS, Kim MH, Rha SW. Alternative rota-flush solution for patients with severe coronary artery calcification who undergo rotational atherectomy. *J Invasive Cardiol* 29:25–8, 2017
 - [18] Gurm HS, Breitbart Y, Vivekanathan D et al. Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy – a propensity-adjusted analysis. *Am Heart J* 151:1031, 2006
 - [19] Williams MS, Collier BS, Väänänen HJ et al. Activation of platelets in platelet-rich plasma by rotablation is speed-dependent and can be inhibited by abciximab (c7E3 Fab; ReoPro). *Circulation* 98:742–8, 1998
 - [20] Bau J, Gutensohn K, Kuck KH et al. Flow-cytometric analysis of platelet activation during rotablation. *Z Kardiol* 89:15–20, 2000
 - [21] Gurm HS, Breitbart Y, Vivekanathan D et al. Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy – a propensity-adjusted analysis. *Am Heart J* 151:1031, 2006
 - [22] Shlofmitz E, Martinsen BJ, Lee M et al. Orbital atherectomy for the treatment of severely calcified coronary lesions: evidence, technique, and best practices. *Expert Rev Med Devices* 14:867–79, 2017
 - [23] Egred M, Andron M, Alahmar A et al. High-speed rotational atherectomy during transradial percutaneous coronary intervention. *J Invasive Cardiol* 20:219–21, 2008
 - [24] You W, Wu X-Q, Ye F et al. Advantages of transradial rotational atherectomy versus transfemoral approach in elderly patients with hard-handling calcified coronary lesions – a single center experience. *Acta Cardiol Sin* 34:464–71, 2018
 - [24] Desai R, Mirza O, Martinsen BJ et al. Plaque modification of severely calcified coronary lesions via orbital atherectomy: single-center observations from a complex Veterans Affairs cohort. *Health Sci Rep* 1:e99, 2018
 - [25] Tanigawa J, Barlis P, Di Mario C. Heavily calcified coronary lesions preclude strut apposition despite high pressure balloon dilatation and rotational atherectomy: in-vivo demonstration with optical coherence tomography. *Circ J* 72:157–60, 2008
 - [26] Jiménez-Valero S, Galeote G, Sánchez-Recalde A et al. Optical coherence tomogra-

- phy after rotational atherectomy. *Rev Esp Cardiol* 62:585–6, 2009
- [27] Tsuchikane E, Suzuki T, Asakura Y et al. Debulking of chronic coronary total occlusions with rotational or directional atherectomy before stenting: Final results of DOCTORS study. *Int J Cardiol* 125:397–403, 2008
- [28] Abdel-Wahab M, Toelg R, Byrne RA et al. High-Speed rotational atherectomy versus modified balloons prior to drug-eluting stent implantation in severely calcified coronary lesions. *Circ Cardiovasc Interv* 11:e007415, 2018, Erratum in: *Circ Cardiovasc Interv* 11:e000040, 2018
- [29] Amemiya K, Yamamoto MH, Maehara A et al. Effect of cutting balloon after rotational atherectomy in severely calcified coronary artery lesions as assessed by optical coherence tomography. *Catheter Cardiovasc Interv* 94:936–44, 2019
- [30] Erbel R, O'Neill W, Auth D et al. High-frequency rotablation of occluded coronary artery during heart catheterization. *Cathet Cardiovasc Diagn* 17:56–8, 1989
- [31] Erbel R, O'Neill W, Auth D et al. High-frequency rotational atherectomy in coronary heart disease. *Dtsch Med Wochenschr* 114:487–95, 1989
- [32] Mohr-Kahaly S, Erbel R, Zotz R et al. Left ventricular contrast echocardiography using Gelifundo – assessment of hemodynamics, contractility and ECG. *Z Kardiol* 76:699–705, 1987
- [33] Zotz R, Stähr P, Erbel R et al. Analysis of high-frequency rotational angioplasty-induced echo contrast. *Cathet Cardiovasc Diagn* 22:137–44, 1991
- [34] Zotz RJ, Erbel R, Philipp A et al. High-speed rotational angioplasty-induced echo contrast in vivo and in vitro optical analysis. *Cathet Cardiovasc Diagn* 26:98–109, 1992
- [35] Kume T, Okura H, Kawamoto T et al. Assessment of the histological characteristics of coronary arterial plaque with severe calcification. *Circ J* 71:643–7, 2007
- [36] Chambers JW, Feldman RL, Himmelstein SI et al. Pivotal trial to evaluate the safety and efficacy of the orbital atherectomy system in treating de novo, severely calcified coronary lesions (ORBIT II). *JACC Cardiovasc Interv* 7:510–8, 2014
- [37] Haude M, Caspari G, Baumgart D et al. Comparison of myocardial perfusion reserve before and after coronary balloon predilatation and after stent implantation in patients with postangioplasty restenosis. *Circulation* 94:286–97, 1996
- [38] van Liebergen RA, Piek JJ, Koch KT et al. Immediate and long-term effect of balloon angioplasty or stent implantation on the absolute and relative coronary blood flow velocity reserve. *Circulation* 98:2133–40, 1998
- [39] Bowers TR, Stewart RE, O'Neill WW et al. Effect of rotablator atherectomy and adjunctive balloon angioplasty on coronary blood flow. *Circulation* 95:1157–64, 1997
- [40] Tanaka T, Shimizu Y, Ishihara A et al. Effect of rotational atherectomy on the coronary microcirculation in patients with angina pectoris. *J Cardiol* 46:43–51, 2005
- [41] Hori M, Inoue M, Kitakaze M et al. Role of adenosine in hyperemic response of coronary blood flow in microembolization. *Am J Physiol* 250(3 Pt 2):H509–18, 1986
- [42] Dietz U, Erbel R, Rupprecht HJ et al. High-frequency rotational ablation following failed percutaneous transluminal coronary angioplasty. *Cathet Cardiovasc Diagn* 31:179–86, 1994
- [43] Haude M, Eick B, Baumgart D et al. High frequency rotational angioplasty. *Z Kardiol* 85 (Suppl 1):17–23, 1996
- [44] Shlofmitz E, Chambers J, Moses JW et al. TCT-389 temporary pacemaker placement incidence with the Diamondback 360® Coronary Orbital Atherectomy System compared to rotational atherectomy. *Am Coll Cardiol* 66(15, Suppl):B157, 2015
- [45] Chambers JW, Diage T. Evaluation of the Diamondback 360 Coronary Orbital Atherectomy System for treating de novo, severely calcified lesions. *Expert Rev Med Devices* 11:457–66, 2014
- [46] Eggebrecht H, Ritzel A, von Birgelen C et al. Acute and long-term outcome after coronary artery perforation during percutaneous coronary interventions. *Z Kardiol* 93:791–8, 2004
- [47] Tomey MI, Kini AS, Sharma SK. Current status of rotational atherectomy. *JACC Cardiovasc Interv* 7:345–53, 2014
- [48] Shimony A, Joseph L, Mottillo S et al. Coronary artery perforation during percutaneous coronary intervention: a systematic review and meta-analysis. *Can J Cardiol* 27:843–50, 2011

- [49] Kiernan T, Yan BP, Rosenfield K et al. Coil embolization of an iatrogenic coronary artery to cardiac vein fistula after rotational atherectomy. *J Interv Cardiol* 21:410–3, 2008
- [50] Kaul U, Singh B, Vijan V et al. Rotablation-included coronary perforation during management of in-stent restenosis. *Indian Heart J* 50:203–5, 1998
- [51] Dietz U, Rupprecht HJ, Ekinici O et al. Angiographic analysis of immediate and long-term results of PTCR vs. PTCA in complex lesions (COBRA study). *Catheter Cardiovasc Interv* 53:359–367, 2001
- [52] Whitlow PL, Bass TA, Kipperman RM et al. Results of the study to determine rotablator and transluminal angioplasty strategy (STRATAS). *Am J Cardiol* 87:699–705, 2001
- [53] Safian RD, Feldman T, Muller DW et al. Coronary Angioplasty and Rotablator Atherectomy Trial (CARAT): immediate and late results of a prospective multicenter randomized trial. *Catheter Cardiovasc Interv* 53:213–20, 2001
- [54] Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 35:2541–619, 2014
- [55] Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *J Am Coll Cardiol* 58:e44–122, 2011
- [56] Koller PT, Mooney MR. Rotablation and stent placement in an unprotected left main coronary ostial stenosis. *J Interv Cardiol* 8:633–8, 1995
- [57] Sperling RT, Ho K, James D et al. Treatment of stent-jailed side branch stenosis with rotational atherectomy. *J Invasive Cardiol* 18:354–8, 2006
- [58] Dill T, Dietz U, Hamm CW et al. A randomized comparison of balloon angioplasty versus rotational atherectomy in complex coronary lesions (COBRA study). *Eur Heart J* 21:1759–66, 2000
- [59] Mangiacapra F, Heyndrickx GR, Puymirat E et al. Comparison of drug-eluting versus bare-metal stents after rotational atherectomy for the treatment of calcified coronary lesions. *Int J Cardiol* 154:373–6, 2012
- [60] de Waha S, Allali A, Büttner HJ et al. Rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: Two-year clinical outcome of the randomized ROTAXUS trial. *Catheter Cardiovasc Interv* 87:691–700, 2016
- [61] Dobrzycki S, Reczuch K, Legutko J et al. Rotational atherectomy in everyday clinical practice. Association of Cardiovascular Interventions of the Polish Society of Cardiology (Asocjacja Interwencji Sercowo-Naczyniowych Polskiego Towarzystwa Kardiologicznego – AISN PTK): Expert opinion. *Kardiol Pol* 76:1576–84, 2018
- [61a] Redfors B, Sharma SK, Saito S et al. Novel micro crown orbital atherectomy for severe lesion calcification: Coronary Orbital Atherectomy System Study (COAST). *Circ Cardiovasc Interv* 13(8):e008993, 2020
- [61b] Lee M, G  n  reux P, Shlofmitz R et al. Orbital atherectomy for treating de novo, severely calcified coronary lesions: 3-year results of the pivotal ORBIT II trial. *Cardiovasc Revasc Med* 18:261–4, 2017
- [61c] Martinsen BJ, Kumar K, Saito S et al. USA orbital atherectomy for calcific coronary lesions: COAST Study, harmonization by doing proof-of-concept. *Cardiovasc Revasc Med* 7:112–7, 2022
- [62] Parikh K, Chandra P, Choksi N et al. Safety and feasibility of orbital atherectomy for the treatment of calcified coronary lesions: the ORBIT I trial. *Catheter Cardiovasc Interv* 81:1134–9, 2013
- [63] Bhatt P, Parikh P, Patel A et al. Long-term safety and performance of the orbital atherectomy system for treating calcified coronary artery lesions: 5-Year follow-up in the ORBIT I trial. *Cardiovasc Revasc Med* 16:213–6, 2015
- [64] Chambers JW, Feldman RL, Himmelstein SI et al. Pivotal trial to evaluate the safety and efficacy of the orbital atherectomy system in treating de novo, severely calci-

- fied coronary lesions (ORBIT II). JACC Cardiovasc Interv 7:510–8, 2014
- [64a] Lee M, Shlofmitz RA, Shlofmitz E et al. Orbital atherectomy for the treatment of small (2,5 mm) severely calcified coronary lesions: ORBIT II sub-analysis. Cardiovasc Revasc Med 19:268–72, 2018
- [65] Iwamoto S, Ohashi M, Shirato H et al. Japan-USA orbital atherectomy for calcific coronary lesions: COAST Study, a harmonization by doing proof-of-concept: the japanese and us regulatory perspective. Cardiovasc Revasc Med 37:118–9, 2022
- [66] Génèreux P, Kirtane AJ, Kandzari DE et al. Randomized evaluation of vessel preparation with orbital atherectomy prior to drug-eluting stent implantation in severely calcified coronary artery lesions: design and rationale of the ECLIPSE trial. Am Heart J 249:1–11, 2022
- [67] Lawton JS, Tamis-Holland JE, Bangalore S et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145: e18–e114, 2022
- Hybrid Procedures). JACC Cardiovasc Interv 10:1523–34, 2017
- [4] Wilson WM, Walsh SJ, Yan AT et al. Hybrid approach improves success of chronic total occlusion angioplasty. Heart 102:1486–93, 2016
- [5] Maeremans J, Walsh S, Knaapen P et al. The hybrid algorithm for treating chronic total occlusions in europe: the RE-CHARGE Registry. J Am Coll Cardiol 68:1958–70, 2016
- [6] Harding SA, Wu EB, Lo S et al. A new algorithm for crossing chronic total occlusions from the Asia Pacific Chronic Total Occlusion Club. JACC Cardiovasc Interv 10:2135–43, 2017
- [7] Galassi AR, Werner GS, Boukhris M et al. Percutaneous recanalisation of chronic total occlusions: 2019 consensus document from the EuroCTO Club. EuroIntervention 15:198–208, 2019
- [8] Goleski PJ, Nakamura K, Liebeskind E et al. Revascularization of coronary chronic total occlusions with subintimal tracking and reentry followed by deferred stenting: experience from a high-volume referral center. Catheter Cardiovasc Interv 93:191–8, 2019
- [9] Brilakis ES, Mashayekhi K, Tsuchikane E et al. Guiding principles for chronic total occlusion percutaneous coronary intervention. Circulation 140:420–33, 2019
- [10] Ge J, on behalf of Chronic Total Occlusion Club China. Strategic roadmap of percutaneous coronary intervention for chronic total occlusions [J]. Cardiol plus 3:30–7, 2018
- [11] Ge J, Ge L, Zhang B et al., on behalf of Chronic Total Occlusion Club China. Active greeting technique: a mother-and-child catheter based technique to facilitate retrograde wire externalization in recanalization of coronary chronic total occlusion. Sci Bull 63:1565–9, 2019
- [12] Tajti P, Burke MN, Karpaliotis D et al. Update in the percutaneous management of coronary chronic total occlusions. JACC Cardiovasc Interv 11:615–25, 2018
- [13] Ge J, Ge L, Huo Y et al. Updated algorithm of chronic total occlusion percutaneous coronary intervention from chronic total occlusion club China. Cardiology Plus 6:81–87, 2021
- [1] Galassi AR, Brilakis ES, Boukhris M et al. Appropriateness of percutaneous revascularization of coronary chronic total occlusions: an overview. Eur Heart J 37:2692–700, 2016
- [1a] Mashayekhi K, Bufe A, Werner GS et al. Behandlung von chronischen Koronarverschlüssen (CTO). Positionspapier der Deutschen Gesellschaft für Kardiologie. Kardiologie 15:320–40, 2021
- [2] Brilakis ES, Grantham JA, Rinfret S et al. A percutaneous treatment algorithm for crossing coronary chronic total occlusions. JACC Cardiovasc Interv 5:367–79, 2012
- [3] Saptontis J, Salisbury AC, Yeh RW et al. Early procedural and health status outcomes after chronic total occlusion angioplasty: a report from the OPEN-CTO Registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion

16.6 PCI bei chronischen Verschlüssen der Koronararterien

16.7 PCI bei Hauptstammstenosen

- [1] Angelini P. Coronary artery anomalies: an entity in search of an identity. *Circulation* 115(10):1296–305; 2007
- [2] El-Menyar AA, Al Suwaidi J, Holmes DR Jr. Left main coronary artery stenosis: state-of-the-art. *Curr Probl Cardiol* 32(3):103–93; 2007
- [3] Medrano-Gracia P, Ormiston J, Webster M et al. A computational atlas of normal coronary artery anatomy. *EuroIntervention* 12(7):845–54; 2016
- [4] Kim HY, Doh JH, Lim HS et al. Identification of coronary artery side branch supplying myocardial mass that may benefit from revascularization. *JACC Cardiovasc Interv* 10(6):571–81; 2017
- [5] Giannoglou GD, Antoniadis AP, Chatzizisis YS et al. Prevalence of narrowing $\geq 50\%$ of the left main coronary artery among 17 300 patients having coronary angiography. *Am J Cardiol* 98(9):1202–05, 2006
- [6] Khan MF, Athappan G. Left main coronary artery disease. *Interv Cardiol* 1:73–91, 2009
- [7] Predescu LM, Zarma L, Platon P et al. Current treatment of left main coronary artery disease. *Cor et Vasa* 58:e328–39, 2016
- [8] Oviedo C, Maehara A, Mintz GS et al. Intravascular ultrasound classification of plaque distribution in left main coronary artery bifurcations: where is the plaque really located? *Circ Cardiovasc Interv* 3(2):105–12, 2010
- [9] Neumann FJ, Sousa-Uva M, Ahlsson A et al., ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 40:87–165, 2019
- [10] Zhou Y, Kassab GS, Molloy S. On the design of the coronary arterial tree: a generalization of Murray's law. *Phys Med Biol* 44(12):2929–45, 1999
- [11] Mintz GS, Lefèvre T, Lassen JF et al. Intravascular ultrasound in the evaluation and treatment of left main coronary artery disease: a consensus statement from the European Bifurcation Club. *EuroIntervention* 14(4):e467–74, 2018
- [12] de la Torre Hernandez JM, Hernández Hernández F, Alfonso F et al. LITRO Study Group (Spanish Working Group on Interventional Cardiology). Prospective application of pre-defined intravascular ultrasound criteria for assessment of intermediate left main coronary artery lesions results from the multicenter LITRO study. *J Am Coll Cardiol* 58(4):351–8, 2011
- [13] Dato I, Burzotta F, Trani C et al. Optical coherence tomography guidance for the management of angiographically intermediate left main bifurcation lesions: Early clinical experience. *Int J Cardiol* 248:108–13, 2017
- [14] Modi BN, van de Hoef TP, Piek JJ et al. Physiological assessment of left main coronary artery disease. *EuroIntervention* 13(7):820–7, 2017
- [15] Lassen JF, Burzotta F, Banning AP et al. Percutaneous coronary intervention for the left main stem and other bifurcation lesions: 12th consensus document from the European Bifurcation Club. *EuroIntervention* 13(13):1540–53, 2018
- [16] Burzotta F, Lassen JF, Banning AP et al. Percutaneous coronary intervention in left main coronary artery disease: the 13th consensus document from the European Bifurcation Club. *EuroIntervention* 14(1):112–20, 2018
- [17] Park SJ, Kim YH, Lee BK et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. *J Am Coll Cardiol* 45:351–6, 2005
- [18] Chieffo A, Hildick-Smith D. The European Bifurcation Club Left Main Study (EBC MAIN): rationale and design of an international, multicentre, randomised comparison of two stent strategies for the treatment of left main coronary bifurcation disease. *EuroIntervention* 12(1):47–52, 2016
- [19] Nam CW, Hur SH, Koo BK et al. Fractional flow reserve versus angiography in left circumflex ostial intervention after left main crossover stenting. *Korean Circ J* 41(6):304–7, 2011
- [20] Park SJ, Kim YH, Park DW et al., MAIN-COMPARE Investigators. Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis. *Circ Cardiovasc Interv* 2(3):167–77, 2009
- [21] Stone GW, Sabik JF, Serruys PW et al., EXCEL Trial Investigators. Everolimus-eluting stents or bypass surgery for left main

- coronary artery disease. *N Engl J Med* 375(23):2223–35, 2016
- [22] Mäkilä T, Holm NR, Lindsay M et al., NOBLE study investigators. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. *Lancet* 388(10061):2743–52, 2016
- [23] Giacoppo D, Collieran R, Cassese S et al. Percutaneous coronary intervention vs. coronary artery bypass grafting in patients with left main coronary artery stenosis: a systematic review and meta-analysis. *JAMA Cardiol* 2(10):1079–88, 2017

16.8 PCI bei verkalkten Stenosen

- [1] Génereux P, Madhavan MV, Mintz GS et al. Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and ACUTY (Acute Catheterization and Urgent Intervention Triage Strategy) TRIALS. *J Am Coll Cardiol* 63:1845–54, 2014
- [2] Bourantas CV, Zhang YJ, Garg S et al. Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. *Heart* 100:1158–64, 2014
- [3] Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 35:2541–619, 2014
- [4] Barbato E, Shlofmitz E, Milkas A et al. State of the art: evolving concepts in the treatment of heavily calcified and undilatable coronary stenoses – from debulking to plaque modification, a 40-year-long journey. *EuroIntervention* 13:696–705, 2017
- [5] Barath P, Fishbein MC, Vari S et al. Cutting balloon: a novel approach to percutaneous angioplasty. *Am J Cardiol* 68:1249–52, 1991
- [6] Okura H, Hayase M, Shimodono S et al. Mechanisms of acute lumen gain following cutting balloon angioplasty in calcified and noncalcified lesions: an intravascular ultrasound study. *Catheter Cardiovasc Interv* 57:429–36, 2002
- [7] Abdel-Wahab M, Toelg R, Byrne RA et al. High-speed rotational atherectomy versus modified balloons prior to drug-eluting stent implantation in severely calcified coronary lesions. *Circ Cardiovasc Interv* 11(10):e007415, 2018. Erratum in: *Circ Cardiovasc Interv* 11(10):e000040, 2018
- [8] Furuichi S, Tobaru T, Asano R et al. Rotational atherectomy followed by cutting-balloon plaque modification for drug-eluting stent implantation in calcified coronary lesions. *J Invasive Cardiol* 24:191–5, 2012
- [9] Kume T, Okura H, Kawamoto T et al. Assessment of the coronary calcification by optical coherence tomography. *EuroIntervention* 6:768–72, 2011
- [10] Kubo T, Shimamura K, Ino Y et al. Superficial calcium fracture after PCI as assessed by OCT. *JACC Cardiovasc Imaging* 8:1228–9, 2015
- [11] Maejima N, Hibi K, Saka K et al. Relationship between thickness of calcium on optical coherence tomography and crack formation after balloon dilatation in calcified plaque requiring rotational atherectomy. *Circ J* 80:1413–9, 2016
- [12] Amemiya K, Yamamoto MH, Maehara A et al. Effect of cutting balloon after rotational atherectomy in severely calcified coronary artery lesions as assessed by optical coherence tomography. *Catheter Cardiovasc Interv* 94:936–44, 2019
- [13] Ai H, Wang X, Suo M et al. Acute- and long-term outcomes of rotational atherectomy followed by cutting balloon versus plain balloon before drug-eluting stent implantation for calcified coronary lesions. *Chin Med J (Engl)* 131:2025–31, 2018
- [13a] Li Q, He Y, Chen L et al. Intensive plaque modification with rotational atherectomy and cutting balloon before drug-eluting stent implantation for patients with severely calcified coronary lesions:

- a pilot clinical study. *BMC Cardiovasc Disord* 16:112, 2016
- [14] de Ribamar Costa J Jr, Mintz GS, Carlier SG et al. Nonrandomized comparison of coronary stenting under intravascular ultrasound guidance of direct stenting without predilation versus conventional predilation with a semi-compliant balloon versus predilation with a new scoring balloon. *Am J Cardiol* 100:812–7, 2007
- [15] Fonseca A, de Ribamar Costa J Jr, Abizaid A et al. Intravascular ultrasound assessment of the novel AngioSculpt scoring balloon catheter for the treatment of complex coronary lesions. *J Invasive Cardiol* 20:21–7, 2008
- [16] Mori S, Otsuka Y, Kawamura A. Usefulness of the SafeCut Dual Wire PTCA catheter for the treatment of calcified lesions. *Invasive Cardiol* 19:E254–6, 2007
- [17] Takano M, Yamamoto M, Murakami D et al. Optical coherence tomography after new scoring balloon angioplasty for in-stent restenosis and de novo coronary lesions. *Int J Cardiol* 141:e51–3, 2010
- [18] Otsuka Y, Koyama T, Imoto Y et al. Prolonged inflation technique using a scoring balloon for severe calcified lesion. *Int Heart J* 58:982–7, 2017
- [19] Erbel R, Schreiner G, Henkel B et al. Improved ischemic tolerance during percutaneous transluminal coronary angioplasty by intracoronary injection of nitroglycerin. *Z Kardiol* 72 Suppl 3:71–3, 1983
- [20] Erbel R, Hüttemann M, Schreiner G et al. Ischämietoleranz des Herzens bei der percutanen transluminalen koronaren Angioplastie. Kontrollierte Studie zum Effekt von Isosorbit-Dinitrat und Nifedipin. *Herz* 12:302–11, 1987
- [21] Busch U, Erbel R, Clas W et al. Verbesserte Ischämietoleranz mit Hilfe eines kontinuierlichen Perfusionskatheters, eines modifizierten Grüntzig-Angioplastiekatheters. *Z Kardiol* 74:435–9, 1985
- [22] Kawase Y, Saito N, Watanabe S et al. Utility of a scoring balloon for a severely calcified lesion: bench test and finite element analysis. *Cardiovasc Interv Ther* 29:134–9, 2014
- [23] Secco GG, Ghione M, Mattesini A et al. Very high-pressure dilatation for undilatable coronary lesions: indications and results with a new dedicated balloon. *Euro-Intervention* 12:359–65, 2016
- [24] Mintz GS, Kovach JA, Javier SP et al. Mechanisms of lumen enlargement after excimer laser coronary angioplasty. An intravascular ultrasound study. *Circulation* 92:3408–14, 1995
- [25] Redfors B, Maehara A, Witzenbichler B et al. Outcomes after successful percutaneous coronary intervention of calcified lesions using rotational atherectomy, cutting-balloon angioplasty, or balloon-only angioplasty before drug-eluting stent implantation. *J Invasive Cardiol* 29:378–86, 2017
- [26] Venuti G, D’Agosta G, Tamburino C et al. Coronary lithotripsy for failed rotational atherectomy, cutting balloon, scoring balloon, and ultra-high-pressure non-compliant balloon. *Catheter Cardiovasc Interv* 94:E111–5, 2019
- [27] Brinton TJ, Ali ZA, Hill JM et al. Feasibility of shockwave coronary intravascular lithotripsy for the treatment of calcified coronary stenoses. *Circulation* 139:834–6, 2019
- [28] Kawamoto H, Latib A, Ruparel N et al. Planned versus provisional rotational atherectomy for severe calcified coronary lesions: insights from the ROTATE multicenter registry. *Catheter Cardiovasc Interv* 88:881–9, 2016
- [29] Wong B, El-Jack S, Newcombe R et al. Shockwave intravascular lithotripsy for calcified coronary lesions: first real-world experience. *J Invasive Cardiol* 31:46–8, 2019
- [30] Watkins S, Good R, Hill J et al. Intravascular lithotripsy to treat a severely underexpanded coronary stent. *EuroIntervention* 15:124–5, 2019
- [31] Sgueglia GA, Gioffrè G, Piccioni F et al. Slender distal radial five French coronary shockwave lithotripsy. *Catheter Cardiovasc Interv* 94:395–8, 2019
- [32] López-Lluya MT, Jurado-Román A, Sánchez-Pérez I et al. Shockwave: useful but potentially dangerous. *JACC Cardiovasc Interv* 12:500–1, 2019
- [33] Matsukawa R, Kozai T, Tokutome M et al. Plaque modification using a cutting balloon is more effective for stenting of heavily calcified lesion than other scoring balloons. *Cardiovasc Interv Ther* 34:325–34, 2019

17 Behandlungsstrategien in besonderen Fällen

17.1 Akuter Myokardinfarkt

- [1] Roffi M, Patrono C, Collet JP et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J* 37:267–315, 2016
- [2] Thygesen K, Alpert JS, Jaffe AS et al., Executive Group on behalf of the Joint European Society of Cardiology (ESC)/ American College of Cardiology (ACC)/ American Heart Association (AHA)/World Heart Federation (WHF). Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). *J Am Coll Cardiol* 72:2231–64, 2018
- [3] Goyal A, Gluckman TJ, Tcheng JE. What's in a name? The new ICD-10 (10th Revision of the International Statistical Classification of Diseases and Related Health Problems) codes and type 2 myocardial infarction. *Circulation* 136:1180–2, 2017
- [4] Giannitsis E, Katus H. Troponins: established and novel indications in the management of cardiovascular disease. *Heart* 104:1714–22, 2018
- [5] Ge J, Erbel R, Zamorano J et al. Coronary artery remodeling in atherosclerotic disease: an intravascular ultrasonic study in vivo. *Coron Artery Dis* 4:981–6, 1993
- [6] Hartmann M, von Birgelen C, Mintz GS et al. Relation between baseline plaque burden and subsequent remodelling of atherosclerotic left main coronary arteries: a serial intravascular ultrasound study with long-term (> or = 12 months) follow-up. *Eur Heart J* 27:1778–84, 2006
- [7] Erbel R, Ge J, Gorge G et al. Intravascular ultrasound classification of atherosclerotic lesions according to American Heart Association recommendation. *Coron Artery Dis* 10:489–99, 1999
- [8] Ge J, Liu F, Gorge G et al. Angiographically „silent“ plaque in the left main coronary artery detected by intravascular ultrasound. *Coron Artery Dis* 6:805–10, 1995
- [9] Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. *Arterioscler Thromb Vasc Biol* 20:1262–75, 2000
- [10] Erbel R. Vulnerable plaque – vulnerable vessel – vulnerable patient. Plaques prone to rupture in atheroma/fibroatheroma. *Herz* 28:483–7, 2003
- [11] Erbel R, Heusch G. Coronary microembolization – its role in acute coronary syndromes and interventions. *Herz* 24:558–75, 1999
- [12] Erbel R, Heusch G. Coronary microembolization. *J Am Coll Cardiol* 36:22–4, 2000
- [13] Erbel R. Progression and regression of atherosclerotic plaques. New results based on intracoronary ultrasound. *Herz* 40:855–62, 2015
- [14] Lyon AR, Bossone E, Schneider B et al. Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 18:8–27, 2016
- [15] Hayes SN, Kim ESH, Saw J et al. Spontaneous coronary artery dissection: current state of the science: a scientific statement from the American Heart Association. *Circulation* 137:e523–57, 2018
- [16] Hawranek M, Wróbel M, Nożyński J et al. Hemorrhagic myocardial infarction: mortality compared with STEMI patients treated with percutaneous coronary intervention. *J Am Coll Cardiol* 68:426–7, 2016

- [17] Baars T, Möhlenkamp S, Eggebrecht H et al. Diagnostik von Thoraxschmerzen, Teil 2 – Kardiale Ursachen müssen immer als Erstes abgeklärt werden. *Pneumo-News* 5:39–43, 2008
- [18] Möhlenkamp S, Schmerund A, Lehmann S et al. Subclinical coronary atherosclerosis and resting ECG abnormalities in an unselected general population. *Atherosclerosis* 196:786–94, 2008
- [19] Mehilli J, Hamm CW, Landmesser U, Massberg S. Kommentar zu den 2015-Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management des akuten Koronarsyndroms ohne ST-Hebungen (NSTEMI-ACS). *Kardiologie* 10:351–8, 2016
- [20] Holmes DR Jr, Berger PB. Troponins, neocortisol, enzyme leaks, creatinine phosphokinase bumps, and infarctlets: what's behind this new lexicon and what does it add? *Circulation* 104:627–9, 2001
- [21] Eggebrecht H, Plicht B, Buck T et al. Echokardiographische Abklärung des Patienten mit akutem Thoraxschmerz auf der Notfallstation. *Intensivmed* 3:64–77, 2006
- [22] Breuckmann F, Post F, Giannitsis E et al. Kriterien der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung für „Chest-Pain-Units“. *Kardiologie* 2:389–94, 2008
- [22a] Giannitsis E, Post F, Haerer W et al. Kriterien der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung für „Chest Pain Units“. *Kardiologie* 14:446–79, 2020
- [23] Post F, Gori T, Giannitsis E et al. Criteria of the German Society of Cardiology for the establishment of chest pain units: update 2014. *Clin Res Cardiol* 104:918–28, 2015
- [23a] Breuckmann F, Rassaf T, Hochadel M et al. German chest pain unit registry: data review after the first decade of certification. *Herz* 46(Suppl 1):24–32, 2021
- [24] Breuckmann F, Hochadel M, Voigtländer T et al. The use of echocardiography in certified chest pain units: results from the German Chest Pain Unit Registry. *Cardiology* 134:75–83, 2016
- [25] Mehilli J, Hamm CW, Landmesser U, Massberg S. Kommentar zu den 2015-Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management des akuten Koronarsyndroms ohne ST-Hebungen (NSTEMI-ACS). *Kardiologie* 10:351–358, 2016
- [25a] Thiele H, Bauersachs J, Mehilli J et al. Kommentar zu den 2020er Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management des akuten Koronarsyndroms bei Patienten ohne persistierende ST-Strecken-Hebung. *Kardiologie* 15:19–31, 2021
- [26] Fox KA, Fitzgerald G, Puymirat E et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. *BMJ Open* 4:e004425, 2014
- [27] http://www.outcomes-umassmed.org/grace/files/GRACE_RiskModel_Coefficients.pdf
- [27a] Collet JP, Thiele H, Barbato E., ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 42:1289–367, 2021. Erratum in: *Eur Heart J* 42:1908, 2021. Erratum in: *Eur Heart J* 42:1925, 2021. Erratum in: *Eur Heart J* 42:2298, 2021
- [28] Subherwal S, Bach RG, Chen AY et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) bleeding score. *Circulation* 119:1873–82, 2009
- [29] <https://www.mdcalc.com/calc/1784/crusade-score-post-mi-bleeding-risk>
- [30] Al-Daydamony MM, Farag El-Sayed M. CRUSADE bleeding score as a predictor of bleeding events in patients with acute coronary syndrome in Zagazig University Hospital. *Indian Heart Journal* 68:632–8, 2016
- [31] Löwel H, Meisinger C. Epidemiologie und demographische Entwicklung am Beispiel kardiovaskulärer Erkrankungen in Deutschland. *Med Klin (Munich)* 101:804–11, 2006
- [31a] Andresen D. 32. Herzbericht 2020. Thieme, Stuttgart, 2021
- [32] Dudas K, Lappas G, Stewart S et al. Trends in out-of-hospital deaths due to coronary heart disease in Sweden (1991 to 2006). *Circulation* 123:46–52, 2011

- [33] Zeymer U, Vogt A, Zahn R et al. Predictors of in-hospital mortality in 1.333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI). Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK). *Eur Heart J* 25:322–8, 2004
- [34] Liosis S, Bauer T, Schiele R et al. Predictors of 1-year mortality in patients with contemporary guideline-adherent therapy after acute myocardial infarction: results from the OMEGA study. *Clin Res Cardiol* 102:671–7, 2013
- [35] Jacksch R, Naber CK, Koslowski B et al. Akutintervention (Primär-PCI) im Rahmen des Essener Herzinfarktverbundes. *Herz* 33:110–4, 2008
- [36] Hailer B, Naber C, Koslowski B et al. Gender-related differences in patients with ST-elevation myocardial infarction: results from the registry study of the ST elevation myocardial infarction network Essen. *Clin Cardiol* 34:294–301, 2011
- [37] Scholz KH, Maier SKG, Maier LS et al. Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial. *Eur Heart J* 39:1065–74, 2018
- [38] Byrne RA, Rossello X, Coughlan JJ et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur Heart J* 44:3720–826, 2023
- [39] Kelm M, Bauersachs J, Kastrati A et al. 2017 ESC Pocket Guidelines. Therapie des akuten Herzinfarktes bei Patienten mit persistierender ST-Streckenhebung. Version 2017. Kurzfassung der 2017 ESC Guidelines for the management of acute myocardial infarction in patients with ST-segment elevation. (European Heart Journal 2017). Börm Bruckmeier Verlag, Grünwald, 2016
- [40] Kelm M, Kastrati A, Nef H et al. für Kommission für Klinische Kardiologische Medizin. Kommentar zu den Leitlinien 2017 der Europäischen Gesellschaft für Kardiologie (ESC) zur Therapie des akuten Herzinfarktes bei Patienten mit ST-Streckenhebung. *Kardiologie* 12:145–9, 2018
- [41] Thiele H, Akin I, Sandri M et al. PCI Strategies in patients with acute myocardial infarction and cardiogenic shock. *N Engl J Med* 377:2419–32, 2017
- [42] Beltrane JF. Assessing patients with myocardial infarction and nonobstructive coronary arteries (MINOCA). *J Intern Med* 273:182–5, 2013
- [43] Pasupathy S, Air T, Dreyer RP et al. Systematic review of patients presenting with suspected myocardial infarction and non-obstructive coronary arteries. *Circulation* 131:861–70, 2015
- [44] Pasupathy S, Air T, Dreyer RP et al. Response to letter regarding article, „Systematic review of patients presenting with suspected myocardial infarction and non-obstructive coronary arteries“. *Circulation* 132:e232, 2015
- [45] Agewall S, Beltrane JF, Reynolds HR et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. *Eur Heart J* 38:143–53, 2017
- [46] Breuckmann F, Nassenstein K, Bucher C et al. Systematic analysis of functional and structural changes after coronary microembolization: a cardiac magnetic resonance imaging study. *JACC Cardiovasc Imaging* 2:121–30, 2009
- [47] Collste O, Sörensson P, Frick M et al. Myocardial infarction with normal coronary arteries is common and associated with normal findings on cardiovascular magnetic resonance imaging: results from the Stockholm Myocardial Infarction with Normal Coronaries study. *J Intern Med* 273:189–96, 2013
- [48] Agewall S, Giannitsis E, Jernberg T et al. Troponin elevation in coronary vs. non-coronary disease. *Eur Heart J* 32:404–11, 2011
- [49] Ouldzein H, Elbaz M, Roncalli J et al. Plaque rupture and morphological characteristics of the culprit lesion in acute coronary syndromes without significant angiographic lesion: analysis by intravascular ultrasound. *Ann Cardiol Angeiol (Paris)* 61:20–6, 2012
- [50] Reynolds HR, Srichai MB, Iqbal SN et al. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. *Circulation* 124:1414–25, 2011

- [51] Davies MJ, Thomas AC. Plaque fissuring – the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. *Br Heart J* 53:363–73, 1985
- [52] Davies MJ, Thomas AC, Knapman PA et al. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. *Circulation* 73:418–27, 1986
- [53] Davies MJ, Bland JM, Hangartner JR et al. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. *Eur Heart J* 10:203–8, 1989
- [54] Falk E, Shah PK, Fuster V. Coronary plaque disruption. *Circulation* 92:657–71, 1995
- [55] Davies MJ. The pathological basis of angina pectoris. *Cardiovasc Drugs Ther* 3(Suppl 1):249–55, 1989
- [56] Ge J, Chirillo F, Schwedtmann J et al. Screening of ruptured plaques in patients with coronary artery disease by intravascular ultrasound. *Heart* 81:621–7, 1999
- [57] Erbel R, Ge J, Gorge G et al. Intravascular ultrasound classification of atherosclerotic lesions according to American Heart Association recommendation. *Coron Artery Dis* 1:489–99, 1999
- [58] Erbel R. Vulnerable Plaque – vulnerables Gefäß – vulnerabler Patient. *Herz* 28:483–7, 2003
- [59] Isner JM, Kishel J, Kent KM et al. Accuracy of angiographic determination of left main coronary arterial narrowing. Angiographic – histologic correlative analysis in 28 patients. *Circulation* 63:1056–64, 1981
- [60] Opolski MP, Spiwak M, Marczak M et al. Mechanisms of myocardial infarction in patients with nonobstructive coronary artery disease: results from the optical coherence tomography study. *ACC Cardiovasc Imaging* 12:2210–21, 2019
- [61] Pathik B, Raman B, Mohd Amin NH et al. Troponin-positive chest pain with unobstructed coronary arteries: incremental diagnostic value of cardiovascular magnetic resonance imaging. *Eur Heart J Cardiovasc Imaging* 17:1146–52, 2016
- [62] Dastidar AG, Baritussio A, De Garate E et al. Prognostic role of CMR and conventional risk factors in myocardial infarction with nonobstructed coronary arteries. *JACC Cardiovasc Imaging* 12:1973–82, 2017
- [63] Roffi M, Patrono C, Collet JP et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 37:267–315, 2016
- [64] Nicoli G, Scalone G, Crea F. Acute myocardial infarction with no obstructive coronary atherosclerosis: mechanism and management. *Eur Heart J* 36:475–81, 2015
- [64a] Lascarrou JB, Merdji H, Le Gouge A et al., CRICS-TRIGGERSEP Group. Targeted temperature management for cardiac arrest with nonshockable rhythm. *N Engl J Med* 381:2327–37, 2019
- [65] Corpus RA, House JA, Marso SP et al. Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction. *Am Heart J* 48:493–500, 2004
- [66] Stone GW, Grines CL, Cox DA et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. *N Engl J Med* 46:957–66, 2002
- [67] Glover GW, Thomas RM, Vamvakas G. Intravascular versus surface cooling for targeted temperature management after out-of-hospital cardiac arrest - an analysis of the TTM trial data. *Crit Care* 20:381, 2016
- [68] Arrich J, Holzer M, Havel C et al. Pre-hospital versus in-hospital initiation of cooling for survival and neuroprotection after out-of-hospital cardiac arrest. *Cochrane Database Syst Rev* 3:CD010570, 2016
- [69] Kim KH, Shin SD, Song KJ et al. Cooling methods of targeted temperature management and neurological recovery after out-of-hospital cardiac arrest: A nationwide multicenter multi-level analysis. *Resuscitation* 125:56–65, 2018
- [70] Lindsay PJ, Buell D, Scales DC. The efficacy and safety of pre-hospital cooling after out-of-hospital cardiac arrest: a systematic review and meta-analysis. *Crit Care* 22:66, 2018
- [71] Nolan JP, Soar J, Cariou A et al., European Resuscitation Council and European Society of Intensive Care Medicine Guidelines for Post-resuscitation Care 2015: Section 5 of the European Resuscitation

- Council Guidelines for Resuscitation 2015. Resuscitation 95:202–22, 2015
- [72] Drinhaus H, Stratogianni A, Schick V et al. Postreanimationstherapie: Klare neue Strategien, aber noch offene Fragen. Dtsch Arztebl 113:14, 2016
- [73] Akers WS, Oh JJ, Oestreich JH et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y₁₂ receptor antagonist. J Clin Pharmacol 50:27–35, 2010
- [74] Droppa M, Geisler T. Cangrelor – Indikationen 2019. J f Kardiologie 26:307–310, 2019
- [75] Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol 2:1886–9, 2003
- [76] Vaduganathan M, Qamar A, Singh A et al. Cangrelor Use Since FDA Approval: A Single-Center, Real-World Experience at a Tertiary Care Hospital. J Am Coll Cardiol 69:463–464, 2017
- [77] Burzotta F, Crea F. Thrombus-aspiration: a victory in war against no reflow. Lancet 371:1889–90, 2008
- [78] Zijlstra F, Gonnings NL. Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS). Lancet 371:1915–20, 2008
- [79] Mahmoud KD, Jolly SS, James S et al. Clinical impact of direct stenting and interaction with thrombus aspiration in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: Thrombectomy Trialists Collaboration. Eur Heart J 39:2472–9, 2018
- [80] Thielmann M, Kottenberg E, Kleinbongard P et al. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet 382:597–604, 2013
- [81] Kholmukhamedov A, Logdon C, Hu J et al. Cyclosporin A in left ventricular remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol 306:H53–9, 2014
- [82] Cung TT, Morel O, Cayla G et al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med 373:1021–31, 2015
- [83] Yingzhong C, Lin C, Chunbin W. Clinical effects of cyclosporine A on reperfusion injury in myocardial infarction: a meta-analysis of randomized controlled trials. Springerplus 5:1117, 2016

17.2 No-Reflow-Phänomen

- [1] Jaffe R, Charron T, Puley G et al. Microvascular obstruction and the „no-reflow“ phenomenon after percutaneous coronary intervention. Circulation 17:3152–6, 2008
- [2] Lincoff AM, Topol EJ. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 8:1361–74, 1993
- [3] Kloner DE, Dai W, Hale SL. No-reflow phenomenon. A new target for therapy of acute myocardial infarction independent of myocardial infarct size. J CV Pharmacol Therapeut 23:273–6, 2018
- [4] Piana RN, Paik GY, Moscucci M et al. Incidence and treatment of „no-reflow“ after percutaneous coronary intervention. Circulation 9:2514–8, 1994
- [5] Mehta RH, Ou FS, Peterson ED et al. Clinical significance of post-procedural TIMI flow in patients with cardiogenic shock undergoing primary percutaneous coronary intervention. JACC Cardiovasc Interv 2:56–64, 2009
- [6] Haeck JD, Koch KT, Bilodeau L et al. Randomized comparison of primary percutaneous coronary intervention with combined proximal embolic protection and thrombus aspiration versus primary percutaneous coronary intervention alone in ST-segment elevation myocardial infarction: the PREPARE (PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST-Elevation) study. JACC Cardiovasc Interv 2:934–43, 2009
- [7] Halkin A, Stone GW, Grines CL et al. Prognostic implications of creatinine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol 7:951–61, 2006
- [8] Bouleti C, Mewton N, Germain S. The no-reflow phenomenon: state of the art. Arch Cardiovasc Dis 108:661–74, 2015
- [8a] Maznyczka AM, Oldroyd KG, Greenwood JP et al. Comparative significance of invasive measures of microvascular injury in

- acute myocardial infarction. *Circ Cardio-vasc Interv* 13:e008505, 2020
- [9] Tanaka A, Kawarabayashi T, Nishibori Y et al. No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction. *Circulation* 105:2148–52, 2002
 - [10] Kotani J, Mintz GS, Castagna MT et al. Usefulness of preprocedural coronary lesion morphology as assessed by intravascular ultrasound in predicting thrombolysis in myocardial infarction frame count after percutaneous coronary intervention in patients with Q-wave acute myocardial infarction. *Am J Cardiol* 1:870–2, 2003
 - [11] Jennings RB, Ganote CE, Reimer KA. Ischemic tissue injury. *Am J Pathol* 1:179–98, 1975
 - [12] Taniyama Y, Ito H, Iwakura K et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. *JACC* 30:1193–9, 1997
 - [13] Leinweber K, Böse D, Vogelsang M et al. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. *J Am Coll Cardiol* 7:981–6, 2006
 - [14] Böse D, von Birgelen C, Zhou XY et al. Impact of atherosclerotic plaque composition on coronary microembolization during percutaneous coronary interventions. *Bas Research Cardiol* 103:587–97, 2008
 - [15] Yu SJ, Buerck JP, O'Rear EA et al. Possible erythrocyte contributions to and exacerbation of the post-thrombolytic no-reflow phenomenon. *Biorheology* 54:81–93, 2018
 - [16] Horn P, Baars T, Kahlert P et al. Release of intracoronary microparticles during stent implantation into stable atherosclerotic lesions under protection with an aspiration device. *PLoS One* 10:e0124904, 2015
 - [17] Caiazzo G, Musci RL, Frediani L et al. State of the Art: No-Reflow Phenomenon. *Cardiol Clin* 38:563–573, 2020
 - [18] Ren F, Mu N, Zhang X et al. Increased platelet-leukocyte aggregates are associated with myocardial no-reflow in patients with ST elevation myocardial infarction. *Am J Med Sci* 352:261–6, 2016
 - [19] Kulickowski W, Miszański-Jamka K, Kaczmarski J et al. No-reflow and platelet reactivity in diabetic patients with ST-segment elevation myocardial infarction: is there a link? *Postępy Kardiologii Interwencyjnej* 13:326–30, 2017
 - [20] Lee WW, Marinelli B, van der Laan AM et al. PET/MRI of inflammation in myocardial infarction. *J Am Coll Cardiol* 59:153–63, 2012
 - [21] Hawranek M, Wróbel M, Nożyński J et al. Hemorrhagic myocardial infarction: mortality compared with STMI patients treated with percutaneous coronary intervention. *J Am Coll Cardiol* 68:426–7, 2016
 - [22] Abbate A, Kontos MC, Biondi-Zoccai GG. No-reflow: the next challenge in treatment of ST-elevation acute myocardial infarction. *Eur Heart J* 9:1795–7, 2008
 - [23] Limbruno U, De Carlo M, Pistoletti S et al. Distal embolization during primary angioplasty: histopathologic features and predictability. *Am Heart J* 50:102–8, 2005
 - [24] Yip HK, Chen MC, Chang HW et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. *Chest* 22:1322–32, 2002
 - [25] Mizote I, Ueda Y, Ohtani T et al. Distal protection improved reperfusion and reduced left ventricular dysfunction in patients with acute myocardial infarction who had angiographically defined ruptured plaque. *Circulation* 12:1001–7, 2005
 - [26] Fukuda D, Tanaka A, Shimada K et al. Predicting angiographic distal embolization following percutaneous coronary intervention in patients with acute myocardial infarction. *Am J Cardiol* 1:403–7, 2003
 - [27] Zhao JL, Yang YJ, Pei WD et al. The effect of statins on the no-reflow phenomenon: an observational study in patients with hyperglycemia before primary angioplasty. *Am J Cardiovasc Drugs* 81–9, 2009
 - [28] Jeong YH, Kim WJ, Park DW et al. Serum B-type natriuretic peptide on admission can predict the „no-reflow“ phenomenon after primary drug-eluting stent implantation for ST-segment elevation myocardial infarction. *Inter J Cardiol* 141:175–81, 2009
 - [29] Niccoli G, Lanza GA, Spaziani C et al. Baseline systemic inflammatory status and no-reflow phenomenon after percutaneous coronary angioplasty for acute myocardial infarction. *Int J Cardiol* 117:306–11, 2007

- [30] Mauri L, Rogers C, Baim DS. Devices for distal protection during percutaneous coronary revascularization. *Circulation* 13:2651–6, 2006
- [31] Iijima R, Shinji H, Ikeda N et al. Comparison of coronary arterial finding by intravascular ultrasound in patients with „transient no-reflow“ versus „reflow“ during percutaneous coronary intervention in acute coronary syndrome. *Am J Cardiol* 7:29–33, 2006
- [32] Soeda T, Higuma T, Abe N et al. Morphological predictors for no reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction caused by plaque rupture. *Eur Heart J Cardiovasc Imaging* 18:103–10, 2017
- [33] Kusuyama T, Kataoka T, Iida H et al. Comparison of temporary occlusion and aspiration system versus the conventional method during coronary stenting for acute myocardial infarction. *Am J Cardiol* 4:1041–3, 2004
- [34] Hong YJ, Jeong MH, Choi YH et al. Impact of plaque components on no-reflow phenomenon after stent deployment in patients with acute coronary syndrome: a virtual histology-intravascular ultrasound analysis. *Eur Heart J* 32:2059–66, 2009
- [35] Ding S, Li Z, Ge H et al. Impact of early ST-segment changes on cardiac magnetic resonance-verified intramyocardial haemorrhage and microvascular obstruction in st-elevation myocardial infarction patients. *Medicine* 94:e1438, 2015
- [36] Ndrepepa G, Tiroch K, Fusaro M et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. *J Am Coll Cardiol* 55:2383–9, 2010
- [37] Nakazawa G, Tanabe K, Onuma Y et al. Efficacy of culprit plaque assessment by 64-slice multidetector computed tomography to predict transient no-reflow phenomenon during percutaneous coronary intervention. *Am Heart J* 155:1150–7, 2008
- [38] Klein LW, Kern MJ, Berger P et al. Society of cardiac angiography and interventions: suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory. *Cath Cardiovasc Interv* 60:194–201, 2003
- [39] Pasceri V, Pristipino C, Pelliccia F et al. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. *Am J Cardiol* 5:1358–61, 2005
- [40] Michaels AD, Appleby M, Otten MH et al. Pretreatment with intragraft Verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. *J Invasive Cardiol* 4:299–302, 2002
- [41] Kaplan BM, Benzuly KH, Kinn JW et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary Verapamil and nitroglycerin. *Cathet Cardiovasc Diagn* 9:113–8, 1996
- [42] Saito T, Hokimoto S, Ishibashi F et al. Pulse infusion thrombolysis (PIT) for large intracoronary thrombus: preventive effect against the „no flow“ phenomenon in revascularization therapy for acute myocardial infarction. *Jpn Circ J* 5:94–8, 2001
- [43] Lim SY, Bae EH, Jeong MH et al. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. *Circulation* 8:928–32, 2004
- [44] Patel T, Shah S, Gulati R et al. Perforated balloon technique: a simple and handy technique to combat no-reflow phenomenon in coronary system. *Catheter Cardiovasc Interv* 92:890–4, 2018
- [45] Fischell TA, Haller S, Pulukurthy S et al. Nicardipine and adenosine „flush cocktail“ to prevent no-reflow during rotational atherectomy. *Cardiovasc Revasc Med* 224–8, 2008
- [46] Marzilli M, Orsini E, Marraccini P et al. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. *Circulation* 01:2154–9, 2000
- [47] Movahed MR, Baweja G. Distal administration of very high doses of intracoronary adenosine for the treatment of resistant no-reflow. *Exp Clin Cardiol* 3:141–3, 2008
- [48] Sakuma T, Motoda C, Tokuyama T et al. Exogenous adenosine triphosphate disodium administration during primary percutaneous coronary intervention reduces no-reflow and preserves left ventricular

- function in patients with acute anterior myocardial infarction: a study using myocardial contrast echocardiography. *Int J Cardiol* 140:200–9, 2010
- [48] Heusch G. Adenosine and maximum coronary vasodilation in humans: myth and misconceptions in the assessment of coronary reserve. *Bas Res Cardiol* 105:1–5, 2010
- [49] Kleinbongard P, Boese D, Baars T et al. Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. *Circ Res* 108:344–52, 2011
- [50] Huang D, Qian J, Ge L et al. REstoration of COronary flow in patients with no-reflow after primary coronary interVENTion of acute myocaRdial infarction (RECOVER). *Am Heart J* 164:394–401, 2012
- [51] Freixa X, Bellera N, Ortiz-Perez JT et al. Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention. *Eur Heart J* 33:103–12, 2012
- [52] Høfsten D, Kelbæk H, Helqvist S et al. The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: ischemic postconditioning or deferred stent implantation versus conventional primary angioplasty and complete revascularization versus treatment of culprit lesion only. rationale and design of the DANAMI 3 trial program. *Am Heart J* 169:613–21, 2015
- [53] Hahn JY, Song YB, Kim EK et al. Ischemic postconditioning during primary percutaneous coronary intervention: the effects of postconditioning on myocardial reperfusion inpatients with ST-segment elevation myocardial infarction (POST) randomized trial. *Circulation* 128:1889–96, 2013
- [54] Baim DS, Mauri L, Cutlip DC. Drug-eluting stenting for unprotected left main coronary artery disease: are we ready to replace bypass surgery? *J Am Coll Cardiol* 7:878–81, 2006
- [55] Burzotta F, Crea F. Thrombus-aspiration: a victory in the war against no-reflow. *Lancet* 71:1889–90, 2008
- [56] Vlaar PJ, Svilaas T, Horst IC et al. Cardiac death and reinfarction after 1 year in the thrombus aspiration during percutaneous coronary intervention in acute myocardial infarction study (TAPAS): a 1-year follow-up study. *Lancet* 71:1915–20, 2008
- [57] Svilaas T, Vlaar PJ, Horst IC et al. Thrombus aspiration during primary percutaneous coronary intervention. *N Engl J Med* 58:557–67, 2008
- [58] Frobert O, Lagerqvist B, Olivecrona GK et al. Thrombus aspiration during ST-segment elevation myocardial infarction. *N Engl J Med* 369:1587–97, 2013
- [59] Jolly SS, Cairns JA, Yusuf S et al. Randomized trial of primary PCI with or without routine manual thrombectomy. *N Engl J Med* 372:1389–98, 2013
- [60] Byrne RA, Rossello X, Coughlan JJ et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur Heart J* 44:3720–3826, 2023
- [61] Baim DS, Wahr D, George B et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. *Circulation* 105:1285–90, 2002
- [62] Silber S, Albertsson P, Avilés FF et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. *Eur Heart J* 26:804–47, 2005
- [63] Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Web Addenda. *Eur Heart J* 34:2949–3003, 2013. Erratum in: *Eur Heart J* 35:2260–61, 2014
- [64] Brennan JM, Al-Hejily W, Dai D et al. Three-year outcomes associated with embolic protection in saphenous vein graft intervention: results in 49,325 senior patients in the Medicare-linked National Cardiovascular Data Registry Cath PCI Registry. *Circ Cardiovasc Interv* 8:e001403, 2015
- [65] Liu W, Zou Z, Jiang H et al. Clinical effect of preoperative high-dose atorvastatin against no-reflow after PCI. *Exp Ther Med* 13:97–102, 2017
- [66] Wang J, Chen Y, Wang C et al. The impact of pre-primary percutaneous coronary intervention β blocker use on the no-reflow phenomenon in patients with

acute myocardial infarction. *Zhonghua Xin Xue Guan Bing Za Zhi* 42:822–6, 2014

17.3 Koronarperforation

- [1] Cowley MJ, Dorros G, Kelsey SF et al. Acute coronary events associated with percutaneous transluminal coronary angioplasty. *Am J Cardiol* 53:12C–6C, 1984
- [2] Dippel EJ, Kereiakes DJ, Tramuta DA et al. Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous management. *Cathet Cardiovasc Interv* 52:279–86, 2001
- [3] Ellis SG, Ajluni S, Arnold AZ et al. Increased coronary perforation in the new device era. Incidence, classification, management, and outcome. *Circulation* 90:2725–30, 1994
- [4] Eggebrecht H, Ritzel A, von Birgelen C et al. Acute and long-term outcome after coronary artery perforation during percutaneous coronary interventions. *Z Kardiol* 93:791–798, 2004
- [5] Gruberg L, Pinnow E, Flood R et al. Incidence, management, and outcome of coronary artery perforation during percutaneous coronary intervention. *Am J Cardiol* 86:680–2, 2000
- [6] Gunning MG, Williams IL, Jewitt DE et al. Coronary artery perforation during percutaneous intervention: incidence and outcome. *Heart* 88:495–8, 2002
- [7] Stankovic G, Orlic D, Corvaja N et al. Incidence, predictors, in-hospital, and late outcome of coronary artery perforations. *Am J Cardiol* 93:213–6, 2004
- [8] Lemmert ME, van Bommel RJ, Diletti R et al. Clinical characteristics and management of coronary artery perforations: a single-center 11-year experience and practical overview. *J Am Heart Assoc* 6:e007049, 2017. <https://www.ahajournals.org/doi/epub/10.1161/JAHA.117.007049>
- [9] Guttman OP, Jones DA, Gulati A et al. Prevalence and outcomes of coronary artery perforation during percutaneous coronary intervention. *EuroIntervention* 13:e595–601, 2017
- [10] Kinnaird T, Anderson R, Ossei-Gerning N et al. Coronary perforation complicating percutaneous coronary intervention in patients with a history of coronary artery bypass surgery: an analysis of 309 perforation cases from the British Cardiovascular Intervention Society Database. *Circ Cardiovasc Interv* 10:e005581, 2017
- [11] Kinnaird T, Shing Kwok C, Kontopantelis E et al. Coronary perforation during PCI between 2006 and 2013: an analysis of 527.121 cases from the BCIS database. *Circ Cardiovasc Interv* 9:e003449, 2016
- [12] Danek BA, Karatasakis A, Tajti P et al. Incidence, treatment, and outcomes of coronary perforation during chronic total occlusion percutaneous coronary intervention. *Am J Cardiol* 120:1285–92, 2017
- [13] Berry JF, von Mering GO, Schmalfuss C et al. Systolic compression of the left anterior descending coronary artery: a case series, review of the literature, and therapeutic options including stenting. *Catheter Cardiovasc Interv* 56:58–63, 2002
- [14] Tomasevic M, Dikic M, Ostojic M. Stenting a myocardial bridge: a wrong decision in STEMI? *Acta Cardiol* 66:89–91, 2011
- [15] Rubio-Alonso B, García-Tejada J, Grandanista C. Coronary perforation to left ventricular cavity following stenting within a myocardial bridge. *Coron Artery Dis* 29:271–3, 2018
- [16] Pourhoseini S, Bakhtiari M, Babaee A et al. Increased risk of coronary perforation during percutaneous intervention of myocardial bridge: what histopathology says. *J Cardiovasc Thorac Res* 9:108–12, 2017. doi: 10.15171/jcvtr.2017.18
- [17] Cortese B, di Palma G, Latini R. Coronary sinus perforation during reducer implantation. *Catheter Cardiovasc Interv* 91:1291–3, 2018
- [18] Mirza AJ, Taha AY, Aldoori JS et al. Coronary artery perforation complicating percutaneous coronary intervention. *Asian Cardiovasc Thorac Ann* 26:101–6, 2018
- [19] Erbel R, O'Neill W, Auth D et al. High-frequency rotablation of occluded coronary artery during heart catheterization. *Cathet Cardiovasc Diagn* 17:56–8, 1989
- [20] Mantis C, Kintis K, Papadakis E et al. Rota-Wire-induced coronary perforation and tamponade during rotational atherectomy. *Kardiol Pol* 76:676, 2018
- [21] Davidson LJ, Ricciardi MJ. Coronary artery perforation complicated by pericardial ab-

- scuss formation: a Clinical Dilemma. *Circ Cardiovasc Interv* 11:e005917, 2018
- [22] Li Y, Xu R, Cai Z et al. Acute purulent pericarditis following staged percutaneous coronary intervention for multivessel disease. *Herz* 38:934–7, 2013
- [23] Roubelakis A, Rawlins J, Baliulis G. Coronary artery rupture caused by stent infection: a rare complication. *Circulation* 131:1302–3, 2015
- [24] Fejka M, Dixon SR, Safian RD et al. Diagnosis, management, and clinical outcome of cardiac tamponade complicating percutaneous coronary intervention. *Am J Cardiol* 90:1183–6, 2002
- [25] Eeckhout E, De Palma R. Coronary perforation: an inconvenient complication. *JACC Cardiovasc Interv* 4:96–7, 2011
- [26] Colombo A, Itoh A, Di Mario C et al. Successful closure of a coronary vessel rupture with a vein graft stent: case report. *Cathet Cardiovasc Diagn* 38:172–4, 1996
- [27] Caputo RP, Amin N, Marvasti M et al. Successful treatment of a saphenous vein graft perforation with an autologous vein-covered stent. *Catheter Cardiovasc Interv* 48:382–6, 1999
- [28] Briguori C, Nishida T, Anzuini A et al. Emergency polytetrafluoroethylene-covered stent implantation to treat coronary ruptures. *Circulation* 102:3028–31, 2000
- [29] Campbell PG, Hall JA, Harcombe AA et al. The Jomed Covered Stent Graft for coronary artery aneurysms and acute perforation: a successful device which needs careful deployment and may not reduce restenosis. *J Invasive Cardiol* 12:272–6, 2002
- [30] Dixon SR, Webster MWI, Ormiston JA et al. Gelfoam embolization of a distal coronary artery guidewire perforation. *Cathet Cardiovasc Interv* 49:214–7, 2000
- [31] George S, Cotton J, Wrigley B. Guidewire-induced coronary perforation successfully treated with subcutaneous fat embolisation: a simple technique available to all. *Catheter Cardiovasc Interv* 86:1186–8, 2015
- [32] Shemisa K, Karatasakis A, Brilakis ES. Management of guidewire-induced distal coronary perforation using autologous fat particles versus coil embolization. *Catheter Cardiovasc Interv* 89:253–8, 2017
- [33] Politi L, Iaccarino D, Sangiorgi GM et al. Huge coronary perforation during percutaneous intervention sealed by injection of polyvinyl alcohol microspheres. *J Cardiovasc Med (Hagerstown)* 16(Suppl 2):S130–2, 2015
- [34] Meincke F, Kuck KH, Bergmann MW. Cardiac tamponade due to coronary perforation during percutaneous interventions successfully treated with microspheres. *Clin Res Cardiol* 103:325–7, 2014
- [35] Gutiérrez-Chico JL. Zambomballooning: A novel technique to seal a coronary perforation complicating the intervention of a chronic total occlusion. *Cardiol J* 24:573–5, 2017
- [36] Takagi K, Furui K, Morishima I et al. Usefulness of the jailed-balloon technique in percutaneous intervention for severe coronary perforation involving left main bifurcation. *JACC Cardiovasc Interv* 10:e209–11, 2017
- [37] Gonzalez-Santos JM, Vallejo JL, Pineda T et al. Emergency surgery after coronary disruption complicating PTCA. Report of four cases. *Thorac Cardiovasc Surg* 33:244–7, 1985
- [38] Tugtekin SM, Alexiou K, Kappert U et al. Chirurgische Therapie nach traumatischen interventionellen Koronarläsionen. *Z Kardiol* 92:833–6, 2003
- [39] Karaman K, Karayakali M, Arisoy A et al. A late complication of coronary artery perforation during primary percutaneous coronary intervention: Coronary arteriovenous fistula. *Türk Kardiyol Dern Ars* 45:739–43, 2017
- [40] Matteucci M, Fina D, Jiritano F et al. Treatment strategies for post-infarction left ventricular free-wall rupture. *Eur Heart J Acute Cardiovasc Care* 8:379–87, 2019
- [41] Nasrin S, Cader FA, Haq MM et al. Right coronary artery perforation extending to the coronary sinus of Valsalva during percutaneous intervention successfully sealed with polytetrafluoroethylene-covered stent: a case report. *BMC Res Notes* 10:537, 2017
- [42] Kaneko U, Kashima Y, Kanno D et al. Giant coronary artery pseudoaneurysm formed after septal artery perforation during retrograde percutaneous coronary intervention: a conservative strategy with serial cardiac computed tomographic imaging. *JACC Cardiovasc Interv* 11:e23–4, 2018

- [43] Yamanaka T, Fukatsu T, Ichinohe Y et al. Spontaneous closure of ventricular septal perforation following percutaneous coronary intervention for acute myocardial infarction. *BMJ Case Rep* Oct 13:bcr-221204, 2017
- [44] Kawamoto H, Tanaka K, Ruparelia N et al. Short-term and long-term outcomes after polytetrafluoroethylene-covered stent implantation for the treatment of coronary perforation. *Am J Cardiol* 116:1822–6, 2015

17.4 Periinterventioneller Schlaganfall

- [1] Wong SC, Minutello R, Hong MK. Neurological complications following percutaneous coronary interventions (a report from the 2000–2001 New York State Angioplasty Registry). *Am J Cardiol* 96:1248–50, 2005
- [2] Hamon M, Baron JC, Viader F et al. Periprocedural stroke and cardiac catheterization. *Circulation* 118:678–83, 2008
- [3] Keeley EC, Grines CL. Scraping of aortic debris by coronary guiding catheters: a prospective evaluation of 1,000 cases. *J Am Coll Cardiol* 2:1861–5, 1998
- [4] Eggebrecht H, Haude M, Woertgen U et al. Systematic use of a collagen-based vascular closure device immediately after cardiac catheterization procedures in 1.317 consecutive patients. *Catheter Cardiovasc Interv* 7:486–95, 2002
- [5] Eggebrecht H, Oldenburg O, Dirsch O et al. Potential embolization by atherosclerotic debris dislodged from aortic wall during cardiac catheterization: histological and clinical findings in 7.621 patients. *Catheter Cardiovasc Interv* 49:389–94, 2000
- [5a] Ringleb P, Köhrmann M, Jansen O et al. Akuttherapie des ischämischen Schlaganfalls, S2e-Leitlinie, 2022, in Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinie für Diagnostik und Therapie in der Neurologie. Online: www.dgn.org/leitlinien, zuletzt bearbeitet 28.11.2022
- [5b] Tužil J, Matějka J, Mamas MA, Doležal T. Short-term risk of periprocedural stroke relative to radial vs. femoral access: systematic review, meta-analysis, study sequential analysis and meta-regression of 2,188,047 real-world cardiac catheterizations. *Expert Rev Cardiovasc Ther* 21:293–304, 2023
- [6] Hamon M, Gomes S, Oppenheim C et al. Cerebral microembolism during cardiac catheterization and risk of acute brain injury: a prospective diffusion-weighted magnetic resonance imaging study. *Stroke* 7:2035–8, 2006
- [7] Kronzon I, Tunick PA. Aortic atherosclerotic disease and stroke. *Circulation* 14:63–75, 2006
- [8] De Marco F, Antonio Fernandez-Diaz J, Lefèvre T et al. Management of cerebrovascular accidents during cardiac catheterization: immediate cerebral angiography versus early neuroimaging strategy. *Catheter Cardiovasc Interv* 70:560–8, 2007
- [9] Al-Mubarak N, Vitek JJ, Mousa I et al. Immediate catheter-based neurovascular rescue for acute stroke complicating coronary procedures. *Am J Cardiol* 90:173–6, 2002
- [10] Janjua N, Brisman JL. Endovascular treatment of acute ischaemic stroke. *Lancet Neurol* 6:1086–93, 2007
- [11] Khatri P, Taylor RA, Palumbo V et al. Treatment of Acute Stroke after Cardiac Catheterization (TASCC) Study Group. The safety and efficacy of thrombolysis for strokes after cardiac catheterization. *J Am Coll Cardiol* 51:906–11, 2008
- [11] Campbell BC, Mitchell PJ, Kleinig TJ et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med*. 372:1009–18, 2015
- [12] Saver JL, Jahan R, Levy EI et al. Solitaire flow restoration device versus the merci retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. *Lancet* 380:1241–9, 2012
- [13] Nogueira RG, Lutsep HL, Gupta R et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. *Lancet* 380:1231–40, 2012. Erratum in: *Lancet* 380:1230, 2012
- [14] Berkhemer O, Fransen P, Beumer D et al. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med* 372:11–20, 2015

- [15] Jovin TG, Chamorro A, Cobo E et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. *N Engl J Med* 372, 2296–306, 2015
- [16] Saver JL, Goyal M, Bonafe A et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. *N Engl J Med* 372:2285–95, 2015
- [17] Bracard S, Ducrocq X, Mas JL et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. *Lancet Neurol* 15: 1138–1147, 2016
- [18] Nogueira RG, Jadhav AP, Haussen DC et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. *N Engl J Med* 378:11–21, 2018
- [19] Saver JL, Goyal M, van der Lugt A et al. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. *JAMA* 316:1279–88, 2016
- [20] Sheinberg DL, McCarthy DJ, Peterson EC et al. DEFUSE-3 Trial: reinforcing evidence for extended endovascular intervention time window for ischemic stroke. *World Neurosurg* 112:275–6, 2018
- [21] Lavine SD, Cockroft K, Hoh B et al. Training guidelines for endovascular stroke intervention: an international multi-society consensus document. *Neuroradiology* 58:537–41, 2016
- [6] Kieny A, Wettlé C, Lipsker D et al. Earlobe crease and cholesterol emboli. *Ann Dermatol Venereol* 142:619–21, 2015
- [7] Sedano Casas A, Gato Díez A, Mora Escudero I et al. Cholesterol emboli-induced ischemic colitis. *Med Clin (Barc)* 141:e7, 2013
- [8] Shaikh AH, Hanif B, Hasan K et al. Cholesterol emboli syndrome – a rare complication of cardiac catheterization. *J Pak Med Assoc* 60:492–4, 2010
- [9] Frank RD, Velden J. Images in clinical medicine. Cholesterol emboli after coronary bypass surgery. *N Engl J Med* 364:265, 2011
- [10] Pervaiz MH, Durga S, Janoudi A et al. PET/CTA detection of muscle inflammation related to cholesterol crystal emboli without arterial obstruction. *J Nucl Cardiol* 25:433–40, 2018
- [11] Zucchelli P, Zuccalà A. The diagnostic dilemma of hypertensive nephrosclerosis: the nephrologist's view. *Am J Kidney Dis* 21(5 Suppl 2):87–91, 1993
- [12] Scolari F, Ravani P, Pola A et al. Predictors of renal and patient outcomes in attheroembolic renal disease: a prospective study. *J Am Soc Nephrol* 4:1584–90, 2003
- [13] Bashore TM, Gehrig T. Cholesterol emboli after invasive procedures. *J Am Coll Cardiol* 42:217–8, 2003
- [14] Elinav E, Chajek-Shaul T, Stern M. Improvement in cholesterol emboli syndrome after iloprost therapy. *BMJ* 24:268–9, 2002
- [15] Koga J, Ohno M, Okamoto K et al. Cholesterol embolization treated with corticosteroids – two case reports. *Angiology* 6:497–501, 2005
- [16] Simon R, Berwert L, Burnier M et al. Severe renal insufficiency secondary to renal cholesterol emboli: therapeutical options revisited. *Rev Med Suisse* 6:432–4, 436–7, 2010

17.5 Cholesterinemboliesyndrom

- [1] Lusco MA, Najafian B, Alpers CE et al. AJKD atlas of renal pathology: cholesterol emboli. *Am J Kidney Dis* 6:e23–4, 2016
- [2] Rupperecht H. Postinterventionelles Cholesterinemboliesyndrom. *Dtsch Med Wochenschr* 32:1833–36, 2007
- [3] Fine MJ, Kapoor W, Falanga V. Cholesterol crystal embolization: a review of 221 cases in the English literature. *Angiology* 8:769–84, 1987
- [4] Ogbechie OA, Morley KW, Sugai D et al. Limited cutaneous pseudovasculitis: a mild variant of cholesterol emboli syndrome. *Circulation* 131:514–5, 2015
- [5] Rousseau A, de Monchy I, Barreau E et al. Retinal emboli in cholesterol crystal embolism. *Case Rep Ophthalmol Med* 2013:421352, 2013

17.6 Koronarembolie

- [1] Shibata T, Kawakami S, Noguchi T et al. Prevalence, clinical features, and prognosis of acute myocardial infarction attributable to coronary artery embolism. *Circulation* 132:241–50, 2015
- [2] Raphael CE, Heit JA, Reeder GS et al. Coronary embolus: an underappreciated

- cause of acute coronary syndromes. *JACC Cardiovasc Interv* 11:172–80, 2018
- [3] Jungbluth A, Erbel R, Darius H et al. Paradoxical coronary embolism: case report and review of the literature. *Am Heart J* 116:879–85, 1988
 - [4] Marchand F. Zur Kenntnis der Embolie und Thrombose der Gehirnarterien, zugleich ein Beitrag zur Casuistik der primären Herztumoren und der gekreuzten Embolie. *Berl Klin Wochenschr* 31:36, 1894
 - [5] Wąsek WC, Samul W, Ryzek R et al. Unique case of ST-segment-elevation myocardial infarction related to paradoxical embolization and simultaneous pulmonary embolization: clinical considerations on indications for patent foramen ovale closure in no-guidelines land. *Circulation* 131:1214–23, 2015
 - [6] Mügge A, Daniel WG, Wenzlaff P et al. Patent foramen ovale or left atrial thrombi in unexplained arterial embolism. *Lancet* 1:282–3, 1989
 - [7] Hausmann D, Mügge A, Becht I et al. Diagnosis of patent foramen ovale by transesophageal echocardiography and association with cerebral and peripheral embolic events. *Am J Cardiol* 70:668–72, 1992
 - [8] Hausmann D, Mügge A, Daniel WG. Identification of patent foramen ovale permitting paradoxical embolism. *J Am Coll Cardiol* 26:1030–8, 1995
 - [9] Nellessen U, Daniel WG, Matheis G et al. Impending paradoxical embolism from atrial thrombus: correct diagnosis by transesophageal echocardiography and prevention by surgery. *J Am Coll Cardiol* 5:1002–4, 1985
 - [10] Fauveau E, Cohen A, Bonnet N et al. Surgical or medical treatment for thrombus straddling the patent foramen ovale: impending paradoxical embolism? Report of four clinical cases and literature review. *Arch Cardiovasc Dis* 101:637–44, 2008
 - [11] Wahl A, Jüni P, Mono ML et al. Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism. *Circulation* 125:803–12, 2012
 - [12] Uchida S, Yamamoto M, Masaoka Y et al. A case of acute pulmonary embolism and acute myocardial infarction with suspected paradoxical embolism after laparoscopic surgery. *Heart Vessels* 14:197–200, 1999
 - [13] Haghi D, Sueselbeck T, Papavassiliu T et al. Paradoxical coronary embolism causing non-ST segment elevation myocardial infarction in a case of pulmonary embolism. *Z Kardiol* 93:824–8, 2004
 - [14] Rovner A, Valika AA, Kovacs A et al. Possible paradoxical embolism as a rare cause for an acute myocardial infarction. *Echocardiography* 23:407–9, 2006
 - [15] Konstantinides S, Geibel A, Kasper W et al. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism. *Circulation* 97:1946–51, 1998
 - [16] Kälisch H, Wieneke H, Erbel R. Acute myocardial infarction in a patient with chronic myelocytic leukemia during chemotherapy with hydroxyurea. *Herz* 35:420–2, 2010
 - [17] Gutersohn A, Zimmermann U, Bartel T et al. A rare case of acute „infective“ myocardial infarction triggered by acute parvovirus B19 myocarditis. *Nat Clin Pract Cardiovasc Med* 2:167–71, 2005
 - [18] Bommer M, Wölfle-Guter M, Bohl S et al. The differential diagnosis and treatment of thrombotic microangiopathies. *Dtsch Arztebl Int* 115:327–34, 2018
 - [19] Patschan D, Witzke O, Dührsen U et al. Acute myocardial infarction in thrombotic microangiopathies – clinical characteristics, risk factors and outcome. *Nephrol Dial Transplant* 21:1549–54, 2006
 - [20] Brunson JG. Coronary embolism in bacterial endocarditis. *Am J Pathol* 29:689–701, 1953
 - [21] Erbel R, Liu F, Ge J et al. Identification of high-risk subgroups in infective endocarditis and the role of echocardiography. *Eur Heart J* 16:588–602, 1995
 - [22] Breuckmann F, Naber CK, Boese D et al. Mitral valve endocarditis leading to acute myocardial and cerebellar infarction in a young adult. *Clin Res Cardiol* 95:657–62, 2006
 - [23] Dauvergne C, Araya M, Valenzuela J et al. Acute myocardial infarction after left-heart catheterization in a patient with severe calcified bicuspid aortic stenosis. *JACC Cardiovasc Interv* 7:e5–6, 2014
 - [24] Murai T, Yonetsu T, Isobe M et al. Coronary embolization caused by pleomorphic

- lung carcinoma. *Intern Med* 55:3607–9, 2016
- [24] Cheng TO. Coronary embolism. *Int J Cardiol* 136:1–3, 2009
- [25] O'Neill W, Timmis GC, Bourdillon PD et al. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. *N Engl J Med* 314:812–8, 1986
- [26] Nunn CM, O'Neill WW, Rothbaum D et al. Long-term outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI-I) trial. *J Am Coll Cardiol* 33:640–6, 1999
- [27] Mehta RH, Harjai KJ, Cox DA et al. Comparison of coronary stenting versus conventional balloon angioplasty on five-year mortality in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. *Am J Cardiol* 96:901–6, 2005
- [28] Kunadian B, Dunning J, Vijayalakshmi K et al. Meta-analysis of randomized trials comparing anti-embolic devices with standard PCI for improving myocardial reperfusion in patients with acute myocardial infarction. *Catheter Cardiovasc Interv* 69:488–96, 2007
- [29] Kuntz RE, Rogers C, Baim DS. Percutaneous coronary intervention-induced emboli during primary PCI for STEMI: too little, too much, or too late? *Am Heart J* 150:4–6, 2005
- [30] Brown ED, Blankenship JC. A mechanism for stroke complicating thrombus aspiration. *Catheter Cardiovasc Interv* 89:93–6, 2017
- [31] Eggebrecht H, Baumgart D, Naber C et al. Extraction of large intracoronary thrombus in acute myocardial infarction by percutaneous Fogarty maneuver: intentional abuse of a novel interventional device. *Catheter Cardiovasc Interv* 55:228–32, 2002
- [32] Satogami K, Ino Y, Kubo T et al. Impact of plaque rupture detected by optical coherence tomography on transmural extent of infarction after successful stenting in ST-segment elevation acute myocardial infarction. *JACC Cardiovasc Interv* 10:1025–33, 2017
- [33] Eick B, Haude M, Altmann C et al. Treatment of a large intracoronary thrombus with urokinase and a chimeric monoclonal platelet aggregation inhibitor. *Dtsch Med Wochenschr* 122:709–15, 1997
- [34] Kahles T, Garcia-Esperon C, Zeller S et al. Mechanical thrombectomy using the new ERIC retrieval device is feasible, efficient, and safe in acute ischemic stroke: A Swiss Stroke Center Experience. *Am J Neuroradiol* 37:114–9, 2016
- [35] Manchurov V, Anisimov K, Khokhlova V et al. The first reported stentriever-based thrombectomy in acute ST-elevation myocardial infarction due to paradoxical coronary embolism. *Eurointerv* 13:e602–3, 2017
- [36] Popovic B, Agrinier N, Bouchahda N et al. Coronary embolism among ST-segment-elevation myocardial infarction patients: mechanisms and management. *Circ Cardiovasc Interv* 11:e005587, 2018

17.7 Bergung von Fremdkörpern

- [1] Alkhouli M, Sievert H et al. Device embolization in structural heart interventions: incidence, outcomes and retrieval techniques. *JACC Cardiovasc Interv* 12:113–26, 2019
- [2] Veldhuijzen FL, Michels HR, el Gamal MI et al. Retrieval of undeployed stents from the right coronary artery: report of two cases. *Cathet Cardiovasc Diagn* 30:245–8, 1993

18 Linksherzunterstützungssysteme

- [1] Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 37:2129–2200, 2016
- [2] Byrne RA, Rossello X, Coughlan JJ et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur Heart J* 44:3720–3826, 2023
- [3] Neumann FJ, Sousa UM, Ahlsson A et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 40:87–165, 2019
- [4] Amin AP, Spertus JA, Curtis JP et al. The evolving landscape of Impella use in the United States among patients undergoing percutaneous coronary intervention with mechanical circulatory support. *Circulation* 141:273–284, 2020
- [5] O'Neill WW, Kleiman NS, Moses J et al. Prospective randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II Study. *Circulation* 126:1717–1727, 2012
- [6] Perera D, Stables R, Thomas M et al., for the BCIS-1 Investigators. Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: a randomized controlled trial. *JAMA* 304:867–874, 2010
- [7] Michels G, Wengenmayer T, Hagl C et al. Recommendations for extracorporeal cardiopulmonary resuscitation (eCPR): consensus statement of DGIIN, DGK, DGTHG, DGfK, DGNI, DGAI, DIVI and GRC. *Clin Res Cardiol* 108:455–464, 2019
- [8] Kantrowitz A, Tjonneland S, Freed PS et al. Initial clinical experience with intra-aortic balloon pumping in cardiogenic shock. *JAMA* 203:113–118, 1968
- [9] Scheidt S, Wilner G, Mueller H et al. Intra-aortic balloon counterpulsation in cardiogenic shock. Report of a co-operative clinical trial. *N Engl J Med* 288:979–984, 1973
- [10] Prondzinsky R, Unverzagt S, Russ M et al. Hemodynamic effects of intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP shock trial. *Shock* 37:378–384, 2012
- [11] Sandhu A, McCoy LA, Negi SI et al. Utilization of mechanical circulatory support in patients undergoing percutaneous coronary intervention: insights from the NCDR. *Circulation* 132:1243–1251, 2015
- [12] Prondzinsky R, Lemm H, Swyter M et al. Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock – the prospective, randomized IABP SHOCK Trial for attenuation of multi-organ dysfunction syndrome. *Crit Care Med* 38:152–160, 2010
- [13] Thiele H, Zeymer U, Neumann F-J et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. *N Engl J Med* 367:1287–1296, 2012
- [14] Thiele H, Zeymer U, Neumann F-J et al. Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock. Final 12-month results of the randomized, open-label trial. *Lancet* 382:1638–1645, 2013
- [15] Thiele H, Zeymer U, Thelemann N et al. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction. Long-term 6-year outcome of the randomized IABP-SHOCK II Trial. *Circulation* 139:395–403, 2019
- [16] Sjaauw KD, Engstrom AE, Vis MM et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? *Eur Heart J* 30:459–468, 2009

- [17] Patel MR, Smalling RW, Thiele H et al. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI Randomized Trial. *JAMA* 306:1329–1337, 2011
- [18] Thiele H, Lauer B, Hambrecht R et al. Reversal of cardiogenic shock by percutaneous left-atrial-to-femoral arterial bypass assistance. *Circulation* 104:2917–2922, 2001
- [19] Thiele H, Sick P, Boudriot E et al. Randomized comparison of intraaortic balloon support versus a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. *Eur Heart J* 26:1276–1283, 2005
- [20] Burkhoff D, Cohen H, Brunckhorst C et al. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. *Am Heart J* 152:469.e1–469.e8, 2006
- [21] Aragon J, Lee MS, Kar S et al. Percutaneous left ventricular assist device: „TandemHeart“ for high-risk coronary intervention. *Catheter Cardiovasc Interv* 65:346–352, 2005
- [22] Vranckx P, Foley DP, Feijter PJ et al. Clinical introduction of the TandemHeart, a percutaneous left ventricular assist device, for circulatory support during high-risk percutaneous coronary intervention. *Int J Cardiovasc Intervent* 5:35–39, 2003
- [23] Seyfarth M, Sibbing D, Bauer I et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. *J Am Coll Cardiol* 52:1584–1588, 2008
- [24] Ouweneel DM, Eriksen E, Sjauw KD et al. Impella CP versus intra-aortic balloon pump support in acute myocardial infarction complicated by cardiogenic shock. The IMPRESS in Severe Shock trial. *J Am Coll Card* 69:278–287, 2017
- [25] Bochaton T, Huot L, Elbaz M et al. Mechanical circulatory support with the Impella® LP5.0 pump and an intra-aortic balloon pump for cardiogenic shock in acute myocardial infarction: the IMPELLA-STIC randomized study. *Arch Cardiovasc Dis* 113:237–243, 2020
- [26] Baumann S, Werner N, Ibrahim K et al. Indication and short-term clinical outcomes of high-risk percutaneous coronary intervention with microaxial Impella® pump: results from the German Impella® registry. *Clin Res Cardiol* 107:653–657, 2018
- [27] Dudek D, Ebner A, Sobczyński R et al. Efficacy and safety of the HeartMate percutaneous heart pump during high-risk percutaneous coronary intervention (from the SHIELD I Trial). *Am J Cardiol* 121:1524–1529, 2018
- [28] van Mieghem NM, Daemen J, Lenzen MJ et al. The PulseCath iVAC 2L left ventricular assist device: conversion to a percutaneous transfemoral approach. *EuroIntervention* 11:835–839, 2015
- [29] den Uil CA, Daemen J, Lenzen MJ et al. Pulsatile iVAC 2L circulatory support in high-risk percutaneous coronary intervention. *EuroIntervention* 12:1689–1696, 2017
- [30] Samol A, Schmidt S, Zeyse M et al. High-risk PCI under support of a pulsatile left ventricular assist device – first German experience with the iVAC2L system. *Int J Cardiol* 297:30–35, 2019
- [31] Russo JJ, Aleksova N, Pitcher I et al. Left ventricular unloading during extracorporeal membrane oxygenation in patients with cardiogenic shock. *J Am Coll Card* 73:654–662, 2019
- [32] Karagiannidis C, Brodie D, Strassmann S et al. Extracorporeal membrane oxygenation: evolving epidemiology and mortality. *Intensive Care Med* 42:889–896, 2016
- [33] Ouweneel DM, Schotborgh JV, Limpens J et al. Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. *Intensive Care Med* 42:1922–1934, 2016
- [34] de Waha S, Graf T, Desch S et al. Outcome of elderly undergoing extracorporeal life support in refractory cardiogenic shock. *Clin Res Cardiol* 106:379–385, 2017
- [35] Brunner S, Guenther SPW, Lackermair K et al. Extracorporeal life support in cardiogenic shock complicating acute myocardial infarction. *J Am Coll Card* 73:2355–2357, 2019

19 Koronarfsteln und Fstelverschluss

- [1] Sommer RJ, Hijazi ZM, Rhodes JF Jr. Pathophysiology of congenital heart disease in the adult. Part I: Shunt lesions. *Circulation* 117:1090–9, 2008
- [2] Yamanaka O, Hobbs RE. Coronary artery anomalies in 126,595 patients undergoing coronary arteriography. *Cathet Cardiovasc Diagn* 21:28–40, 1990
- [3] Krause W. Über den Ursprung einer accessorischen A. coronaria cordis aus der A. pulmonalis. *Z Rat Med* 24:225–7, 1865
- [4] Francisco ARG, Nobre de Menezes M, Pinto FJ et al. Acquired fistula from left anterior descending artery to coronary sinus: an unusual finding during percutaneous coronary intervention. *Rev Port Cardiol* 37:355–7, 2018
- [5] Gupta M. Coronary artery fistula. Background, pathophysiology, etiology, epidemiology, prognosis, treatment, medication. the heart org/Medscape, 2020. <https://emedicine.medscape.com/article/895749-overview> (18.11.22)
- [6] Klein LW. A new hypothesis of the developmental origin of congenital left anterior descending coronary artery to pulmonary artery fistulas. *Catheter Cardiovasc Interv* 1:568–71, 2008
- [7] Schlesinger MJ, Zoll PM, Wessler S. The conus artery: a third coronary artery. *Am Heart* 38:823–36, 1949
- [8] O'Leary EL, Garza L, Williams M et al. Images in cardiovascular medicine. Vieussens' ring. *Circulation* 98:487–8, 1998
- [9] Hansen MW, Merchant N. Images in cardiovascular medicine. Vieussens' ring: combining computed tomography coronary angiography and magnetic resonance imaging in assessing collateral pathways. *Circulation* 114:e545–6, 2006
- [10] Zenooz NA, Habibi R, Mammen L et al. Coronary artery fistulas: CT findings. *Radiographics* 29:781–9, 2009
- [11] Pan YY, Chen G, Chen B et al. Prevalence of coronary artery fistula in a single center of China. *Chin Med J (Engl)* 131:1492–5, 2018
- [12] Thebesius A. *Disputatio medica inauguralis de circulo sanguinis in corde*. Lugduni Batavorum, Leiden, 1708
- [13] Ansari A. Anatomy and clinical significance of ventricular Thebesian veins. *Clin Anat* 14:102–10, 2001
- [14] Adjedj J, Meert V, Vanderheyden M et al. Direct coronary drainage to the left ventricle via Thebesian veins: series report with histologic and cardiac CT analysis. *EuroIntervention* 11:1564, 2016
- [15] Snodgrass B. The prognosis of Thebesian veins can be obfuscated by conflating the vessels (veins) of Thebesius with coronary artery-cameral connections. *Am J Cardiol* 120:e75, 2017
- [16] Snipelisky D, Reddy YN, Lennon RJ et al. Cardiac structural changes and long-term survival in patients with prominent Thebesian veins. *Am J Cardiol* 118:1264–7, 2016
- [17] Cornel JH, Ten Cate FJ, Serruys PW. Myocardial contrast echocardiography can depict Thebesian vein outflow in humans. *Am Heart J* 123:1373–4, 1992
- [18] Schamroth C. Coronary artery fistula. *J Am Coll Cardiol* 53:523, 2009
- [19] Libertini R, Walbridge D, Jones HR et al. Giant circumflex artery aneurysm with a coronary sinus fistula. *Ann Thorac Surg* 106:e223–5, 2018
- [20] Challoumas D, Pericleous A, Dimitrakaki IA et al. Coronary arteriovenous fistulae: a review. *Int J Angiol* 23:1–10, 2014
- [21] Maleszka A, Kleikamp G, Minami K et al. Giant coronary arteriovenous fistula: a case report and review of the literature. *Z Kardiol* 94:38–43, 2005
- [22] Palloschi A, Aprigliano G. Myocardial ischemia due to a large coronary-pulmonary fistula with plexus-like morphology. *J Cardiovasc Med (Hagerstown)* 9:1163–5, 2008

- [23] Taha ME, Al-Khafaji J, Abdalla AO et al. Coronary artery-left ventricular fistula and Takotsubo cardiomyopathy – an association or an incidental finding? A Case Report. *Am J Case Rep* 19:614–8, 2018
- [24] Lim JJ, Jung JI, Lee BY et al. Prevalence and types of coronary artery fistulas detected with coronary CT angiography. *AJR Am J Roentgenol* 203:W237–43, 2014
- [25] Yang Y, Bartel T, Caspari G et al. Echocardiographic detection of coronary artery fistula into the pulmonary artery. *Eur J Echocardiogr* 2:292–4, 2001
- [26] Strange JW, Bucciarelli-Ducci C, Mathur A et al. Images in cardiovascular medicine. Multiple coronary fistulae: a cause of sub-endocardial ischemia. *Circulation* 117:853–6, 2008
- [27] Akcay M, Sayit AT, Gulel O et al. Multimodality imaging of a rare type of coronary cameral fistula. *J Saudi Heart Assoc* 30:276–8, 2018
- [28] Chiricolo A, Pantin E, Raffel B et al. Ruptured giant coronary artery aneurysm with coronary artery to pulmonary artery fistula presenting as cardiac tamponade diagnosed by intraoperative transesophageal echocardiography: a case report. *A A Pract* 11:68–70, 2018
- [29] Abdelmoneim SS, Mookadam F, Moustafa S et al. Coronary artery fistula: single-center experience spanning 17 years. *J Interv Cardiol* 20:265–74, 2007
- [30] Demirkilic U, Ozal E, Bingol H et al. Surgical treatment of coronary artery fistulas: 15 years' experience. *Asian Cardiovasc Thorac Ann* 2:133–8, 2004
- [31] Hol PK, Geiran O, Andersen K et al. Improvement of coronary artery fistula surgery by intraoperative imaging. *Ann Thorac Surg* 8:2193–5, 2004
- [32] Van Loo I, Sonck J, Tanaka K et al. Thoracoscopic off-pump closure of a large left circumflex coronary artery fistula: A novel minimally invasive approach. *J Thorac Cardiovasc* 156:e159–61, 2018
- [33] Reidy JF, Sowton E, Ross DN. Transcatheter occlusion of coronary to bronchial anastomosis by detachable balloon combined with coronary angioplasty at the same procedure. *Br Heart J* 49:284–7, 1983
- [34] Reidy JF, Anjos RT, Qureshi SA et al. Transcatheter embolization in the treatment of coronary artery fistulas. *J Am Coll Cardiol* 18:187–92, 1991
- [35] Strunk BL, Hieshima GB, Shafton EP. Treatment of congenital coronary arteriovenous malformations with microparticle embolization. *Cathet Cardiovasc Diagn* 22:133–6, 1991
- [36] Dorros G, Thota V, Ramireddy K et al. Catheter-based techniques for closure of coronary fistulae. *Catheter Cardiovasc Interv* 46:143–50, 1999
- [37] Kambara AM, Pedra CA, Esteves CA et al. Transcatheter embolization of congenital coronary arterial fistulas in adults. *Cardiol Young* 9:371–6, 1999
- [38] Okubo M, Nykanen D, Benson LN. Outcomes of transcatheter embolization in the treatment of coronary artery fistulas. *Catheter Cardiovasc Interv* 2:510–7, 2001
- [39] Armsby LR, Keane JF, Sherwood MC et al. Management of coronary artery fistulae. Patient selection and results of transcatheter closure. *J Am Coll Cardiol* 39:1026–32, 2002
- [40] Oldenburg O, Philipp T, Forsting M et al. Percutaneous, catheter-based coil embolization of coronary fistula: determination of hemodynamic relevance. *J Interv Cardiol* 6:343–6, 2003
- [41] Naber CK, Doerfler A, Churzidze S et al. Percutaneous coil embolization of a large, congenital coronary-pulmonary fistula using hydrophilic-coated detachable platinum coils. *Herz* 9:218–9, 2004
- [42] Kharouf R, Cao QL, Hijazi ZM. Transcatheter closure of coronary artery fistula complicated by myocardial infarction. *J Invasive Cardiol* 9:E146–9, 2007
- [43] Collins N, Mehta R, Benson L et al. Percutaneous coronary artery fistula closure in adults: technical and procedural aspects. *Catheter Cardiovasc Interv* 69:872–80, 2008
- [44] Kiernan T, Yan BP, Rosenfield K et al. Coil embolization of an iatrogenic coronary artery to cardiac vein fistula after rotational atherectomy. *J Interv Cardiol* 1:410–3, 2008
- [45] Wiegand G, Sieverding L, Kaulitz R et al. Transarterial and transvenous approach for transcatheter closure of a large coronary artery fistula with the Amplatzer vascular plug. *Pediatr Cardiol* 30:172–5, 2009
- [46] Said SM, Burkhart HM, Schaff HV et al. Late outcome of repair of congenital coronary artery fistulas – a word of caution. *J Thor Cardiovasc Surg* 145:455–60, 2013

- [47] Warnes CA, Williams RG, Bashore TM et al. ACC/AHA 2008 Guidelines for the management of adults with congenital heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 118(23):2395–451, 2008
- [48] Stout KK, Daniels CJ, Aboulhosn JA et al. 2018 AHA/ACC Guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 73:e81–e192, 2019

20 Interventionelle Therapie struktureller Herzerkrankungen

20.1 Aortenklappenstenose

- [1] Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. *Circulation* 111:920–925, 2005
- [2] Baumgartner H, Hung J, Bermejo J et al. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *J Am Soc Echocardiogr* 30:372–392, 2017
- [3] Baumgartner H, Falk V, Bax JJ et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 38:2739–2791, 2017
- [3a] Vahanian A, Beyersdorf F, Praz F et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 43(7):561–632, 2021
- [3b] Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. ESC Pocket Guidelines. Herzklappenerkrankungen, Version 2021. Börm Bruckmeier, Grünwald, 2022
- [4] Schwarz F, Baumann P, Manthey J et al. The effect of aortic valve replacement on survival. *Circulation* 66:1105–1110, 1982
- [5] Cribier A, Eltchaninoff H, Bash A et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. *Circulation* 106:3006–3008, 2002
- [6] Omran H, Schmidt H, Hackenbroch M et al. Silent and apparent cerebral embolism after retrograde catheterisation of the aortic valve in valvular stenosis: a prospective, randomised study. *Lancet* 361:1241–1246, 2003
- [7] Cribier A, Savin T, Saoudi N et al. Percutaneous transluminal valvuloplasty of acquired aortic stenosis in elderly patients: an alternative to valve replacement. *Lancet* 1:63–67, 1986
- [8] Cribier A, Remadi F, Koning R et al. Emergency balloon valvuloplasty as initial treatment of patients with aortic stenosis and cardiogenic shock. *N Engl J Med* 326:646, 1992
- [9] Otto CM, Mickel MC, Kennedy JW et al. Three-year outcome after balloon aortic valvuloplasty. Insights into prognosis of valvular aortic stenosis. *Circulation* 89:642–650, 1994
- [10] Serruys PW, Luijten HE, Beatt KJ et al. Percutaneous balloon valvuloplasty for calcific aortic stenosis. A treatment „sine cure“? *Eur Heart J* 9:782–794, 1988
- [11] Lieberman EB, Bashore TM, Hermiller JB et al. Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. *J Am Coll Cardiol* 26:1522–1528, 1995
- [12] Litvack F, Jakubowski AT, Buchbinder NA et al. Lack of sustained clinical improvement in an elderly population after percutaneous aortic valvuloplasty. *Am J Cardiol* 62:270–275, 1988
- [13] Sack S, Kahlert P, Khandanpour S et al. Revival of an old method with new techniques: balloon aortic valvuloplasty of the calcified aortic stenosis in the elderly. *Clin Res Cardiol* 97:288–297, 2008
- [14] Agatiello C, Eltchaninoff H, Tron C et al. Balloon aortic valvuloplasty in the adult. Immediate results and in-hospital complications in the latest series of 141 consecutive patients at the University Hospital of Rouen (2002–2005). *Arch Mal Coeur Vaiss* 99:195–200, 2006
- [15] Sack S, Henrichs KJ, Erbel R et al. Echocardiographic and angiographic evaluation

- of left ventricular function during percutaneous transluminal aortic valvuloplasty. *Cathet Cardiovasc Diagn* 26:82–91, 1992
- [16] Ben-Dor I, Maluenda G, Dvir D et al. Outcomes of concomitant percutaneous coronary intervention and balloon aortic valvuloplasty. *Catheter Cardiovasc Interv* 82:E835–E841, 2013
 - [17] Vahanian A, Baumgartner H, Bax J et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. *Eur Heart J* 28:230–268, 2007
 - [18] Charlson E, Legedza AT, Hamel MB. Decision-making and outcomes in severe symptomatic aortic stenosis. *J Heart Valve Dis* 15:312–321, 2006
 - [19] Iung B, Baron G, Butchart EG et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. *Eur Heart J* 24:1231–1243, 2003
 - [20] Roques F, Nashef SA, Michel P et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. *Eur J Cardiothorac Surg* 15:816–822, 1999; discussion 822–833, 1999
 - [21] Vaquette B, Corbineau H, Laurent M et al. Valve replacement in patients with critical aortic stenosis and depressed left ventricular function: predictors of operative risk, left ventricular function recovery, and long term outcome. *Heart* 91:1324–1329, 2005
 - [22] Nashef SA, Roques F, Michel P et al. European system for cardiac operative risk evaluation (EuroSCORE). *Eur J Cardiothorac Surg* 16:9–13, 1999
 - [23] O'Brien SM, Shahian DM, Filardo G et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2 – isolated valve surgery. *Ann Thorac Surg* 88:S23–S42, 2009
 - [24] Iung B, Cachier A, Baron G et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery. *Eur Heart J* 26:2714–2720, 2005
 - [25] Hanzel GS, Harrity PJ, Schreiber TL et al. Retrograde percutaneous aortic valve implantation for critical aortic stenosis. *Catheter Cardiovasc Interv* 64:322–326, 2005
 - [26] Webb JG, Chandavimol M, Thompson CR et al. Percutaneous aortic valve implantation retrograde from the femoral artery. *Circulation* 113:842–850, 2006
 - [27] Lichtenstein SV, Cheung A, Ye J et al. Transapical transcatheter aortic valve implantation in humans: initial clinical experience. *Circulation* 114:591–596, 2006
 - [28] Cribier A, Eltchaninoff H, Tron C et al. Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. *J Am Coll Cardiol* 43:698–703, 2004
 - [29] Cribier A, Eltchaninoff H, Tron C et al. Treatment of calcific aortic stenosis with the percutaneous heart valve: mid-term follow-up from the initial feasibility studies: the French experience. *J Am Coll Cardiol* 47:1214–1223, 2006
 - [30] Ye J, Cheung A, Lichtenstein SV et al. Transapical aortic valve implantation in humans. *J Thorac Cardiovasc Surg* 131:1194–1196, 2006
 - [31] Webb JG, Pasupati S, Humphries K et al. Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis. *Circulation* 116:755–763, 2007
 - [32] Walther T, Simon P, Dewey T et al. Transapical minimally invasive aortic valve implantation: multicenter experience. *Circulation* 116: 1240–1245, 2007
 - [33] Grube E, Laborde JC, Zickmann B et al. First report on a human percutaneous transluminal implantation of a self-expanding valve prosthesis for interventional treatment of aortic valve stenosis. *Catheter Cardiovasc Interv* 66:465–469, 2005
 - [34] Grube E, Laborde JC, Gerckens U et al. Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. *Circulation* 114:1616–1624, 2006
 - [35] Grube E, Schuler G, Buellesfeld L et al. Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. *J Am Coll Cardiol* 50:69–76, 2007
 - [36] Grube E, Buellesfeld L, Mueller R et al. Progress and current status of percutaneous aortic valve replacement: results of three device generations of the CoreValve

- Revalving system. *Circ Cardiovasc Interv* 1:167–175, 2008
- [37] Piazza N, Grube E, Gerckens U et al. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) core-valve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. *Euro-Intervention* 4:242–249, 2008
- [38] Leon MB, Smith CR, Mack M et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med* 363:1597–1607, 2010
- [39] Smith CR, Leon MB, Mack MJ et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med* 364:2187–2198, 2011
- [40] Adams DH, Popma JJ, Reardon MJ et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. *N Engl J Med* 370:1790–1798, 2014
- [41] Leon MB, Smith CR, Mack MJ et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. *N Engl J Med* 374:1609–1620, 2016
- [42] Reardon MJ, Van Mieghem NM, Popma JJ et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. *N Engl J Med* 376:1321–1331, 2017
- [43] Popma JJ, Deeb GM, Yakubov SJ et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. *N Engl J Med* 380:1706–1715, 2019
- [44] Mack MJ, Leon MB, Thourani VH et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. *N Engl J Med* 380:1695–1705, 2019
- [45] Abdel-Wahab M, Mehilli J, Frerker C et al. Comparison of balloon-expandable vs self-expandable valves in patients undergoing transcatheter aortic valve replacement: the CHOICE randomized clinical trial. *JAMA* 311:1503–1514, 2014
- [46] Feldman TE, Reardon MJ, Rajagopal V et al. Effect of mechanically expanded vs self-expanding transcatheter aortic valve replacement on mortality and major adverse clinical events in high-risk patients with aortic stenosis: The REPRISE III randomized clinical trial. *JAMA* 319:27–37, 2018
- [47] Lanz J, Kim WK, Walther T et al. Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial. *Lancet* 394:1619–1628, 2019
- [48] Figulla HR, Cremer J, Walther T et al. Positionspapier zur kathetergeführten Aortenklappenintervention. *Kardiologie* 3:199–206, 2009
- [49] Kuck KH, Eggebrecht H, Figulla HR et al. Positionspapier zu Qualitätskriterien zur Durchführung der transkatheteren Aortenklappenimplantation (TAVI). *Kardiologie* 9:11–26, 2015
- [50] Kuck KH, Eggebrecht H, Elsässer A et al. Qualitätskriterien zur Durchführung der kathetergestützten Aortenklappenimplantation (TAVI). Aktualisierung des Positionspapiers der Deutschen Gesellschaft für Kardiologie. *Kardiologie* 10:282–300, 2016
- [51] Vahanian A, Alfieri O, Al-Attar N et al. Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 29:1463–1470, 2008
- [52] Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) et al. Guidelines on the management of valvular heart disease (version 2012). *Eur Heart J* 33:2451–2496, 2012
- [53] Baumgartner H, Cremer J, Eggebrecht H et al. Kommentar zu den Leitlinien (2017) der ESC/EACTS zum Management von Herzklappenerkrankungen. *Kardiologie* 12:184–193:2018
- [54] Hildebrandt HA, Mahabadi AA, Totzeck M et al. Imaging for planning of transcatheter aortic valve implantation. *Herz* 42:554–563, 2017; Erratum: *Herz* 42:564, 2017
- [55] Gerckens U, Pizzulli L, Raisakis K. Alcohol septal ablation as a bail-out procedure for suicide left ventricle after transcatheter aortic valve implantation. *J Invasive Cardiol* 25:E114–E117, 2013

- [56] Binder RK, Webb JG, Willson AB et al. The impact of integration of a multidetector computed tomography annulus area sizing algorithm on outcomes of transcatheter aortic valve replacement: a prospective, multicenter, controlled trial. *J Am Coll Cardiol* 62:431–438, 2013
- [57] Blanke P, Reinöhl J, Schlensak C et al. Prosthesis oversizing in balloon-expandable transcatheter aortic valve implantation is associated with contained rupture of the aortic root. *Circ Cardiovasc Interv* 5:540–548, 2012
- [58] Nietlispach F, Leipsic J, Al-Bugami S et al. CT of the ilio-femoral arteries using direct aortic contrast injection: proof of feasibility in patients screened towards percutaneous aortic valve replacement. *Swiss Med Wkly* 139:458–462, 2009
- [59] Otto CM, Kumbhani DJ, Alexander KP et al. 2017 ACC Expert consensus decision pathway for transcatheter aortic valve replacement in the management of adults with aortic stenosis: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol* 69:1313–1346, 2017
- [60] Bundesministerium für Gesundheit. Richtlinie über Maßnahmen zur Qualitätssicherung bei der Durchführung von minimal-invasiven Herzklappeninterventionen gemäß § 137 Absatz 1 Satz 1 Nummer 2 für nach § 108 SGB V zugelassene Krankenhäuser (Richtlinie zu minimalinvasiven Herzklappeninterventionen/MHI-RK). *BAnz AT* 24.07.2015 B6, 2015
- [61] Schymik G, Wendler O, Hengstenberg C et al. Outcomes of transfemoral balloon expandable transcatheter aortic valve implantation: comparison of two subsequent valve generations. *Catheter Cardiovasc Interv* 96:930–939, 2020
- [62] Thomas M, Schymik G, Walther T et al. Thirty-day results of the Sapien aortic Bioprosthesis European Outcome (SOURCE) Registry: a European registry of transcatheter aortic valve implantation using the Edwards Sapien valve. *Circulation* 122:62–69, 2010
- [63] Schymik G, Lefèvre T, Bartorelli AL et al. European experience with the second-generation Edwards Sapien XT transcatheter heart valve in patients with severe aortic stenosis: 1-year outcomes from the SOURCE XT Registry. *JACC Cardiovasc Interv* 8:657–669, 2015
- [64] Wendler O, Schymik G, Treede H et al. SOURCE 3 Registry: design and 30-day results of the European postapproval registry of the latest generation of the Sapien 3 transcatheter heart valve. *Circulation* 135:1123–1132, 2017
- [65] Wendler O, Schymik G, Treede H et al. SOURCE 3: 1-year outcomes post-transcatheter aortic valve implantation using the latest generation of the balloon-expandable transcatheter heart valve. *Eur Heart J* 38:2717–272, 2017
- [66] Saia F, Gandolfo C, Palmerini T et al. In-hospital and thirty-day outcomes of the SAPIEN 3 Ultra balloon-expandable transcatheter aortic valve: the S3U registry. *EuroIntervention* 15:1240–1247, 2020
- [67] Buellesfeld L, Gerckens U, Schuler G et al. 2-year follow-up of patients undergoing transcatheter aortic valve implantation using a self-expanding valve prosthesis. *J Am Coll Cardiol* 57:1650–1657, 2011
- [68] Ussia GP, Barbanti M, Petronio AS et al. Transcatheter aortic valve implantation: 3-year outcomes of self-expanding CoreValve prosthesis. *Eur Heart J* 33:969–976, 2012
- [69] Grube E, Van Mieghem NM, Bleiziffer S et al. Clinical outcomes with a repositionable self-expanding transcatheter aortic valve prosthesis: the international FORWARD study. *J Am Coll Cardiol* 70:845–853, 2017
- [70] Manoharan G, Van Mieghem NM, Windecker S et al. 1-year outcomes with the Evolut R self-expanding transcatheter aortic valve: from the international FORWARD study. *JACC Cardiovasc Interv* 11:2326–2334, 2018
- [71] Popma JJ, Reardon MJ, Khabbaz K et al. Early clinical outcomes after transcatheter aortic valve replacement using a novel self-expanding bioprosthesis in patients with severe aortic stenosis who are suboptimal for surgery: results of the Evolut R U.S. study. *JACC Cardiovasc Interv* 10:268–275, 2017
- [72] Forrest JK, Mangi AA, Popma JJ et al. Early outcomes with the Evolut PRO repositionable self-expanding transcatheter aortic valve with pericardial wrap. *JACC Cardiovasc Interv* 11:160–168, 2018

- [73] Möllmann H, Hengstenberg C, Hilker M et al. Real-world experience using the ACURATE neo prosthesis: 30-day outcomes of 1000 patients enrolled in the SAVI TF registry. *EuroIntervention* 13:e1764-e1770, 2018
- [74] Kim WK, Hengstenberg C, Hilker M et al. The SAVI-TF Registry: 1-year outcomes of the European post-market registry using the ACURATE neo transcatheter heart valve under real-world conditions in 1000 patients. *JACC Cardiovasc Interv* 11:1368–1374, 2018
- [75] Wenaweser P, Stortecky S, Schütz T et al. Transcatheter aortic valve implantation with the NVT Allegra transcatheter heart valve system: first-in-human experience with a novel self-expanding transcatheter heart valve. *EuroIntervention* 12:71–77, 2016
- [76] Manoharan G, Linke A, Moellmann H et al. Multicentre clinical study evaluating a novel resheathable annular functioning self-expanding transcatheter aortic valve system: safety and performance results at 30 days with the Portico system. *EuroIntervention* 12:768–774, 2016
- [77] Linke A, Holzhey D, Möllmann H et al. Treatment of aortic stenosis with a self-expanding, resheathable transcatheter valve: one-year results of the international multicenter Portico transcatheter aortic valve implantation system study. *Circ Cardiovasc Interv* 11:e005206, 2018
- [78] Hyman MC, Vemulapalli S, Szeto WY et al. Conscious sedation versus general anesthesia for transcatheter aortic valve replacement: insights from the National Cardiovascular Data Registry Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. *Circulation* 136:2132–2140, 2017
- [79] Walther T, Simon P, Dewey T et al. Transapical minimally invasive aortic valve implantation: multicenter experience. *Circulation* 116:I240–I245, 2007
- [80] Ruge H, Lange R, Bleiziffer S et al. First successful aortic valve implantation with the CoreValve ReValving system via right subclavian artery access: a case report. *Heart Surg Forum* 11:E323–E324, 2008
- [81] Fraccaro C, Napodano M, Tarantini G et al. Expanding the eligibility for transcatheter aortic valve implantation the transsubclavian retrograde approach using: the III generation CoreValve revalving system. *JACC Cardiovasc Interv* 2:828–833, 2009
- [82] Petronio AS, De Carlo M, Bedogni F et al. Safety and efficacy of the subclavian approach for transcatheter aortic valve implantation with the CoreValve revalving system. *Circ Cardiovasc Interv* 3:359–366, 2010
- [83] Testa L, Brambilla N, Laudisa ML et al. Right subclavian approach as a feasible alternative for transcatheter aortic valve implantation with the CoreValve ReValving system. *EuroIntervention* 8:685–690, 2012
- [84] Schäfer U, Ho Y, Frerker C et al. Direct percutaneous access technique for transaxillary transcatheter aortic valve implantation: „the Hamburg Sankt Georg approach“. *JACC Cardiovasc Interv* 5:477–486, 2012
- [85] Bauernschmitt R, Schreiber C, Bleiziffer S et al. Transcatheter aortic valve implantation through the ascending aorta: an alternative option for no-access patients. *Heart Surg Forum* 12:E63–E64, 2009
- [86] Bapat V, Attia R. Transaortic transcatheter aortic valve implantation: step-by-step guide. *Semin Thorac Cardiovasc Surg* 24:206–211, 2012
- [87] Cocchieri R, Petzina R, Romano M et al. Outcomes after transaortic transcatheter aortic valve implantation: long-term findings from the European ROUTE†. *Eur J Cardiothorac Surg* 55:737–743, 2019
- [88] Philipsen TE, Rodrigus IE, Claeys MJ et al. Alternative access in transcatheter aortic valve implantation: brachiocephalic artery access. *Innovations (Phila)* 7:372–375, 2012
- [89] Kiser AC, Caranasos TG, Peterson MD et al. Suprasternal transcatheter aortic valve replacement in patients with marginal femoral access. *Innovations (Phila)* 13:1–4, 2018
- [90] Modine T, Lemesle G, Azzaoui R et al. Aortic valve implantation with the CoreValve ReValving System via left carotid artery access: first case report. *J Thorac Cardiovasc Surg* 140:928–929, 2010
- [91] Mylotte D, Sudre A, Teiger E et al. Transcarotid transcatheter aortic valve replacement: feasibility and safety. *JACC Cardiovasc Interv* 9:472–480, 2016
- [92] Debry N, Delhay C, Azmoun A et al. Transcarotid transcatheter aortic valve replacement: general or local anesthesia.

- JACC Cardiovasc Interv 9:2113–2120, 2016
- [93] Lederman RJ, Babaliaros VC, Greenbaum AB. How to perform transcaval access and closure for transcatheter aortic valve implantation. *Catheter Cardiovasc Interv* 86:1242–1254, 2015
- [94] Greenbaum AB, O'Neill WW, Paone G et al. Caval-aortic access to allow transcatheter aortic valve replacement in otherwise ineligible patients: initial human experience. *J Am Coll Cardiol* 63:2795–2804, 2014
- [95] Greenbaum AB, Babaliaros VC, Chen MY, Stine AM, Rogers T, O'Neill WW, Paone G, Thourani VH, Muhammad KI, Leonard RA, Ramee S, Froendle JF, Lederman RJ. Transcaval access and closure for transcatheter aortic valve replacement: a prospective investigation. *J Am Coll Cardiol* 69:511–521, 2017
- [96] Costa G, De Backer O, Pilgrim T et al. Feasibility and safety of transcatheter aortic valve implantation: a multicentre European registry. *EuroIntervention* 15:e1319–e1324, 2020
- [97] Fröhlich GM, Baxter PD, Malkin CJ et al. Comparative survival after transapical, direct aortic, and subclavian transcatheter aortic valve implantation (data from the UK TAVI registry). *Am J Cardiol* 116:1555–1559, 2015
- [98] Rodés-Cabau J, Puri R, Chamandi C. The caval-aortic access for performing TAVR: pushing the limits of alternative access for nontransfemoral candidates. *J Am Coll Cardiol* 69:522–525, 2017
- [99] Lanz J, Greenbaum A, Pilgrim T et al. Current state of alternative access for transcatheter aortic valve implantation. *EuroIntervention* 14:AB40–AB52, 2018
- [100] Toutouzas K, Benetos G, Voudris V et al. Pre-dilatation versus no pre-dilatation for implantation of a self-expanding valve in all comers undergoing TAVR: the DIRECT trial. *JACC Cardiovasc Interv* 12:767–777, 2019
- [101] Dumonteil N, Terkelsen C, Frerker C et al. Outcomes of transcatheter aortic valve replacement without predilation of the aortic valve: insights from 1544 patients included in the SOURCE 3 registry. *Int J Cardiol* 296:32–37, 2019
- [102] Auffret V, Regueiro A, Campelo-Parada F et al. Feasibility, safety, and efficacy of transcatheter aortic valve replacement without balloon predilation: a systematic review and meta-analysis. *Catheter Cardiovasc Interv* 90:839–850, 2017
- [103] Butter C, Okamoto M, Schymik G et al. Degree of valve calcification in patients undergoing transfemoral transcatheter aortic valve implantation with and without balloon aortic valvuloplasty: findings from the multicenter EASE-IT TF registry. *Catheter Cardiovasc Interv* 94:469–478, 2019
- [104] Cilingiroglu M, Margmakiolis K. Predilatation for transcatheter aortic valve replacement: still have a role. *Catheter Cardiovasc Interv* 94:479–480, 2019
- [105] Patsalis PC, Al-Rashid F, Neumann T et al. Preparatory balloon aortic valvuloplasty during transcatheter aortic valve implantation for improved valve sizing. *JACC Cardiovasc Interv* 6:965–971, 2013
- [106] Sinning JM, Hammerstingl C, Vasa-Nicotera M et al. Aortic regurgitation index defines severity of peri-prosthetic regurgitation and predicts outcome in patients after transcatheter aortic valve implantation. *J Am Coll Cardiol* 59:1134–1141, 2012
- [107] Patsalis PC, Konorza TF, Al-Rashid F et al. Incidence, outcome and correlates of residual paravalvular aortic regurgitation after transcatheter aortic valve implantation and importance of haemodynamic assessment. *EuroIntervention* 8:1398–1406, 2013
- [108] Patsalis PC, Konorza TF, Al-Rashid F et al. Hemodynamic assessment of paravalvular aortic regurgitation after TAVI: estimated myocardial supply-demand ratio and cardiovascular mortality. *Am J Physiol Heart Circ Physiol* 304:H1023–H1028, 2013
- [109] Kahlert P, Al-Rashid F, Plicht B et al. Incidence, predictors, origin and prevention of early and late neurological events after transcatheter aortic valve implantation (TAVI): a comprehensive review of current data. *J Thromb Thrombolysis* 35:436–449, 2013
- [110] Kahlert P, Knipp SC, Schlamann M et al. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study. *Circulation* 121:870–878, 2010

- [111] Ghanem A, Müller A, Nähle CP et al. Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusion-weighted magnetic resonance imaging. *J Am Coll Cardiol* 55:1427–1432, 2010
- [112] Arnold M, Schulz-Heise S, Achenbach S et al. Embolic cerebral insults after transapical aortic valve implantation detected by magnetic resonance imaging. *JACC Cardiovasc Interv* 3:1126–1132, 2010
- [113] Rodés-Cabau J, Dumont E, Boone RH et al. Cerebral embolism following transcatheter aortic valve implantation: comparison of transfemoral and transapical approaches. *J Am Coll Cardiol* 57:18–28, 2011
- [114] Astarci P, Glineur D, Kefer J et al. Magnetic resonance imaging evaluation of cerebral embolization during percutaneous aortic valve implantation: comparison of transfemoral and trans-apical approaches using Edwards Sapiens valve. *Eur J Cardiothorac Surg* 40:475–479, 2011
- [115] Fairbairn TA, Mather AN, Bijsterveld P et al. Diffusion-weighted MRI determined cerebral embolic infarction following transcatheter aortic valve implantation: assessment of predictive risk factors and the relationship to subsequent health status. *Heart* 98:18–23, 2012
- [116] Lansky AJ, Schofer J, Tchetché D et al. A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTION device during transcatheter aortic valve implantation: results from the DEFLECT III trial. *Eur Heart J* 36:2070–2078, 2015
- [117] Haussig S, Mangner N, Dwyer MG et al. Effect of a cerebral protection device on brain lesions following transcatheter aortic valve implantation in patients with severe aortic stenosis: the CLEAN-TAVI randomized clinical trial. *JAMA* 316:592–601, 2016
- [118] Van Mieghem NM, van Gils L, Ahmad H et al. Filter-based cerebral embolic protection with transcatheter aortic valve implantation: the randomised MISTRAL-C trial. *EuroIntervention* 12:499–507, 2016
- [119] Kapadia SR, Kodali S, Makkar R et al. Protection against cerebral embolism during transcatheter aortic valve replacement. *J Am Coll Cardiol* 69:367–377, 2017
- [120] Dvir D, Webb JG, Bleiziffer S et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. *JAMA* 312:162–170, 2014
- [121] Bernardi FLM, Dvir D, Rodés-Cabau J et al. Valve-in-valve challenges: how to avoid coronary obstruction. *Front Cardiovasc Med* 6:120, 2019
- [122] Makkar RR, Fontana G, Jilaihwai H et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. *N Engl J Med* 373:2015–2024, 2015
- [123] Chakravarty T, Søndergaard L, Friedman J et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. *Lancet* 389:2383–2392, 2017
- [124] Rodés-Cabau J, Masson JB, Welsh RC et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin versus Aspirin + Clopidogrel following transcatheter aortic valve implantation) randomized clinical trial. *JACC Cardiovasc Interv* 10:1357–1365, 2017
- [125] Dangas GD, Tijssen JGP, Wöhrle J et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. *N Engl J Med* 382:120–129, 2019
- [126] De Backer O, Dangas GD, Jilaihwai H et al. Reduced leaflet motion after transcatheter aortic-valve replacement. *N Engl J Med* 382:130–139, 2019
- [127] Collet JP, Berti S, Cequier A et al. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial. *Am Heart J* 200:44–50, 2018
- [128] Nijenhuis VJ, Bennaghmouch N, Hassell M et al. Rationale and design of POPULAR-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation. *Am Heart J* 173:77–85, 2016
- [129] Van Mieghem NM, Unverdorben M, Valgimigli M et al. Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation: Rationale and design of the ENVISAGE-TAVI AF trial. *Am Heart J* 205:63–69, 2018
- [130] Spitzer E, Van Mieghem NM, Pibarot P et al. Rationale and design of The Transca-

- theter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure (TAVR UNLOAD) trial. *Am Heart J* 182:80–88, 2016
- [131] Thielmann M, Eggebrecht H, Wendt D et al. New techniques for the treatment of valvular aortic stenosis – transcatheter aortic valve implantation with the Sapien heart valve. *Minim Invasive Ther Allied Technol* 18:131–141, 2009
- [132] Yoon SH, Lefèvre T, Ahn JM et al. Transcatheter aortic valve replacement with early- and new-generation devices in bicuspid aortic valve stenosis. *J Am Coll Cardiol* 68:1195–1205, 2016
- [133] Yoon SH, Makkar, R. Transcatheter aortic valve replacement for bicuspid aortic valve: challenges and pitfalls. *Interv Cardiol Clin* 7:477–488, 2018
- [134] Yoon SH, Sharma R, Chakravarty T et al. Transcatheter aortic valve replacement in bicuspid aortic valve stenosis: where do we stand. *J Cardiovasc Surg (Torino)* 59:381–391, 2018
- [135] Kahlert P, Al-Rashid F, Weber M et al. Vascular access site complications after percutaneous transfemoral aortic valve implantation. *Herz* 34:398–408, 2009
- [136] Marquis-Gravel G, Redfors B, Leon MB et al. Medical treatment of aortic stenosis. *Circulation* 134:1766–1784, 2016
- [137] Brandenburg VM, Schurgers LJ, Kaesler N et al. Prevention of vasculopathy by vitamin K supplementation: can we turn fiction into fact? *Atherosclerosis* 240:10–16, 2015
- [138] Willems BA, Vermeer C, Reutelingsperger CP et al. The realm of vitamin K dependent proteins: shifting from coagulation toward calcification. *Mol Nutr Food Res* 58:1620–1635, 2014
- [139] Cranenburg EC, Vermeer C, Koos R et al. The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. *J Vasc Res* 45:427–436, 2008
- [140] Lees JS, Chapman FA, Witham MD et al. Vitamin K status, supplementation and vascular disease: a systematic review and meta-analysis. *Heart* 105:938–945, 2019
- [141] Brandenburg VM, Reinartz S, Kaesler N et al. Slower progress of aortic valve calcification with vitamin K supplementation: results from a prospective interventional proof-of-concept study. *Circulation* 135:2081–2083, 2017; correction in *Circulation* 141:e54, 2020
- [142] Koos R, Mahnken AH, Sinha AM et al. Aortic valve calcification as a marker for aortic stenosis severity: assessment on 16-MDCT. *Am J Roentgenol* 183(6):1813–1818, 2004
- [143] Westenfeld R, Krüger T, Schlieper G et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. *Am J Kidney Dis* 2012;59: 186–95.
- [144] Oikonomaki T, Papasotiriou M, Ntriniias T et al. The effect of vitamin K2 supplementation on vascular calcification in haemodialysis patients: a 1-year follow-up randomized trial. *Int Urol Nephrol*. 2019 Nov;51(11):2037-2044..

20.2 Aortenklappeninsuffizienz

- [1] Iung B, Baron G, Butchart EB et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. *Eur Heart J* 24:1231–1243, 2003
- [2] Baumgartner H, Falk V, Baxx J et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 38:2739–2791, 2017
- [2a] Vahanian A, Beyersdorf F, Praz F et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 43(7):561–632, 2021
- [3] Habib G, Lancellotti P, Altunes MJ et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). *Eur Heart J* 36:3075–3128, 2015
- [4] Erbel R, Aboyans V, Boileau C et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the

- adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). *Eur Heart J* 35:2873–2926, 2014
- [5] Hildebrandt HA, Erbel R, Kahlert P. Compassionate use of the self-expandable Medtronic CoreValve prosthesis for the treatment of pure aortic regurgitation in a patient at prohibitive risk for surgical valve replacement. *Catheter Cardiovasc Interv* 82:E939–E942, 2013
- [6] Roy DA, Schaefer U, Guetta V et al. Transcatheter aortic valve implantation for pure severe native aortic valve regurgitation. *J Am Coll Cardiol* 61:1577–1584, 2013
- [7] Takagi H, Hari Y, Kawai N et al. Meta-analysis and meta-regression of transcatheter aortic valve implantation for pure native aortic regurgitation. *Heart Lung Circ* 29:729–741, 2019
- [8] Wernly B, Eder S, Navarese EP et al. Transcatheter aortic valve replacement for pure aortic valve regurgitation: „on-label“ versus „off-label“ use of TAVR devices. *Clin Res Cardiol* 108:921–930, 2019
- [9] Vahanian A, Alfieri O, Al-Attar N et al. Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 29:1463–1470, 2008
- [10] Hensey M, Murdoch DJ, Sathananthan J et al. First-in-human experience of a new-generation transfemoral transcatheter aortic valve for the treatment of severe aortic regurgitation: the J-Valve transfemoral system. *EuroIntervention* 14:e1553–e1555, 2019
- Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 43(7):561–632, 2021
- [3] Wilkins GT, Weyman AE, Abascal VM et al. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and mechanism of dilatation. *Br Heart J* 60:299–308, 1988
- [4] Iung B, Cormier B, Ducimetiere P et al. Immediate results of percutaneous mitral commissurotomy: a predictive model on a series of 1514 patients. *Circulation* 94:2124–2130, 1996
- [5] Nobuyoshi M, Arita T, Shirai S et al. Percutaneous balloon mitral valvuloplasty: a review. *Circulation* 119:e211–e219, 2009
- [6] Meneguz-Moreno RA, Costa JR Jr, Gomes NL et al. Very long term follow-up after percutaneous balloon mitral valvuloplasty. *JACC Cardiovasc Interv* 11:1945–1952, 2018
- [7] Maisano F, Taramasso M. Mitral valve-in-valve, valve-in-ring, and valve-in-MAC: the good, the bad, and the ugly. *European Heart J* 40:452–455, 2019
- [8] Yoon SH, Whisenant BK, Bleiziffer S et al. Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification. *Eur Heart J* 40:441–451, 2019

20.3 Mitralklappenstenose

- [1] Inoue K, Owaki T, Nakamura T et al. Clinical application of transvenous mitral commissurotomy by a new balloon catheter. *J Thorac Cardiovasc Surg* 87:394–402, 1984
- [2] Vahanian A, Beyersdorf F, Praz F et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease:

20.4 Mitralklappeninsuffizienz

- [1] Nkomo VT, Gardin JM, Skelton TN et al. Burden of valvular heart diseases: a population-based study. *Lancet* 368:1005–1011, 2006
- [2] Nishimura RA, Otto CM, Bonow RO et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 129:2440–2492, 2014
- [3] Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D et al. Quantitative determinants of the outcome of asymptomatic

- mitral regurgitation. *N Engl J Med* 352:875–883, 2005
- [4] Rossi A, Dini FL, Faggiano P et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure: a quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. *Heart* 97:1675–1680, 2011
 - [5] Ellis SG, Whitlow PL, Raymond RE et al. Impact of mitral regurgitation on long-term survival after percutaneous coronary intervention. *Am J Cardiol* 89:315–318, 2002
 - [6] Vahanian A, Beyersdorf F, Praz F et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 43(7):561–632, 2021
 - [7] Attizzani GF, Ohno Y, Capodanno D et al. Extended use of percutaneous edge-to-edge mitral valve repair beyond EVEREST (Endovascular Valve Edge-to-Edge Repair) criteria: 30-day and 12-month clinical and echocardiographic outcomes from the GRASP (Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation) registry. *JACC Cardiovasc Interv* 8:74–82, 2015
 - [8] Lesevic H, Karl M, Braun D et al. Long-term outcomes after MitraClip implantation according to the presence or absence of EVEREST inclusion criteria. *Am J Cardiol* 119:1255–1261, 2017
 - [9] Feldman T, Foster E, Glower DD et al. Percutaneous repair or surgery for mitral regurgitation. *N Engl J Med* 364:1395–406, 2011
 - [10] Stone GW, Lindenfeld J, Abraham WT et al. Transcatheter mitral-valve repair in patients with heart failure. *N Engl J Med* 379:2307–2318, 2018
 - [11] Obadia JF, Messika-Zeitoun D, Leurent G et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. *N Engl J Med* 379:2297–2306, 2018
 - [12] Praz F, Spargias K, Chrissosheris M et al. Compassionate use of the Pascal transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study. *Lancet* 390:773–780, 2017
 - [13] Rottländer D, Degen H, Haude M. The Carillon: strategies for optimal patient selection and optimised results. *EuroIntervention* 12:Y64–Y66, 2016
 - [14] Rottländer D, Schneider T, Degen H et al. Coronary sinus to mitral valve annulus topography and response to the percutaneous coronary sinus-based mitral valve contour system. *EuroIntervention* 15:923–926, 2019
 - [15] Schofer J, Siminiak T, Haude M et al. Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the Carillon Mitral Annuloplasty Device European Union Study. *Circulation* 120:326–333, 2009
 - [16] Siminiak T, Wu JC, Haude M et al. Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial. *Eur J Heart Fail* 14:931–938, 2012
 - [17] Lipiecki J, Siminiak T, Sievert H et al. Coronary sinus-based percutaneous annuloplasty as treatment for functional mitral regurgitation: the TITAN II trial. *Open Heart* 3:e000411, 2016
 - [18] Witte KK, Lipiecki J, Siminiak T et al. The REDUCE FMR trial: a randomized sham-controlled study of percutaneous mitral annuloplasty in functional mitral regurgitation. *JACC Heart Fail* 7:945–955, 2019
 - [19] Maisano F, Taramasso M, Nickenig G et al. Cardioband, a transcatheter surgical-like direct mitral valve annuloplasty system: early results of the feasibility trial. *Eur Heart J* 37:817–825, 2016
 - [20] Nickenig G, Hammerstingl C, Schueler R et al. Transcatheter mitral annuloplasty in chronic functional mitral regurgitation: 6-month results with the cardioband percutaneous mitral repair system. *JACC Cardiovasc Interv* 9:2039–2047, 2016
 - [21] Messika-Zeitoun D, Nickenig G, Latib A et al. Transcatheter mitral valve repair for functional mitral regurgitation using the Cardioband system: 1 year outcomes. *Eur Heart J* 40:466–472, 2019
 - [22] Nickenig G, Schueler R, Dager A et al. Treatment of chronic functional mitral valve regurgitation with a percutaneous annuloplasty system. *J Am Coll Cardiol* 67:2927–36, 2018

- [23] Colli A, Manzan E, Aidietis A et al. An early European experience with transapical off-pump mitral valve repair with NeoChord implantation. *Eur J Cardiothorac Surg* 54:460–466, 2018
- [24] von Bardeleben RS, Colli A, Schulz E et al. First in human transcatheter COMBO mitral valve repair with direct ring annuloplasty and neochord leaflet implantation to treat degenerative mitral regurgitation: feasibility of the simultaneous toolbox concept guided by 3D echo and computed tomography fusion imaging. *Eur Heart J* 39:1314–1315, 2018
- [25] Colli A, Manzan E, Rucinskas K et al. Acute safety and efficacy of the NeoChord procedure. *Interact Cardiovasc Thorac Surg* 20:575–80, 2015
- [26] Bapat V, Rajagopal V, Meduri C et al. Early experience with new transcatheter mitral valve replacement. *J Am Coll Cardiol* 71:12–21, 2018
- [27] Webb JG, Murdoch DJ, Boone RH et al. Percutaneous transcatheter mitral valve replacement: first-in-human experience with a new transseptal system. *J Am Coll Cardiol* 73:1239–1246, 2019
- [28] Cullen MW, Cabalka AK, Alli OO et al. Transvenous, antegrade melody valve-in-valve implantation for bioprosthetic mitral and tricuspid valve dysfunction: a case series in children and adults. *JACC Cardiovasc Interv* 6:598–605, 2013
- [29] Descoutures F, Himbert D, Maisano F et al. Transcatheter valve-in-ring implantation after failure of surgical mitral repair. *Eur J Cardiothorac Surg* 44:e8–e15, 2013
- [30] Søndergaard L, De Backer O, Franzen OW et al. First-in-human case of transfemoral CardiAQ mitral valve implantation. *Circ Cardiovasc Interv* 8:e002135, 2015
- [31] Shah M, Jorde UP. Percutaneous mitral valve interventions (repair): current indications and future perspectives. *Front Cardiovasc Med* 6:88, 2019
- [32] Muller DWM, Farivar RS, Jansz P et al. Transcatheter mitral valve peplacement for patients with symptomatic mitral regurgitation: a global feasibility trial. *J Am Coll Cardiol* 69:381–391, 2017.
- [33] Testa L, Latib A, Montone RA et al. Transcatheter mitral valve regurgitation treatment: state of the art and a glimpse to the future. *J Thorac Cardiovasc Surg* 152:319–327, 2016

20.5 Trikuspidalklappeninterventionen

- [1] Taramasso M, Vanermen H, Maisano F et al. The growing importance of secondary tricuspid regurgitation. *J Am Coll Cardiol* 59:703–710, 2012
- [2] Stuge O, Liddicoat J. Emerging opportunities for cardiac surgeons within structural heart disease. *J Thorac Cardiovasc Surg* 132:1258–1261, 2006
- [3] Cohen SR, Sell JE, McIntosh CL et al. Tricuspid regurgitation in patients with acquired, chronic, pure mitral regurgitation. *J Thorac Cardiovasc Surg* 94:488–497, 1987
- [4] Matsunaga A, Duran CM. Progression of tricuspid regurgitation after repaired functional ischemic mitral regurgitation. *Circulation* 112:1453–1457, 2005
- [5] Fukuda S, Song JM, Gillinov AM et al. Tricuspid valve tethering predicts residual tricuspid regurgitation after tricuspid annuloplasty. *Circulation* 111:975–979, 2005
- [6] Di Mauro M, Bivona A, Iaco AL et al. Mitral valve surgery for functional mitral regurgitation: prognostic role of tricuspid regurgitation. *Eur J Cardiothorac Surg* 35:635–640, 2009
- [7] Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. *J Am Coll Cardiol* 43:405–409, 2004
- [8] Taramasso M, Maisano F, De Bonis M et al. Prognostic impact and late evolution of untreated moderate functional tricuspid regurgitation in patients undergoing aortic valve replacement. *J Card Surg* 31:9–14, 2016
- [8a] Vahanian A, Beyersdorf F, Praz F et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 43(7):561–632, 2021
- [9] Hammerstingl C, Schueler R, Malasa M et al. Transcatheter treatment of severe tricuspid regurgitation with the MitraClip system. *Eur Heart J* 37:849–853, 2016
- [10] Braun D, Orban M, Orban M et al. Transcatheter edge-to-edge repair for severe tri-

- cuspid regurgitation using the triple-orifice technique versus the bicuspidalization technique. *JACC Cardiovasc Interv* 11:1790–1792, 2018
- [11] Taramasso M, Alessandrini H, Latib A et al. Outcomes after current transcatheter tricuspid valve intervention: mid-term results from the international TriValve registry. *JACC Cardiovasc Interv* 12:155–165, 2019
 - [12] Nickenig G, Kowalski M, Hausleiter J et al. Transcatheter treatment of severe tricuspid regurgitation with the edge-to-edge MitraClip technique. *Circulation* 135:1802–1814, 2017
 - [13] Orban M, Besler C, Braun D et al. Six-month outcome after transcatheter edge-to-edge repair of severe tricuspid regurgitation in patients with heart failure. *Eur J Heart Fail* 20:1055–1062, 2018
 - [14] Braun D, Nabauer M, Orban M et al. One-year results of transcatheter treatment of severe tricuspid regurgitation using edge-to-edge repair technique. *EuroIntervention* 14:e413–e415, 2018
 - [15] Nickenig G, Weber M, Lurz P et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. *Lancet* 394:2002–2011, 2019
 - [16] Fam NP, Ho EC, Zahrani M et al. Transcatheter tricuspid valve repair with the Pascal system. *JACC Cardiovasc Interv* 11:407–408, 2018
 - [17] Anderson A, Hausleiter J, von Bardeleben RS et al. One year outcomes of the TRI-REPAIR study assessing Cardioband tricuspid valve reconstruction system for patients with functional tricuspid regurgitation. *J Card Failure* 25:11, 2019
 - [18] Nickenig G, Weber M, Schueler R et al. 6-month outcomes of tricuspid valve reconstruction for patients with severe tricuspid regurgitation. *J Am Coll Cardiol* 73:1905–1915, 2019
 - [19] Hahn RT, Meduri CU, Davidson CJ et al. Early feasibility study of a transcatheter tricuspid valve annuloplasty: SCOUT trial 30-day results. *J Am Coll Cardiol* 69:1795–1806, 2017
 - [20] Giannini F, Colombo A. Percutaneous treatment of tricuspid valve in refractory right heart failure. *Eur Heart J Suppl* 21:B43–B47, 2019
 - [21] Figulla HR, Kiss K, Lauten A. Transcatheter interventions for tricuspid regurgitation – heterotopic technology: TricValve. *EuroIntervention*, 12:116–118, 2016
 - [22] Lauten A, Figulla HR, Unbehaun A et al. Interventional treatment of severe tricuspid regurgitation: early clinical experience in a multicenter, observational, first-in-man study. *Circ Cardiovasc Interv* 11:e006061, 2018
 - [23] Toggweiler S, De Boeck B, Brinkert M et al. First-in-man implantation of the Tricento transcatheter heart valve for the treatment of severe tricuspid regurgitation. *EuroIntervention* 14:758–761, 2018
 - [24] Werner P, Russo M, Scherzer S et al. Transcatheter caval valve implantation of the Tricento valve for tricuspid regurgitation using advanced intraprocedural imaging. *JACC Case Reports* 1:720–721, 2019
 - [25] Dreger H, Mattig I, Hewing B et al. Treatment of severe TRicuspid regurgitation in patients with advanced heart failure with CAval vein implantation of the edwards Sapien XT VALve (TRICAVAL): a randomized controlled trial. *EuroIntervention* 15:1506–1513, 2020
 - [26] Kenny D, Hijazi ZM, Walsh KP. Transcatheter tricuspid valve replacement with the Edwards Sapien valve. *Catheter Cardiovasc Interv* 78:267–270, 2011
 - [27] Calvert PA, Himbert D, Brochet E et al. Transfemoral implantation of an Edwards Sapien valve in a tricuspid bio-prosthesis without fluoroscopic landmarks. *EuroIntervention* 7:1336–1339, 2012
 - [28] Hoendermis ES, Douglas YL, van den Heuvel AF. Percutaneous Edwards Sapien valve implantation in the tricuspid position: case report and review of the literature. *EuroIntervention* 8:628–633, 2012
 - [29] Perlman GY, Dvir D. Treatment of tricuspid regurgitation with the Forma repair system. *Front Cardiovasc Med* 5:140–146, 2018

20.6 Defekte im interatrialen Septum

- [1] Baumgartner H, De Backer J, Babu-Narayan SV et al., ESC Scientific Document Group. 2020 ESC Guidelines for the management of adult congenital heart

- disease. *Eur Heart J* 42:563–645, 2020
- [2] Parsons FG, Keith A. Seventh report of the Committee of Collective Investigation of the Anatomical Society of Great Britain and Ireland, 1896–97. *J Anat Physiol* 32:164–186, 1897
 - [3] Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. *Mayo Clin Proc* 59:17–20, 1984
 - [4] Lechat P, Mas JL, Lascault G et al. Prevalence of patent foramen ovale in patients with stroke. *N Engl J Med* 318:1148–1152, 1988
 - [5] Webster MW, Chancellor AM, Smith HJ et al. Patent foramen ovale in young stroke patients. *Lancet* 2(8601):11–12, 1988
 - [6] Hausmann D, Mügge A, Becht I et al. Diagnosis of patent foramen ovale by transesophageal echocardiography and association with cerebral and peripheral embolic events. *Am J Cardiol* 70:668–672, 1992
 - [7] Van Camp G, Schulze D, Cosyns B et al. Relation between patent foramen ovale and unexplained stroke. *Am J Cardiol* 71:596–598, 1993
 - [8] Meier B. Catheter-based closure of the patent foramen ovale. *Circulation* 120:1837–1841, 2009
 - [9] Konstantinides S, Geibel A, Kasper W et al. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism. *Circulation* 97:1946–1951, 1998
 - [9a] Desai AJ, Fuller CJ, Jesurum JT et al. Patent foramen ovale and cerebrovascular diseases. *Nat Clin Pract Cardiovasc Med* 3:446–455, 2006
 - [10] Nellessen U, Daniel WG, Matheis G et al. Impending paradoxical embolism from atrial thrombus: correct diagnosis by transesophageal echocardiography and prevention by surgery. *J Am Coll Cardiol* 5:1002–1004, 1985
 - [11] Ghanem A, Liebetrau C, Diener H-C et al. Interventioneller PFO-Verschluss. Konsensuspapier der Arbeitsgruppe Interventionelle Kardiologie (AGIK) der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung (DGK) gemeinsam mit der Deutschen Gesellschaft für Neurologie (DGN) und der Deutschen Schlaganfallge-
sellschaft (DSG). *Der Kardiologe* 12(6):415–423, 2018
 - [12] Diener H-C, Grau A, Baldus S et al. Kryptogener Schlaganfall und offenes Foramen ovale, S2e-Leitlinie, 2018. In: Deutsche Gesellschaft für Neurologie (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie. Online: www.dgn.org/leitlinien (abgerufen am 12.11.2018)
 - [13] Wahl A, Praz F, Findling O et al. Percutaneous closure of patent foramen ovale for migraine headaches refractory to medical treatment. *Catheter Cardiovasc Interv* 74:124–129, 2009
 - [14] Mattle HP, Evers S, Hildick-Smith D et al. Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. *Eur Heart J* 37:2029–2036, 2016
 - [15] Kent DM, Ruthazer R, Weimar C et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. *Neurology* 81:619–625, 2013
 - [16] Silver MD, Dorsey JS. Aneurysm of the septum primum in the adults. *Arch Path Lab Med* 102:62–65, 1978
 - [17] Topaz O, Edwards JE, Bojack-Mackey S et al. Aneurysm of fossa ovalis in adults: a pathologic study. *Cardiovasc Pathol* 12:219–225, 2003
 - [18] Olivares-Reyes A, Chan S, Lazar EJ et al. Atrial septal aneurysm: a new classification in two hundred five adults. *J Am Soc Echocardiogr* 10:644–656, 1997
 - [19] Topaz O. Aneurysm of the atrial septum with fenestrations – the crossroads of pathophysiology and intervention. *Catheter Cardiovasc Interv* 79:1178–1179, 2012
 - [20] Schreiner G, Erbel R, Mohr-Kahaly S et al. Detection of aneurysms of the atrial septum using transesophageal echocardiography. *Z Kardiol* 74:440–444, 1985
 - [21] Schnieder M, Siddiqui T, Karch A et al. Clinical relevance of patent foramen ovale and atrial septum aneurysm in stroke: findings of a single-center cross-sectional study. *Eur Neurol* 78:264–269, 2017
 - [22] Hanley PC, Tajik AJ, Hynes JK et al. Diagnosis and classification of atrial septal aneurysm by two-dimensional echocardiography: report of 80 consecutive cases. *J Am Coll Cardiol* 6:1370–1382, 1985
 - [23] Mügge A, Daniel WG, Angermann C et al. Atrial septal aneurysm in adult patients: a multicenter study using transthoracic and

- transesophageal echocardiography. *Circulation* 91:2785–2792, 1995
- [24] Lethen H, Flachskampf FA, Hanrath P. Aneurysm des Vorhofseptums. Diagnostik und therapeutische Konsequenzen. *Dtsch Med Wschr* 119:229–234, 1994
- [25] Yetkin E, Atalay H, Ileri M. Atrial septal aneurysm: prevalence and covariates in adults. *Int J Cardiol* 223:656–659, 2016
- [26] Rana BS, Thomas MR, Calvert PA et al. Echocardiographic evaluation of patent foramen ovale prior to device closure. *JACC Cardiovasc Imaging* 3:749–760, 2010
- [27] Kutty S, Sengupta PP, Khandheria BK. Patent foramen ovale: the known and the to be known. *J Am Coll Cardiol* 59:1665–1671, 2012
- [28] Maggioro P, Bellingue J, Chieng D et al. Ischaemic stroke and the echocardiographic „Bubble Study“: are we screening the right patients? *Heart Lung Circ* 28:1183–1189, 2019
- [29] Shanks M, Manawadu D, Vonder Muhll I et al. Detection of patent foramen ovale by 3D echocardiography. *JACC Cardiovasc Imaging* 5:329–331, 2012
- [30] Hildick-Smith D, Williams T, MacCarthy P et al. Occlutech Percutaneous Patent foramen Ovale closure: Safety and Efficacy registry (OPPOSE). *Int J Cardiol* 245:99–104, 2017
- [31] Pizzino F, Khandheria, Carerj S et al. PFO: Button me up, but wait ... Comprehensive evaluation of the patient. *J Cardiol* 67:485–492, 2016
- [32] Bartel T, Müller S. Contemporary echocardiographic guiding tools for device closure of interatrial communications. *Cardiovasc Diagn Ther* 3:38–46, 2013
- [33] Lambertz H, Schweizer P, Erbel R et al. Value of contrast echocardiography in the diagnosis of tricuspid insufficiency. *Z Kardiol* 71:771–778, 1982
- [34] Mohr-Kahaly S, Erbel R, Zotz R et al. Left ventricular contrast echocardiography using Gelifundol – assessment of hemodynamics, contractility and ECG. *Z Kardiol* 76:699–705, 1987
- [35] Becher H. Kontrastechokardiographie: klinische Anwendung und Zukunftsperspektiven. *Herz* 27:201–216, 2002
- [35a] https://www.ema.europa.eu/en/documents/overview/sonovue-epar-summary-public_de.pdf (abgerufen 21.11.2022)
- [35b] <https://www.ema.europa.eu/en/medicines/human/EPAR/liminity> (Update 29.06.2022) (abgerufen 21.11.2022)
- [35c] Senior R, Lindner JR, Edvardsen T et al. Ultrasound contrast agent hypersensitivity in patients allergic to polyethylene glycol: position statement by the European Association of Cardiovascular Imaging. *Eur Heart J – Cardiovasc Imag* 22:959–960, 2021
- [35d] <http://www.ema.europa.eu/medicines/human/EPAR/optison> (Update 27.06.2022) (abgerufen 21.11.2022)
- [36] Wally D, Knotzer H, Kilo J et al. The Eustachian valve as a pitfall in persistent foramen ovale and atrial septum defect closure. *J Cardiothorac Vasc Anesth* 25:680–682, 2011
- [37] Rana BS, Shapiro LM, McCarthy KP et al. Three-dimensional imaging of the atrial septum and patent foramen ovale anatomy: defining the morphological phenotypes of patent foramen ovale. *Eur J Echocardiogr* 11:i19–i25, 2010
- [38] Porter TR, Mulvagh SL, Abdelmoneim SS et al. Clinical applications of ultrasonic enhancing agents in echocardiography: 2018 American Society of Echocardiography guidelines update. *J Am Soc Echocardiogr* 31:241–274, 2018
- [38a] Pristipino C, Sievert H, Ascenzo FD et al. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. *EuroIntervention* 20;14:1389–1402, 2019
- [39] Bradley EA, Chakinala M, Billadello JJ. Usefulness of medical therapy for pulmonary hypertension and delayed atrial septal defect closure. *Am J Cardiol* 112:1471–1476, 2013
- [40] Kijima Y, Akagi T, Takaya Y et al. Treat and repair strategy in patients with atrial septal defect and significant pulmonary arterial hypertension. *Circ J* 80:227–234, 2016
- [41] Oka S, Nakamura J, Tokumasu Y et al. „Treat and repair“ strategy for atrial septal defect with significant pulmonary arterial hypertension in an elderly Case. *Austin Cardio & Cardiovasc Case Rep* 4:1030, 2019
- [42] Liang F, Yang S, Yao L et al. Ambrisentan and tadalafil synergistically relax endothe-

- lin-induced contraction of rat pulmonary arteries. *Hypertension* 59:705–711, 2012
- [43] Sitbon O, Channick R, Chin KM et al. Selexipag for the treatment of pulmonary arterial hypertension. *N Engl J Med* 373:2522–2533, 2015
- [44] Yao A. „Treat-and-repair“ strategy for atrial septal defect and associated pulmonary arterial hypertension. *Circ J* 80:69–71, 2016
- [45] Patel K, Doshi R, Goyal H et al. Transcatheter patent foramen ovale closure versus standard medical therapy for prevention of recurrent stroke: updated meta-analysis with an importance on shunt size. *Eur J Intern* 57:e31–e33, 2018
- [46] Garg L, Haleem A, Varade S et al. Patent foramen ovale closure in the setting of cryptogenic stroke: a meta-analysis of five randomized trials. *J Stroke Cerebrovasc Dis* 27:2484–2493, 2018
- [47] Pristipino C, Sievert H, D’Ascenzo F et al. European position paper on the management of patients with patent foramen ovale: general approach and left circulation thromboembolism. *EuroIntervention* 40:3182–3195, 2019
- [48] Meier B. PFO closure, when the going gets tough ... *Catheter Cardiovasc Interv* 64:345–347, 2007
- [49] Wahl A, Tai T, Praz F et al. Late results after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism using the Amplatzer PFO occluder without intraprocedural echocardiography: effect of device size. *JACC Cardiovasc Interv* 2:116–123, 2009
- [50] Bartel T, Konorza T, Neudorf U et al. Intracardiac echocardiography: an ideal guiding tool for device closure of interatrial communications. *Eur J Echocardiogr* 6:92–96, 2005
- [51] Pavlovic M, Buellesfeld L, Meier B. Tools & techniques: PFO/ASD closure. *Euro-Intervention* 7:408–410, 2011
- [52] Carroll JD, Saver J, Thaler DE et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. *New Engl J Med* 368:1092–1100, 2013
- [52a] Saver JL, Carroll JD, Thaler DE et al., RESPECT Investigators. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. *N Engl J Med* 377:1022–1032, 2017
- [53] Hornung M, Bertog SC, Franke J et al. Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale. *Eur Heart J* 34:3362–3369, 2013
- [54] Stortecky S, da Costa BR, Mattle HP et al. Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis. *Eur Heart J* 36:120–128, 2015
- [55] Hildick-Smith D, Williams T, MacCarthy P et al. Occlutech Percutaneous Patent foramen Ovale closure: Safety and Efficacy registry (OPPOSE). *Int J Cardiol* 245:99–104, 2017
- [56] Krizanec F, Sievert H, Pfeiffer D et al. The Occlutech Figulla PFO and ASD occluder: a new nitinol wire mesh device for closure of atrial septal defects. *J Invasive Cardiol* 22:182–187, 2010
- [57] Saguner AM, Wahl A, Praz F et al. Figulla PFO occluder versus Amplatzer PFO occluder for percutaneous closure of patent foramen ovale. *Catheter Cardiovasc Interv* 77:709–714, 2011
- [58] Trabattoni D, Gaspardone A, Sgueglia GA et al. Amplatzer versus Figulla occluder for transcatheter patent foramen ovale closure. *EuroIntervention* 12:2092–2099, 2017
- [59] Neuser J, Akin M, Bavendiek U et al. Mid-term results of interventional closure of patent foramen ovale with the Occlutech Figulla® Flex II occlude. *BMC Cardiovasc Disord* 16:217, 2016
- [60] Astarcioglu MA, Kalcik M, Sen T et al. Ceraflex versus Amplatzer occluder for secundum atrial septal defect closure. Multi-center clinical experience. *Herz* 40(Suppl 2):146–150, 2015
- [61] Peirone A, Contreras A, Ferrero A et al. Immediate and short-term outcomes after percutaneous atrial septal defect closure using the new Nit-Occlud ASD-R device. *Catheter Cardiovasc Interv* 84:464–470, 2014
- [62] Araszkievicz A, Slawek S, Trojnaraska O et al. Interventional closure of patent foramen ovale with Nit-Occlud® device in prevention of recurrent neurologic events: long-term results. *Catheter Cardiovasc Interv* 92:159–164, 2018
- [63] Sigler M, Söderberg B, Schmitt B et al. Carag bioresorbable septal occluder (CBSO):

- histopathology of experimental implants. *EuroIntervention* 13:1655–1661, 2018
- [64] Gaspardone A, De Marco F, Sgueglia GA et al. Novel percutaneous suture-mediated patent foramen ovale closure technique: early results of the NobleStitch EL Italian Registry. *EuroIntervention* 14:e272–e279, 2018
- [65] Meier B. Closure of the patent foramen ovale, if only a stitch in time saved nine. *EuroIntervention* 14:e250–251, 2018
- [66] Li Y, Zhou K, Hua Y et al. Amplatzer occluder versus CardioSeal/StarFlex occluder: a meta-analysis of the efficacy and safety of transcatheter occlusion for patent foramen ovale and atrial septal defect. *Cardiol Young* 23:582–596, 2013
- [67] Trabattoni D, Gaspardone A, Sgueglia GA et al. Amplatzer versus Figulla occluder for transcatheter patent foramen ovale closure. *EuroIntervention* 12:2092–2099, 2017
- [68] Bock M, Mohrs OK, Voigtlaender T et al. MRT-Sicherheitsaspekte und -Artefakte von Vorhofseptum-Okkludersystemen bei 1,5 Tesla: eine Phantomstudie. *Fortschr Röntgenstr* 178:272–277, 2006
- [69] Windecker S, Wahl A, Chatterjee T et al. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism. Long-term risk of recurrent thromboembolic events. *Circulation* 101:893–898, 2000
- [70] Meier B. Pacman sign during device closure of the patent foramen ovale. *Catheter Cardiovasc Interv* 60:221–223, 2003
- [71] Meier B. Closure of patent foramen ovale: technique, pitfalls, complications, and follow up. *Heart* 91:444–448, 2005
- [72] Wahl A, Kunz M, Moschovitis A et al. Long-term results after fluoroscopy-guided closure of patent foramen ovale for secondary prevention of paradoxical embolism. *Heart* 94:336–341, 2008
- [2] Leute A, Kirchhof P, Breithardt G et al. German Competence Network on Atrial Fibrillation (AFNET): a nationwide cooperation for better research and patient care. *Med Klin* 101:662–666, 2006
- [3] Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. *Circulation* 110:1042–1026, 2004
- [4] Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke* 22:983–988, 1991
- [5] Lin HJ, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation: the Framingham Study. *Stroke* 27:1760–1764, 1996
- [6] Garcia DA, Hylek E. Reducing the risk for stroke in patients who have atrial fibrillation. *Cardiol Clin* 26:267–275, 2008
- [7] Block PC, Burstein S, Casale PN et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) study. *JACC Cardiovasc Interv* 2:594–600, 2009
- [8] The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. *N Engl J Med* 333:5–10, 1995
- [9] The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. *N Engl J Med* 323:1505–1511, 1990
- [10] Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med* 146:857–867, 2007
- [11] Walker AM, Bennett D. Epidemiology and outcomes in patients with atrial fibrillation in the United States. *Heart Rhythm* 5:1365–1372, 2008
- [12] Go AS, Hylek EM, Borowsky LH et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. *Ann Intern Med* 131:927–934, 1999
- [13] Holmes DR, Reddy VY, Turi ZG et al. PROTECT AF Investigators. Percutaneous clo-

20.7 Interventioneller Vorhofohrverschluss

- [1] Erbel R, Möhlenkamp S, Jöckel KH et al. Cardiovascular risk factors and signs of subclinical atherosclerosis in the Heinz Nixdorf Recall Study. *Dtsch Arztebl Int* 105:1–8, 2008

- sure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. *Lancet* 374:534–542, 2009
- [14] Alberg H. Atrial fibrillation: a study of atrial thrombus and systemic embolism in a necropsy material. *Acta Med Scand* 185:373–379, 1969
- [15] Stoddard MF, Dawkins PR, Prince CR et al. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. *J Am Coll Cardiol* 25:452–459, 1995
- [16] Klein AL, Grimm RA, Murray RD et al. Assessment of cardioversion using transesophageal echocardiography investigators: use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. *N Engl J Med* 344:1411–1420, 2001
- [17] Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. *Ann Thorac Surg* 61:755–759, 1996
- [18] Sievert H, Lesh MD, Trepels T et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. *Circulation* 105:1887–1889, 2002
- [19] Hanna IR, Kolm P, Martin R et al. Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO): six-month echocardiographic follow-up. *J Am Coll Cardiol* 43:1868–1872, 2004
- [20] Ostermayer SH, Reisman M, Kramer PH et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. *J Am Coll Cardiol* 46:9–14, 2005
- [21] Sievert H, Bayard YL. Percutaneous closure of the left atrial appendage: a major step forward. *JACC Cardiovasc Interv* 2:601–602, 2009
- [22] Fountain RB, Holmes DR, Chandrasekaran K et al. The Protect AF (Watchman) left atrial appendage system for embolic (Protection in patients with atrial fibrillation) trial. *Am Heart J* 151:956–961, 2006
- [23] Sick PB, Schuler G, Hauptmann KE et al. Initial worldwide experience with the Watchman left atrial appendage system for stroke prevention in atrial fibrillation. *J Am Coll Cardiol* 49:1490–1495, 2007
- [23a] Grygier M, Olasińska-Wisniewska A, Araszkievicz A et al. The Watchman FLX – a new device for left atrial appendage occlusion – design, potential benefits and first clinical experience. *Adv Interv Cardiol* 13: 62–66, 2017
- [24] Reddy VY, Sievert H, Halperin J. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation- a randomized clinical trial. *JAMA* 312(19):1988–1998, 2014
- [25] Reddy VY, Doshi SK, Kar S et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. *J Am Coll Cardiol* 70:2976–2978, 2017
- [26] Reddy VY, Möbius-Winkler S, Miller MA et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP Study (ASA Plavix feasibility study with Watchman left atrial appendage closure technology). *J Am Coll Cardiol* 61:2551–2556, 2013
- [27] Singh SM, Micieli A, Wijeyesundera HC. Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. *Circulation* 127:2414–2423, 2013
- [28] Toumanidis S, Sideris EB, Agricola T et al. Transcatheter patch occlusion of the left atrial appendage using surgical adhesives in high-risk patients with atrial fibrillation. *J Am Coll Cardiol* 58:2236–2240, 2011
- [29] Meier B, Blaauw Y, Khattab AA et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. *Europace* 16:1397–1416, 2014
- [30] Plicht B, Konorza TFM, Kahlert P et al. Risk factors for thrombus formation on the Amplatzer cardiac plug after left atrial appendage occlusion. *J Am Coll Cardiol Interv* 6:606–613, 2013
- [31] Freixa X, Chan JLK, Tzikas A et al. The Amplatzer™ cardiac plug 2 for left atrial appendage occlusion: novel features and first-in-man experience. *EuroIntervention* 8:1094–1098, 2013

- [31a] Lakkireddy D, Thaler D, Ellis CR et al. Amplatzer Amulet Left Atrial Appendage Occluder versus Watchman Device for Stroke Prophylaxis (Amulet IDE): a randomized, controlled trial. *Circulation* 144:1543–1552, 2021
- [31b] Osmancik P, Herman D, Neuzil P et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. *J Am Coll Cardiol* 75:3122–3135, 2020
- [32] Hindricks G, Potpara T, Dagres N et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 42:373–498, 2021
- [33] Crystal E, Lamy A, Connolly SJ et al. Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention. *Am Heart J* 145:174–178, 2003
- [34] Healey JS, Crystal E, Lamy A et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. *Am Heart J* 150:288–293, 2005
- [35] Heist EK, Refaat M, Danik SB et al. Analysis of the left atrial appendage by magnetic resonance angiography in patients with atrial fibrillation. *Heart Rhythm* 3:1313–1318, 2006
- [36] Kanderian AS, Gillinov AM, Pettersson GB et al. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. *J Am Coll Cardiol* 52:924–929, 2008
- [37] Salzberg SP, Gillinov AM, Anyanwu A et al. Surgical left atrial appendage occlusion: evaluation of a novel device with magnetic resonance imaging. *Eur J Cardiothorac Surg* 34:766–770, 2008
- [38] Salzberg SP, Plass A, Emmert MY et al. Left atrial appendage clip occlusion: Early clinical results. *J Thorac Cardiovasc Surg* 139:1269–1274, 2009
- [39] Pisters R, Lane DA, Nieuwlaet R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* 138:1093–1100, 2010

20.8 Hypertroph-obstruktive Kardiomyopathie (HOCM)

- [1] Morrow AG, Braunwald E. Functional aortic stenosis; a malformation characterized by resistance to left ventricular outflow without anatomic obstruction. *Circulation* 20:181–189, 1959
- [2] Elliott P, Andersson B, Arbustini E et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J* 29:270–276, 2008
- [3] Elliott PM, Anastakis A, Borger MA et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J* 35:2733–2779, 2014
- [3a] Arbelo E, Protonotarios A, Gimeno JR et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. *Eur Heart J* 44:3503–3626, 2023
- [4] Messmer BJ. Surgery for hypertrophic obstructive cardiomyopathy (HOCM): what to do with concomitant mitral insufficiency? *J Thorac Dis* 9:E381–E383, 2017
- [5] Teo EP, Teoh JG, Hung J. Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy. *Curr Opin Cardiol* 30:475–482, 2015
- [6] Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 124:2761–2796, 2011
- [6a] Ommen SR, Mital S, Burke MA et al. AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol* 76:3022–3055, 2020
- [7] Morrow AG, Reitz BA, Epstein SE et al. Operative treatment in hypertrophic subaortic stenosis: techniques, and the results

- of pre and postoperative assessments in 83 patients. *Circulation* 52:88–102, 1975
- [8] Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. *Lancet* 346:211–214, 1995
 - [9] Kuhn H. Transcatheter ablation of septal hypertrophy (TASH): a 5-year experience. *Z Kardiol* 89:559–564, 2000
 - [10] Gleichmann U, Seggewiss H, Faber L et al. Kathetertherapie der hypertrophen obstruktiven Kardiomyopathie. *Dtsch Med Wochenschr* 121:679–685, 1996
 - [11] Holmes DR, Valeti US, Nishimura RA. Alcohol septal ablation for hypertrophic cardiomyopathy: indications and technique. *Catheter Cardiovasc Interv* 66:375–389, 2005
 - [12] Nishimura RA, Seggewiss H, Schaff HV. Hypertrophic obstructive cardiomyopathy: surgical myectomy and septal ablation. *Circ Res* 121:771–783, 2017
 - [13] Batzner A, Pfeiffer B, Neugebauer A et al. Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. *J Amer Coll Cardiol* 72:3095–4097, 2018
 - [14] Kashtanov M, Rzhannikova A, Chernyshev S et al. Results of ten-year follow-up of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy. *Int J Angiol* 27:202–207, 2018
 - [15] Mateo JJS, Gimeno JR. Alcohol septal ablation in hypertrophic cardiomyopathy. *Glob Cardiol Sci Pract* 2018:30, 2018
 - [16] Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. *Circulation* 98:2415–2421, 1998
 - [17] Koljaja-Batzner A, Pfeiffer B, Seggewiss H. Septal collateralization to right coronary artery in alcohol septal ablation: solution to a dangerous pitfall. *JACC Cardiovasc Interv* 11:2009–2011, 2018
 - [18] Gimeno JR, Tomé MT, McKenna WJ. Alcohol septal ablation in hypertrophic cardiomyopathy: an opportunity to be taken. *Rev Esp Cardiol (Engl Ed)* 65:314–318, 2012
 - [19] Veselka J, Jensen MK, Liebrechts M et al. Low procedure-related mortality achieved with alcohol septal ablation in European patients. *Int J Cardiol* 209:194–195, 2016
 - [20] Veselka J, Faber L, Jensen MK et al. Effect of institutional experience on outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy. *Can J Cardiol* 34:16–22, 2018
 - [21] Oto A, Aytemir K, Okutucu S et al. Cyanoacrylate for septal ablation in hypertrophic cardiomyopathy. *J Interv Cardiol* 24:77–84, 2011
 - [22] Asil S, Kaya B, Canpolat U et al. Septal reduction therapy using nonalcohol agent in hypertrophic obstructive cardiomyopathy: single center experience. *Catheter Cardiovasc Interv* 92:557–565, 2017
 - [23] Erbel R, Heusch G. Coronary microembolization – its role in acute coronary syndromes and interventions. *Herz* 24:558–575, 1999
 - [24] Erbel R, Heusch G. Coronary microembolization. *J Am Coll Cardiol* 39:22–24, 2000
 - [25] Skyschally A, Haude M, Dörge H et al. Glucocorticoid treatment prevents progressive myocardial dysfunction resulting from experimental coronary microembolization. *Circulation* 109:2337–2342, 2004
 - [26] Dickmann B, Baars T, Heusch G et al. Transcatheter septal ablation in hypertrophic obstructive cardiomyopathy by embolizing microspheres. *Eur Heart J* 34:2489, 2013
 - [27] Gross CM, Schulz-Menger J, Kramer J et al. Percutaneous transluminal septal artery ablation using polyvinyl alcohol foam particles for septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: acute and 3-year outcomes. *J Endovasc Ther* 11:705–711, 2004
 - [28] Vriesendorp PA, Van Mieghem NM, Vletter WB et al. Microsphere embolisation as an alternative for alcohol in percutaneous transluminal septal myocardial ablation. *Neth Heart J* 21:245–248, 2013
 - [29] O'Mahony C, Jichi F, Pavlou M et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). *Eur Heart J* 35:2010–2020, 2014
 - [30] Cherif E, Ghazal S. Alcohol septal ablation after suboptimal surgical septal myectomy. *CASE (Phila)* 2:210–217, 2018
 - [31] Nguyen A, Schaff HV, Hang D et al. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a propensity score-matched

- cohort. *J Thorac Cardiovasc Surg* 157:306–315, 2019
- [32] Osman M, Kheiri B, Osman K et al. Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: systematic review and meta-analysis. *Clin Cardiol* 42:190–197, 2019
- [33] Veselka J, Zemánek D, Jahnlová D et al. Risk and causes of death in patients after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. *Can J Cardiol* 31:1245–1251, 2015
- [34] Sari M, Izgi C, Kahveci G et al. Infarction of the septomarginal band and tricuspid papillary muscle rupture related to alcohol septal ablation for hypertrophic cardiomyopathy. *Echocardiography* 35:880–884, 2018
- [35] Chowdhary S, Galiwango P, Woo A et al. Inferior infarction following alcohol septal ablation: a consequence of „collateral damage“? *Catheter Cardiovasc Interv* 69:236–242, 2007
- [36] Kashtanov M, Rzhannikova A, Chernyshev S et al. Results of ten-year follow-up of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy. *Int J Angiol* 27:202–207, 2018
- [37] Batzner A, Pfeiffer B, Neugebauer A et al. Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. *J Amer Coll Cardiol* 72:3095–4097, 2018
- [38] Charron P, Elliott PM, Gimeno JR et al. The Cardiomyopathy Registry of the EURObservational Research Programs of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. *Eur Heart J* 39:1784–1793, 2018
- [39] Iacob M, Pinte F, Tintoiu I et al. Microcoil embolisation for ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy. *Kardiol Pol* 61:350–355, 2004
- [40] Durand E, Mousseaux E, Coste P et al. Non-surgical septal myocardial reduction by coil embolisation for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up. *Eur Heart J* 29:348–355, 2008
- [40a] Okutucu S, Aytemir K, Oto A. Glue septal ablation: a promising alternative to alcohol septal ablation. *JRSM Cardiovasc Dis* 5:2048004016636313, 2016
- [41] Lawrenz T, Borchert B, Leuner C et al. Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months' follow-up in 19 patients. *J Am Coll Cardiol* 57:572–576, 2011
- [42] Szumowski Ł, Dąbrowski M, Tyczynski P et al. Endocardial radiofrequency ablation for septal hypertrophy. *Kardiol Pol* 74:700, 2016
- [43] Liu L, Liu B, Li J et al. Percutaneous intramyocardial septal radiofrequency ablation of hypertrophic obstructive cardiomyopathy: a novel minimally invasive treatment for reduction of outflow tract obstruction. *EuroIntervention* 13:e2112–e2113, 2018
- [44] Liu L, Li J, Zuo L et al. Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy. *J Am Coll Cardiol* 72:1898–1909, 2018
- [45] Keane D, Hynes B, King G et al. Feasibility study of percutaneous transvalvular endomyocardial cryoablation for the treatment of hypertrophic obstructive cardiomyopathy. *J Invasive Cardiol* 19:247–251, 2007
- [46] Oto A, Aytemir K, Okutucu S et al. Cyanoacrylate for septal ablation in hypertrophic cardiomyopathy. *J Interv Cardiol* 24:77–84, 2011
- [47] Arnold AD, Howard JP, Chiew K et al. Right ventricular pacing for hypertrophic obstructive cardiomyopathy: meta-analysis and meta-regression of clinical trials. *Eur Heart J Qualit Care Clin Outcomes* 5:321–335, 2019
- [48] Olivetto I, Oreziak A, Barriales-Villa R et al.; EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 396(10253):759–769, 2020. Erratum in: *Lancet* 396(10253):758, 2020

20.9 Interventionelle Pulmonal-klappenimplantation

- [1] Bonhoeffer P, Boudjemline Y, Saliba Z et al. Transcatheter implantation of a bovine valve in pulmonary position: a lamb study. *Circulation* 102:813–816, 2000
- [2] Bonhoeffer P, Boudjemline Y, Saliba Z et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. *Lancet* 356:1403–1405, 2000
- [3] Bonhoeffer P, Boudjemline Y, Qureshi SA et al. Percutaneous insertion of the pulmonary valve. *J Am Coll Cardiol* 39:1664–1669, 2002
- [4] Sridharan S, Coats L, Khambadkone S et al. Images in cardiovascular medicine. Transcatheter right ventricular outflow tract intervention: the risk to the coronary circulation. *Circulation* 113:e934–e935, 2006
- [5] Nordmeyer J, Ewert P, Gewillig M et al. Acute and midterm outcomes of the post-approval MELODY Registry: a multicentre registry of transcatheter pulmonary valve implantation. *Eur Heart J* 40:2255–2264, 2019
- [6] Cribier A, Eltchaninoff H, Bash A et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. *Circulation* 106:3006–3008, 2002
- [7] Cribier A, Remadi F, Koning R et al. Emergency balloon valvuloplasty as initial treatment of patients with aortic stenosis and cardiogenic shock. *N Engl J Med* 326:646, 1992
- [8] Zahn EM. Self-expanding pulmonary valves for large diameter right ventricular outflow tracts. *Int Cardiol Clin* 8:73–80, 2019
- [9] Metzner A, Stock UA, Iino K et al. Percutaneous pulmonary valve replacement: autologous tissue-engineered valved stents. *Cardiovasc Res* 88:453–461, 2010
- [10] Spriestersbach H, Prudlo A, Bartosch M et al. First percutaneous implantation of a completely tissue-engineered self-expanding pulmonary heart valve prosthesis using a newly developed delivery system: a feasibility study in sheep. *Cardiovasc Interv Ther* 32:36–47, 2017
- [11] Schmitt B, Spriestersbach H, H-Ici DO et al. Percutaneous pulmonary valve replacement using completely tissue-engineered off-the-shelf heart valves: six-month in vitro functionality and matrix remodeling in sheep. *EuroIntervention* 12:62–70, 2016
- [12] Ewert P. Pulmonalklappeninsuffizienz bei EmaH – interventionelle Therapie. *Kardiologie up2date* 16:43–54, 2020
- [13] Zhang X, Puehler T, Seiler J et al. Tissue engineered transcatheter pulmonary valved stent implantation: current state and future prospect. *Int J Mol Sci* 23:723, 2022
- [14] Baumgartner H, De Backer J, Babu-Narayan SV et al. 2020 ESC Guidelines for the management of adult congenital heart disease. *Eur Heart J* 42:563–645, 2021

21 Aortenisthmusstenose (ISTA)

- [1] Schmaltz AA, Bauer U, Baumgartner H et al. Medizinische Leitlinie zur Behandlung von Erwachsenen mit angeborenen Herzfehlern der deutsch-österreichisch-schweizerischen kardiologischen Fachgesellschaften. *J Cardiol* 17:1–20, 2010
- [2] Baumgartner H, Bonhoeffer P, De Groot NM et al. ESC guidelines for the management of grown-up congenital heart disease (new version 2010). *Eur Heart J* 31:2915–57, 2013
- [3] Stout KK, Daniels CJ, Aboulhosn JA et al. 2018 AHA/ACC Guideline for the management of adults with congenital heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 73:1494–563, 2019
- [4] Schmaltz AA, Bauer UMM. Erwachsene mit angeborenen Herzfehlern. *Herz* 38:639–54, 2013
- [5] Hager A, Kanz S, Kämmerer H et al. Coarctation Long-term Assessment (COALA): significance of arterial hypertension in a cohort of 404 patients up to 27 years after surgical repair of isolated coarctation of the aorta, even in the absence of restenosis and prosthetic material. *J Thorac Cardiovasc Surg* 134:738–45, 2007
- [6] Aboulhosn J, Child JS. Left ventricular outflow obstruction: subaortic stenosis, bicuspid aortic valve, supraaortic stenosis, and coarctation of the aorta. *Circulation* 114:2412–22, 2006
- [7] Siu SC, Silversides CK. Bicuspid aortic valve disease. *J Am Coll Cardiol* 55:2789–800, 2010
- [8] Erbel R, Aboyans V, Boileau C et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). *Eur Heart J* 35:2873–926, 2014
- [9] Connolly HM, Huston J 3rd, Brown RD Jr et al. Intracranial aneurysms in patients with coarctation of the aorta: a prospective magnetic resonance angiographic study of 100 patients. *Mayo Clin Proc* 78:1491–9, 2003
- [10] Cook SC, Hickey J, Maul TM et al. Assessment of the cerebral circulation in adults with coarctation of the aorta. *Congenit Heart Dis* 8:289–95, 2013
- [11] Correia AS, Gonçalves A, Paiva M et al. Long-term follow-up after aortic coarctation repair: the unsolved issue of exercise-induced hypertension. *Rev Port Cardiol* 32:879–83, 2013
- [11a] Haas NA, Rickes C, Kozlik-Feldmann R et al. Leitlinie Pädiatrische Kardiologie: Aortenisthmusstenose. Deutsche Gesellschaft für pädiatrische Kardiologie, AWMF-Register Nr 023/010, Klasse 2k, 2018
- [11b] Dittrich S, Arenz C, Krogmann O et al. German registry for cardiac operations and interventions in patients with congenital heart disease: report 2021 and 9 years' longitudinal observations on Fallot and coarctation patients. *Thorac Cardiovasc Surg* 70 (S 03):e21–e33, 2022
- [12] Lock JE, Niemi T, Burke BA et al. Transcatheter angioplasty of experimental aortic coarctation. *Circulation* 66:1280–6, 1982
- [13] Singer MI, Rowen M, Dorsey TJ. Transluminal aortic balloon angioplasty for coarctation of the aorta in the newborn. *Am Heart J* 103:131–2, 1982
- [14] D'Souza VJ, Velasquez G, Weesner KM et al. Transluminal angioplasty of aortic coarctation with a two-balloon technique. *Am J Cardiol* 54:457–8, 1984
- [15] Rheuban KS, Gutgesell HP, Carpenter MA et al. Aortic aneurysm after patch angio-

- plasty for aortic isthmic coarctation in childhood. *Am J Cardiol* 58:178–80, 1986
- [16] Erbel R, Sievert H, Bussmann WD et al. Aortenisthmusstenose-Dilatation im Erwachsenenalter. Eine deutsche kooperative Studie. *Z Kardiol* 77:797–804, 1988
- [17] Krabill KA, Bass JL, Lucas RV Jr et al. Dissecting transverse aortic arch aneurysm after percutaneous transluminal balloon dilation angioplasty of an aortic coarctation. *Pediatr Cardiol* 8:39–42, 1987
- [18] Erbel R, Bednarczyk I, Pop T et al. Detection of dissection of the aortic intima and media after angioplasty of coarctation of the aorta. An angiographic, computer tomographic, and echocardiographic comparative study. *Circulation* 81:805–14, 1990
- [19] Erbel R, Gorge G, Gerber T et al. Dissection following balloon angioplasty of aortic coarctation: review of the literature. *J Interv Cardiol* 5:99–109, 1992
- [20] Kaemmerer H, Ehrenheim Ch, Wilken W et al. Klinische und kernspintomographische Verlaufskontrollen bei Kindern nach Dilatation einer Aortenisthmusstenose (CoA). *Z Kardiol* 79:766–73, 1990
- [21] Beekman RH, Muller DW, Reynolds PI et al. Balloon-expandable stent treatment of experimental coarctation of the aorta: early hemodynamic and pathological evaluation. *J Interv Cardiol* 6:113–23, 1993
- [22] Morrow WR, Smith VC, Ehler WJ et al. Balloon angioplasty with stent implantation in experimental coarctation of the aorta. *Circulation* 89:2677–83, 1994
- [23] Thanopoulos BV, Triposkiadis F, Margatakis A et al. Long segment coarctation of the thoracic aorta: treatment with multiple balloon-expandable stent implantation. *Am Heart J* 133:470–3, 1997
- [24] Gunn J, Cleveland T, Gaines P. Covered stent to treat co-existent coarctation and aneurysm of the aorta in a young man. *Heart* 82:351, 1999
- [24a] Meadows J, Minahan M, McElhinney DB et al.; COAST Investigators. Intermediate outcomes in the prospective, multicenter Coarctation of the Aorta Stent Trial (COAST). *Circulation* 131:1656–64, 2015
- [24b] Kische S, D’Ancona G, Stoekicht Y. Percutaneous treatment of adult isthmic aortic coarctation: acute and long-term clinical and imaging outcome with a self-expandable uncovered nitinol stent. *Circ Cardiovasc Interv* 8(1):e001799, 2015
- [25] Firoozi A, Mohebbi B, Noohi F et al. Self-expanding versus balloon-expandable stents in patients with isthmic coarctation of the aorta. *Am J Cardiol* 122:1062–7, 2018
- [25a] Schmidt SAC, Armstrong A, Kennedy KF et al. Procedural characteristics and outcome of transcatheter interventions for aortic coarctation: a report from the IMPACT registry. *J Soc Cardiovasc Angiogr Interv* 1:100393, 2022
- [26] Lampropoulos K, Budts W, Gewillig M. Dual wire technique for aortic coarctation stent placement. *Catheter Cardiovasc Interv* 78:425–7, 2011
- [27] Forbes TJ, Kim DW, Du W et al., CCISC Investigators. Comparison of surgical, stent, and balloon angioplasty treatment of native coarctation of the aorta: an observational study by the CCISC (Congenital Cardiovascular Interventional Study Consortium). *J Am Coll Cardiol*. 58:2664–74, 2011
- [27a] Hascoët S, Jalal Z, Baruteau A et al. Stenting in paediatric and adult congenital heart diseases: a French multicentre study in the current era. *Arch Cardiovasc Dis* 108:650–60, 2015
- [27b] Hartman EM, Groenendijk IM, Heuvelman HM et al. The effectiveness of stenting of coarctation of the aorta: a systematic review. *EuroIntervention* 11:660–8, 2015
- [28] Golden AB, Hellebrand WE. Coarctation of the aorta: stenting in children and adults. *Cath Cardiovasc Interv* 9:289–99, 2007
- [29] Forbes TJ, Garekar S, Amin Z et al. Procedural results and acute complications in stenting native and recurrent coarctation of the aorta in patients over 4 years of age: a multi-institutional study. *Catheter Cardiovasc Interv* 70:276–85, 2007
- [30] Forbes TJ, Gorda ST. Intravascular stent therapy for coarctation of the aorta. *Houston Methodist/DeBakey-Journal* 2:82–7, 2014
- [31] Tretter JT, Jines TK, McElhinney DB. Aortic wall injury related to endovascular therapy for aortic coarctation. *Circ Cardiovasc Interv* 8:e002840, 2015

22 Endovaskuläre thorakale und abdominelle Aortentherapie

- [1] Czerny M, Schmidli J, Adler S et al. Current options and recommendations for the treatment of thoracic aortic pathologies involving the aortic arch: an expert consensus document of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Society of Vascular Surgery (ESVS). *Eur J Cardiothorac Surg* 55:133–162, 2019
- [2] Nienaber C, Kische S, Rousseau H et al. Endovascular repair of type b aortic dissection: long term results of the randomized INvestigation of STEnt-grafts in Aortic Dissection (INSTEAD-XL) Trial. *Circ Cardiovasc Intervent* 6:407–416, 2013
- [3] Erbel R, Aboyans V, Boileau C et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). *Eur Heart J* 35:2873–2926, 2014
- [4] Evangelista A, Czerny M, Nienaber C et al. Interdisciplinary expert consensus on management of type B intramural hematoma and penetrating aortic ulcer. *Eur J Cardiothorac Surg* 47:209–217, 2015
- [5] Wanhainen A, Verzini F, Van Herzele I et al. Editor's choice: European Society for Vascular Surgery (ESVS) 2019 Clinical practice guidelines on the management of abdominal aorto-iliac artery aneurysms. *Eur J Vasc Endovasc Surg* 57:8–93, 2019

23 Hybridraum – aus der Sicht des Herzchirurgen

- [1] Meisner H, Struck E, Schmidt-Habelmann P et al. Intraoperative Kontrollen der Revascularisation und Indikation zur Reintervention. *Thoraxchir Vask Chir* 25:172–180, 1977
- [2] Neumann FJ, Sousa-Uva M, Ahlsson A et al., ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 40:87–165, 2019
- [3] Davidavicius G, Van Praet F, Mansour S et al. Hybrid revascularization strategy: a pilot study on the association of robotically enhanced minimally invasive direct coronary artery bypass surgery and fractional-flow-reserve-guided percutaneous coronary intervention. *Circulation* 112(Suppl 9):I317–I322, 2005
- [4] Halkos ME, Vassiliades TA, Douglas JS et al. Hybrid coronary revascularization versus off-pump coronary artery bypass grafting for the treatment of multivessel coronary artery disease. *Ann Thorac Surg* 92:1695–1701, 2011; discussion 1701–1702, 2011
- [5] Panoulas VF, Colombo A, Margonato A et al. Hybrid coronary revascularization: promising, but yet to take off. *J Am Coll Cardiol* 65:85–97, 2015
- [6] Gąsior M, Zembala MO, Tajstra M et al., POL-MIDES (HYBRID) Study Investigators. Hybrid revascularization for multivessel coronary artery disease. *JACC Cardiovasc Interv* 7:1277–1283, 2014
- [7] Tajstra M, Hrapkowicz T, Hawranek M et al., POL-MIDES Study Investigators. Hybrid coronary revascularization in selected patients with multivessel disease: 5-year clinical outcomes of the prospective randomized pilot study. *JACC Cardiovasc Interv* 11:847–852, 2018
- [8] Sardar P, Kundu A, Bischoff M et al. Hybrid coronary revascularization versus coronary artery bypass grafting in patients with multivessel coronary artery disease: a meta-analysis. *Catheter Cardiovasc Interv* 91:203–212, 2018
- [9] Thielmann M, Sharma V, Al-Attar N et al. ESC Joint Working Groups on Cardiovascular Surgery and the Cellular Biology of the Heart Position Paper: Perioperative myocardial injury and infarction in patients undergoing coronary artery bypass graft surgery. *Eur Heart J* 14:2392–2407, 2017
- [10] Thielmann M, Massoudy P, Schmermund A et al. Diagnostic discrimination between graft-related and non-graft-related perioperative myocardial infarction with cardiac troponin I after coronary artery bypass surgery. *Eur Heart J* 26:2440–2447, 2005
- [11] Thielmann M, Massoudy P, Jaeger BR et al. Emergency re-revascularization with percutaneous coronary intervention, reoperation, or conservative treatment in patients with acute perioperative graft failure following coronary artery bypass surgery. *Eur J Cardiothorac Surg* 30:117–125, 2006
- [12] DeSanctis RW, Doroghazi RM, Austen WG et al. Aortic dissection. *N Engl J Med* 317:1060–1067, 1987
- [13] Jakob H, Tsagakis K, Dohle DS et al. Hybrid room technology as a prerequisite for the modern therapy of aortic dissection. *Herz* 36:525–530, 2011
- [14] Tsagakis K, Konorza T, Dohle DS et al. Hybrid operating room concept for combined diagnostics, intervention and surgery in acute type A dissection. *EJCTS* 43:397–404, 2013
- [15] Deeb GM, Williams DM, Bolling SF et al. Surgical delay for acute type A dissection with malperfusion. *Ann Thorac Surg* 64:1669–1675, 1997
- [16] Tsagakis K, Pizanis N, Kamler M et al. ICU controlled delay for acute type A aortic dissection repair after intervention for total visceral malperfusion: a way out of a di-

- lemma? Thorac Cardiovasc Surg 56:298–300, 2008
- [17] Dohle DS, Tsagakis K, Ibrahim S et al. Controlled delayed aortic repair in acute aortic syndrome and multiorgan failure: an option in selected cases. Thorac Cardiovasc Surg Rep 4:52–55, 2015
- [18] Tsagakis K, Janosi R, Frey U et al. True lumen stabilization to overcome malperfusion in acute type I aortic dissection. Semin Thorac Cardiovasc Surg 31:740–748, 2019
- [19] Tsagakis K, Kamler M, Benedik J et al. Angioscopy – a valuable tool in guiding hybrid stent grafting and decision making during type A aortic dissection surgery. Eur J Cardiothorac Surg 38:507–509, 2010
- [20] Jakob H, Tsagakis K. DeBakey type I dissection: when hybrid stent-grafting is indicated? J Cardiovasc Surg 51:633–640, 2010
- [21] Jakob H, Moughal S, Bashir M. Frozen elephant trunk with straight vascular prosthesis: single-center experience with a review of current trends. J Cardiovasc Surg (Torino) 61:301–307, 2020
- [22] Thielmann M, Eggebrecht H, Wendt D et al. New techniques for the treatment of valvular aortic stenosis – transcatheter aortic valve implantation with the SAPIEN heart valve. Minim Invasive Ther Allied Technol 18:131–141, 2009
- [23] Augoustides JG, Patel PA, Savino JS et al. The heart team approach to acute type A dissection: a new paradigm in the era of the integrated Penn classification and the Essen concept. Eur J Cardiothorac Surg 43:404–405, 2013

24 Nierenarterieninterventionen

- [1] Hirsch AT, Haskal ZJ, Hertzner NR et al., American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. *Circulation* 113:e463–654, 2006
- [2] Wieneke H, Konorza T, Eggebrecht H et al. Die Nierenarterienstenose. Pathophysiologie – Diagnostik – Therapie. *Med Klinik* 104:349–355, 2009
- [3] De Bruyne B, Manoharan G, Pijls NH et al. Assessment of renal artery stenosis severity by pressure gradient measurements. *J Am Coll Cardiol* 48:1851–1855, 2006
- [4] Oberhuber A, Vonend O, Radermacher J et al. Leitlinie – S2K Erkrankungen der Nierenarterie 004–008. AWMF online (Stand 1.9.2019) S. 21–22, 2019
- [5] Krum H, Schlaich M, Withburn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. *Lancet* 373:1275–1281, 2009
- [6] Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation and systemic hypertension. *Am J Cardiol* 105:570–576, 2010
- [7] Misra S, Thatipelli MR, Howe PW et al. Preliminary study of the use of drug-eluting stents in atherosclerotic renal artery stenosis 4 mm in diameter and smaller. *J Vasc Interv Radiol* 19:833–839, 2008
- [8] Zähringer M, Pattynama PM, Talen A et al. Drug-eluting stents in renal artery stenosis. *Eur Radiol* 18:678–682, 2008
- [9] Ahn J, Park SH, Shin WY et al. Use of drug-eluting stent with provisional T-Stenting technique in the treatment of renal artery bifurcation stenosis; long-term angiographic follow-up. *J Korean Med Sci* 26:1512–1514, 2011
- [10] Hasija P, Chadha D, Kalra R. Kissing stenting of aorto-ostial lesions in juxtaposed renal arteries. *BMJ Case Rep pii: bcr2014205373*, 2014
- [11] Oberhuber A, Vonend O, Radermacher J et al. Leitlinie – S2K Erkrankungen der Nierenarterie 004–008. AWMF online (Stand 1.9.2019) S. 21–22, 2019
- [12] Kongoji K, Mitarai T, Kasahara M et al. Minimally invasive percutaneous transluminal renal artery stenting. *Int J Cardiol* 252:52–56, 2018
- [13] Zeller T, Rastan A, Schwarzwälder U et al. Treatment of in-stent restenosis following stent: supported renal artery angioplasty. *Catheter Cardiovasc Interv* 70:454–459, 2007

- [14] N'Dandu ZM, Badawi RA, White CJ et al. Optimal treatment of renal artery in-stent stenosis: repeat stent placement versus angioplasty alone. *Catheter Cardiovasc Interv* 71:701–705, 2008
- [15] Patel PM, Eisenberg J, Islam MA et al. Percutaneous revascularization of persistent renal artery in-stent stenosis. *Vasc Med* 14:259–264, 2009
- [16] David MG, Saad WE, Bismuth JX et al. Endovascular revascularization of renal artery stenosis in solitary functioning kidney. *J Vasc Surg* 49:953–960, 2009
- [17] Oberhuber A, Vonend O, Radermacher J et al. Leitlinie – S2K Erkrankungen der Nierenarterie 004–008. AWMF online (Stand 1.9.2019) S. 21–22, 2019
- [18] Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J* 39:3021–3104, 2018
- [19] Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension* 42:1206–1252, 2003
- [20] Bruening F. Die operative Behandlung des Halsbrustsympathikus und Bemerkungen über die operative Behandlung der abnormen Blutdrucksteigerung. *Klin Wochenschr* 2:777–780, 1923
- [21] Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1266 cases. *J Am Med Assoc* 152:1501–1504, 1953
- [22] Hart EC, Charkoudian N. Sympathetic neural mechanisms in human blood pressure regulation. *Curr Hypertens Rep* 13:237–243, 2011
- [23] Patel HC, Hayward C, Di Mario C. Symplcity HTN 3: the death knell for renal denervation in hypertension? *Glob Cardiol Sci Pract* 2014:94–98, 2014
- [24] Townsend RR, Mahfoud F, Kandzari DE et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of concept trial. *Lancet* 390:2160–2170, 2017
- [25] Kandzari DE, Böhm M, Mahfoud F et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of concept randomised trial. *Lancet* 391:2346–2355, 2018
- [26] Azizi M, Schmieder RE, Mahfoud F et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. *Lancet* 391:2335–2345, 2018
- [27] Schmieder RE, Redon J, Grassi G et al. ESH position paper: renal denervation: an interventional therapy of resistant hypertension. *J Hypertens* 30:837–841, 2012
- [28] Mahfoud F, Vonend O, Bruck H et al. Expert consensus statement on interventional renal sympathetic denervation for hypertension treatment. *Dtsch Med Wochenschr* 136:2418–2424, 2011
- [29] Blondin D, Vonend O, Potthoff SA. Renale Denervation. *Interventionelle Radiologie* 1:59–84, 2013
- [30] Schmieder RE, Redon J, Grassi G et al. ESH position paper: renal denervation: an interventional therapy of resistant hypertension. *J Hypertens* 30:837–841, 2012
- [31] Pollak R, Prusak BF, Mozes MF. Anatomic abnormalities of cadaver kidneys procured for purposes of transplantation. *Am Surg* 52:233–235, 1986

25 Lungenembolie

- [1] <http://www.gbe-bund.de/svg/L247432.svg>
- [2] Konstantinides SV, Torbicki A, Agnelli G et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. *Eur Heart J* 35:3033–3069, 2014; corrigendum *Eur Heart J* 36:2666, 2015
- [3] Lankeit M, Hobohm L, Konstantinides S. Akute Lungenembolie – Update 2018. *Kardiologie up2date* 14:67–81, 2018
- [4] Wilkens H, Held M. Lungenembolie Status 2018. *Dtsch Arztebl (Suppl Perspektiven der Pneumologie und Allergologie 2)* 115:8–14, 2018
- [5] Cohen AT, Agnelli G, Anderson FA et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. *Thromb Haemost* 98:756–764, 2007
- [6] Konstantinides S, Geibel A, Heusel G et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. *N Engl J Med* 347:1143–1150, 2002
- [6a] Gesundheitsberichterstattung des Bundes – gemeinsam getragen von RKI und DESTATIS. http://www.gbe-bund.de/oowa/921install/servlet/oowa/aw92/WS0100/_XWD_PROC?_XWD_2/2/xs_setlinie/1/_XWD_28#SVG
- [7] Shojania KG, Burton EC. The vanishing nonforensic autopsy. *N Engl J Med* 358:873–875, 2008
- [8] Goldhaber S, Visani L, De Rosa M. Acute Pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). *Lancet* 33:1386–1389, 1999
- [9] Pollack CV, Schreiber D, Goldhaber SZ et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). *J Am Coll Cardiol* 57:700–706, 2011
- [10] Wells PS, Ginsberg JS, Anderson DR et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. *Ann Intern Med* 29:997–1005, 1998
- [11] Gibson NS, Sohne M, Kruip MJ et al. Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. *Thromb Haemost* 99:229–234, 2008
- [12] Klok FA, Mos IC, Nijkeuter M et al. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. *Arch Intern Med* 168:2131–2136, 2008
- [13] Douma RA, Mos IC, Erkens PM et al. Performance of 4 clinical decision rules in the diagnostic management of acute pulmonary embolism: a prospective cohort study. *Ann Intern Med* 154:709–718, 2011
- [14] Douma RA, Gibson NS, Gerdes VE et al. Validity and clinical utility of the simplified Wells rule for assessing clinical probability for the exclusion of pulmonary embolism. *Thromb Haemost* 101:197, 2009
- [15] Ceriani E, Combescure C, Le Gal G et al. Clinical prediction rules for pulmonary embolism: a systematic review and meta-analysis. *J Thromb Haemost* 8:957–970, 2010
- [16] European Working Group on Echocardiography. The European Cooperative Study on the clinical significance of right heart thrombi. *Eur Heart J* 10:1046–1059, 1989
- [18] Torbicki A, Galié N, Covezzoli A et al. Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. *J Am Coll Cardiol* 41:2245–2251, 2003
- [19] Mollazadeh R, Ostovan MA, Abdi Ardekani AR. Right cardiac thrombus in transit among patients with pulmonary thromboemboli. *Clin Cardiol* 32:E27–E31, 2009

- [20] Wittlich N, Erbel R, Eichler A et al. Detection of central pulmonary artery thromboemboli by transesophageal echocardiography in patients with severe pulmonary embolism. *J Am Soc Echocardiogr* 5:515–524, 1992
- [21] Erbel R, Wittlich N, Schuster S et al. Assessment of pulmonary embolism. *Int J Card Imaging* 9(Suppl 2):39–49, 1993
- [22] Stein PD, Fowler SE, Goodman LR et al. Multidetector computed tomography for acute pulmonary embolism. *N Engl J Med* 354:2317–2327, 2006
- [23] Perrier A, Roy PM, Sanchez O et al. Multidetector-row computed tomography in suspected pulmonary embolism. *N Engl J Med* 352:1760–1768, 2005
- [24] van Belle A, Büller HR, Huisman MV et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. *JAMA* 295:172–179, 2006
- [25] Anderson DR, Kahn SR, Rodger MA et al. Computed tomographic pulmonary angiography vs. ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. *JAMA* 298:2743–2753, 2007
- [26] Righini M, Le Gal G, Aujesky D et al. Diagnosis of pulmonary embolism by multidetector CT alone or combined with venous ultrasonography of the leg: a randomised non-inferiority trial. *Lancet* 371:1343–1352, 2008
- [27] Stein PD, Goodman LR, Hull RD et al. Diagnosis and management of isolated subsegmental pulmonary embolism: review and assessment of the options. *Clin Appl Thromb Hemost* 18:20–26, 2012
- [28] Gutte H, Mortensen J, Jensen CV et al. Detection of pulmonary embolism with combined ventilation-perfusion SPECT and low-dose CT: head-to-head comparison with multidetector CT angiography. *J Nucl Med* 50:1987–1992, 2009
- [29] Reinartz P, Kaiser HJ, Wildberger JE et al. SPECT imaging in the diagnosis of pulmonary embolism: automated detection of match and mismatch defects by means of image-processing techniques. *J Nucl Med* 47:968–973, 2006
- [30] Walsh PN, Greenspan RH, Simon M et al. An angiographic severity index for pulmonary embolism. *Circulation* 47(Suppl II):101–108, 1973
- [31] Schmitz-Rode T, Janssens U, Hanrath P et al. Fragmentation of massive pulmonary embolism by pigtail rotation catheter: possible complication. *Eur Radiol* 11:2047–2049, 2000
- [32] Konstantinides SV, Erbel C, Lankeit MK, Tiefenbacher C für die Kommission für Klinische Kardiovaskuläre Medizin der DGK. ESC Pocket Guidelines. Management der akuten Lungenembolie. Börm Bruckmeier, Grünwald, 2019
- [33] Schouten HJ, Geersing GJ, Koek H et al. Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: systematic review and meta-analysis. *BMJ* 346:f2492, 2013
- [34] Righini M, Van Es J, Den Exter PL et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the A3JUST-PE study. *JAMA* 311:1117–1124, 2014
- [35] Lankeit M, Jiménez D, Kostrubiec M et al. Predictive value of the high-sensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. *Circulation* 124:2716–2724, 2011
- [36] Konstantinidis S, Bauersachs J, Mayer E et al. Management der akuten Lungenembolie. Übersetzte ESC Pocket Guidelines von 2014. Börm Bruckmeier, Grünwald, 2014
- [37] Konstantinidis SV, Meyer G, Becattini C et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). *Eur Heart J* 41:543–603, 2020
- [38] Aujesky D, Obrosky DS, Stone RA et al. Derivation and validation of a prognostic model for pulmonary embolism. *Am J Respir Crit Care Med* 172:1041–1046, 2005
- [39] Jimenez D, Aujesky D, Moores L et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. *Arch Intern Med* 170:1383–1389, 2010
- [40] Kuo WT, Sista AK, Faintuch S et al. Society of Interventional Radiology position statement on catheter-directed therapy for

- acute pulmonary embolism. *J Vasc Interv Radiol* 29:293–297, 2018
- [41] Nellessen U, Daniel WG, Matheis G et al. Impending paradoxical embolism from atrial thrombus: correct diagnosis by transesophageal echocardiography and prevention by surgery. *J Am Coll Cardiol* 5:1002–1004, 1985
- [42] Mathew TC, Ramsaran EK, Aragam JR. Impending paradoxical embolism in acute pulmonary embolism: diagnosis by transesophageal echocardiography and treatment by emergent surgery. *Am Heart J* 129:826–827, 1995
- [43] Myers PO, Bounameaux H, Panos A et al. Impending paradoxical embolism: systematic review of prognostic factors and treatment. *Chest* 137:164–170, 2010
- [44] Konstantinides S, Geibel A, Kasper W et al. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism. *Circulation* 97:1946–1951, 1998
- [45] Kälsch H, Sack S, Erbel R et al. Acute massive pulmonary embolism detected with angiography and intravascular ultrasound treated by pulmonary embolectomy. The hybrid concept. *Herz* 31:366–367, 2006
- [46] Thielmann M, Pasa S, Wendt D et al. Prognostic significance of cardiac troponin I on admission for surgical treatment of acute pulmonary embolism: a single-centre experience over more than 10 years. *Eur J Cardiothorac Surg* 42:951–957, 2012
- [47] Kilic A, Shah AS, Conte JV et al. Nationwide outcomes of surgical embolectomy for acute pulmonary embolism. *J Thorac Cardiovasc Surg* 145:373–377, 2013
- [48] Neely RC, Byrne JG, Gosev I et al. Surgical embolectomy for acute massive and sub-massive pulmonary embolism in a series of 115 patients. *Ann Thorac Surg* 100:1245–1251; discussion 100:1251–1252, 2015
- [49] Keeling WB, Leshnower BG, Lasajanak Y et al. Midterm benefits of surgical pulmonary embolectomy for acute pulmonary embolus on right ventricular function. *J Thorac Cardiovasc Surg* 152:872–878, 2016
- [50] Aymard T, Kadner A, Widmer A et al. Massive pulmonary embolism: surgical embolectomy versus thrombolytic therapy: should surgical indications be revisited? *Eur J Cardiothorac Surg* 43:90–94, 2013
- [51] Konorza TFM, Kälsch H, Plicht B et al. Perkutane Dilatation der Pulmonalarterien und kombinierte selektive Thrombolyse-therapie mittels Urokinase und Heparin als neue Therapieoption bei chronisch embolischer Lungenembolie. *Clin Res Cardiol* 98(Suppl 1), 2009
- [52] Engelberger RP, Kucher N. Catheter-based reperfusion treatment of pulmonary embolism. *Circulation* 124:2139–2144, 2011
- [53] Jaber WA, Fong PP, Weisz G et al. Acute pulmonary embolism: with an emphasis on an interventional approach. *J Am Coll Cardiol* 67:991–1002, 2016
- [54] Zarghouni M, Charles HW, Maldonado TS et al. Catheter-directed interventions for pulmonary embolism. *Cardiovasc Diagn Ther* 6:651–661, 2016
- [54a] Yeager SB. Balloon selection for double balloon valvotomy. *J Am Coll Cardiol* 9:467–468, 1987
- [55] Kuo WT, Gould MK, Louie JD et al. Catheter directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. *J Vasc Interv Radiol* 20:1431–1440, 2009
- [55a] Singh M, Shafi I, Rali P et al. Contemporary catheter-based treatment options for management of acute pulmonary embolism. *Curr Treat Options Cardiovasc Med* 23:44, 2021
- [56] Greenfield LJ, Proctor MC, Williams DM et al. Long-term experience with transvenous catheter pulmonary embolectomy. *J Vasc Surg* 18:450–458, 1993
- [57] Schmitz-Rode T, Janssens U, Schild HH et al. Fragmentation of massive pulmonary embolism using a pigtail rotation catheter. *Chest* 114:1427–1436, 1998
- [58] Goldhaber SZ. Integration of catheter thrombectomy into our armamentarium to treat acute pulmonary embolism. *Chest* 114:1237–1238, 1998
- [59] Schmitz-Rode T, Janssens U, Duda SH et al. Massive pulmonary embolism: percutaneous emergency treatment by pigtail rotation catheter. *J Am Coll Cardiol* 36:375–380, 2000
- [59a] <https://evtoday.com/device-guide/euro-pean/mechanical-thrombectomythrombolysis-1>, 20.03.2022

- [60] Schmitz-Rode T, Janssens U, Hanrath P et al. Fragmentation of massive pulmonary embolism by pigtail rotation catheter: possible complication. *Eur Radiol* 11:2047–2049, 2001
- [61] Freitas B, Steiner S, Bausback Y et al. Rotarex®S Mechanical debulking in acute and subacute arterial lesions: single-center experience with 525 patients. *Angiology* 18:233–241, 2016
- [62] Devic Z, Kuo WT. Percutaneous pulmonary embolism thrombectomy and thrombolysis: technical tips and tricks. *Semin Intervent Radiol* 35:129–135, 2018
- [63] Lichtenberg M, Stahlhoff WF, Özkapi A et al. Safety, procedural success and outcome of the Aspirex®S endovascular thrombectomy system in the treatment of iliofemoral deep vein thrombosis: data from the Arnsberg Aspirex registry. *Vasa* 48:341–346, 2019
- [64] Tukaye DN, McDaniel M, Liberman H et al. Percutaneous pulmonary embolus mechanical thrombectomy. *JACC Cardiovasc Interv* 10:94–95, 2017
- [65] Tu T, Toma C, Tapson VF et al. A Prospective, single-arm, multicenter trial of catheter-directed mechanical thrombectomy for intermediate-risk acute pulmonary embolism: The FLARE Study. *JACC Cardiovasc Interv* 12:859–869, 2019
- [65a] Toma C, Bunte MC, Cho KH et al. Percutaneous mechanical thrombectomy in a real-world pulmonary embolism population: interim results of the FLASH registry. *Catheter Cardiovasc Interv* 99:1345–1355, 2022
- [66] Das S, Das N, Serota H et al. A retrospective review of patients with massive and submassive pulmonary embolism treated with AngioJet rheolytic thrombectomy with decreased complications due to changes in thrombolytic use and procedural modifications. *Vascular* 26:163–168, 2018
- [67] Shen Y, Wang X, Jin SS et al. Increased risk of acute kidney injury with percutaneous mechanical thrombectomy using AngioJet compared with catheter-directed thrombolysis. *J Vasc Surg Venous Lymphat Disord* 7:29–37, 2019
- [68] Engelberger RP, Kucher N. Catheter-based reperfusion treatment of pulmonary embolism. *Circulation* 124:2139–2144, 2011
- [69] Engelberger RP, Kucher N. Ultrasound-assisted thrombolysis for acute pulmonary embolism: a systematic review. *Eur Heart J* 35:758–764, 2014
- [70] Kucher N, Boekstegers P, Muller OJ et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. *Circulation* 129:479–486, 2014
- [71] Rao G, Xu H, Wang JJ et al. Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute pulmonary embolism: a multicenter comparison of patient-centered outcomes. *Vasc Med* 24:241–247, 2019
- [72] Craig SH, Nelson SM. Ekosonic Endovascular System (EKOS) in a trauma patient with intracranial bleed, recent major surgery, and massive pulmonary embolus: a case report. *Radiol Case Rep* 13:156–160, 2018
- [72a] Klok FA, Piazza G, Sharp ASP et al. Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: rationale and design of the HI-PEITHO study. *Am Heart J* 251:43–53, 2022
- [73] Engelberger RP, Spirk D, Willenberg T et al. Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis. *Circ Cardiovasc Interv* 8:e002027, 2015
- [74] Stuck AK, Engelberger RP, Saengprakai W et al. Pharmacomechanical or ultrasound-assisted thrombolysis, balloon angioplasty and provisional surgical decompression for upper extremity deep vein thrombosis due to thoracic outlet syndrome. *Thromb Res* 145:109–111, 2016
- [74a] Bashir R, Foster M, Iskander A et al. Pharmacomechanical catheter-directed thrombolysis with the bashir endovascular catheter for acute pulmonary embolism: the RESCUE Study. *JACC Cardiovasc Interv* 15:2427–2436, 2022
- [74b] Hobohm L, Schmidt FP, Gori T et al. In-hospital outcomes of catheter-directed thrombolysis in patients with pulmonary embolism. *Eur Heart J Acute Cardiovasc Care* 10:258–264, 2021
- [75] Schmitz-Rode T, Verma R, Pfeffer JG et al. Temporary pulmonary stent placement as emergency treatment of pulmonary embolism: first experimental evaluation. *J Am Coll Cardiol* 48:812–816, 2006

- [76] Winters BD, Weaver SJ, Pfoh ER et al. Rapid-response systems as a patient safety strategy: a systematic review. *Ann Intern Med* 158:417–425, 2013
- [77] Provias T, Dudzinski DM, Jaff MR et al. The Massachusetts General Hospital Pulmonary Embolism Response Team (MGH PERT): creation of a multidisciplinary program to improve care of patients with massive and submassive pulmonary embolism. *Hosp Pract (1995)* 42:31–37, 2014
- [78] Reza N, Dudzinski DM. Pulmonary embolism response teams. *Curr Treat Options Cardiovasc Med* 17:387, 2013
- [79] Dudzinski DM, Horowitz JM. Start-up, organization and performance of a multidisciplinary pulmonary embolism response team for the diagnosis and treatment of acute pulmonary embolism. *Rev Esp Cardiol (Engl Ed)* 70:9–13, 2017
- [80] Kabrhel C. Achieving multidisciplinary collaboration for the creation of a pulmonary embolism response team: creating a “team of rivals”. *Semin Intervent Radiol* 34:16–24, 2017
- [81] Kuo WT, Banerjee A, Kim PS et al. Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT): initial results from a prospective multicenter registry. *Chest* 148:667–673, 2015
- [82] Xenos ES, Davis GA, He Q et al. The implementation of a pulmonary embolism response team in the management of intermediate- or high-risk pulmonary embolism. *J Vasc Surg Venous Lymphat Disord* 7:493–500, 2019
- [83] Rosovsky R, Chang Y, Rosenfield K et al. Changes in treatment and outcomes after creation of a pulmonary embolism response team (PERT), a 10-year analysis. *J Thromb Thrombolysis* 47:31–40, 2014

26 Simulationstraining in der interventionellen Kardiologie

- [1] Gallagher AG, Ritter EM, Champion H et al. Virtual reality simulation for the operating room. Proficiency-based training as a paradigm shift in surgical skills training. *Ann Surg* 241:364–372, 2005
- [2] Voelker W, Lengenfelder B, Petersen J et al. An innovative hybrid-model to train the management of acute pericardial tamponade in the cath lab (abstract). *Simul Healthc* 4(Suppl 5):172, 2009
- [3] Hays RT, Jacobs JW, Prince C et al. Flight simulator training effectiveness: a meta-analysis. *Mil Psychol* 4:63–74, 1992
- [4] Müller MP, Hänsel M, Fichtner A et al. Excellence in performance and stress reduction during two different full scale simulator training courses: a pilot study. *Resuscitation* 80:919–924, 2009
- [5] Schuetz M, Moenk S, Vollmer S et al. High degree of realism in teaching percutaneous coronary interventions by combining a virtual reality trainer with a full scale patient simulator. *Simul Healthc* 3:242–246, 2008
- [6] Lipner R, Messenger J, Kangilaski R et al. A technical and cognitive skills evaluation of performance in interventional cardiology procedures using medical simulation in healthcare. *Simul Healthc* 5:65–74, 2010
- [7] Voelker W, WA Schöbel, E Kaiser et al. *Manuel der Arbeitsgruppe Interventionelle Kardiologie der DGK zu den Anforderungen an Simulationskurse in der invasiven/interventionellen Kardiologie.* *Kardiologie* 11:44–47, 2017
- [8] Schächinger V, Naber CK, Kreuzer J et al. Curriculum Interventionelle Kardiologie. *Kardiologie* 6:315–323, 2012
- [9] Bagai A, O'Brien S, Al Lawati H et al. Mentored simulation training improves procedural skills in cardiac catheterization: a randomized, controlled pilot study. *Circ Cardiovasc Interv* 5:672–679, 2012
- [10] Casey DB, Stewart D, Vidovich M. Diagnostic coronary angiography: initial results of a simulation program. *Cardiovasc Revasc Med* 17:102–105, 2016
- [11] Schimmel DR, Sweis R, Cohen ER et al. Targeting clinical outcomes: endovascular simulation improves diagnostic coronary angiography skills. *Catheter Cardiovasc Inter* 87:383–388, 2016
- [12] Voelker W, Petri N, Tönissen C et al. Does simulation-based training improve procedural skills of beginners in interventional cardiology? A stratified randomized study. *J Interv Cardiol* 29:75–82, 2016
- [13] Westerdahl DE. The necessity of high-fidelity simulation in cardiology training programs *J Am Coll Cardiol* 67:1375–1378, 2016